[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-Ko_y0_OEuV3BRLKL2x5-DllCXhxhGjoDTY30_9A1l0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"H. Lee Moffitt Cancer Center and Research Institute",[4],534,false,146,5,68508,164,156,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Breast Cancer",39,{"name":18,"count":19},"Prostate Cancer",26,{"name":21,"count":22},"Multiple Myeloma",23,{"name":24,"count":22},"Pancreatic Cancer",{"name":26,"count":27},"Lung Cancer",22,{"name":29,"count":30},"Smoking Cessation",17,{"name":32,"count":33},"Melanoma",16,{"name":35,"count":36},"Leukemia",15,[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02415621","Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer","2019-08-12","Abiraterone Acetate",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02721459","XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III\u002FIV Melanoma","2019-10-31","XL888",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03071406","Randomized Study of Nivolumab+Ipilimumab+\u002F- SBRT for Metastatic Merkel Cell Carcinoma","2022-04-06","Nivolumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03511196","Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","2022-06-22","Adaptive Androgen Deprivation Therapy",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03722407","Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion","2022-09-19","Ruxolitinib",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03923270","Radiotherapy and Durvalumab\u002FDurvalumab Combo (Tremelimumab\u002FOlaparid) for Small Cell Lung Cancer","2023-06-01","Durvalumab",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05108428","Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma","2023-10-09","Capecitabine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04151667","Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","2023-11-08","Daratumumab",{"nctId":79,"briefTitle":80,"date":81,"intervention":52},"NCT03377023","Phase I\u002FII Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer","2023-11-28",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT02638090","Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)","2024-01-21","Vorinostat",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,124,494,702,971,1067,1178,1263,1384,1440,1500,1542,1603,1705,1755,1810,1840,1888,1931,1960,1988,2016,2044,2072,2226,2327,2406,2432,2532,2582,2622,2648,2677,2709,2738,2768,2797,2834,2856,2888,2919,2941,2977,2995,3019,3037,3055,3073,3091,3109,3127,3145,3163,3181,3199,3217,3235,3263,3281,3305,3323,3341,3365,3383,3401,3425,3443,3468,3486,3504,3522,3546,3568,3591,3609,3634,3652,3670,3688,3706,3730,3748,3772,3790,3808,3832,3850,3880,3898,3920,3938,3956,3974,3992,4010,4028,4046,4064,4087,4105,4128,4146,4164,4197,4255,4306,4374,4416,4450,4491,4517,4539,4570,4604,4630,4665,4687,4715,4737,4762,4780,4803,4821,4839,4857,4875,4893,4916,4934,4952,4974,4998,5022,5040,5058,5076,5094,5117,5135,5153,5176,5194,5219,5237,5255,5273,5349,5375,5435,5454,5472,5490,5513,5537,5561,5583,5601,5619,5637,5710,5740,5764,5782,5807,5825,5849,5867,5885,5903,5921,6005,6043,6089,6143,6181,6223,6267,6306,6354,6385,6415,6441,6467,6499,6539,6565,6594,6620,6642,6664,6686,6708,6734,6756,6778,6800,6827,6863,6886,6907,6930,6953,6971,6989,7007,7025,7049,7077,7095,7118,7136,7154,7176,7194,7212,7239,7257,7275,7299,7317,7335,7358,7376,7394,7418,7436,7454,7477,7495,7522,7540,7558,7576,7594,7615,7633,7651,7676,7694,7712,7730,7752,7770,7788,7810,7828,7851,7869,7892,7914,7932,7960,7978,8003,8021,8039,8057,8075,8099,8117,8135,8158,8180,8198,8222,8240,8258,8284,8307,8325,8343,8361,8379,8406,8424,8448,8473,8491,8509,8531,8549,8567,8591,8609,8627,8648,8669,8690,8708,8734,8752,8775,8793,8811,8829,8847,8865,8883,8901,8919,8941,8959,8977,8995,9017,9042,9060,9078,9096,9114,9132,9154,9180,9198,9219,9237,9255,9273,9309,9331,9359,9391,9420,9444,9466,9498,9521,9539,9561,9579,9597,9615,9636,9657,9675,9693,9711,9729,9754,9772,9793,9811,9829,9847,9869,9887,9905,9926,9944,9966,9984,10012,10030,10048,10066,10091,10117,10138,10164,10182,10206,10224,10242,10260,10284,10302,10320,10338,10356,10374,10392,10415,10433,10458,10476,10498,10516,10538,10556,10581,10599,10617,10635,10653,10671,10696,10714,10732,10750,10768,10791,10809,10832,10856,10874,10897,10915,10933,10951,10976,11000,11024,11067,11111,11151,11184,11209,11240,11266,11295,11322,11344,11365,11392,11410,11428,11452,11470,11488,11510,11528,11546,11564,11582,11603,11628,11646,11669,11694,11712,11736,11757,11780,11803,11821],{"intervention":96,"totalTrials":97,"cells":98},"F-DCFPyL",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":120,"NA":122},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":97,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT03495427","PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w\u002F High Decipher Test Scores","RECRUITING",[90,91],"2029-02","2029-05","2019-12-18",60,[18,118],"Recurrent Prostate Cancer",[96],{"trials":121,"activeCount":101},[],{"trials":123,"activeCount":101},[],{"intervention":52,"totalTrials":125,"cells":126},28,{"EARLY_PHASE1":127,"PHASE1":190,"PHASE2":328,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":128,"activeCount":189,"soonestReadout":179},[129,144,161,174],{"nctId":130,"briefTitle":131,"status":111,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":141},"NCT04741997","Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",[88],"2026-07-22","2027-07","2021-05-24",50,[138,139,140],"Melanoma Stage III","Melanoma Stage IV","BRAF V600 Mutation",[142,143,52],"Encorafenib Pill","Binimetinib Pill",{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":155},"NCT02652455","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma","COMPLETED",[88],"2020-08-30","2016-03-08",11,[153,154],"Melanoma (Skin)","Skin Cancer",[52,156,157,158,159,160],"CD137","Cyclophosphamide","Fludarabine","TIL","Interleukin-2",{"nctId":162,"briefTitle":163,"status":147,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":97,"conditions":168,"interventions":171},"NCT05704933","Pilot Study of Nivolumab w\u002FIpilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases",[88],"2024-06-07","2024-08-20","2023-06-06",[169,170],"Metastatic Melanoma","Metastasis to Brain",[52,172,173],"Ipilimumab","Nivolumab + Relatlimab",{"nctId":175,"briefTitle":176,"status":177,"phases":178,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":186},"NCT03543969","Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma","ACTIVE_NOT_RECRUITING",[88],"2024-12-27","2026-12","2018-06-14",14,[153,154,184,185],"Skin Melanoma","Skin Carcinoma",[187,188,52],"Encorafenib","Binimetinib",2,{"trials":191,"activeCount":189,"soonestReadout":292},[192,204,216,227,246,260,274,288,302,315],{"nctId":193,"briefTitle":194,"status":147,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":202},"NCT04610671","Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC",[89],"2024-07-25","2020-10-26",21,[200,201],"Muscle-Invasive Bladder Carcinoma","Bladder Cancer",[203,52],"CG0070",{"nctId":205,"briefTitle":206,"status":147,"phases":207,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT02829931","Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas",[89],"2021-08-11","2022-11-22","2016-08-22",33,[213],"Malignant Glioma",[52,215,172],"Bevacizumab",{"nctId":217,"briefTitle":218,"status":147,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":182,"conditions":223,"interventions":226},"NCT03807765","Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases",[89],"2020-09-08","2025-03-18","2019-01-30",[224,225],"Metastatic Breast Cancer","Brain Metastases",[52],{"nctId":228,"briefTitle":229,"status":147,"phases":230,"primaryCompletion":231,"completion":208,"start":232,"enrollment":233,"conditions":234,"interventions":244},"NCT03758781","IRX-2 Regimen Combined With Nivolumab in Recurrent\u002FMetastatic Solid Tumors",[89],"2021-02-21","2019-02-13",12,[235,236,237,238,239,240,241,242,243],"Metastatic Cancer","Recurrent Cancer","Solid Tumor","Renal Cell Carcinoma","Urothelial Carcinoma","NSCLC","Squamous Cell Carcinoma","Non-Small Cell Lung Cancer","Squamous Cell Carcinoma of the Head and Neck",[245,52],"IRX 2",{"nctId":247,"briefTitle":248,"status":249,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":258},"NCT04610658","Immune Checkpoint Inhibition With Lurbinectedin Relapsed\u002FRecurrent SCLC","TERMINATED",[89],"2023-03-24","2020-11-23",9,[255,256,257],"Small-cell Lung Cancer","Relapsed Small Cell Lung Cancer","Recurrent Small Cell Lung Cancer",[52,172,259],"Lurbinectedin",{"nctId":261,"briefTitle":262,"status":147,"phases":263,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":272},"NCT03712943","Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer",[89],"2021-09-01","2024-01-18","2018-10-23",52,[269,270,271],"Colorectal Cancer","Metastatic Colorectal Cancer","Colon Cancer",[273,52],"Regorafenib",{"nctId":275,"briefTitle":276,"status":111,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":286},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[89],"2026-06","2027-12","2023-03-10",20,[283,284,285],"Non Small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer","Recurrent Non Small Cell Lung Cancer",[287,52,157,158,160],"Tumor-infiltrating Lymphocytes",{"nctId":289,"briefTitle":290,"status":177,"phases":291,"primaryCompletion":292,"completion":293,"start":294,"enrollment":198,"conditions":295,"interventions":300},"NCT03628209","Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma",[89],"2024-12-29","2026-04","2019-10-03",[296,297,298,299],"Osteosarcoma","Osteosarcoma in Children","Osteosarcoma Recurrent","Sarcoma",[52,301],"Azacitidine",{"nctId":303,"briefTitle":304,"status":147,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":281,"conditions":309,"interventions":314},"NCT03215810","Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer",[89],"2021-02-13","2023-06-09","2017-10-11",[242,310,241,311,312,313],"Metastatic Non-small Cell Lung Cancer","Advanced NSCLC","Adenosquamous Carcinoma","Adenocarcinomas",[52,157,158,160],{"nctId":316,"briefTitle":317,"status":147,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":324},"NCT01176474","Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC\u002F IV Melanoma",[89],"2020-08","2023-01-06","2010-08-13",73,[153],[325,52,326,327,172],"NY-ESO-1 157-165","gp100:280-288","Montanide ISA 51 vegetable grade",{"trials":329,"activeCount":487,"soonestReadout":51},[330,342,354,366,378,389,399,418,428,439,450,460,470,477],{"nctId":331,"briefTitle":332,"status":249,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT03663166","Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)",[89,90],"2021-10-22","2018-11-20",19,[338],"Carcinoma, Non-Small-Cell Lung",[340,341,52],"Platinum Based Chemotherapy","ipilimumab",{"nctId":343,"briefTitle":344,"status":345,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":101,"conditions":350,"interventions":352},"NCT02466568","Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung","WITHDRAWN",[89,90],"2019-07","2020-07","2018-07",[26,351],"Adenocarcinoma of the Lung",[52,353],"GM.CD40L Vaccine",{"nctId":355,"briefTitle":356,"status":147,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":365},"NCT02829918","Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers",[90],"2019-03-27","2023-05-24","2016-10-05",54,[363,364],"Biliary Tract Cancer","Biliary Tract Neoplasms",[52],{"nctId":367,"briefTitle":368,"status":177,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":376},"NCT04863885","Combination of Ipi\u002FNivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients",[89,90],"2025-09-12","2027-10","2021-04-30",46,[375],"Metastatic Urothelial Carcinoma",[172,52,377],"Sacituzumab govitecan",{"nctId":379,"briefTitle":380,"status":111,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT04562129","IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients",[90],"2026-07","2029-11","2020-09-24",29,[138,139,387],"Inoperable Disease",[160,172,52],{"nctId":79,"briefTitle":80,"status":177,"phases":390,"primaryCompletion":81,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":397},[89,90],"2026-08","2018-02-02",66,[283,395,396],"Lung Cancer, Nonsmall Cell","Non Small Cell Lung Cancer Metastatic",[52,172,398],"Nintedanib",{"nctId":400,"briefTitle":401,"status":147,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":416},"NCT03370276","Cetuximab & Nivolumab in Patients With Recurrent\u002FMetastatic Head & Neck Squamous Cell Carcinoma",[89,90],"2021-09-04","2023-12-23","2017-12-20",95,[408,409,410,411,412,413,414,415],"Squamous Cell Carcinoma of the Oropharynx","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Hypopharynx","Squamous Cell Carcinoma of the Paranasal Sinus","Head and Neck Squamous Cell Carcinoma","Squamous Cell Cancer","Head and Neck Carcinoma",[52,417],"Cetuximab",{"nctId":419,"briefTitle":420,"status":111,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":427},"NCT06295159","Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",[90],"2028-11","2024-05-17",90,[138,139,426,32],"Advanced Melanoma",[52,173,172],{"nctId":429,"briefTitle":430,"status":147,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":198,"conditions":435,"interventions":438},"NCT03043599","Ipilimumab + Nivolumab w\u002FThoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer",[89,90],"2018-10-26","2023-11-16","2017-02-13",[436,437],"Small Cell Lung Cancer","Extensive-stage Small Cell Lung Cancer",[172,52],{"nctId":440,"briefTitle":441,"status":177,"phases":442,"primaryCompletion":443,"completion":180,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT03543189","Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy",[89,90],"2026-06-01","2018-10-03",44,[18,447],"Prostate Disease",[52,449],"Androgen Deprivation Therapy",{"nctId":451,"briefTitle":452,"status":147,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":30,"conditions":457,"interventions":458},"NCT04526730","Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients",[90],"2024-03-26","2025-05-22","2020-12-22",[32],[459,52],"Tavo",{"nctId":461,"briefTitle":462,"status":249,"phases":463,"primaryCompletion":464,"completion":465,"start":466,"enrollment":182,"conditions":467,"interventions":468},"NCT03406715","Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)",[90],"2022-03-23","2022-05-16","2018-03-15",[436,26,256],[52,172,469],"Dendritic Cell based p53 Vaccine",{"nctId":49,"briefTitle":50,"status":177,"phases":471,"primaryCompletion":51,"completion":472,"start":473,"enrollment":136,"conditions":474,"interventions":476},[90],"2026-09-19","2017-03-14",[475,154],"Merkel Cell Carcinoma",[52,172],{"nctId":478,"briefTitle":479,"status":147,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":22,"conditions":484,"interventions":485},"NCT03834623","Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma",[90],"2021-06-29","2021-08-04","2019-05-14",[32],[486,52],"CC-122",6,{"trials":489,"activeCount":101},[],{"trials":491,"activeCount":101},[],{"trials":493,"activeCount":101},[],{"intervention":495,"totalTrials":30,"cells":496},"Pembrolizumab",{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":547,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":498,"activeCount":101},[],{"trials":500,"activeCount":97,"soonestReadout":505},[501,515,528,537],{"nctId":502,"briefTitle":503,"status":177,"phases":504,"primaryCompletion":505,"completion":391,"start":506,"enrollment":507,"conditions":508,"interventions":511},"NCT06236425","TBio-4101 and Pembro wi\u002F or w\u002Fo Chemo in Recurrent\u002FMetastatic HNSCC",[89],"2025-04-09","2024-03-14",7,[509,510],"Squamous Cell Carcinoma of Head and Neck","Metastatic Squamous Cell Carcinoma",[512,495,513,157,158,514],"TBio-4101","Platinum based chemotherapy","Aldesleukin",{"nctId":516,"briefTitle":517,"status":147,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":198,"conditions":522,"interventions":526},"NCT03426891","Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma",[89],"2021-10-18","2023-06-28","2018-03-16",[523,524,525],"Glioblastoma","Brain Tumor","GBM",[495,86,527],"Temozolomide",{"nctId":529,"briefTitle":530,"status":147,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":189,"conditions":534,"interventions":536},"NCT06378047","Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer",[89],"2025-09-15","2024-04-10",[24,535],"Locally Advanced Pancreatic Cancer",[495],{"nctId":538,"briefTitle":539,"status":147,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT02313272","Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas",[89],"2018-09-13","2021-08-09","2015-07-28",32,[213],[495,215],{"trials":548,"activeCount":487,"soonestReadout":85},[549,560,575,588,599,608,623,634,640,651,660,673,685],{"nctId":550,"briefTitle":551,"status":552,"phases":553,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":558},"NCT06219174","Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)","SUSPENDED",[89,90],"2029-08","2024-08-07",45,[283,26],[495,559],"Difluoromethylornithine",{"nctId":561,"briefTitle":562,"status":111,"phases":563,"primaryCompletion":564,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":570},"NCT06109467","Neratinib In Combination With Chemotherapy\u002FTrastuzumab\u002FPembrolizumab In HER2 Gastroesophageal Cancer",[90],"2028-04","2024-01-12",36,[568,569],"GastroEsophageal Cancer","Gastric Cancer",[571,572,573,574,495],"Neratinib","Trastuzumab","Oxaliplatin","5-Fluorouracil + leucovorin",{"nctId":576,"briefTitle":577,"status":147,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":586},"NCT03332498","Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",[89,90],"2019-12-05","2021-09-09","2018-01-24",40,[271,269,584,585],"Colorectal Carcinoma","Colon Disease",[495,587],"Ibrutinib",{"nctId":589,"briefTitle":590,"status":147,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":598},"NCT02964078","Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer",[90],"2019-03-26","2025-10-30","2017-04-25",27,[597],"Kidney Cancer",[495,160],{"nctId":600,"briefTitle":601,"status":249,"phases":602,"primaryCompletion":603,"completion":603,"start":604,"enrollment":9,"conditions":605,"interventions":607},"NCT03514017","Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia",[90],"2023-05-16","2019-05-31",[606],"Chronic Lymphocytic Leukemia",[495,587],{"nctId":609,"briefTitle":610,"status":111,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT06745882","Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w\u002F NSCLC",[90],"2030-01","2025-06-13",318,[616],"Non-small Cell Lung Cancer",[618,619,620,495,621,622],"Cisplatin","Carboplatin","Pemetrexed","Abraxane","Paclitaxel",{"nctId":624,"briefTitle":625,"status":147,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT02440425","Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer",[90],"2020-04","2021-05-27","2015-10-20",42,[632],"Ovarian Cancer",[495,622],{"nctId":83,"briefTitle":84,"status":177,"phases":635,"primaryCompletion":85,"completion":382,"start":636,"enrollment":637,"conditions":638,"interventions":639},[89,90],"2016-03-22",120,[26,616],[86,495],{"nctId":641,"briefTitle":642,"status":111,"phases":643,"primaryCompletion":180,"completion":279,"start":644,"enrollment":645,"conditions":646,"interventions":649},"NCT05524935","Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma",[90],"2022-10-11",37,[647,648],"Uveal Melanoma","Ocular Melanoma",[495,650],"Olaparib",{"nctId":652,"briefTitle":653,"status":111,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":30,"conditions":657,"interventions":659},"NCT07007273","Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma",[90],"2030-07","2025-06-20",[658],"Cutaneous Sarcoma",[495],{"nctId":661,"briefTitle":662,"status":147,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":281,"conditions":667,"interventions":671},"NCT03290079","Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors",[90],"2023-01-10","2024-05-13","2017-12-15",[668,669,670],"Neuroendocrine Tumors","Neuroendocrine Carcinoma","Neuroendocrine Cancer",[495,672],"Lenvatinib",{"nctId":674,"briefTitle":675,"status":552,"phases":676,"primaryCompletion":677,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":683},"NCT06860386","Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC",[90],"2026-09","2028-02","2025-02-25",75,[238,682],"Clear Cell Renal Cell Carcinoma",[495,684],"Axitinib",{"nctId":686,"briefTitle":687,"status":177,"phases":688,"primaryCompletion":689,"completion":677,"start":690,"enrollment":19,"conditions":691,"interventions":694},"NCT04869137","Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma",[90],"2025-09-13","2021-05-28",[475,692,693],"Neuroendocrine Carcinoma of the Skin","Trabecular Carcinoma of the Skin",[695,495],"Lenvatinib Oral Product",{"trials":697,"activeCount":101},[],{"trials":699,"activeCount":101},[],{"trials":701,"activeCount":101},[],{"intervention":157,"totalTrials":22,"cells":703},{"EARLY_PHASE1":704,"PHASE1":710,"PHASE2":813,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":705,"activeCount":101},[706],{"nctId":145,"briefTitle":146,"status":147,"phases":707,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":708,"interventions":709},[88],[153,154],[52,156,157,158,159,160],{"trials":711,"activeCount":812,"soonestReadout":505},[712,724,738,742,762,766,775,790,794],{"nctId":713,"briefTitle":714,"status":111,"phases":715,"primaryCompletion":716,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT06193486","Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC",[89],"2029-01-13","2033-12-13","2024-10-26",30,[721],"Metastatic Castration-resistant Prostate Cancer",[723,158,157],"MSGV1-PSCA-8T28Z",{"nctId":725,"briefTitle":726,"status":147,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":736},"NCT05694364","Dose Escalation\u002FDose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies",[89],"2024-04-18","2023-01-25",3,[606,732,733,734,735],"Mantle Cell Lymphoma","Acute Lymphoblastic Leukemia","Diffuse Large B Cell Lymphoma","Triple Negative Breast Cancer Malignancies",[158,157,737],"PRGN-3007",{"nctId":502,"briefTitle":503,"status":177,"phases":739,"primaryCompletion":505,"completion":391,"start":506,"enrollment":507,"conditions":740,"interventions":741},[89],[509,510],[512,495,513,157,158,514],{"nctId":743,"briefTitle":744,"status":147,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":544,"conditions":749,"interventions":757},"NCT03018223","Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT",[89],"2018-12-15","2021-03-18","2017-01-31",[750,751,752,753,754,755,756,21],"Non-Hodgkin's Lymphoma","Acute Leukemia in Remission","Chronic Myeloid Leukemia","Primary Myelofibrosis","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndromes","Hodgkin Lymphoma",[158,758,157,759,760,761],"Busulfan","Sirolimus","Mycophenolate mofetil","Granulocyte-colony stimulating factor",{"nctId":275,"briefTitle":276,"status":111,"phases":763,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":764,"interventions":765},[89],[283,284,285],[287,52,157,158,160],{"nctId":767,"briefTitle":768,"status":147,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":253,"conditions":773,"interventions":774},"NCT04052334","Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma",[89],"2023-05-26","2023-06-16","2019-09-27",[299],[159,160,158,157],{"nctId":776,"briefTitle":777,"status":147,"phases":778,"primaryCompletion":779,"completion":780,"start":209,"enrollment":30,"conditions":781,"interventions":789},"NCT05628883","Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed\u002FRefractory Melanoma",[89],"2024-12-03","2025-03-06",[169,782,783,784,785,648,647,786,787,788],"Unresectable Melanoma","Acral Melanoma","Mucosal Melanoma","Cutaneous Melanoma","Iris Melanoma","Conjunctival Melanoma","Non-Cutaneous Melanoma",[512,157,158,160],{"nctId":303,"briefTitle":304,"status":147,"phases":791,"primaryCompletion":306,"completion":307,"start":308,"enrollment":281,"conditions":792,"interventions":793},[89],[242,310,241,311,312,313],[52,157,158,160],{"nctId":795,"briefTitle":796,"status":111,"phases":797,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":800,"interventions":802},"NCT07194044","Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes",[89],"2030-10","2026-02-05",[801],"Metastatic Ewing Sarcoma",[803,804,157,805,806,807,808,809,527,810,811],"Vincristine","Doxorubicin","Ifosfamide","Actinomycin","Irinotecan","Cabozantinib","Topotecan","Etoposide","Liposomal doxorubicin",4,{"trials":814,"activeCount":189,"soonestReadout":391},[815,826,840,850,863,877,889,899,910,923,933,942,953],{"nctId":816,"briefTitle":817,"status":147,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":823},"NCT00601796","Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer",[90],"2012-06","2006-10",24,[26],[824,157,825],"Vaccine Treatment","All-trans retinoic acid",{"nctId":827,"briefTitle":828,"status":147,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":837},"NCT00005797","Bone Marrow Transplant in Treating Patients With Hematologic Cancers",[90],"2007-07","1993-03",125,[834,35,835,755,836],"Chronic Myeloproliferative Disorders","Multiple Myeloma and Malignant Plasma Cell Neoplasms","Myelodysplastic\u002FMyeloproliferative Neoplasms",[838,157,839],"busulfan","VP-16",{"nctId":841,"briefTitle":842,"status":147,"phases":843,"primaryCompletion":844,"completion":830,"start":845,"enrollment":846,"conditions":847,"interventions":848},"NCT00005798","Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer",[90],"2001-08","1995-07",209,[15],[619,157,849],"Thiotepa",{"nctId":851,"briefTitle":852,"status":147,"phases":853,"primaryCompletion":820,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":859},"NCT00005613","Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease",[90],"2010-06","1996-03",147,[858],"Lymphoma",[860,861,862],"cyclophosphamide","etoposide","BCNU",{"nctId":864,"briefTitle":865,"status":249,"phases":866,"primaryCompletion":830,"completion":830,"start":867,"conditions":868,"interventions":871},"NCT00005852","Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant",[90],"1996-06",[834,869,35,858,870,755],"Graft Versus Host Disease","Multiple Myeloma and Plasma Cell Neoplasm",[872,873,874,860,875,876],"anti-thymocyte globulin","filgrastim","muromonab-CD3","cyclosporine","methylprednisolone",{"nctId":878,"briefTitle":879,"status":147,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":886},"NCT01432600","Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide",[89,90],"2016-08","2011-11",80,[885],"Myeloma",[887,888,157],"Pomalidomide","Dexamethasone",{"nctId":890,"briefTitle":891,"status":249,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"conditions":895,"interventions":896},"NCT00005641","Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation",[90],"2000-09","1997-09",[834,869,35,870,755],[872,838,860,875,897,898,876],"leucovorin calcium","methotrexate",{"nctId":900,"briefTitle":901,"status":249,"phases":902,"primaryCompletion":903,"completion":903,"start":904,"enrollment":730,"conditions":905,"interventions":906},"NCT00005612","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer",[89,90],"2004-02","1999-08",[632],[873,907,860,861,908,909],"carboplatin","paclitaxel","topotecan hydrochloride",{"nctId":911,"briefTitle":912,"status":147,"phases":913,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":919},"NCT00101101","Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma",[90],"2012-10","2021-06-14","2004-07",43,[858],[157,804,803,920,888,921,922],"Prednisone","Autologous Tumor Cell-Based Vaccine","IL-2",{"nctId":924,"briefTitle":925,"status":147,"phases":926,"primaryCompletion":927,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":932},"NCT00005622","Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders",[90],"2005-09","2009-07","1996-05",72,[834,35,835,755,836],[860],{"nctId":934,"briefTitle":935,"status":111,"phases":936,"primaryCompletion":114,"completion":937,"start":938,"enrollment":566,"conditions":939,"interventions":940},"NCT06961357","Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma",[89,90],"2030-05","2025-12-03",[32],[157,158,160,941],"TIL Product",{"nctId":943,"briefTitle":944,"status":147,"phases":945,"primaryCompletion":946,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":951},"NCT00750815","Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)",[89,90],"2012-12","2013-05","2008-09",58,[21],[157,952],"Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone",{"nctId":954,"briefTitle":955,"status":177,"phases":956,"primaryCompletion":391,"completion":957,"start":958,"enrollment":233,"conditions":959,"interventions":961},"NCT04388839","Evolutionary Therapy for Rhabdomyosarcoma",[90],"2027-08","2020-12-29",[960],"Rhabdomyosarcoma",[803,157,962,963,964],"Vinorelbine","Actinomycin D","Cyclophosphamide Pill",{"trials":966,"activeCount":101},[],{"trials":968,"activeCount":101},[],{"trials":970,"activeCount":101},[],{"intervention":172,"totalTrials":36,"cells":972},{"EARLY_PHASE1":973,"PHASE1":979,"PHASE2":1003,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":974,"activeCount":101},[975],{"nctId":162,"briefTitle":163,"status":147,"phases":976,"primaryCompletion":165,"completion":166,"start":167,"enrollment":97,"conditions":977,"interventions":978},[88],[169,170],[52,172,173],{"trials":980,"activeCount":101},[981,985,989,999],{"nctId":205,"briefTitle":206,"status":147,"phases":982,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":983,"interventions":984},[89],[213],[52,215,172],{"nctId":247,"briefTitle":248,"status":249,"phases":986,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":987,"interventions":988},[89],[255,256,257],[52,172,259],{"nctId":990,"briefTitle":991,"status":147,"phases":992,"primaryCompletion":993,"completion":994,"start":995,"enrollment":30,"conditions":996,"interventions":997},"NCT02032810","Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III\u002FIV Melanoma",[89],"2017-09-06","2019-09-25","2014-01-07",[32,154],[998,172],"Panobinostat",{"nctId":316,"briefTitle":317,"status":147,"phases":1000,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":1001,"interventions":1002},[89],[153],[325,52,326,327,172],{"trials":1004,"activeCount":487,"soonestReadout":51},[1005,1009,1013,1017,1021,1025,1029,1038,1042],{"nctId":331,"briefTitle":332,"status":249,"phases":1006,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":1007,"interventions":1008},[89,90],[338],[340,341,52],{"nctId":367,"briefTitle":368,"status":177,"phases":1010,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":1011,"interventions":1012},[89,90],[375],[172,52,377],{"nctId":379,"briefTitle":380,"status":111,"phases":1014,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":1015,"interventions":1016},[90],[138,139,387],[160,172,52],{"nctId":79,"briefTitle":80,"status":177,"phases":1018,"primaryCompletion":81,"completion":391,"start":392,"enrollment":393,"conditions":1019,"interventions":1020},[89,90],[283,395,396],[52,172,398],{"nctId":419,"briefTitle":420,"status":111,"phases":1022,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":1023,"interventions":1024},[90],[138,139,426,32],[52,173,172],{"nctId":429,"briefTitle":430,"status":147,"phases":1026,"primaryCompletion":432,"completion":433,"start":434,"enrollment":198,"conditions":1027,"interventions":1028},[89,90],[436,437],[172,52],{"nctId":1030,"briefTitle":1031,"status":111,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":482,"enrollment":1035,"conditions":1036,"interventions":1037},"NCT04996823","Axitinib + Ipilimumab in Advanced Melanoma",[90],"2026-08-20","2027-03-29",25,[32],[172,684],{"nctId":461,"briefTitle":462,"status":249,"phases":1039,"primaryCompletion":464,"completion":465,"start":466,"enrollment":182,"conditions":1040,"interventions":1041},[90],[436,26,256],[52,172,469],{"nctId":49,"briefTitle":50,"status":177,"phases":1043,"primaryCompletion":51,"completion":472,"start":473,"enrollment":136,"conditions":1044,"interventions":1045},[90],[475,154],[52,172],{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":101},[],{"trials":1051,"activeCount":101},[1052],{"nctId":1053,"briefTitle":1054,"status":147,"phases":1055,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":1059,"conditions":1060,"interventions":1061},"NCT01701674","Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",[93],"2016-04-21","2025-08-21","2012-10-09",13,[169],[172,1062,1063,1064,1065,1066],"Administration of Lymphodepletion","Cyclophosphamide as Part of Lymphodepletion","Fludarabine as Part of Lymphodepletion","High Dose IL-2","Adoptive Cell Therapy with TIL",{"intervention":158,"totalTrials":182,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1075,"PHASE2":1121,"PHASE3":1162,"PHASE4":1164,"NA":1176},{"trials":1070,"activeCount":101},[1071],{"nctId":145,"briefTitle":146,"status":147,"phases":1072,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":1073,"interventions":1074},[88],[153,154],[52,156,157,158,159,160],{"trials":1076,"activeCount":730,"soonestReadout":505},[1077,1081,1085,1089,1101,1105,1109,1113,1117],{"nctId":713,"briefTitle":714,"status":111,"phases":1078,"primaryCompletion":716,"completion":717,"start":718,"enrollment":719,"conditions":1079,"interventions":1080},[89],[721],[723,158,157],{"nctId":725,"briefTitle":726,"status":147,"phases":1082,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":1083,"interventions":1084},[89],[606,732,733,734,735],[158,157,737],{"nctId":502,"briefTitle":503,"status":177,"phases":1086,"primaryCompletion":505,"completion":391,"start":506,"enrollment":507,"conditions":1087,"interventions":1088},[89],[509,510],[512,495,513,157,158,514],{"nctId":1090,"briefTitle":1091,"status":147,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT00313508","Dendritic Cell Vaccination During Lymphoid Reconstruction",[89],"2012-03","2006-02",18,[1097,153],"Intraocular Melanoma",[1099,158,1100],"Autologous Dendritic Cells","Autologous Lymphocyte",{"nctId":743,"briefTitle":744,"status":147,"phases":1102,"primaryCompletion":746,"completion":747,"start":748,"enrollment":544,"conditions":1103,"interventions":1104},[89],[750,751,752,753,754,755,756,21],[158,758,157,759,760,761],{"nctId":275,"briefTitle":276,"status":111,"phases":1106,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":1107,"interventions":1108},[89],[283,284,285],[287,52,157,158,160],{"nctId":767,"briefTitle":768,"status":147,"phases":1110,"primaryCompletion":770,"completion":771,"start":772,"enrollment":253,"conditions":1111,"interventions":1112},[89],[299],[159,160,158,157],{"nctId":776,"briefTitle":777,"status":147,"phases":1114,"primaryCompletion":779,"completion":780,"start":209,"enrollment":30,"conditions":1115,"interventions":1116},[89],[169,782,783,784,785,648,647,786,787,788],[512,157,158,160],{"nctId":303,"briefTitle":304,"status":147,"phases":1118,"primaryCompletion":306,"completion":307,"start":308,"enrollment":281,"conditions":1119,"interventions":1120},[89],[242,310,241,311,312,313],[52,157,158,160],{"trials":1122,"activeCount":97,"soonestReadout":114},[1123,1148,1158],{"nctId":1124,"briefTitle":1125,"status":147,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1146},"NCT04191187","Reduced Intensity Flu\u002FMel\u002FTBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies",[90],"2024-02-11","2024-02-14","2019-12-06",34,[1132,733,1133,1134,1135,755,1136,1137,1138,732,756,1139,1140,1141,1142,1143,1144,1145],"Acute Myeloid Leukemia","Biphenotypic Acute Leukemia","Undifferentiated Leukemia","Prolymphocytic Leukemia","Chronic Myelogenous Leukemia","Myeloproliferative Neoplasm","Relapsed Large Cell Lymphoma","Burkitt Lymphoma","Relapsed T-Cell Lymphoma","Relapsed Chronic Lymphocytic Leukemia","Relapsed Small Lymphocytic Lymphoma","Relapsed Marginal B-cell Lymphoma","Relapsed Follicular Lymphoma","Lymphoplasmacytic Lymphoma",[158,1147],"Melphalan",{"nctId":1149,"briefTitle":1150,"status":147,"phases":1151,"primaryCompletion":1152,"completion":483,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT00948922","Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma",[90],"2017-04-20","2009-06-18",124,[21],[1157,1147,158],"Bortezomib",{"nctId":934,"briefTitle":935,"status":111,"phases":1159,"primaryCompletion":114,"completion":937,"start":938,"enrollment":566,"conditions":1160,"interventions":1161},[89,90],[32],[157,158,160,941],{"trials":1163,"activeCount":101},[],{"trials":1165,"activeCount":101},[1166],{"nctId":1167,"briefTitle":1168,"status":147,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":930,"conditions":1172,"interventions":1175},"NCT00361140","Busulfan Safety\u002FEfficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)",[92],"2012-02","2005-08",[755,1173,1174,885,858],"Myeloproliferative Disorders","Leukemia, Lymphocytic",[758,158],{"trials":1177,"activeCount":101},[],{"intervention":572,"totalTrials":507,"cells":1179},{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1195,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1181,"activeCount":101},[],{"trials":1183,"activeCount":97,"soonestReadout":293},[1184],{"nctId":1185,"briefTitle":1186,"status":111,"phases":1187,"primaryCompletion":293,"completion":180,"start":1188,"enrollment":125,"conditions":1189,"interventions":1191},"NCT05378464","Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab \u002FTrastuzumab in Patients w\u002F Metastatic HER2+ Breast Cancer",[89],"2022-05-31",[1190],"HER2-positive Breast Cancer",[1192,572,1193,1194],"Dendritic Cell (DC1) Vaccine","Pepinemab","T-Cell therapy",{"trials":1196,"activeCount":730,"soonestReadout":1251},[1197,1210,1221,1225,1237,1247],{"nctId":1198,"briefTitle":1199,"status":147,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1208},"NCT03112590","Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer",[89,90],"2021-03-31","2023-02-20","2017-06-23",51,[15,1206,1207,1190],"Breast Cancer, Male","Breast Cancer Female",[1209,622,572],"Interferon-gamma",{"nctId":1211,"briefTitle":1212,"status":345,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":101,"conditions":1216,"interventions":1217},"NCT02336984","A Phase I\u002FII Trial of HER-2\u002FNeu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS",[89,90],"2016-04-04","2014-06",[15],[1218,1219,1220],"HER-2 pulsed DC1","trastuzumab","pertuzumab",{"nctId":561,"briefTitle":562,"status":111,"phases":1222,"primaryCompletion":564,"completion":564,"start":565,"enrollment":566,"conditions":1223,"interventions":1224},[90],[568,569],[571,572,573,574,495],{"nctId":1226,"briefTitle":1227,"status":177,"phases":1228,"primaryCompletion":1229,"completion":1230,"start":1231,"enrollment":211,"conditions":1232,"interventions":1235},"NCT04588545","Radiation Therapy Followed by Intrathecal Trastuzumab\u002FPertuzumab in HER2+ Breast Leptomeningeal Disease",[89,90],"2027-04","2027-05","2020-12-10",[1190,1233,1234],"Leptomeningeal Metastasis","Leptomeningeal Disease",[1236,572],"Pertuzumab",{"nctId":1238,"briefTitle":1239,"status":147,"phases":1240,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":36,"conditions":1244,"interventions":1245},"NCT02139358","Phase I\u002FIIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer",[89,90],"2018-04-24","2020-03-16","2014-09-05",[15],[1246,572,1236],"Gemcitabine",{"nctId":1248,"briefTitle":1249,"status":111,"phases":1250,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1256},"NCT05325632","Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",[90],"2027-02","2027-09","2021-10-28",53,[1190],[1218,572,1236,622],{"trials":1258,"activeCount":101},[],{"trials":1260,"activeCount":101},[],{"trials":1262,"activeCount":101},[],{"intervention":1264,"totalTrials":1265,"cells":1266},"Docetaxel",10,{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1284,"PHASE3":1368,"PHASE4":1380,"NA":1382},{"trials":1268,"activeCount":101},[],{"trials":1270,"activeCount":97,"soonestReadout":1275},[1271],{"nctId":1272,"briefTitle":1273,"status":177,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":198,"conditions":1278,"interventions":1282},"NCT03611738","Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC",[89],"2025-04-28","2027-03","2019-02-01",[616,26,1279,1280,284,1281],"Non-small Cell Lung Cancer Metastatic","Non-small Cell Lung Cancer Stage IIIB","EGFR Negative Non-Small Cell Lung Cancer",[1283,1264],"Ceritinib",{"trials":1285,"activeCount":189,"soonestReadout":1332},[1286,1296,1306,1317,1328,1341,1351,1358],{"nctId":1287,"briefTitle":1288,"status":147,"phases":1289,"primaryCompletion":914,"completion":914,"start":1290,"enrollment":556,"conditions":1291,"interventions":1294},"NCT00504257","Avastin in Combination With Docetaxel in Ovarian\u002FFallopian Tube\u002FPeritoneum Carcinoma",[90],"2007-03",[1292,632,1293],"Fallopian Tube Cancer","Malignant Tumor of Peritoneum",[1295,1264],"Avastin",{"nctId":1297,"briefTitle":1298,"status":147,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":445,"conditions":1302,"interventions":1303},"NCT00231465","Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer",[90],"2012-08","2003-07",[242],[1304,1305],"docetaxel","ZD1839",{"nctId":1307,"briefTitle":1308,"status":249,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":630,"conditions":1312,"interventions":1315},"NCT00216008","Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.",[90],"2007-02","2005-07",[1313,1314],"Esophageal Adenocarcinomas","Adenocarcinomas of the Gastroesophageal Junction",[1304,1316],"cisplatin",{"nctId":1318,"briefTitle":1319,"status":177,"phases":1320,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1035,"conditions":1323,"interventions":1325},"NCT06734130","Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer",[90],"2029-01","2025-01-10",[1324],"Metastatic Castration Sensitive Prostate Cancer",[1326,1327,1264],"Luteinizing Hormone-Releasing Hormone (LHRH) analog","Androgen Receptor Signal Inhibitor",{"nctId":1329,"briefTitle":1330,"status":177,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":544,"conditions":1335,"interventions":1337},"NCT05189457","First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer",[90],"2027-07-15","2028-07","2022-01-25",[18,1336],"Stage IV Prostate Cancer",[1338,1339,1264,1340],"Luteinizing Hormone Releasing Hormone","New Hormonal Agent","Tislelizumab",{"nctId":1342,"briefTitle":1343,"status":249,"phases":1344,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":253,"conditions":1348,"interventions":1349},"NCT01754623","GTX-RT in Borderline Resectable Pancreatic Cancer",[90],"2014-09","2014-10","2013-02",[24],[72,1246,1264,1350],"5-Fluorouracil",{"nctId":1352,"briefTitle":1353,"status":147,"phases":1354,"primaryCompletion":1355,"completion":1355,"start":903,"enrollment":1254,"conditions":1356,"interventions":1357},"NCT00215930","The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer",[90],"2009-10",[338],[962,1264,1246,619],{"nctId":1359,"briefTitle":1360,"status":147,"phases":1361,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":556,"conditions":1365,"interventions":1366},"NCT00005800","Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer",[90],"2006-01","2012-05","1999-04",[15],[1367,1264,804],"Filgrastim",{"trials":1369,"activeCount":101},[1370],{"nctId":1371,"briefTitle":1372,"status":147,"phases":1373,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1379},"NCT00499109","Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC",[91],"2013-04","2013-11","2007-05",275,[242],[1264,962,619,1246],{"trials":1381,"activeCount":101},[],{"trials":1383,"activeCount":101},[],{"intervention":160,"totalTrials":253,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1392,"PHASE2":1410,"PHASE3":1434,"PHASE4":1436,"NA":1438},{"trials":1387,"activeCount":101},[1388],{"nctId":145,"briefTitle":146,"status":147,"phases":1389,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":1390,"interventions":1391},[88],[153,154],[52,156,157,158,159,160],{"trials":1393,"activeCount":97,"soonestReadout":278},[1394,1398,1402,1406],{"nctId":275,"briefTitle":276,"status":111,"phases":1395,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":1396,"interventions":1397},[89],[283,284,285],[287,52,157,158,160],{"nctId":767,"briefTitle":768,"status":147,"phases":1399,"primaryCompletion":770,"completion":771,"start":772,"enrollment":253,"conditions":1400,"interventions":1401},[89],[299],[159,160,158,157],{"nctId":776,"briefTitle":777,"status":147,"phases":1403,"primaryCompletion":779,"completion":780,"start":209,"enrollment":30,"conditions":1404,"interventions":1405},[89],[169,782,783,784,785,648,647,786,787,788],[512,157,158,160],{"nctId":303,"briefTitle":304,"status":147,"phases":1407,"primaryCompletion":306,"completion":307,"start":308,"enrollment":281,"conditions":1408,"interventions":1409},[89],[242,310,241,311,312,313],[52,157,158,160],{"trials":1411,"activeCount":189,"soonestReadout":382},[1412,1422,1426,1430],{"nctId":1413,"briefTitle":1414,"status":147,"phases":1415,"primaryCompletion":1416,"completion":819,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1420},"NCT00031564","Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2",[90],"2005-06","2000-05",49,[597],[160,1421],"B7-1",{"nctId":589,"briefTitle":590,"status":147,"phases":1423,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":1424,"interventions":1425},[90],[597],[495,160],{"nctId":379,"briefTitle":380,"status":111,"phases":1427,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":1428,"interventions":1429},[90],[138,139,387],[160,172,52],{"nctId":934,"briefTitle":935,"status":111,"phases":1431,"primaryCompletion":114,"completion":937,"start":938,"enrollment":566,"conditions":1432,"interventions":1433},[89,90],[32],[157,158,160,941],{"trials":1435,"activeCount":101},[],{"trials":1437,"activeCount":101},[],{"trials":1439,"activeCount":101},[],{"intervention":62,"totalTrials":9,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1457,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1443,"activeCount":101},[],{"trials":1445,"activeCount":101},[1446],{"nctId":1447,"briefTitle":1448,"status":147,"phases":1449,"primaryCompletion":1450,"completion":1451,"start":1452,"enrollment":151,"conditions":1453,"interventions":1455},"NCT01702064","Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients",[89],"2016-10-17","2019-01-09","2013-02-21",[1454],"Chronic Phase Chronic Myeloid Leukemia",[1456,62],"Nilotinib",{"trials":1458,"activeCount":730,"soonestReadout":61},[1459,1470,1480,1489],{"nctId":1460,"briefTitle":1461,"status":177,"phases":1462,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":821,"conditions":1466,"interventions":1468},"NCT03610971","Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",[90],"2025-09-25","2026-10","2019-11-19",[1454,1467],"Chronic Myeloid Leukemia, Chronic Phase",[62,1469],"BCR-ABL Tyrosine Kinase Inhibitor",{"nctId":1471,"briefTitle":1472,"status":147,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":136,"conditions":1477,"interventions":1479},"NCT01776723","A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib",[89,90],"2018-11-28","2022-05-10","2013-02-20",[1478],"Myelomonocytic Leukemia",[62],{"nctId":1481,"briefTitle":1482,"status":111,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":637,"conditions":1486,"interventions":1488},"NCT06660355","Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy",[90],"2028-12","2024-12-23",[1487],"Chronic Graft-versus-host Disease (cGVHD)",[62,920],{"nctId":59,"briefTitle":60,"status":177,"phases":1490,"primaryCompletion":61,"completion":443,"start":1491,"enrollment":385,"conditions":1492,"interventions":1493},[90],"2019-08-28",[754,35],[62],{"trials":1495,"activeCount":101},[],{"trials":1497,"activeCount":101},[],{"trials":1499,"activeCount":101},[],{"intervention":377,"totalTrials":730,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1503,"activeCount":101},[],{"trials":1505,"activeCount":101},[],{"trials":1507,"activeCount":730,"soonestReadout":370},[1508,1522,1526],{"nctId":1509,"briefTitle":1510,"status":111,"phases":1511,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":1513,"interventions":1514},"NCT06409390","Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer",[90],"2024-08-14",[224],[1515,1516,1517,377,1518,1519,1520,1521],"Taxotere","Cytoxan","Trastuzumab deruxtecan","Xeloda","Fulvestrant","Ribociclib","Abemaciclib",{"nctId":367,"briefTitle":368,"status":177,"phases":1523,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":1524,"interventions":1525},[89,90],[375],[172,52,377],{"nctId":1527,"briefTitle":1528,"status":111,"phases":1529,"primaryCompletion":1251,"completion":1251,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1534},"NCT06238921","Sacituzumab Govitecan and Zimberelimab w\u002FSRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases",[89,90],"2024-12-19",31,[15,1533],"Triple Negative Breast Cancer",[1535,377],"Zimberelimab",{"trials":1537,"activeCount":101},[],{"trials":1539,"activeCount":101},[],{"trials":1541,"activeCount":101},[],{"intervention":803,"totalTrials":487,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1575,"PHASE3":1585,"PHASE4":1599,"NA":1601},{"trials":1545,"activeCount":101},[],{"trials":1547,"activeCount":97,"soonestReadout":798},[1548,1560,1571],{"nctId":1549,"briefTitle":1550,"status":147,"phases":1551,"primaryCompletion":1552,"completion":1553,"start":1554,"enrollment":19,"conditions":1555,"interventions":1558},"NCT01528046","Metformin in Children With Relapsed or Refractory Solid Tumors",[89],"2019-09-26","2020-02-03","2012-09-24",[1556,1557],"Solid Tumors","Primary Brain Tumors",[803,807,527,1559],"Metformin",{"nctId":1561,"briefTitle":1562,"status":147,"phases":1563,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":182,"conditions":1567,"interventions":1568},"NCT01324180","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",[89],"2016-11-16","2017-07-27","2011-07-18",[733],[1559,803,888,1569,804,1570],"PEG-asparaginase","Intrathecal chemotherapy",{"nctId":795,"briefTitle":796,"status":111,"phases":1572,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":1573,"interventions":1574},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":1576,"activeCount":97,"soonestReadout":391},[1577,1581],{"nctId":911,"briefTitle":912,"status":147,"phases":1578,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":1579,"interventions":1580},[90],[858],[157,804,803,920,888,921,922],{"nctId":954,"briefTitle":955,"status":177,"phases":1582,"primaryCompletion":391,"completion":957,"start":958,"enrollment":233,"conditions":1583,"interventions":1584},[90],[960],[803,157,962,963,964],{"trials":1586,"activeCount":101},[1587],{"nctId":1588,"briefTitle":1589,"status":249,"phases":1590,"primaryCompletion":1300,"completion":1300,"start":1591,"enrollment":424,"conditions":1592,"interventions":1593},"NCT00215943","Phase III Randomized Trial of Thalidomide\u002FDexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)",[91],"2003-06",[21],[1594,1595,1596,1597,1598],"zoledronic acid","dexamethasone","thalidomide","vincristine","adriamycin",{"trials":1600,"activeCount":101},[],{"trials":1602,"activeCount":101},[],{"intervention":622,"totalTrials":151,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1635,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1606,"activeCount":101},[],{"trials":1608,"activeCount":101},[1609,1620],{"nctId":1610,"briefTitle":1611,"status":147,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":821,"conditions":1616,"interventions":1618},"NCT01256268","Carboplatin\u002FTaxol\u002FRidaforolimus in Endometrial, Ovarian and Solids",[89],"2016-02-03","2017-08-03","2011-06-13",[1617,632],"Endometrial Cancer",[1619,622,907],"Ridaforolimus",{"nctId":1621,"briefTitle":1622,"status":147,"phases":1623,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1633},"NCT03177291","Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC",[89],"2021-05-09","2024-12-04","2017-09-26",48,[26,283,1629,1630,1631,1632],"Advanced Cancer","Metastatic Lung Cancer","Squamous Cell Lung Cancer","Non-Squamous Non-Small Cell Neoplasm of Lung",[1634,619,622,620],"Pirfenidone",{"trials":1636,"activeCount":189,"soonestReadout":1251},[1637,1641,1649,1653,1657,1661,1673,1677,1686],{"nctId":1198,"briefTitle":1199,"status":147,"phases":1638,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":1639,"interventions":1640},[89,90],[15,1206,1207,1190],[1209,622,572],{"nctId":1642,"briefTitle":1643,"status":147,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":16,"conditions":1647,"interventions":1648},"NCT00226590","Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC",[90],"2008-07","2003-04",[26],[1246,619,622],{"nctId":609,"briefTitle":610,"status":111,"phases":1650,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":1651,"interventions":1652},[90],[616],[618,619,620,495,621,622],{"nctId":624,"briefTitle":625,"status":147,"phases":1654,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":1655,"interventions":1656},[90],[632],[495,622],{"nctId":1248,"briefTitle":1249,"status":111,"phases":1658,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1659,"interventions":1660},[90],[1190],[1218,572,1236,622],{"nctId":1662,"briefTitle":1663,"status":147,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1670},"NCT00617409","To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid",[90],"2015-09-21","2019-01-31","2007-10-02",69,[436],[622,1671,1672],"Drug: Ad.p53-DC vaccines","All -trans Retinoic Acid",{"nctId":900,"briefTitle":901,"status":249,"phases":1674,"primaryCompletion":903,"completion":903,"start":904,"enrollment":730,"conditions":1675,"interventions":1676},[89,90],[632],[873,907,860,861,908,909],{"nctId":1678,"briefTitle":1679,"status":147,"phases":1680,"primaryCompletion":1681,"completion":81,"start":1682,"enrollment":630,"conditions":1683,"interventions":1684},"NCT02513563","AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer",[90],"2022-11-27","2015-10-13",[26],[619,622,1685],"AZD1775",{"nctId":1687,"briefTitle":1688,"status":147,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":136,"conditions":1693,"interventions":1697},"NCT02779855","Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",[89,90],"2020-09-20","2025-08-26","2017-05-02",[15,1694,1695,1696],"Ductal Carcinoma","Invasive Breast Carcinoma","Invasive Ductal Breast Carcinoma",[1698,622],"Talimogene laherparepvec",{"trials":1700,"activeCount":101},[],{"trials":1702,"activeCount":101},[],{"trials":1704,"activeCount":101},[],{"intervention":920,"totalTrials":9,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1717,"PHASE2":1719,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1708,"activeCount":97,"soonestReadout":56},[1709],{"nctId":54,"briefTitle":55,"status":177,"phases":1710,"primaryCompletion":56,"completion":677,"start":1711,"enrollment":30,"conditions":1712,"interventions":1715},[88],"2018-09-17",[18,1336,1713,1714],"Advanced Prostate Cancer","Adenocarcinoma of the Prostate",[57,1716,920],"Abiraterone",{"trials":1718,"activeCount":101},[],{"trials":1720,"activeCount":97,"soonestReadout":1484},[1721,1733,1741,1745],{"nctId":1722,"briefTitle":1723,"status":147,"phases":1724,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":125,"conditions":1728,"interventions":1731},"NCT01133275","Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS",[90],"2015-01-31","2019-11-21","2010-04-28",[1729,1730],"Myelodysplastic Syndrome","MDS",[920,1732],"Lenalidomide",{"nctId":1734,"briefTitle":1735,"status":147,"phases":1736,"primaryCompletion":319,"completion":1737,"start":1738,"enrollment":595,"conditions":1739,"interventions":1740},"NCT01054144","Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma",[90],"2020-11-24","2010-01-14",[21],[1732,920,888],{"nctId":1481,"briefTitle":1482,"status":111,"phases":1742,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":637,"conditions":1743,"interventions":1744},[90],[1487],[62,920],{"nctId":911,"briefTitle":912,"status":147,"phases":1746,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":1747,"interventions":1748},[90],[858],[157,804,803,920,888,921,922],{"trials":1750,"activeCount":101},[],{"trials":1752,"activeCount":101},[],{"trials":1754,"activeCount":101},[],{"intervention":1756,"totalTrials":812,"cells":1757},"Rituximab",{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1771,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1759,"activeCount":101},[],{"trials":1761,"activeCount":97,"soonestReadout":1464},[1762],{"nctId":1763,"briefTitle":1764,"status":111,"phases":1765,"primaryCompletion":1464,"completion":1464,"start":1766,"enrollment":507,"conditions":1767,"interventions":1768},"NCT05581030","CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)",[89],"2023-05-01",[733],[1769,1770,1756],"Hyper CVAD Protocol","Calaspargase Pegol",{"trials":1772,"activeCount":97,"soonestReadout":1796},[1773,1783,1792],{"nctId":1774,"briefTitle":1775,"status":147,"phases":1776,"primaryCompletion":1777,"completion":1778,"start":1779,"enrollment":385,"conditions":1780,"interventions":1782},"NCT00609869","Lenalidomide in Comb w\u002FRituximab for Pts w\u002FCD5+\u002FCD20+ Hem Malignancies Who Relapse\u002FProgress After Rituximab",[90],"2014-02","2015-08","2007-10",[1781,732],"Lymphocytic Leukemia",[1732,1756],{"nctId":1784,"briefTitle":1785,"status":147,"phases":1786,"primaryCompletion":1374,"completion":1787,"start":830,"enrollment":630,"conditions":1788,"interventions":1790},"NCT00496340","Phase II Trial of Pentostatin and Targeted Busulfan",[90],"2013-08",[1789],"Hematologic Malignancies",[1791,758,1756],"Pentostatin",{"nctId":1793,"briefTitle":1794,"status":111,"phases":1795,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":917,"conditions":1798,"interventions":1802},"NCT06350318","Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",[90],"2029-03","2024-04-19",[1799,1800,1801],"Follicular Lymphoma","Marginal Zone Lymphoma","B-Cell Lymphoma",[1803,1756],"Zanubrutinib",{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":101},[],{"trials":1809,"activeCount":101},[],{"intervention":1236,"totalTrials":812,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":189,"soonestReadout":1251},[1818,1822,1826,1830],{"nctId":1211,"briefTitle":1212,"status":345,"phases":1819,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":101,"conditions":1820,"interventions":1821},[89,90],[15],[1218,1219,1220],{"nctId":1226,"briefTitle":1227,"status":177,"phases":1823,"primaryCompletion":1229,"completion":1230,"start":1231,"enrollment":211,"conditions":1824,"interventions":1825},[89,90],[1190,1233,1234],[1236,572],{"nctId":1238,"briefTitle":1239,"status":147,"phases":1827,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":36,"conditions":1828,"interventions":1829},[89,90],[15],[1246,572,1236],{"nctId":1248,"briefTitle":1249,"status":111,"phases":1831,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":1832,"interventions":1833},[90],[1190],[1218,572,1236,622],{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":101},[],{"intervention":301,"totalTrials":812,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1850,"PHASE3":1882,"PHASE4":1884,"NA":1886},{"trials":1843,"activeCount":101},[],{"trials":1845,"activeCount":97,"soonestReadout":292},[1846],{"nctId":289,"briefTitle":290,"status":177,"phases":1847,"primaryCompletion":292,"completion":293,"start":294,"enrollment":198,"conditions":1848,"interventions":1849},[89],[296,297,298,299],[52,301],{"trials":1851,"activeCount":97,"soonestReadout":371},[1852,1862,1871],{"nctId":1853,"briefTitle":1854,"status":111,"phases":1855,"primaryCompletion":371,"completion":1856,"start":1857,"enrollment":645,"conditions":1858,"interventions":1859},"NCT06511882","Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD",[90],"2028-08","2024-11-07",[1132],[301,1860,1861],"Decitabine","Venetoclax",{"nctId":1863,"briefTitle":1864,"status":147,"phases":1865,"primaryCompletion":1866,"completion":1867,"start":1868,"enrollment":821,"conditions":1869,"interventions":1870},"NCT00387647","Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy",[90],"2013-10","2014-08","2006-08",[35],[301],{"nctId":1872,"briefTitle":1873,"status":147,"phases":1874,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1880},"NCT03072043","Phase 1b\u002F2 Safety and Efficacy of APR-246 w\u002FAzacitidine for tx of TP53 Mutant Myeloid Neoplasms",[89,90],"2019-11-15","2021-12-08","2017-05-18",55,[1729,1132,1137,754],[1881,301],"APR-246",{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"intervention":1889,"totalTrials":730,"cells":1890},"Cemiplimab",{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1905,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1892,"activeCount":101},[],{"trials":1894,"activeCount":101},[1895],{"nctId":1896,"briefTitle":1897,"status":147,"phases":1898,"primaryCompletion":1899,"completion":1900,"start":1901,"enrollment":1059,"conditions":1902,"interventions":1904},"NCT05064085","Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer",[89],"2024-09-09","2025-03-13","2021-10-12",[1903],"Hormone Receptor-positive Breast Cancer",[1889,72],{"trials":1906,"activeCount":189,"soonestReadout":1921},[1907,1917],{"nctId":1908,"briefTitle":1909,"status":111,"phases":1910,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":544,"conditions":1913,"interventions":1915},"NCT06121180","Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",[90],"2030-10-31","2024-11-04",[1914],"Metastatic Uveal Melanoma",[1916,1889],"ZIV-Aflibercept",{"nctId":1918,"briefTitle":1919,"status":177,"phases":1920,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":27,"conditions":1923,"interventions":1924},"NCT06855212","Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC",[90],"2028-03","2025-02-26",[413],[1889,417],{"trials":1926,"activeCount":101},[],{"trials":1928,"activeCount":101},[],{"trials":1930,"activeCount":101},[],{"intervention":1716,"totalTrials":189,"cells":1932},{"EARLY_PHASE1":1933,"PHASE1":1939,"PHASE2":1941,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1934,"activeCount":97,"soonestReadout":56},[1935],{"nctId":54,"briefTitle":55,"status":177,"phases":1936,"primaryCompletion":56,"completion":677,"start":1711,"enrollment":30,"conditions":1937,"interventions":1938},[88],[18,1336,1713,1714],[57,1716,920],{"trials":1940,"activeCount":101},[],{"trials":1942,"activeCount":97,"soonestReadout":1464},[1943],{"nctId":1944,"briefTitle":1945,"status":111,"phases":1946,"primaryCompletion":1464,"completion":180,"start":1947,"enrollment":19,"conditions":1948,"interventions":1950},"NCT05751941","Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer",[90],"2023-02-14",[18,1949],"Metastatic Prostate Cancer",[1716,1951,1952,1953],"Enzalutamide","Apalutamide","Sipuleucel-T",{"trials":1955,"activeCount":101},[],{"trials":1957,"activeCount":101},[],{"trials":1959,"activeCount":101},[],{"intervention":1521,"totalTrials":189,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1963,"activeCount":101},[],{"trials":1965,"activeCount":101},[],{"trials":1967,"activeCount":189,"soonestReadout":1976},[1968,1972],{"nctId":1509,"briefTitle":1510,"status":111,"phases":1969,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":1970,"interventions":1971},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"nctId":1973,"briefTitle":1974,"status":111,"phases":1975,"primaryCompletion":1976,"completion":180,"start":1977,"enrollment":1531,"conditions":1978,"interventions":1980},"NCT04923542","Stereotactic Radiation & Abemaciclib in the Management of HR+\u002FHER2- Breast Cancer Brain Metastases",[89,90],"2026-11-05","2021-11-30",[225,1979],"HR+ Metastatic Breast Cancer",[1521,1981],"Endocrine therapy",{"trials":1983,"activeCount":101},[],{"trials":1985,"activeCount":101},[],{"trials":1987,"activeCount":101},[],{"intervention":1860,"totalTrials":189,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":2004,"PHASE3":2010,"PHASE4":2012,"NA":2014},{"trials":1991,"activeCount":101},[],{"trials":1993,"activeCount":97,"soonestReadout":1276},[1994],{"nctId":1995,"briefTitle":1996,"status":111,"phases":1997,"primaryCompletion":1276,"completion":1276,"start":1998,"enrollment":1130,"conditions":1999,"interventions":2001},"NCT06327685","Avapritinib With Decitabine in Patients With SM-AHN",[89],"2024-03-13",[2000],"Systemic Mastocytosis With an Associated Hematologic Neoplasm",[2002,1860,2003],"Avapritinib","Decitabine\u002FCedazuridine",{"trials":2005,"activeCount":97,"soonestReadout":371},[2006],{"nctId":1853,"briefTitle":1854,"status":111,"phases":2007,"primaryCompletion":371,"completion":1856,"start":1857,"enrollment":645,"conditions":2008,"interventions":2009},[90],[1132],[301,1860,1861],{"trials":2011,"activeCount":101},[],{"trials":2013,"activeCount":101},[],{"trials":2015,"activeCount":101},[],{"intervention":1861,"totalTrials":189,"cells":2017},{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2019,"activeCount":101},[],{"trials":2021,"activeCount":101},[],{"trials":2023,"activeCount":189,"soonestReadout":371},[2024,2028],{"nctId":1853,"briefTitle":1854,"status":111,"phases":2025,"primaryCompletion":371,"completion":1856,"start":1857,"enrollment":645,"conditions":2026,"interventions":2027},[90],[1132],[301,1860,1861],{"nctId":2029,"briefTitle":2030,"status":111,"phases":2031,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":267,"conditions":2034,"interventions":2036},"NCT06660368","BCL2i CLAG-M in R\u002FR Acute Myeloid Leukemia",[90],"2027-11","2024-11-26",[2035],"Relapsed or Refractory Acute Myeloid Leukemia (AML)",[2037,1861],"Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen",{"trials":2039,"activeCount":101},[],{"trials":2041,"activeCount":101},[],{"trials":2043,"activeCount":101},[],{"intervention":188,"totalTrials":189,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2052,"PHASE2":2054,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2047,"activeCount":97,"soonestReadout":179},[2048],{"nctId":175,"briefTitle":176,"status":177,"phases":2049,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":2050,"interventions":2051},[88],[153,154,184,185],[187,188,52],{"trials":2053,"activeCount":101},[],{"trials":2055,"activeCount":97,"soonestReadout":2060},[2056],{"nctId":2057,"briefTitle":2058,"status":177,"phases":2059,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":507,"conditions":2063,"interventions":2064},"NCT05170334","Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma",[90],"2025-12-01","2028-01","2021-12-15",[1914],[188,2065],"Belinostat",{"trials":2067,"activeCount":101},[],{"trials":2069,"activeCount":101},[],{"trials":2071,"activeCount":101},[],{"intervention":1246,"totalTrials":33,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2143,"PHASE3":2216,"PHASE4":2222,"NA":2224},{"trials":2075,"activeCount":101},[],{"trials":2077,"activeCount":101},[2078,2090,2100,2111,2124,2134],{"nctId":2079,"briefTitle":2080,"status":147,"phases":2081,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":281,"conditions":2084,"interventions":2086},"NCT00480584","A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer",[89],"2012-11","2007-04",[2085],"Metastatic Pancreatic Carcinoma",[2087,2088,2089],"gemcitabine","capecitabine","erlotinib",{"nctId":2091,"briefTitle":2092,"status":147,"phases":2093,"primaryCompletion":2094,"completion":2095,"start":2096,"enrollment":281,"conditions":2097,"interventions":2098},"NCT01385956","SOM 230 and Gemcitabine in Advanced Pancreatic Cancer",[89],"2014-05","2014-11","2011-06",[24],[2099,1246],"SOM 230 LAR",{"nctId":2101,"briefTitle":2102,"status":147,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":36,"conditions":2107,"interventions":2108},"NCT02155088","BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer",[89],"2016-12-01","2020-01-31","2014-10-30",[24],[2109,1246,2110],"BYL719","(nab)-paclitaxel",{"nctId":2112,"briefTitle":2113,"status":147,"phases":2114,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":1265,"conditions":2118,"interventions":2123},"NCT02300610","Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer",[89],"2017-08-07","2019-04-19","2015-02-11",[201,2119,2120,2121,2122],"Carcinoma, Transitional Cell","Renal Pelvis Cancer","Ureter Cancer","Urethra Cancer",[1951,618,1246],{"nctId":2125,"briefTitle":2126,"status":147,"phases":2127,"primaryCompletion":2128,"completion":2129,"start":2130,"enrollment":1035,"conditions":2131,"interventions":2132},"NCT02138383","Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer",[89],"2016-12-15","2019-10-07","2014-05-22",[24],[1951,1246,2133],"Nab-paclitaxel",{"nctId":2135,"briefTitle":2136,"status":147,"phases":2137,"primaryCompletion":2096,"completion":2096,"start":2138,"enrollment":2139,"conditions":2140,"interventions":2141},"NCT01198821","Gem-TABS in Unresectable Pancreatic Carcinoma",[89],"2010-08",8,[24],[2142,1246],"Sodium bicarbonate",{"trials":2144,"activeCount":97,"soonestReadout":2162},[2145,2158,2167,2171,2185,2197,2201,2208,2212],{"nctId":2146,"briefTitle":2147,"status":147,"phases":2148,"primaryCompletion":2149,"completion":2150,"start":2151,"enrollment":2152,"conditions":2153,"interventions":2156},"NCT02945800","Nab-Paclitaxel and Gemcitabine for Recurrent\u002FRefractory Sarcoma",[90],"2024-11-19","2025-02-17","2016-10-25",59,[296,2154,960,2155],"Ewing Sarcoma","Soft Tissue Sarcoma",[2157,1246],"nab-Paclitaxel",{"nctId":2159,"briefTitle":2160,"status":111,"phases":2161,"primaryCompletion":2162,"completion":2162,"start":2163,"enrollment":917,"conditions":2164,"interventions":2165},"NCT06597565","A Phase II Study of ACR-368 and Low Dose Gemcitabine in R\u002FM HNSCC",[90],"2028-08-23","2024-09-25",[413],[1246,2166],"ACR-368",{"nctId":1642,"briefTitle":1643,"status":147,"phases":2168,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":16,"conditions":2169,"interventions":2170},[90],[26],[1246,619,622],{"nctId":2172,"briefTitle":2173,"status":147,"phases":2174,"primaryCompletion":2175,"completion":2176,"start":2177,"enrollment":821,"conditions":2178,"interventions":2183},"NCT02631590","Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma",[90],"2019-10-25","2021-03-05","2016-07-05",[2179,2180,2181,2182],"Biliary Carcinoma","Gall Bladder Carcinoma","Cholangiocarcinoma","Gastrointestinal Tumor",[618,1246,2184],"Copanlisib",{"nctId":2186,"briefTitle":2187,"status":147,"phases":2188,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1130,"conditions":2192,"interventions":2195},"NCT02611037","Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma",[90],"2021-10-16","2024-01-26","2016-03-04",[2193,2194],"Malignant Pleural Mesothelioma","Mesothelioma",[618,2196,1246],"Methotrexate",{"nctId":1238,"briefTitle":1239,"status":147,"phases":2198,"primaryCompletion":1241,"completion":1242,"start":1243,"enrollment":36,"conditions":2199,"interventions":2200},[89,90],[15],[1246,572,1236],{"nctId":2202,"briefTitle":2203,"status":147,"phases":2204,"primaryCompletion":2205,"completion":2205,"start":903,"enrollment":267,"conditions":2206,"interventions":2207},"NCT00226577","Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.",[90],"2008-12",[26],[1246,620],{"nctId":1342,"briefTitle":1343,"status":249,"phases":2209,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":253,"conditions":2210,"interventions":2211},[90],[24],[72,1246,1264,1350],{"nctId":1352,"briefTitle":1353,"status":147,"phases":2213,"primaryCompletion":1355,"completion":1355,"start":903,"enrollment":1254,"conditions":2214,"interventions":2215},[90],[338],[962,1264,1246,619],{"trials":2217,"activeCount":101},[2218],{"nctId":1371,"briefTitle":1372,"status":147,"phases":2219,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":2220,"interventions":2221},[91],[242],[1264,962,619,1246],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[],{"intervention":888,"totalTrials":233,"cells":2227},{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2236,"PHASE3":2317,"PHASE4":2323,"NA":2325},{"trials":2229,"activeCount":101},[],{"trials":2231,"activeCount":101},[2232],{"nctId":1561,"briefTitle":1562,"status":147,"phases":2233,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":182,"conditions":2234,"interventions":2235},[89],[733],[1559,803,888,1569,804,1570],{"trials":2237,"activeCount":97,"soonestReadout":76},[2238,2248,2258,2262,2271,2281,2285,2292,2302,2313],{"nctId":2239,"briefTitle":2240,"status":147,"phases":2241,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":125,"conditions":2245,"interventions":2246},"NCT02186834","Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma",[89,90],"2017-11-08","2018-03-14","2014-09-23",[21],[2247,811,888],"Selinexor",{"nctId":2249,"briefTitle":2250,"status":345,"phases":2251,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":101,"conditions":2255,"interventions":2256},"NCT02802163","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",[89,90],"2020-09","2020-12","2017-06",[21],[998,2257,1732,888],"Carfilzomib",{"nctId":1734,"briefTitle":1735,"status":147,"phases":2259,"primaryCompletion":319,"completion":1737,"start":1738,"enrollment":595,"conditions":2260,"interventions":2261},[90],[21],[1732,920,888],{"nctId":2263,"briefTitle":2264,"status":147,"phases":2265,"primaryCompletion":1374,"completion":1374,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2269},"NCT00617591","Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)",[90],"2008-01",57,[21],[1732,2270,888],"Pegylated Liposomal Doxorubicin",{"nctId":2272,"briefTitle":2273,"status":249,"phases":2274,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":1095,"conditions":2278,"interventions":2279},"NCT03411031","Elotuzumab Plus Lenalidomide (Elo\u002FRev) for Serologic Relapse\u002FProgression While on Lenalidomide",[90],"2021-02-18","2021-11-04","2018-10-04",[21],[2280,1732,888],"Elotuzumab",{"nctId":878,"briefTitle":879,"status":147,"phases":2282,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":2283,"interventions":2284},[89,90],[885],[887,888,157],{"nctId":74,"briefTitle":75,"status":177,"phases":2286,"primaryCompletion":76,"completion":2287,"start":2288,"enrollment":211,"conditions":2289,"interventions":2290},[90],"2026-05-07","2019-11-22",[21],[77,888,2291,1157],"Lenalidomide Pill",{"nctId":2293,"briefTitle":2294,"status":147,"phases":2295,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":27,"conditions":2299,"interventions":2300},"NCT02780609","Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma",[89,90],"2021-02-20","2021-02-23","2017-07-20",[21],[2247,1147,888,2301],"Fosaprepitant",{"nctId":2303,"briefTitle":2304,"status":249,"phases":2305,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":97,"conditions":2308,"interventions":2309},"NCT00609765","Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors",[90],"2008-03","2007-08",[24],[1295,2310,804,2311,888,2312],"Fluorouracil","Streptozocin","Ondansetron",{"nctId":911,"briefTitle":912,"status":147,"phases":2314,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":2315,"interventions":2316},[90],[858],[157,804,803,920,888,921,922],{"trials":2318,"activeCount":101},[2319],{"nctId":1588,"briefTitle":1589,"status":249,"phases":2320,"primaryCompletion":1300,"completion":1300,"start":1591,"enrollment":424,"conditions":2321,"interventions":2322},[91],[21],[1594,1595,1596,1597,1598],{"trials":2324,"activeCount":101},[],{"trials":2326,"activeCount":101},[],{"intervention":619,"totalTrials":233,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2361,"PHASE3":2396,"PHASE4":2402,"NA":2404},{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":101},[2333,2337,2347,2351],{"nctId":1610,"briefTitle":1611,"status":147,"phases":2334,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":821,"conditions":2335,"interventions":2336},[89],[1617,632],[1619,622,907],{"nctId":2338,"briefTitle":2339,"status":147,"phases":2340,"primaryCompletion":2341,"start":2342,"conditions":2343,"interventions":2345},"NCT00006086","BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer",[89],"2003-02","2000-06",[2344],"Unspecified Adult Solid Tumor, Protocol Specific",[2346,907],"BMS-188797",{"nctId":1621,"briefTitle":1622,"status":147,"phases":2348,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1627,"conditions":2349,"interventions":2350},[89],[26,283,1629,1630,1631,1632],[1634,619,622,620],{"nctId":2352,"briefTitle":2353,"status":147,"phases":2354,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":336,"conditions":2358,"interventions":2359},"NCT01795586","A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients",[89],"2015-02-24","2022-05-11","2013-02-06",[15],[2360,619],"Eribulin",{"trials":2362,"activeCount":97,"soonestReadout":612},[2363,2367,2376,2380,2384,2388,2392],{"nctId":1642,"briefTitle":1643,"status":147,"phases":2364,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":16,"conditions":2365,"interventions":2366},[90],[26],[1246,619,622],{"nctId":2368,"briefTitle":2369,"status":147,"phases":2370,"primaryCompletion":2371,"completion":2094,"start":1646,"enrollment":2372,"conditions":2373,"interventions":2374},"NCT00049218","Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[89,90],"2007-06",56,[26],[2375,619,810],"Autologous dendritic cell-adenovirus p53 vaccine",{"nctId":841,"briefTitle":842,"status":147,"phases":2377,"primaryCompletion":844,"completion":830,"start":845,"enrollment":846,"conditions":2378,"interventions":2379},[90],[15],[619,157,849],{"nctId":609,"briefTitle":610,"status":111,"phases":2381,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":2382,"interventions":2383},[90],[616],[618,619,620,495,621,622],{"nctId":900,"briefTitle":901,"status":249,"phases":2385,"primaryCompletion":903,"completion":903,"start":904,"enrollment":730,"conditions":2386,"interventions":2387},[89,90],[632],[873,907,860,861,908,909],{"nctId":1678,"briefTitle":1679,"status":147,"phases":2389,"primaryCompletion":1681,"completion":81,"start":1682,"enrollment":630,"conditions":2390,"interventions":2391},[90],[26],[619,622,1685],{"nctId":1352,"briefTitle":1353,"status":147,"phases":2393,"primaryCompletion":1355,"completion":1355,"start":903,"enrollment":1254,"conditions":2394,"interventions":2395},[90],[338],[962,1264,1246,619],{"trials":2397,"activeCount":101},[2398],{"nctId":1371,"briefTitle":1372,"status":147,"phases":2399,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":2400,"interventions":2401},[91],[242],[1264,962,619,1246],{"trials":2403,"activeCount":101},[],{"trials":2405,"activeCount":101},[],{"intervention":962,"totalTrials":730,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2422,"PHASE4":2428,"NA":2430},{"trials":2409,"activeCount":101},[],{"trials":2411,"activeCount":101},[],{"trials":2413,"activeCount":97,"soonestReadout":391},[2414,2418],{"nctId":1352,"briefTitle":1353,"status":147,"phases":2415,"primaryCompletion":1355,"completion":1355,"start":903,"enrollment":1254,"conditions":2416,"interventions":2417},[90],[338],[962,1264,1246,619],{"nctId":954,"briefTitle":955,"status":177,"phases":2419,"primaryCompletion":391,"completion":957,"start":958,"enrollment":233,"conditions":2420,"interventions":2421},[90],[960],[803,157,962,963,964],{"trials":2423,"activeCount":101},[2424],{"nctId":1371,"briefTitle":1372,"status":147,"phases":2425,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":2426,"interventions":2427},[91],[242],[1264,962,619,1246],{"trials":2429,"activeCount":101},[],{"trials":2431,"activeCount":101},[],{"intervention":1732,"totalTrials":233,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2449,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2435,"activeCount":101},[],{"trials":2437,"activeCount":101},[2438],{"nctId":2439,"briefTitle":2440,"status":147,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":27,"conditions":2445,"interventions":2446},"NCT00840931","Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)",[89],"2014-02-17","2019-12","2009-02-02",[35],[2447,2448],"lenalidomide","bystander vaccine",{"trials":2450,"activeCount":97,"soonestReadout":2491},[2451,2455,2467,2471,2475,2479,2483,2487,2497,2505,2515],{"nctId":1774,"briefTitle":1775,"status":147,"phases":2452,"primaryCompletion":1777,"completion":1778,"start":1779,"enrollment":385,"conditions":2453,"interventions":2454},[90],[1781,732],[1732,1756],{"nctId":2456,"briefTitle":2457,"status":147,"phases":2458,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":556,"conditions":2462,"interventions":2464},"NCT01496976","Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL\u002FSLL",[90],"2021-10-06","2024-09-11","2012-03-30",[606,2463],"Small Lymphocytic Lymphoma",[2465,2466,1732],"High Dose Methylprednisolone","Ofatumumab",{"nctId":1722,"briefTitle":1723,"status":147,"phases":2468,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":125,"conditions":2469,"interventions":2470},[90],[1729,1730],[920,1732],{"nctId":2249,"briefTitle":2250,"status":345,"phases":2472,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":101,"conditions":2473,"interventions":2474},[89,90],[21],[998,2257,1732,888],{"nctId":1734,"briefTitle":1735,"status":147,"phases":2476,"primaryCompletion":319,"completion":1737,"start":1738,"enrollment":595,"conditions":2477,"interventions":2478},[90],[21],[1732,920,888],{"nctId":2263,"briefTitle":2264,"status":147,"phases":2480,"primaryCompletion":1374,"completion":1374,"start":2266,"enrollment":2267,"conditions":2481,"interventions":2482},[90],[21],[1732,2270,888],{"nctId":2272,"briefTitle":2273,"status":249,"phases":2484,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":1095,"conditions":2485,"interventions":2486},[90],[21],[2280,1732,888],{"nctId":2488,"briefTitle":2489,"status":111,"phases":2490,"primaryCompletion":2491,"completion":2061,"start":2492,"enrollment":125,"conditions":2493,"interventions":2495},"NCT06760156","Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym",[90],"2027-01","2025-03-19",[2494],"Large B-cell Lymphoma",[2496,1732],"Tafasitamab",{"nctId":2498,"briefTitle":2499,"status":147,"phases":2500,"primaryCompletion":994,"completion":2501,"start":2502,"enrollment":385,"conditions":2503,"interventions":2504},"NCT01497496","Ofatumumab\u002FMethylprednisolone and Ofatumumab\u002FLenalidomide for Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)",[90],"2020-03-20","2012-01-26",[606,2463],[2465,2466,1732],{"nctId":2506,"briefTitle":2507,"status":147,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":30,"conditions":2512,"interventions":2513},"NCT01373294","Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer",[90],"2015-01-09","2018-12-10","2011-11-30",[201],[2514,1732],"Bacille Calmette-Guerrin",{"nctId":2516,"briefTitle":2517,"status":147,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":1204,"conditions":2522,"interventions":2523},"NCT00831766","Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)",[89,90],"2015-02-17","2020-11-16","2009-06-25",[1729,1132],[2524,2525,1732],"Idarubicin","Cytarabine",{"trials":2527,"activeCount":101},[],{"trials":2529,"activeCount":101},[],{"trials":2531,"activeCount":101},[],{"intervention":618,"totalTrials":507,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2550,"PHASE3":2576,"PHASE4":2578,"NA":2580},{"trials":2535,"activeCount":101},[],{"trials":2537,"activeCount":101},[2538,2546],{"nctId":2539,"briefTitle":2540,"status":147,"phases":2541,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":281,"conditions":2544,"interventions":2545},"NCT02158234","Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck",[89],"2021-08-24","2014-07-16",[243],[618],{"nctId":2112,"briefTitle":2113,"status":147,"phases":2547,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":1265,"conditions":2548,"interventions":2549},[89],[201,2119,2120,2121,2122],[1951,618,1246],{"trials":2551,"activeCount":97,"soonestReadout":612},[2552,2560,2564,2568,2572],{"nctId":2553,"briefTitle":2554,"status":147,"phases":2555,"primaryCompletion":1376,"completion":1376,"start":1301,"enrollment":198,"conditions":2556,"interventions":2558},"NCT00215995","Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas",[90],[2557,569],"Esophageal Cancer",[618,807,2559],"ZD 1839",{"nctId":2172,"briefTitle":2173,"status":147,"phases":2561,"primaryCompletion":2175,"completion":2176,"start":2177,"enrollment":821,"conditions":2562,"interventions":2563},[90],[2179,2180,2181,2182],[618,1246,2184],{"nctId":2186,"briefTitle":2187,"status":147,"phases":2565,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1130,"conditions":2566,"interventions":2567},[90],[2193,2194],[618,2196,1246],{"nctId":609,"briefTitle":610,"status":111,"phases":2569,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":2570,"interventions":2571},[90],[616],[618,619,620,495,621,622],{"nctId":1307,"briefTitle":1308,"status":249,"phases":2573,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":630,"conditions":2574,"interventions":2575},[90],[1313,1314],[1304,1316],{"trials":2577,"activeCount":101},[],{"trials":2579,"activeCount":101},[],{"trials":2581,"activeCount":101},[],{"intervention":620,"totalTrials":9,"cells":2583},{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2592,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2585,"activeCount":101},[],{"trials":2587,"activeCount":101},[2588],{"nctId":1621,"briefTitle":1622,"status":147,"phases":2589,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1627,"conditions":2590,"interventions":2591},[89],[26,283,1629,1630,1631,1632],[1634,619,622,620],{"trials":2593,"activeCount":97,"soonestReadout":612},[2594,2600,2604,2608],{"nctId":2595,"briefTitle":2596,"status":249,"phases":2597,"primaryCompletion":2266,"completion":2266,"start":2371,"enrollment":97,"conditions":2598,"interventions":2599},"NCT00612677","Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem",[90],[26],[573,620],{"nctId":609,"briefTitle":610,"status":111,"phases":2601,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":2602,"interventions":2603},[90],[616],[618,619,620,495,621,622],{"nctId":2202,"briefTitle":2203,"status":147,"phases":2605,"primaryCompletion":2205,"completion":2205,"start":903,"enrollment":267,"conditions":2606,"interventions":2607},[90],[26],[1246,620],{"nctId":2609,"briefTitle":2610,"status":249,"phases":2611,"primaryCompletion":948,"completion":948,"start":2612,"enrollment":2139,"conditions":2613,"interventions":2614},"NCT00351039","Phase I\u002FII Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer",[89,90],"2006-07",[242],[215,2615,620],"Erlotinib",{"trials":2617,"activeCount":101},[],{"trials":2619,"activeCount":101},[],{"trials":2621,"activeCount":101},[],{"intervention":1951,"totalTrials":730,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2636,"PHASE3":2642,"PHASE4":2644,"NA":2646},{"trials":2625,"activeCount":101},[],{"trials":2627,"activeCount":101},[2628,2632],{"nctId":2112,"briefTitle":2113,"status":147,"phases":2629,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":1265,"conditions":2630,"interventions":2631},[89],[201,2119,2120,2121,2122],[1951,618,1246],{"nctId":2125,"briefTitle":2126,"status":147,"phases":2633,"primaryCompletion":2128,"completion":2129,"start":2130,"enrollment":1035,"conditions":2634,"interventions":2635},[89],[24],[1951,1246,2133],{"trials":2637,"activeCount":97,"soonestReadout":1464},[2638],{"nctId":1944,"briefTitle":1945,"status":111,"phases":2639,"primaryCompletion":1464,"completion":180,"start":1947,"enrollment":19,"conditions":2640,"interventions":2641},[90],[18,1949],[1716,1951,1952,1953],{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":101},[],{"trials":2647,"activeCount":101},[],{"intervention":573,"totalTrials":730,"cells":2649},{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2651,"activeCount":101},[],{"trials":2653,"activeCount":101},[],{"trials":2655,"activeCount":97,"soonestReadout":564},[2656,2660,2667],{"nctId":561,"briefTitle":562,"status":111,"phases":2657,"primaryCompletion":564,"completion":564,"start":565,"enrollment":566,"conditions":2658,"interventions":2659},[90],[568,569],[571,572,573,574,495],{"nctId":2661,"briefTitle":2662,"status":147,"phases":2663,"primaryCompletion":830,"completion":830,"start":2664,"enrollment":821,"conditions":2665,"interventions":2666},"NCT00215982","Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer",[90],"2004-12",[269],[2088,573,807],{"nctId":2595,"briefTitle":2596,"status":249,"phases":2668,"primaryCompletion":2266,"completion":2266,"start":2371,"enrollment":97,"conditions":2669,"interventions":2670},[90],[26],[573,620],{"trials":2672,"activeCount":101},[],{"trials":2674,"activeCount":101},[],{"trials":2676,"activeCount":101},[],{"intervention":684,"totalTrials":730,"cells":2678},{"EARLY_PHASE1":2679,"PHASE1":2681,"PHASE2":2683,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":97,"soonestReadout":1033},[2685,2695,2699],{"nctId":2686,"briefTitle":2687,"status":147,"phases":2688,"primaryCompletion":2689,"completion":2690,"start":2691,"enrollment":719,"conditions":2692,"interventions":2694},"NCT01435122","A Study of Axitinib in Advanced Carcinoid Tumors",[90],"2017-01-11","2018-02-13","2011-10-25",[2693],"Carcinoid Tumor",[684],{"nctId":1030,"briefTitle":1031,"status":111,"phases":2696,"primaryCompletion":1033,"completion":1034,"start":482,"enrollment":1035,"conditions":2697,"interventions":2698},[90],[32],[172,684],{"nctId":674,"briefTitle":675,"status":552,"phases":2700,"primaryCompletion":677,"completion":678,"start":679,"enrollment":680,"conditions":2701,"interventions":2702},[90],[238,682],[495,684],{"trials":2704,"activeCount":101},[],{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"intervention":86,"totalTrials":730,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2726,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2712,"activeCount":101},[],{"trials":2714,"activeCount":101},[2715,2722],{"nctId":2716,"briefTitle":2717,"status":147,"phases":2718,"primaryCompletion":2719,"completion":2719,"start":948,"enrollment":336,"conditions":2720,"interventions":2721},"NCT00762255","A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma",[89],"2013-07",[523],[86,215,807],{"nctId":516,"briefTitle":517,"status":147,"phases":2723,"primaryCompletion":519,"completion":520,"start":521,"enrollment":198,"conditions":2724,"interventions":2725},[89],[523,524,525],[495,86,527],{"trials":2727,"activeCount":97,"soonestReadout":85},[2728],{"nctId":83,"briefTitle":84,"status":177,"phases":2729,"primaryCompletion":85,"completion":382,"start":636,"enrollment":637,"conditions":2730,"interventions":2731},[89,90],[26,616],[86,495],{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"intervention":417,"totalTrials":730,"cells":2739},{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2741,"activeCount":101},[],{"trials":2743,"activeCount":101},[],{"trials":2745,"activeCount":97,"soonestReadout":1921},[2746,2750,2758],{"nctId":1918,"briefTitle":1919,"status":177,"phases":2747,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":27,"conditions":2748,"interventions":2749},[90],[413],[1889,417],{"nctId":2751,"briefTitle":2752,"status":147,"phases":2753,"primaryCompletion":2754,"completion":1778,"start":2755,"enrollment":595,"conditions":2756,"interventions":2757},"NCT00673738","Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)",[90],"2013-12","2008-04",[26],[417],{"nctId":400,"briefTitle":401,"status":147,"phases":2759,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":2760,"interventions":2761},[89,90],[408,409,410,411,412,413,414,415],[52,417],{"trials":2763,"activeCount":101},[],{"trials":2765,"activeCount":101},[],{"trials":2767,"activeCount":101},[],{"intervention":1157,"totalTrials":730,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2771,"activeCount":101},[],{"trials":2773,"activeCount":101},[],{"trials":2775,"activeCount":97,"soonestReadout":76},[2776,2780,2784],{"nctId":74,"briefTitle":75,"status":177,"phases":2777,"primaryCompletion":76,"completion":2287,"start":2288,"enrollment":211,"conditions":2778,"interventions":2779},[90],[21],[77,888,2291,1157],{"nctId":1149,"briefTitle":1150,"status":147,"phases":2781,"primaryCompletion":1152,"completion":483,"start":1153,"enrollment":1154,"conditions":2782,"interventions":2783},[90],[21],[1157,1147,158],{"nctId":2785,"briefTitle":2786,"status":147,"phases":2787,"primaryCompletion":1093,"completion":1093,"start":1416,"enrollment":719,"conditions":2788,"interventions":2790},"NCT00307086","Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants",[90],[21,2789],"Plasma Cell Leukemia",[1157,1147],{"trials":2792,"activeCount":101},[],{"trials":2794,"activeCount":101},[],{"trials":2796,"activeCount":101},[],{"intervention":2798,"totalTrials":189,"cells":2799},"Lovaza®",{"EARLY_PHASE1":2800,"PHASE1":2812,"PHASE2":2814,"PHASE3":2828,"PHASE4":2830,"NA":2832},{"trials":2801,"activeCount":101},[2802],{"nctId":2803,"briefTitle":2804,"status":147,"phases":2805,"primaryCompletion":2806,"completion":2807,"start":2808,"enrollment":566,"conditions":2809,"interventions":2810},"NCT01823991","COGNUTRIN in Breast Cancer Survivors",[88],"2017-04-05","2018-05-02","2014-07-30",[15],[2811,2798],"VitaBlue™",{"trials":2813,"activeCount":101},[],{"trials":2815,"activeCount":97,"soonestReadout":2820},[2816],{"nctId":2817,"briefTitle":2818,"status":177,"phases":2819,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":336,"conditions":2823,"interventions":2826},"NCT03598309","Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers",[90],"2025-05-29","2026-05","2019-06-05",[2824,2825],"Lung Diseases","Lung Cancer, Protection Against",[2827,2798],"Curcumin C3 complex®",{"trials":2829,"activeCount":101},[],{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"intervention":1218,"totalTrials":189,"cells":2835},{"EARLY_PHASE1":2836,"PHASE1":2838,"PHASE2":2840,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2837,"activeCount":101},[],{"trials":2839,"activeCount":101},[],{"trials":2841,"activeCount":97,"soonestReadout":1251},[2842,2846],{"nctId":1211,"briefTitle":1212,"status":345,"phases":2843,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":101,"conditions":2844,"interventions":2845},[89,90],[15],[1218,1219,1220],{"nctId":1248,"briefTitle":1249,"status":111,"phases":2847,"primaryCompletion":1251,"completion":1252,"start":1253,"enrollment":1254,"conditions":2848,"interventions":2849},[90],[1190],[1218,572,1236,622],{"trials":2851,"activeCount":101},[],{"trials":2853,"activeCount":101},[],{"trials":2855,"activeCount":101},[],{"intervention":2857,"totalTrials":189,"cells":2858},"Fedratinib Pill",{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2871,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2860,"activeCount":101},[],{"trials":2862,"activeCount":101},[2863],{"nctId":2864,"briefTitle":2865,"status":249,"phases":2866,"primaryCompletion":2867,"completion":2867,"start":2868,"enrollment":233,"conditions":2869,"interventions":2870},"NCT05127174","Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms",[89],"2025-01-03","2022-03-14",[1137],[2857],{"trials":2872,"activeCount":97,"soonestReadout":2877},[2873],{"nctId":2874,"briefTitle":2875,"status":177,"phases":2876,"primaryCompletion":2877,"completion":293,"start":2878,"enrollment":1035,"conditions":2879,"interventions":2881},"NCT05177211","Fedratinib in Myelodysplastic \u002FMyeloproliferative Neoplasms (MDS\u002FMPNs) and Chronic Neutrophilic Leukemia (CNL)",[90],"2025-04-10","2022-03-01",[1137,2880,1730],"Chronic Neutrophilic Leukemia",[2857],{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[],{"trials":2887,"activeCount":101},[],{"intervention":1520,"totalTrials":189,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2907,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[2894],{"nctId":2895,"briefTitle":2896,"status":147,"phases":2897,"primaryCompletion":2898,"completion":2899,"start":2900,"enrollment":507,"conditions":2901,"interventions":2904},"NCT02586675","TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer",[89],"2017-05-08","2021-10-27","2016-02-23",[15,2902,2903],"Breast Cancer - Female","Breast Cancer - Male",[2905,1520,2906],"Tamoxifen","Goserelin",{"trials":2908,"activeCount":97,"soonestReadout":1229},[2909],{"nctId":1509,"briefTitle":1510,"status":111,"phases":2910,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":2911,"interventions":2912},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"trials":2914,"activeCount":101},[],{"trials":2916,"activeCount":101},[],{"trials":2918,"activeCount":101},[],{"intervention":173,"totalTrials":189,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2927,"PHASE2":2929,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2922,"activeCount":101},[2923],{"nctId":162,"briefTitle":163,"status":147,"phases":2924,"primaryCompletion":165,"completion":166,"start":167,"enrollment":97,"conditions":2925,"interventions":2926},[88],[169,170],[52,172,173],{"trials":2928,"activeCount":101},[],{"trials":2930,"activeCount":97,"soonestReadout":422},[2931],{"nctId":419,"briefTitle":420,"status":111,"phases":2932,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":2933,"interventions":2934},[90],[138,139,426,32],[52,173,172],{"trials":2936,"activeCount":101},[],{"trials":2938,"activeCount":101},[],{"trials":2940,"activeCount":101},[],{"intervention":2942,"totalTrials":189,"cells":2943},"Atezolizumab",{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2958,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2945,"activeCount":101},[],{"trials":2947,"activeCount":101},[2948],{"nctId":2949,"briefTitle":2950,"status":249,"phases":2951,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":189,"conditions":2954,"interventions":2956},"NCT05093608","SELINEXOR in Combination w\u002FBevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma",[89],"2022-10-12","2021-11-03",[2955],"Hepatocellular Carcinoma",[2957,215,2942],"Selinexor Pill",{"trials":2959,"activeCount":97,"soonestReadout":2964},[2960],{"nctId":2961,"briefTitle":2962,"status":177,"phases":2963,"primaryCompletion":2964,"completion":2964,"start":2965,"enrollment":198,"conditions":2966,"interventions":2970},"NCT03614949","SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer",[90],"2028-10","2019-01-29",[2967,2968,2969],"Cervical Cancer","Cervical Cancer Recurrent","Cervical Cancer Metastatic",[2942],{"trials":2972,"activeCount":101},[],{"trials":2974,"activeCount":101},[],{"trials":2976,"activeCount":101},[],{"intervention":2827,"totalTrials":97,"cells":2978},{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2980,"activeCount":101},[],{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":97,"soonestReadout":2820},[2985],{"nctId":2817,"briefTitle":2818,"status":177,"phases":2986,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":336,"conditions":2987,"interventions":2988},[90],[2824,2825],[2827,2798],{"trials":2990,"activeCount":101},[],{"trials":2992,"activeCount":101},[],{"trials":2994,"activeCount":101},[],{"intervention":2996,"totalTrials":97,"cells":2997},"Canakinumab",{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3002,"PHASE3":3013,"PHASE4":3015,"NA":3017},{"trials":2999,"activeCount":101},[],{"trials":3001,"activeCount":101},[],{"trials":3003,"activeCount":97,"soonestReadout":3008},[3004],{"nctId":3005,"briefTitle":3006,"status":177,"phases":3007,"primaryCompletion":3008,"completion":382,"start":3009,"enrollment":1059,"conditions":3010,"interventions":3011},"NCT04798339","Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA",[89,90],"2025-05-26","2021-03-30",[755],[2996,3012],"Darbepoetin Alfa",{"trials":3014,"activeCount":101},[],{"trials":3016,"activeCount":101},[],{"trials":3018,"activeCount":101},[],{"intervention":3012,"totalTrials":97,"cells":3020},{"EARLY_PHASE1":3021,"PHASE1":3023,"PHASE2":3025,"PHASE3":3031,"PHASE4":3033,"NA":3035},{"trials":3022,"activeCount":101},[],{"trials":3024,"activeCount":101},[],{"trials":3026,"activeCount":97,"soonestReadout":3008},[3027],{"nctId":3005,"briefTitle":3006,"status":177,"phases":3028,"primaryCompletion":3008,"completion":382,"start":3009,"enrollment":1059,"conditions":3029,"interventions":3030},[89,90],[755],[2996,3012],{"trials":3032,"activeCount":101},[],{"trials":3034,"activeCount":101},[],{"trials":3036,"activeCount":101},[],{"intervention":1952,"totalTrials":97,"cells":3038},{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3040,"activeCount":101},[],{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":97,"soonestReadout":1464},[3045],{"nctId":1944,"briefTitle":1945,"status":111,"phases":3046,"primaryCompletion":1464,"completion":180,"start":1947,"enrollment":19,"conditions":3047,"interventions":3048},[90],[18,1949],[1716,1951,1952,1953],{"trials":3050,"activeCount":101},[],{"trials":3052,"activeCount":101},[],{"trials":3054,"activeCount":101},[],{"intervention":1953,"totalTrials":97,"cells":3056},{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3058,"activeCount":101},[],{"trials":3060,"activeCount":101},[],{"trials":3062,"activeCount":97,"soonestReadout":1464},[3063],{"nctId":1944,"briefTitle":1945,"status":111,"phases":3064,"primaryCompletion":1464,"completion":180,"start":1947,"enrollment":19,"conditions":3065,"interventions":3066},[90],[18,1949],[1716,1951,1952,1953],{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[],{"trials":3072,"activeCount":101},[],{"intervention":1469,"totalTrials":97,"cells":3074},{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3085,"PHASE4":3087,"NA":3089},{"trials":3076,"activeCount":101},[],{"trials":3078,"activeCount":101},[],{"trials":3080,"activeCount":97,"soonestReadout":1463},[3081],{"nctId":1460,"briefTitle":1461,"status":177,"phases":3082,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":821,"conditions":3083,"interventions":3084},[90],[1454,1467],[62,1469],{"trials":3086,"activeCount":101},[],{"trials":3088,"activeCount":101},[],{"trials":3090,"activeCount":101},[],{"intervention":571,"totalTrials":97,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3103,"PHASE4":3105,"NA":3107},{"trials":3094,"activeCount":101},[],{"trials":3096,"activeCount":101},[],{"trials":3098,"activeCount":97,"soonestReadout":564},[3099],{"nctId":561,"briefTitle":562,"status":111,"phases":3100,"primaryCompletion":564,"completion":564,"start":565,"enrollment":566,"conditions":3101,"interventions":3102},[90],[568,569],[571,572,573,574,495],{"trials":3104,"activeCount":101},[],{"trials":3106,"activeCount":101},[],{"trials":3108,"activeCount":101},[],{"intervention":574,"totalTrials":97,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":97,"soonestReadout":564},[3117],{"nctId":561,"briefTitle":562,"status":111,"phases":3118,"primaryCompletion":564,"completion":564,"start":565,"enrollment":566,"conditions":3119,"interventions":3120},[90],[568,569],[571,572,573,574,495],{"trials":3122,"activeCount":101},[],{"trials":3124,"activeCount":101},[],{"trials":3126,"activeCount":101},[],{"intervention":2166,"totalTrials":97,"cells":3128},{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3130,"activeCount":101},[],{"trials":3132,"activeCount":101},[],{"trials":3134,"activeCount":97,"soonestReadout":2162},[3135],{"nctId":2159,"briefTitle":2160,"status":111,"phases":3136,"primaryCompletion":2162,"completion":2162,"start":2163,"enrollment":917,"conditions":3137,"interventions":3138},[90],[413],[1246,2166],{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"trials":3144,"activeCount":101},[],{"intervention":1515,"totalTrials":97,"cells":3146},{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3148,"activeCount":101},[],{"trials":3150,"activeCount":101},[],{"trials":3152,"activeCount":97,"soonestReadout":1229},[3153],{"nctId":1509,"briefTitle":1510,"status":111,"phases":3154,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":3155,"interventions":3156},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[],{"intervention":1516,"totalTrials":97,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3166,"activeCount":101},[],{"trials":3168,"activeCount":101},[],{"trials":3170,"activeCount":97,"soonestReadout":1229},[3171],{"nctId":1509,"briefTitle":1510,"status":111,"phases":3172,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":3173,"interventions":3174},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[],{"trials":3180,"activeCount":101},[],{"intervention":1517,"totalTrials":97,"cells":3182},{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3187,"PHASE3":3193,"PHASE4":3195,"NA":3197},{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":101},[],{"trials":3188,"activeCount":97,"soonestReadout":1229},[3189],{"nctId":1509,"briefTitle":1510,"status":111,"phases":3190,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":3191,"interventions":3192},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"trials":3194,"activeCount":101},[],{"trials":3196,"activeCount":101},[],{"trials":3198,"activeCount":101},[],{"intervention":1518,"totalTrials":97,"cells":3200},{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3202,"activeCount":101},[],{"trials":3204,"activeCount":101},[],{"trials":3206,"activeCount":97,"soonestReadout":1229},[3207],{"nctId":1509,"briefTitle":1510,"status":111,"phases":3208,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":3209,"interventions":3210},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"trials":3212,"activeCount":101},[],{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":101},[],{"intervention":1519,"totalTrials":97,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":97,"soonestReadout":1229},[3225],{"nctId":1509,"briefTitle":1510,"status":111,"phases":3226,"primaryCompletion":1229,"completion":1229,"start":1512,"enrollment":36,"conditions":3227,"interventions":3228},[90],[224],[1515,1516,1517,377,1518,1519,1520,1521],{"trials":3230,"activeCount":101},[],{"trials":3232,"activeCount":101},[],{"trials":3234,"activeCount":101},[],{"intervention":3236,"totalTrials":97,"cells":3237},"Pneumococcal conjugate vaccine",{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3257,"PHASE4":3259,"NA":3261},{"trials":3239,"activeCount":101},[],{"trials":3241,"activeCount":101},[],{"trials":3243,"activeCount":97,"soonestReadout":3248},[3244],{"nctId":3245,"briefTitle":3246,"status":177,"phases":3247,"primaryCompletion":3248,"completion":3249,"start":2275,"enrollment":19,"conditions":3250,"interventions":3255},"NCT04745559","Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy",[90],"2025-07-31","2027-06",[3251,3252,3253,3254,1799],"Diffuse Large-Cell Lymphoma","Primary Mediastinal Large B-Cell Lymphoma (PMBCL)","Transformed Follicular Lymphoma (TFL)","High-grade B-cell Lymphoma (HGBCL)",[3236,3256],"CD19 targeted CAR T Cell Therapy",{"trials":3258,"activeCount":101},[],{"trials":3260,"activeCount":101},[],{"trials":3262,"activeCount":101},[],{"intervention":3256,"totalTrials":97,"cells":3264},{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3269,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3266,"activeCount":101},[],{"trials":3268,"activeCount":101},[],{"trials":3270,"activeCount":97,"soonestReadout":3248},[3271],{"nctId":3245,"briefTitle":3246,"status":177,"phases":3272,"primaryCompletion":3248,"completion":3249,"start":2275,"enrollment":19,"conditions":3273,"interventions":3274},[90],[3251,3252,3253,3254,1799],[3236,3256],{"trials":3276,"activeCount":101},[],{"trials":3278,"activeCount":101},[],{"trials":3280,"activeCount":101},[],{"intervention":3282,"totalTrials":97,"cells":3283},"Itacitinib",{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3285,"activeCount":101},[],{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":97,"soonestReadout":3294},[3290],{"nctId":3291,"briefTitle":3292,"status":111,"phases":3293,"primaryCompletion":3294,"completion":2491,"start":3295,"enrollment":595,"conditions":3296,"interventions":3297},"NCT05757219","Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",[90],"2026-06-20","2023-05-19",[734],[3282,3298],"Chimeric antigen receptor (CAR) T-cell therapy",{"trials":3300,"activeCount":101},[],{"trials":3302,"activeCount":101},[],{"trials":3304,"activeCount":101},[],{"intervention":3298,"totalTrials":97,"cells":3306},{"EARLY_PHASE1":3307,"PHASE1":3309,"PHASE2":3311,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3308,"activeCount":101},[],{"trials":3310,"activeCount":101},[],{"trials":3312,"activeCount":97,"soonestReadout":3294},[3313],{"nctId":3291,"briefTitle":3292,"status":111,"phases":3314,"primaryCompletion":3294,"completion":2491,"start":3295,"enrollment":595,"conditions":3315,"interventions":3316},[90],[734],[3282,3298],{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[],{"trials":3322,"activeCount":101},[],{"intervention":2037,"totalTrials":97,"cells":3324},{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[],{"trials":3330,"activeCount":97,"soonestReadout":2032},[3331],{"nctId":2029,"briefTitle":2030,"status":111,"phases":3332,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":267,"conditions":3333,"interventions":3334},[90],[2035],[2037,1861],{"trials":3336,"activeCount":101},[],{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"intervention":3342,"totalTrials":97,"cells":3343},"Testosterone cypionate",{"EARLY_PHASE1":3344,"PHASE1":3346,"PHASE2":3348,"PHASE3":3359,"PHASE4":3361,"NA":3363},{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":101},[],{"trials":3349,"activeCount":97,"soonestReadout":1252},[3350],{"nctId":3351,"briefTitle":3352,"status":111,"phases":3353,"primaryCompletion":1252,"completion":1252,"start":3354,"enrollment":233,"conditions":3355,"interventions":3356},"NCT07476001","Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC",[90],"2026-03-03",[721],[3342,3357,3358],"ADT with Luteinizing hormone-releasing hormone (LHRH) analog","PSMA-617",{"trials":3360,"activeCount":101},[],{"trials":3362,"activeCount":101},[],{"trials":3364,"activeCount":101},[],{"intervention":3357,"totalTrials":97,"cells":3366},{"EARLY_PHASE1":3367,"PHASE1":3369,"PHASE2":3371,"PHASE3":3377,"PHASE4":3379,"NA":3381},{"trials":3368,"activeCount":101},[],{"trials":3370,"activeCount":101},[],{"trials":3372,"activeCount":97,"soonestReadout":1252},[3373],{"nctId":3351,"briefTitle":3352,"status":111,"phases":3374,"primaryCompletion":1252,"completion":1252,"start":3354,"enrollment":233,"conditions":3375,"interventions":3376},[90],[721],[3342,3357,3358],{"trials":3378,"activeCount":101},[],{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"intervention":3358,"totalTrials":97,"cells":3384},{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3389,"PHASE3":3395,"PHASE4":3397,"NA":3399},{"trials":3386,"activeCount":101},[],{"trials":3388,"activeCount":101},[],{"trials":3390,"activeCount":97,"soonestReadout":1252},[3391],{"nctId":3351,"briefTitle":3352,"status":111,"phases":3392,"primaryCompletion":1252,"completion":1252,"start":3354,"enrollment":233,"conditions":3393,"interventions":3394},[90],[721],[3342,3357,3358],{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":101},[],{"trials":3400,"activeCount":101},[],{"intervention":3402,"totalTrials":97,"cells":3403},"Vitamin E Delta Tocotrienol",{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"trials":3409,"activeCount":97,"soonestReadout":677},[3410],{"nctId":3411,"briefTitle":3412,"status":177,"phases":3413,"primaryCompletion":677,"completion":677,"start":3414,"enrollment":812,"conditions":3415,"interventions":3418},"NCT06519097","Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)",[90],"2024-07-09",[3416,3417],"Neoplasm of Pancreas","IPMN, Pancreatic",[3402],{"trials":3420,"activeCount":101},[],{"trials":3422,"activeCount":101},[],{"trials":3424,"activeCount":101},[],{"intervention":1916,"totalTrials":97,"cells":3426},{"EARLY_PHASE1":3427,"PHASE1":3429,"PHASE2":3431,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3428,"activeCount":101},[],{"trials":3430,"activeCount":101},[],{"trials":3432,"activeCount":97,"soonestReadout":1911},[3433],{"nctId":1908,"briefTitle":1909,"status":111,"phases":3434,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":544,"conditions":3435,"interventions":3436},[90],[1914],[1916,1889],{"trials":3438,"activeCount":101},[],{"trials":3440,"activeCount":101},[],{"trials":3442,"activeCount":101},[],{"intervention":3444,"totalTrials":97,"cells":3445},"Dostarlimab",{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3447,"activeCount":101},[],{"trials":3449,"activeCount":101},[],{"trials":3451,"activeCount":97,"soonestReadout":3456},[3452],{"nctId":3453,"briefTitle":3454,"status":111,"phases":3455,"primaryCompletion":3456,"completion":2032,"start":3457,"enrollment":1035,"conditions":3458,"interventions":3460},"NCT05526989","Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma",[90],"2026-11","2022-12-28",[3459],"Penile Carcinoma",[3444,3461],"Niraparib",{"trials":3463,"activeCount":101},[],{"trials":3465,"activeCount":101},[],{"trials":3467,"activeCount":101},[],{"intervention":3461,"totalTrials":97,"cells":3469},{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":101},[],{"trials":3475,"activeCount":97,"soonestReadout":3456},[3476],{"nctId":3453,"briefTitle":3454,"status":111,"phases":3477,"primaryCompletion":3456,"completion":2032,"start":3457,"enrollment":1035,"conditions":3478,"interventions":3479},[90],[3459],[3444,3461],{"trials":3481,"activeCount":101},[],{"trials":3483,"activeCount":101},[],{"trials":3485,"activeCount":101},[],{"intervention":621,"totalTrials":97,"cells":3487},{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3489,"activeCount":101},[],{"trials":3491,"activeCount":101},[],{"trials":3493,"activeCount":97,"soonestReadout":612},[3494],{"nctId":609,"briefTitle":610,"status":111,"phases":3495,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":3496,"interventions":3497},[90],[616],[618,619,620,495,621,622],{"trials":3499,"activeCount":101},[],{"trials":3501,"activeCount":101},[],{"trials":3503,"activeCount":101},[],{"intervention":1981,"totalTrials":97,"cells":3505},{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3510,"PHASE3":3516,"PHASE4":3518,"NA":3520},{"trials":3507,"activeCount":101},[],{"trials":3509,"activeCount":101},[],{"trials":3511,"activeCount":97,"soonestReadout":1976},[3512],{"nctId":1973,"briefTitle":1974,"status":111,"phases":3513,"primaryCompletion":1976,"completion":180,"start":1977,"enrollment":1531,"conditions":3514,"interventions":3515},[89,90],[225,1979],[1521,1981],{"trials":3517,"activeCount":101},[],{"trials":3519,"activeCount":101},[],{"trials":3521,"activeCount":101},[],{"intervention":3523,"totalTrials":97,"cells":3524},"Luspatercept",{"EARLY_PHASE1":3525,"PHASE1":3527,"PHASE2":3529,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3526,"activeCount":101},[],{"trials":3528,"activeCount":101},[],{"trials":3530,"activeCount":97,"soonestReadout":3535},[3531],{"nctId":3532,"briefTitle":3533,"status":177,"phases":3534,"primaryCompletion":3535,"completion":677,"start":3536,"enrollment":487,"conditions":3537,"interventions":3539},"NCT05732961","Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS\u002FMPN Neoplasms",[90],"2026-03-26","2023-02-21",[755,1137,3538],"Anemia",[3523],{"trials":3541,"activeCount":101},[],{"trials":3543,"activeCount":101},[],{"trials":3545,"activeCount":101},[],{"intervention":3547,"totalTrials":97,"cells":3548},"Afatinib 40 MG",{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3550,"activeCount":101},[],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":97,"soonestReadout":1251},[3555],{"nctId":3556,"briefTitle":3557,"status":111,"phases":3558,"primaryCompletion":1251,"completion":1921,"start":3559,"enrollment":1035,"conditions":3560,"interventions":3561},"NCT05070403","Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma",[90],"2021-10-01",[241],[3547],{"trials":3563,"activeCount":101},[],{"trials":3565,"activeCount":101},[],{"trials":3567,"activeCount":101},[],{"intervention":3569,"totalTrials":97,"cells":3570},"Pirtobrutinib",{"EARLY_PHASE1":3571,"PHASE1":3573,"PHASE2":3575,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3572,"activeCount":101},[],{"trials":3574,"activeCount":101},[],{"trials":3576,"activeCount":97,"soonestReadout":554},[3577],{"nctId":3578,"briefTitle":3579,"status":111,"phases":3580,"primaryCompletion":554,"completion":554,"start":3581,"enrollment":116,"conditions":3582,"interventions":3583},"NCT06553872","Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R\u002FR MCL",[90],"2024-08-23",[732],[3569,3584],"Brexucabtagene Autoleucel",{"trials":3586,"activeCount":101},[],{"trials":3588,"activeCount":101},[],{"trials":3590,"activeCount":101},[],{"intervention":3584,"totalTrials":97,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3594,"activeCount":101},[],{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":97,"soonestReadout":554},[3599],{"nctId":3578,"briefTitle":3579,"status":111,"phases":3600,"primaryCompletion":554,"completion":554,"start":3581,"enrollment":116,"conditions":3601,"interventions":3602},[90],[732],[3569,3584],{"trials":3604,"activeCount":101},[],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[],{"intervention":3610,"totalTrials":97,"cells":3611},"Sunphenon",{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3613,"activeCount":101},[],{"trials":3615,"activeCount":101},[],{"trials":3617,"activeCount":97,"soonestReadout":3622},[3618],{"nctId":3619,"briefTitle":3620,"status":177,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":3624,"conditions":3625,"interventions":3627},"NCT04300855","Clinical Trial of Green Tea Catechins in Men on Active Surveillance",[90],"2027-02-27","2020-08-21",115,[18,3626],"Prostate Adenocarcinoma",[3610],{"trials":3629,"activeCount":101},[],{"trials":3631,"activeCount":101},[],{"trials":3633,"activeCount":101},[],{"intervention":650,"totalTrials":97,"cells":3635},{"EARLY_PHASE1":3636,"PHASE1":3638,"PHASE2":3640,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3637,"activeCount":101},[],{"trials":3639,"activeCount":101},[],{"trials":3641,"activeCount":97,"soonestReadout":180},[3642],{"nctId":641,"briefTitle":642,"status":111,"phases":3643,"primaryCompletion":180,"completion":279,"start":644,"enrollment":645,"conditions":3644,"interventions":3645},[90],[647,648],[495,650],{"trials":3647,"activeCount":101},[],{"trials":3649,"activeCount":101},[],{"trials":3651,"activeCount":101},[],{"intervention":2496,"totalTrials":97,"cells":3653},{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3664,"PHASE4":3666,"NA":3668},{"trials":3655,"activeCount":101},[],{"trials":3657,"activeCount":101},[],{"trials":3659,"activeCount":97,"soonestReadout":2491},[3660],{"nctId":2488,"briefTitle":2489,"status":111,"phases":3661,"primaryCompletion":2491,"completion":2061,"start":2492,"enrollment":125,"conditions":3662,"interventions":3663},[90],[2494],[2496,1732],{"trials":3665,"activeCount":101},[],{"trials":3667,"activeCount":101},[],{"trials":3669,"activeCount":101},[],{"intervention":2065,"totalTrials":97,"cells":3671},{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3676,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3673,"activeCount":101},[],{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":97,"soonestReadout":2060},[3678],{"nctId":2057,"briefTitle":2058,"status":177,"phases":3679,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":507,"conditions":3680,"interventions":3681},[90],[1914],[188,2065],{"trials":3683,"activeCount":101},[],{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[],{"intervention":398,"totalTrials":97,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3700,"PHASE4":3702,"NA":3704},{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[],{"trials":3695,"activeCount":97,"soonestReadout":81},[3696],{"nctId":79,"briefTitle":80,"status":177,"phases":3697,"primaryCompletion":81,"completion":391,"start":392,"enrollment":393,"conditions":3698,"interventions":3699},[89,90],[283,395,396],[52,172,398],{"trials":3701,"activeCount":101},[],{"trials":3703,"activeCount":101},[],{"trials":3705,"activeCount":101},[],{"intervention":3707,"totalTrials":97,"cells":3708},"Melphalan\u002FHDS",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3710,"activeCount":101},[],{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":97,"soonestReadout":3719},[3715],{"nctId":3716,"briefTitle":3717,"status":111,"phases":3718,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":1095,"conditions":3721,"interventions":3722},"NCT07276386","Phase 2 Combination of Melphalan\u002FHDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",[90],"2030-12","2025-12-31",[1914],[3707,3723],"Tebentafusp",{"trials":3725,"activeCount":101},[],{"trials":3727,"activeCount":101},[],{"trials":3729,"activeCount":101},[],{"intervention":3723,"totalTrials":97,"cells":3731},{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3733,"activeCount":101},[],{"trials":3735,"activeCount":101},[],{"trials":3737,"activeCount":97,"soonestReadout":3719},[3738],{"nctId":3716,"briefTitle":3717,"status":111,"phases":3739,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":1095,"conditions":3740,"interventions":3741},[90],[1914],[3707,3723],{"trials":3743,"activeCount":101},[],{"trials":3745,"activeCount":101},[],{"trials":3747,"activeCount":101},[],{"intervention":3749,"totalTrials":97,"cells":3750},"Tecartus",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3752,"activeCount":101},[],{"trials":3754,"activeCount":101},[],{"trials":3756,"activeCount":97,"soonestReadout":3761},[3757],{"nctId":3758,"briefTitle":3759,"status":111,"phases":3760,"primaryCompletion":3761,"completion":3761,"start":3762,"enrollment":116,"conditions":3763,"interventions":3765},"NCT06144606","Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",[90],"2028-11-15","2023-12-26",[3764,733],"B-Cell Lymphoblastic Leukemia",[3749],{"trials":3767,"activeCount":101},[],{"trials":3769,"activeCount":101},[],{"trials":3771,"activeCount":101},[],{"intervention":77,"totalTrials":97,"cells":3773},{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3784,"PHASE4":3786,"NA":3788},{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[],{"trials":3779,"activeCount":97,"soonestReadout":76},[3780],{"nctId":74,"briefTitle":75,"status":177,"phases":3781,"primaryCompletion":76,"completion":2287,"start":2288,"enrollment":211,"conditions":3782,"interventions":3783},[90],[21],[77,888,2291,1157],{"trials":3785,"activeCount":101},[],{"trials":3787,"activeCount":101},[],{"trials":3789,"activeCount":101},[],{"intervention":2291,"totalTrials":97,"cells":3791},{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3802,"PHASE4":3804,"NA":3806},{"trials":3793,"activeCount":101},[],{"trials":3795,"activeCount":101},[],{"trials":3797,"activeCount":97,"soonestReadout":76},[3798],{"nctId":74,"briefTitle":75,"status":177,"phases":3799,"primaryCompletion":76,"completion":2287,"start":2288,"enrollment":211,"conditions":3800,"interventions":3801},[90],[21],[77,888,2291,1157],{"trials":3803,"activeCount":101},[],{"trials":3805,"activeCount":101},[],{"trials":3807,"activeCount":101},[],{"intervention":3809,"totalTrials":97,"cells":3810},"Digoxin",{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3815,"PHASE3":3826,"PHASE4":3828,"NA":3830},{"trials":3812,"activeCount":101},[],{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":97,"soonestReadout":1251},[3817],{"nctId":3818,"briefTitle":3819,"status":111,"phases":3820,"primaryCompletion":1251,"completion":1251,"start":3821,"enrollment":22,"conditions":3822,"interventions":3825},"NCT06701812","Digoxin Medulloblastoma Study",[90],"2026-01-15",[3823,3824],"Medulloblastoma","Medulloblastoma, Non-WNT\u002FNon-SHH",[3809],{"trials":3827,"activeCount":101},[],{"trials":3829,"activeCount":101},[],{"trials":3831,"activeCount":101},[],{"intervention":1535,"totalTrials":97,"cells":3833},{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3835,"activeCount":101},[],{"trials":3837,"activeCount":101},[],{"trials":3839,"activeCount":97,"soonestReadout":1251},[3840],{"nctId":1527,"briefTitle":1528,"status":111,"phases":3841,"primaryCompletion":1251,"completion":1251,"start":1530,"enrollment":1531,"conditions":3842,"interventions":3843},[89,90],[15,1533],[1535,377],{"trials":3845,"activeCount":101},[],{"trials":3847,"activeCount":101},[],{"trials":3849,"activeCount":101},[],{"intervention":3851,"totalTrials":97,"cells":3852},"DC1 Vaccine",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3854,"activeCount":101},[],{"trials":3856,"activeCount":101},[],{"trials":3858,"activeCount":97,"soonestReadout":3863},[3859],{"nctId":3860,"briefTitle":3861,"status":177,"phases":3862,"primaryCompletion":3863,"completion":279,"start":3864,"enrollment":3865,"conditions":3866,"interventions":3872},"NCT03384914","Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer",[90],"2025-12-22","2018-02-19",119,[1207,1206,3867,3868,3869,3870,1190,3871],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Residual Disease","HER2 Positive Breast Carcinoma",[3851,3873],"WOKVAC Vaccine",{"trials":3875,"activeCount":101},[],{"trials":3877,"activeCount":101},[],{"trials":3879,"activeCount":101},[],{"intervention":3873,"totalTrials":97,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3886,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3883,"activeCount":101},[],{"trials":3885,"activeCount":101},[],{"trials":3887,"activeCount":97,"soonestReadout":3863},[3888],{"nctId":3860,"briefTitle":3861,"status":177,"phases":3889,"primaryCompletion":3863,"completion":279,"start":3864,"enrollment":3865,"conditions":3890,"interventions":3891},[90],[1207,1206,3867,3868,3869,3870,1190,3871],[3851,3873],{"trials":3893,"activeCount":101},[],{"trials":3895,"activeCount":101},[],{"trials":3897,"activeCount":101},[],{"intervention":3899,"totalTrials":97,"cells":3900},"Chimeric Antigen Receptor T-Cell Therapy",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3914,"PHASE4":3916,"NA":3918},{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[],{"trials":3906,"activeCount":97,"soonestReadout":180},[3907],{"nctId":3908,"briefTitle":3909,"status":111,"phases":3910,"primaryCompletion":180,"completion":180,"start":76,"enrollment":595,"conditions":3911,"interventions":3913},"NCT06104592","Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R\u002FR LBCL",[90],[2494,3912],"Relapsed Non-Hodgkin Lymphoma",[3899],{"trials":3915,"activeCount":101},[],{"trials":3917,"activeCount":101},[],{"trials":3919,"activeCount":101},[],{"intervention":1326,"totalTrials":97,"cells":3921},{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3926,"PHASE3":3932,"PHASE4":3934,"NA":3936},{"trials":3923,"activeCount":101},[],{"trials":3925,"activeCount":101},[],{"trials":3927,"activeCount":97,"soonestReadout":1321},[3928],{"nctId":1318,"briefTitle":1319,"status":177,"phases":3929,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1035,"conditions":3930,"interventions":3931},[90],[1324],[1326,1327,1264],{"trials":3933,"activeCount":101},[],{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[],{"intervention":1327,"totalTrials":97,"cells":3939},{"EARLY_PHASE1":3940,"PHASE1":3942,"PHASE2":3944,"PHASE3":3950,"PHASE4":3952,"NA":3954},{"trials":3941,"activeCount":101},[],{"trials":3943,"activeCount":101},[],{"trials":3945,"activeCount":97,"soonestReadout":1321},[3946],{"nctId":1318,"briefTitle":1319,"status":177,"phases":3947,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1035,"conditions":3948,"interventions":3949},[90],[1324],[1326,1327,1264],{"trials":3951,"activeCount":101},[],{"trials":3953,"activeCount":101},[],{"trials":3955,"activeCount":101},[],{"intervention":449,"totalTrials":97,"cells":3957},{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":3968,"PHASE4":3970,"NA":3972},{"trials":3959,"activeCount":101},[],{"trials":3961,"activeCount":101},[],{"trials":3963,"activeCount":97,"soonestReadout":443},[3964],{"nctId":440,"briefTitle":441,"status":177,"phases":3965,"primaryCompletion":443,"completion":180,"start":444,"enrollment":445,"conditions":3966,"interventions":3967},[89,90],[18,447],[52,449],{"trials":3969,"activeCount":101},[],{"trials":3971,"activeCount":101},[],{"trials":3973,"activeCount":101},[],{"intervention":941,"totalTrials":97,"cells":3975},{"EARLY_PHASE1":3976,"PHASE1":3978,"PHASE2":3980,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3977,"activeCount":101},[],{"trials":3979,"activeCount":101},[],{"trials":3981,"activeCount":97,"soonestReadout":114},[3982],{"nctId":934,"briefTitle":935,"status":111,"phases":3983,"primaryCompletion":114,"completion":937,"start":938,"enrollment":566,"conditions":3984,"interventions":3985},[89,90],[32],[157,158,160,941],{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[],{"intervention":1338,"totalTrials":97,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4004,"PHASE4":4006,"NA":4008},{"trials":3995,"activeCount":101},[],{"trials":3997,"activeCount":101},[],{"trials":3999,"activeCount":97,"soonestReadout":1332},[4000],{"nctId":1329,"briefTitle":1330,"status":177,"phases":4001,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":544,"conditions":4002,"interventions":4003},[90],[18,1336],[1338,1339,1264,1340],{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[],{"intervention":1339,"totalTrials":97,"cells":4011},{"EARLY_PHASE1":4012,"PHASE1":4014,"PHASE2":4016,"PHASE3":4022,"PHASE4":4024,"NA":4026},{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":97,"soonestReadout":1332},[4018],{"nctId":1329,"briefTitle":1330,"status":177,"phases":4019,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":544,"conditions":4020,"interventions":4021},[90],[18,1336],[1338,1339,1264,1340],{"trials":4023,"activeCount":101},[],{"trials":4025,"activeCount":101},[],{"trials":4027,"activeCount":101},[],{"intervention":1340,"totalTrials":97,"cells":4029},{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4040,"PHASE4":4042,"NA":4044},{"trials":4031,"activeCount":101},[],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":97,"soonestReadout":1332},[4036],{"nctId":1329,"briefTitle":1330,"status":177,"phases":4037,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":544,"conditions":4038,"interventions":4039},[90],[18,1336],[1338,1339,1264,1340],{"trials":4041,"activeCount":101},[],{"trials":4043,"activeCount":101},[],{"trials":4045,"activeCount":101},[],{"intervention":1803,"totalTrials":97,"cells":4047},{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":97,"soonestReadout":1796},[4054],{"nctId":1793,"briefTitle":1794,"status":111,"phases":4055,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":917,"conditions":4056,"interventions":4057},[90],[1799,1800,1801],[1803,1756],{"trials":4059,"activeCount":101},[],{"trials":4061,"activeCount":101},[],{"trials":4063,"activeCount":101},[],{"intervention":4065,"totalTrials":97,"cells":4066},"Enfortumab Vedotin",{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4081,"PHASE4":4083,"NA":4085},{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[],{"trials":4072,"activeCount":97,"soonestReadout":4077},[4073],{"nctId":4074,"briefTitle":4075,"status":111,"phases":4076,"primaryCompletion":4077,"completion":4077,"start":4078,"enrollment":582,"conditions":4079,"interventions":4080},"NCT06553885","Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC",[90],"2029-09","2025-04-01",[270,2955],[4065],{"trials":4082,"activeCount":101},[],{"trials":4084,"activeCount":101},[],{"trials":4086,"activeCount":101},[],{"intervention":695,"totalTrials":97,"cells":4088},{"EARLY_PHASE1":4089,"PHASE1":4091,"PHASE2":4093,"PHASE3":4099,"PHASE4":4101,"NA":4103},{"trials":4090,"activeCount":101},[],{"trials":4092,"activeCount":101},[],{"trials":4094,"activeCount":97,"soonestReadout":689},[4095],{"nctId":686,"briefTitle":687,"status":177,"phases":4096,"primaryCompletion":689,"completion":677,"start":690,"enrollment":19,"conditions":4097,"interventions":4098},[90],[475,692,693],[695,495],{"trials":4100,"activeCount":101},[],{"trials":4102,"activeCount":101},[],{"trials":4104,"activeCount":101},[],{"intervention":4106,"totalTrials":97,"cells":4107},"Elranatamab",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4122,"PHASE4":4124,"NA":4126},{"trials":4109,"activeCount":101},[],{"trials":4111,"activeCount":101},[],{"trials":4113,"activeCount":97,"soonestReadout":4118},[4114],{"nctId":4115,"briefTitle":4116,"status":111,"phases":4117,"primaryCompletion":4118,"completion":4118,"start":4119,"enrollment":16,"conditions":4120,"interventions":4121},"NCT06947083","Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma",[90],"2029-04","2025-05-27",[885],[4106],{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"trials":4127,"activeCount":101},[],{"intervention":963,"totalTrials":97,"cells":4129},{"EARLY_PHASE1":4130,"PHASE1":4132,"PHASE2":4134,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4131,"activeCount":101},[],{"trials":4133,"activeCount":101},[],{"trials":4135,"activeCount":97,"soonestReadout":391},[4136],{"nctId":954,"briefTitle":955,"status":177,"phases":4137,"primaryCompletion":391,"completion":957,"start":958,"enrollment":233,"conditions":4138,"interventions":4139},[90],[960],[803,157,962,963,964],{"trials":4141,"activeCount":101},[],{"trials":4143,"activeCount":101},[],{"trials":4145,"activeCount":101},[],{"intervention":964,"totalTrials":97,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4149,"activeCount":101},[],{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":97,"soonestReadout":391},[4154],{"nctId":954,"briefTitle":955,"status":177,"phases":4155,"primaryCompletion":391,"completion":957,"start":958,"enrollment":233,"conditions":4156,"interventions":4157},[90],[960],[803,157,962,963,964],{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[],{"intervention":4165,"totalTrials":189,"cells":4166},"Vyxeos",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4189,"PHASE3":4191,"PHASE4":4193,"NA":4195},{"trials":4168,"activeCount":101},[],{"trials":4170,"activeCount":189,"soonestReadout":4183},[4171,4179],{"nctId":4172,"briefTitle":4173,"status":111,"phases":4174,"primaryCompletion":1229,"completion":1229,"start":4175,"enrollment":1095,"conditions":4176,"interventions":4177},"NCT05558124","CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML",[89],"2023-02-16",[1132],[4165,4178],"Gemtuzumab Ozogamicin",{"nctId":4180,"briefTitle":4181,"status":111,"phases":4182,"primaryCompletion":4183,"completion":1276,"start":4184,"enrollment":27,"conditions":4185,"interventions":4187},"NCT05024552","Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML",[89],"2027-02-15","2022-02-25",[4186],"Acute Myeloid Leukemia With FLT3\u002FITD Mutation",[4188,4165],"Gilteritinib",{"trials":4190,"activeCount":101},[],{"trials":4192,"activeCount":101},[],{"trials":4194,"activeCount":101},[],{"trials":4196,"activeCount":101},[],{"intervention":861,"totalTrials":507,"cells":4198},{"EARLY_PHASE1":4199,"PHASE1":4201,"PHASE2":4207,"PHASE3":4249,"PHASE4":4251,"NA":4253},{"trials":4200,"activeCount":101},[],{"trials":4202,"activeCount":97,"soonestReadout":798},[4203],{"nctId":795,"briefTitle":796,"status":111,"phases":4204,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":4205,"interventions":4206},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":4208,"activeCount":101},[4209,4219,4223,4227,4231,4240],{"nctId":4210,"briefTitle":4211,"status":147,"phases":4212,"primaryCompletion":2612,"completion":4213,"start":4214,"enrollment":4215,"conditions":4216,"interventions":4217},"NCT00005793","A Phase I\u002FII Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide",[89,90],"2006-11","1999-07",41,[35],[2525,4218,810,809],"Daunorubicin",{"nctId":2368,"briefTitle":2369,"status":147,"phases":4220,"primaryCompletion":2371,"completion":2094,"start":1646,"enrollment":2372,"conditions":4221,"interventions":4222},[89,90],[26],[2375,619,810],{"nctId":851,"briefTitle":852,"status":147,"phases":4224,"primaryCompletion":820,"completion":854,"start":855,"enrollment":856,"conditions":4225,"interventions":4226},[90],[858],[860,861,862],{"nctId":900,"briefTitle":901,"status":249,"phases":4228,"primaryCompletion":903,"completion":903,"start":904,"enrollment":730,"conditions":4229,"interventions":4230},[89,90],[632],[873,907,860,861,908,909],{"nctId":4232,"briefTitle":4233,"status":249,"phases":4234,"primaryCompletion":4235,"completion":4235,"start":4236,"conditions":4237,"interventions":4238},"NCT00006032","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer",[90],"2001-04","2000-03",[15],[861,4239,909],"ifosfamide",{"nctId":4241,"briefTitle":4242,"status":147,"phases":4243,"primaryCompletion":820,"completion":4244,"start":4245,"enrollment":595,"conditions":4246,"interventions":4247},"NCT00006373","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma",[90],"2011-12","2000-02",[858],[861,4239,909,4248],"Mesna",{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[],{"intervention":807,"totalTrials":507,"cells":4256},{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4282,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4258,"activeCount":101},[],{"trials":4260,"activeCount":97,"soonestReadout":798},[4261,4270,4274,4278],{"nctId":4262,"briefTitle":4263,"status":249,"phases":4264,"primaryCompletion":4265,"completion":4266,"start":4267,"enrollment":730,"conditions":4268,"interventions":4269},"NCT02283359","Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus",[89],"2015-12","2016-01","2014-12",[2557,569],[2247,807],{"nctId":2716,"briefTitle":2717,"status":147,"phases":4271,"primaryCompletion":2719,"completion":2719,"start":948,"enrollment":336,"conditions":4272,"interventions":4273},[89],[523],[86,215,807],{"nctId":1549,"briefTitle":1550,"status":147,"phases":4275,"primaryCompletion":1552,"completion":1553,"start":1554,"enrollment":19,"conditions":4276,"interventions":4277},[89],[1556,1557],[803,807,527,1559],{"nctId":795,"briefTitle":796,"status":111,"phases":4279,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":4280,"interventions":4281},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":4283,"activeCount":101},[4284,4288,4292],{"nctId":2553,"briefTitle":2554,"status":147,"phases":4285,"primaryCompletion":1376,"completion":1376,"start":1301,"enrollment":198,"conditions":4286,"interventions":4287},[90],[2557,569],[618,807,2559],{"nctId":2661,"briefTitle":2662,"status":147,"phases":4289,"primaryCompletion":830,"completion":830,"start":2664,"enrollment":821,"conditions":4290,"interventions":4291},[90],[269],[2088,573,807],{"nctId":4293,"briefTitle":4294,"status":147,"phases":4295,"primaryCompletion":4296,"completion":4296,"start":4297,"enrollment":1265,"conditions":4298,"interventions":4299},"NCT00005626","Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)",[90],"2003-11","1998-02",[35,858],[807],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[],{"intervention":67,"totalTrials":9,"cells":4307},{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4343,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4309,"activeCount":101},[],{"trials":4311,"activeCount":97,"soonestReadout":66},[4312,4320,4328],{"nctId":4313,"briefTitle":4314,"status":552,"phases":4315,"primaryCompletion":564,"completion":564,"start":4316,"enrollment":233,"conditions":4317,"interventions":4318},"NCT06963346","Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents",[89],"2025-06-24",[201],[4319,67],"Romidepsin",{"nctId":64,"briefTitle":65,"status":177,"phases":4321,"primaryCompletion":66,"completion":180,"start":4322,"enrollment":1035,"conditions":4323,"interventions":4325},[89],"2019-06-06",[4324,255],"Small Cell Lung Cancer Extensive Stage",[67,4326,4327,4326],"Tremelimumab","Olaparib Pill",{"nctId":4329,"briefTitle":4330,"status":147,"phases":4331,"primaryCompletion":4332,"completion":4333,"start":4334,"enrollment":336,"conditions":4335,"interventions":4341},"NCT03381183","IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma",[89],"2022-05-12","2023-06-30","2019-08-21",[241,243,510,4336,4337,4338,4339,4340],"Oral Cavity Squamous Cell Carcinoma","Oropharynx Squamous Cell Carcinoma","Paranasal Sinus Squamous Cell Carcinoma","Hypopharynx Squamous Cell Carcinoma","Larynx Squamous Cell Carcinoma",[67,4342],"IRX-2 Regimen",{"trials":4344,"activeCount":101},[4345,4358],{"nctId":4346,"briefTitle":4347,"status":249,"phases":4348,"primaryCompletion":4349,"completion":4350,"start":4351,"enrollment":30,"conditions":4352,"interventions":4354},"NCT03874325","Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer",[90],"2020-11-15","2021-01-06","2019-04-26",[15,4353],"Hormone Receptor Positive Tumor",[67,4355,4356,4357],"Anastrozole 1mg","Letrozole 2.5mg","Exemestane 25 MG",{"nctId":4359,"briefTitle":4360,"status":249,"phases":4361,"primaryCompletion":4362,"completion":4363,"start":4364,"enrollment":30,"conditions":4365,"interventions":4367},"NCT02901548","Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder",[90],"2020-07-24","2021-09-07","2017-02-16",[4366,201],"Carcinoma in Situ of Bladder",[67],{"trials":4369,"activeCount":101},[],{"trials":4371,"activeCount":101},[],{"trials":4373,"activeCount":101},[],{"intervention":527,"totalTrials":9,"cells":4375},{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4401,"PHASE3":4410,"PHASE4":4412,"NA":4414},{"trials":4377,"activeCount":101},[],{"trials":4379,"activeCount":97,"soonestReadout":798},[4380,4384,4388,4397],{"nctId":516,"briefTitle":517,"status":147,"phases":4381,"primaryCompletion":519,"completion":520,"start":521,"enrollment":198,"conditions":4382,"interventions":4383},[89],[523,524,525],[495,86,527],{"nctId":1549,"briefTitle":1550,"status":147,"phases":4385,"primaryCompletion":1552,"completion":1553,"start":1554,"enrollment":19,"conditions":4386,"interventions":4387},[89],[1556,1557],[803,807,527,1559],{"nctId":4389,"briefTitle":4390,"status":249,"phases":4391,"primaryCompletion":4392,"completion":4392,"start":4393,"enrollment":1265,"conditions":4394,"interventions":4395},"NCT00437957","Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases",[89],"2009-04","2006-12",[225],[527,4396],"Valproic Acid",{"nctId":795,"briefTitle":796,"status":111,"phases":4398,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":4399,"interventions":4400},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":4402,"activeCount":101},[4403],{"nctId":4404,"briefTitle":4405,"status":249,"phases":4406,"primaryCompletion":2371,"completion":2371,"start":2612,"enrollment":97,"conditions":4407,"interventions":4409},"NCT00365222","Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma",[90],[523,4408],"Gliosarcoma",[527],{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[],{"trials":4415,"activeCount":101},[],{"intervention":804,"totalTrials":9,"cells":4417},{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4430,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4419,"activeCount":101},[],{"trials":4421,"activeCount":97,"soonestReadout":798},[4422,4426],{"nctId":1561,"briefTitle":1562,"status":147,"phases":4423,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":182,"conditions":4424,"interventions":4425},[89],[733],[1559,803,888,1569,804,1570],{"nctId":795,"briefTitle":796,"status":111,"phases":4427,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":4428,"interventions":4429},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":4431,"activeCount":101},[4432,4436,4440],{"nctId":2303,"briefTitle":2304,"status":249,"phases":4433,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":97,"conditions":4434,"interventions":4435},[90],[24],[1295,2310,804,2311,888,2312],{"nctId":911,"briefTitle":912,"status":147,"phases":4437,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":4438,"interventions":4439},[90],[858],[157,804,803,920,888,921,922],{"nctId":1359,"briefTitle":1360,"status":147,"phases":4441,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":556,"conditions":4442,"interventions":4443},[90],[15],[1367,1264,804],{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":101},[],{"intervention":4451,"totalTrials":730,"cells":4452},"Vemurafenib",{"EARLY_PHASE1":4453,"PHASE1":4455,"PHASE2":4473,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4454,"activeCount":101},[],{"trials":4456,"activeCount":97,"soonestReadout":46},[4457,4466],{"nctId":4458,"briefTitle":4459,"status":147,"phases":4460,"primaryCompletion":4461,"completion":4462,"start":4463,"enrollment":198,"conditions":4464,"interventions":4465},"NCT01657591","Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III\u002FIV Melanoma",[89],"2016-09-20","2021-09-21","2012-07-27",[32],[47,4451],{"nctId":44,"briefTitle":45,"status":177,"phases":4467,"primaryCompletion":46,"completion":4468,"start":4469,"enrollment":19,"conditions":4470,"interventions":4471},[89],"2026-11-04","2016-09-07",[32,154],[47,4451,4472],"Cobimetinib",{"trials":4474,"activeCount":101},[4475],{"nctId":4476,"briefTitle":4477,"status":147,"phases":4478,"primaryCompletion":2459,"completion":4479,"start":4480,"enrollment":30,"conditions":4481,"interventions":4482},"NCT01659151","Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma",[90],"2025-08-19","2012-08-03",[169],[4483,4451,4484],"High Dose Interleukin-2","Lymphodepletion",{"trials":4486,"activeCount":101},[],{"trials":4488,"activeCount":101},[],{"trials":4490,"activeCount":101},[],{"intervention":4239,"totalTrials":730,"cells":4492},{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4501,"PHASE3":4511,"PHASE4":4513,"NA":4515},{"trials":4494,"activeCount":101},[],{"trials":4496,"activeCount":97,"soonestReadout":798},[4497],{"nctId":795,"briefTitle":796,"status":111,"phases":4498,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":4499,"interventions":4500},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":4502,"activeCount":101},[4503,4507],{"nctId":4232,"briefTitle":4233,"status":249,"phases":4504,"primaryCompletion":4235,"completion":4235,"start":4236,"conditions":4505,"interventions":4506},[90],[15],[861,4239,909],{"nctId":4241,"briefTitle":4242,"status":147,"phases":4508,"primaryCompletion":820,"completion":4244,"start":4245,"enrollment":595,"conditions":4509,"interventions":4510},[90],[858],[861,4239,909,4248],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[],{"trials":4516,"activeCount":101},[],{"intervention":340,"totalTrials":189,"cells":4518},{"EARLY_PHASE1":4519,"PHASE1":4521,"PHASE2":4527,"PHASE3":4533,"PHASE4":4535,"NA":4537},{"trials":4520,"activeCount":101},[],{"trials":4522,"activeCount":97,"soonestReadout":505},[4523],{"nctId":502,"briefTitle":503,"status":177,"phases":4524,"primaryCompletion":505,"completion":391,"start":506,"enrollment":507,"conditions":4525,"interventions":4526},[89],[509,510],[512,495,513,157,158,514],{"trials":4528,"activeCount":101},[4529],{"nctId":331,"briefTitle":332,"status":249,"phases":4530,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":4531,"interventions":4532},[89,90],[338],[340,341,52],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"intervention":4540,"totalTrials":189,"cells":4541},"Cemiplimab-Rwlc",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4553,"PHASE3":4564,"PHASE4":4566,"NA":4568},{"trials":4543,"activeCount":101},[],{"trials":4545,"activeCount":97,"soonestReadout":1921},[4546],{"nctId":4547,"briefTitle":4548,"status":111,"phases":4549,"primaryCompletion":1921,"completion":1921,"start":334,"enrollment":566,"conditions":4550,"interventions":4552},"NCT04975152","Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",[89],[475,4551],"Cutaneous Squamous Cell Carcinoma",[4540],{"trials":4554,"activeCount":101},[4555],{"nctId":4556,"briefTitle":4557,"status":249,"phases":4558,"primaryCompletion":4559,"completion":4559,"start":4560,"enrollment":730,"conditions":4561,"interventions":4563},"NCT04242173","Cemiplimab-rwlc for Unresectable Locally Recurrent and\u002For Metastatic CSCC",[90],"2022-05-26","2020-06-25",[4551,4562],"Cutaneous Squamous Cell Carcinoma of the Head and Neck",[4540],{"trials":4565,"activeCount":101},[],{"trials":4567,"activeCount":101},[],{"trials":4569,"activeCount":101},[],{"intervention":808,"totalTrials":189,"cells":4571},{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4580,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4573,"activeCount":101},[],{"trials":4575,"activeCount":97,"soonestReadout":798},[4576],{"nctId":795,"briefTitle":796,"status":111,"phases":4577,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":4578,"interventions":4579},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":4581,"activeCount":101},[4582],{"nctId":4583,"briefTitle":4584,"status":249,"phases":4585,"primaryCompletion":4586,"completion":579,"start":4587,"enrollment":487,"conditions":4588,"interventions":4595},"NCT03630120","Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer",[90],"2019-11-14","2018-08-06",[4589,4590,4591,4592,4593,4594],"Thyroid Cancer","Thyroid Cancer, Medullary","Differentiated Thyroid Cancer","Papillary Thyroid Cancer","Follicular Thyroid Cancer","Poorly Differentiated Thyroid Gland Carcinoma",[672,4596,808,4597],"Sorafenib","Vandetanib",{"trials":4599,"activeCount":101},[],{"trials":4601,"activeCount":101},[],{"trials":4603,"activeCount":101},[],{"intervention":203,"totalTrials":189,"cells":4605},{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4622,"PHASE3":4624,"PHASE4":4626,"NA":4628},{"trials":4607,"activeCount":101},[],{"trials":4609,"activeCount":97,"soonestReadout":1252},[4610,4614],{"nctId":193,"briefTitle":194,"status":147,"phases":4611,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":4612,"interventions":4613},[89],[200,201],[203,52],{"nctId":4615,"briefTitle":4616,"status":177,"phases":4617,"primaryCompletion":1252,"completion":1252,"start":4618,"enrollment":281,"conditions":4619,"interventions":4621},"NCT06253845","Study of CG0070 After Transurethral Resection in Patients With IR NMIBC",[89],"2024-03-01",[4620],"Non-muscle Invasive Bladder Cancer",[203],{"trials":4623,"activeCount":101},[],{"trials":4625,"activeCount":101},[],{"trials":4627,"activeCount":101},[],{"trials":4629,"activeCount":101},[],{"intervention":4631,"totalTrials":189,"cells":4632},"Dendritic Cell Vaccine",{"EARLY_PHASE1":4633,"PHASE1":4648,"PHASE2":4657,"PHASE3":4659,"PHASE4":4661,"NA":4663},{"trials":4634,"activeCount":101},[4635],{"nctId":4636,"briefTitle":4637,"status":147,"phases":4638,"primaryCompletion":4639,"completion":4640,"start":4641,"enrollment":1531,"conditions":4642,"interventions":4646},"NCT03387553","HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer",[88],"2023-08-29","2026-02-19","2018-06-06",[15,1207,1206,4643,1190,3871,4644,4645],"Invasive Breast Cancer","Stage II Breast Cancer","Stage III Breast Cancer",[4631,4647],"Neoadjuvant Chemotherapy",{"trials":4649,"activeCount":97,"soonestReadout":391},[4650],{"nctId":4651,"briefTitle":4652,"status":177,"phases":4653,"primaryCompletion":391,"completion":391,"start":4654,"enrollment":36,"conditions":4655,"interventions":4656},"NCT05809752","A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)",[89],"2023-08-22",[1234,1533,1190],[4631],{"trials":4658,"activeCount":101},[],{"trials":4660,"activeCount":101},[],{"trials":4662,"activeCount":101},[],{"trials":4664,"activeCount":101},[],{"intervention":512,"totalTrials":189,"cells":4666},{"EARLY_PHASE1":4667,"PHASE1":4669,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4685},{"trials":4668,"activeCount":101},[],{"trials":4670,"activeCount":97,"soonestReadout":505},[4671,4675],{"nctId":502,"briefTitle":503,"status":177,"phases":4672,"primaryCompletion":505,"completion":391,"start":506,"enrollment":507,"conditions":4673,"interventions":4674},[89],[509,510],[512,495,513,157,158,514],{"nctId":776,"briefTitle":777,"status":147,"phases":4676,"primaryCompletion":779,"completion":780,"start":209,"enrollment":30,"conditions":4677,"interventions":4678},[89],[169,782,783,784,785,648,647,786,787,788],[512,157,158,160],{"trials":4680,"activeCount":101},[],{"trials":4682,"activeCount":101},[],{"trials":4684,"activeCount":101},[],{"trials":4686,"activeCount":101},[],{"intervention":1283,"totalTrials":189,"cells":4688},{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4707,"PHASE3":4709,"PHASE4":4711,"NA":4713},{"trials":4690,"activeCount":101},[],{"trials":4692,"activeCount":97,"soonestReadout":1275},[4693,4703],{"nctId":4694,"briefTitle":4695,"status":147,"phases":4696,"primaryCompletion":4697,"completion":4698,"start":4699,"enrollment":595,"conditions":4700,"interventions":4701},"NCT03501368","Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma",[89],"2022-10-28","2024-12-30","2018-06-27",[32,782,426],[1283,4702],"Trametinib",{"nctId":1272,"briefTitle":1273,"status":177,"phases":4704,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":198,"conditions":4705,"interventions":4706},[89],[616,26,1279,1280,284,1281],[1283,1264],{"trials":4708,"activeCount":101},[],{"trials":4710,"activeCount":101},[],{"trials":4712,"activeCount":101},[],{"trials":4714,"activeCount":101},[],{"intervention":47,"totalTrials":189,"cells":4716},{"EARLY_PHASE1":4717,"PHASE1":4719,"PHASE2":4729,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4718,"activeCount":101},[],{"trials":4720,"activeCount":97,"soonestReadout":46},[4721,4725],{"nctId":4458,"briefTitle":4459,"status":147,"phases":4722,"primaryCompletion":4461,"completion":4462,"start":4463,"enrollment":198,"conditions":4723,"interventions":4724},[89],[32],[47,4451],{"nctId":44,"briefTitle":45,"status":177,"phases":4726,"primaryCompletion":46,"completion":4468,"start":4469,"enrollment":19,"conditions":4727,"interventions":4728},[89],[32,154],[47,4451,4472],{"trials":4730,"activeCount":101},[],{"trials":4732,"activeCount":101},[],{"trials":4734,"activeCount":101},[],{"trials":4736,"activeCount":101},[],{"intervention":4738,"totalTrials":97,"cells":4739},"Ropeginterferon alfa-2b",{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4754,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4741,"activeCount":101},[],{"trials":4743,"activeCount":97,"soonestReadout":4748},[4744],{"nctId":4745,"briefTitle":4746,"status":111,"phases":4747,"primaryCompletion":4748,"completion":4748,"start":4749,"enrollment":4750,"conditions":4751,"interventions":4753},"NCT07047885","Ropeginterferon in Patients w\u002FCutaneous T-Cell Lymphoma (CTCL)",[89],"2028-06","2025-08-27",38,[4752],"Cutaneous T Cell Lymphoma",[4738],{"trials":4755,"activeCount":101},[],{"trials":4757,"activeCount":101},[],{"trials":4759,"activeCount":101},[],{"trials":4761,"activeCount":101},[],{"intervention":723,"totalTrials":97,"cells":4763},{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4772,"PHASE3":4774,"PHASE4":4776,"NA":4778},{"trials":4765,"activeCount":101},[],{"trials":4767,"activeCount":97,"soonestReadout":716},[4768],{"nctId":713,"briefTitle":714,"status":111,"phases":4769,"primaryCompletion":716,"completion":717,"start":718,"enrollment":719,"conditions":4770,"interventions":4771},[89],[721],[723,158,157],{"trials":4773,"activeCount":101},[],{"trials":4775,"activeCount":101},[],{"trials":4777,"activeCount":101},[],{"trials":4779,"activeCount":101},[],{"intervention":4781,"totalTrials":97,"cells":4782},"Asciminib",{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4795,"PHASE3":4797,"PHASE4":4799,"NA":4801},{"trials":4784,"activeCount":101},[],{"trials":4786,"activeCount":97,"soonestReadout":383},[4787],{"nctId":4788,"briefTitle":4789,"status":111,"phases":4790,"primaryCompletion":383,"completion":383,"start":4791,"enrollment":566,"conditions":4792,"interventions":4794},"NCT07250087","Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",[89],"2026-01-21",[4793],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[4781],{"trials":4796,"activeCount":101},[],{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":101},[],{"trials":4802,"activeCount":101},[],{"intervention":2002,"totalTrials":97,"cells":4804},{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4813,"PHASE3":4815,"PHASE4":4817,"NA":4819},{"trials":4806,"activeCount":101},[],{"trials":4808,"activeCount":97,"soonestReadout":1276},[4809],{"nctId":1995,"briefTitle":1996,"status":111,"phases":4810,"primaryCompletion":1276,"completion":1276,"start":1998,"enrollment":1130,"conditions":4811,"interventions":4812},[89],[2000],[2002,1860,2003],{"trials":4814,"activeCount":101},[],{"trials":4816,"activeCount":101},[],{"trials":4818,"activeCount":101},[],{"trials":4820,"activeCount":101},[],{"intervention":2003,"totalTrials":97,"cells":4822},{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4831,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":97,"soonestReadout":1276},[4827],{"nctId":1995,"briefTitle":1996,"status":111,"phases":4828,"primaryCompletion":1276,"completion":1276,"start":1998,"enrollment":1130,"conditions":4829,"interventions":4830},[89],[2000],[2002,1860,2003],{"trials":4832,"activeCount":101},[],{"trials":4834,"activeCount":101},[],{"trials":4836,"activeCount":101},[],{"trials":4838,"activeCount":101},[],{"intervention":514,"totalTrials":97,"cells":4840},{"EARLY_PHASE1":4841,"PHASE1":4843,"PHASE2":4849,"PHASE3":4851,"PHASE4":4853,"NA":4855},{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":97,"soonestReadout":505},[4845],{"nctId":502,"briefTitle":503,"status":177,"phases":4846,"primaryCompletion":505,"completion":391,"start":506,"enrollment":507,"conditions":4847,"interventions":4848},[89],[509,510],[512,495,513,157,158,514],{"trials":4850,"activeCount":101},[],{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":101},[],{"trials":4856,"activeCount":101},[],{"intervention":4326,"totalTrials":97,"cells":4858},{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4867,"PHASE3":4869,"PHASE4":4871,"NA":4873},{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":97,"soonestReadout":66},[4863],{"nctId":64,"briefTitle":65,"status":177,"phases":4864,"primaryCompletion":66,"completion":180,"start":4322,"enrollment":1035,"conditions":4865,"interventions":4866},[89],[4324,255],[67,4326,4327,4326],{"trials":4868,"activeCount":101},[],{"trials":4870,"activeCount":101},[],{"trials":4872,"activeCount":101},[],{"trials":4874,"activeCount":101},[],{"intervention":4327,"totalTrials":97,"cells":4876},{"EARLY_PHASE1":4877,"PHASE1":4879,"PHASE2":4885,"PHASE3":4887,"PHASE4":4889,"NA":4891},{"trials":4878,"activeCount":101},[],{"trials":4880,"activeCount":97,"soonestReadout":66},[4881],{"nctId":64,"briefTitle":65,"status":177,"phases":4882,"primaryCompletion":66,"completion":180,"start":4322,"enrollment":1035,"conditions":4883,"interventions":4884},[89],[4324,255],[67,4326,4327,4326],{"trials":4886,"activeCount":101},[],{"trials":4888,"activeCount":101},[],{"trials":4890,"activeCount":101},[],{"trials":4892,"activeCount":101},[],{"intervention":4894,"totalTrials":97,"cells":4895},"Mitomycin C",{"EARLY_PHASE1":4896,"PHASE1":4898,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4914},{"trials":4897,"activeCount":101},[],{"trials":4899,"activeCount":97,"soonestReadout":1921},[4900],{"nctId":4901,"briefTitle":4902,"status":4903,"phases":4904,"primaryCompletion":1921,"completion":1921,"start":391,"enrollment":821,"conditions":4905,"interventions":4907},"NCT07487168","Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors","NOT_YET_RECRUITING",[89],[4906],"Peritoneal Carcinomatosis",[4894],{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[],{"trials":4915,"activeCount":101},[],{"intervention":4178,"totalTrials":97,"cells":4917},{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4926,"PHASE3":4928,"PHASE4":4930,"NA":4932},{"trials":4919,"activeCount":101},[],{"trials":4921,"activeCount":97,"soonestReadout":1229},[4922],{"nctId":4172,"briefTitle":4173,"status":111,"phases":4923,"primaryCompletion":1229,"completion":1229,"start":4175,"enrollment":1095,"conditions":4924,"interventions":4925},[89],[1132],[4165,4178],{"trials":4927,"activeCount":101},[],{"trials":4929,"activeCount":101},[],{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":101},[],{"intervention":4188,"totalTrials":97,"cells":4935},{"EARLY_PHASE1":4936,"PHASE1":4938,"PHASE2":4944,"PHASE3":4946,"PHASE4":4948,"NA":4950},{"trials":4937,"activeCount":101},[],{"trials":4939,"activeCount":97,"soonestReadout":4183},[4940],{"nctId":4180,"briefTitle":4181,"status":111,"phases":4941,"primaryCompletion":4183,"completion":1276,"start":4184,"enrollment":27,"conditions":4942,"interventions":4943},[89],[4186],[4188,4165],{"trials":4945,"activeCount":101},[],{"trials":4947,"activeCount":101},[],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[],{"intervention":4953,"totalTrials":97,"cells":4954},"Follicle Stimulating Hormone Receptor T Cells",{"EARLY_PHASE1":4955,"PHASE1":4957,"PHASE2":4966,"PHASE3":4968,"PHASE4":4970,"NA":4972},{"trials":4956,"activeCount":101},[],{"trials":4958,"activeCount":97,"soonestReadout":382},[4959],{"nctId":4960,"briefTitle":4961,"status":111,"phases":4962,"primaryCompletion":382,"completion":114,"start":4963,"enrollment":1265,"conditions":4964,"interventions":4965},"NCT05316129","Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer",[89],"2022-04-28",[632],[4953],{"trials":4967,"activeCount":101},[],{"trials":4969,"activeCount":101},[],{"trials":4971,"activeCount":101},[],{"trials":4973,"activeCount":101},[],{"intervention":4975,"totalTrials":97,"cells":4976},"Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes",{"EARLY_PHASE1":4977,"PHASE1":4979,"PHASE2":4990,"PHASE3":4992,"PHASE4":4994,"NA":4996},{"trials":4978,"activeCount":101},[],{"trials":4980,"activeCount":97,"soonestReadout":4985},[4981],{"nctId":4982,"briefTitle":4983,"status":177,"phases":4984,"primaryCompletion":4985,"completion":2491,"start":4986,"enrollment":253,"conditions":4987,"interventions":4989},"NCT05768347","Intravesical Adoptive Cell Therapy w\u002F TIL for BCG Exposed High Grade NMIBC",[89],"2025-10-10","2023-08-10",[239,4988],"Non-Invasive Bladder Urothelial Carcinoma",[4975],{"trials":4991,"activeCount":101},[],{"trials":4993,"activeCount":101},[],{"trials":4995,"activeCount":101},[],{"trials":4997,"activeCount":101},[],{"intervention":4999,"totalTrials":97,"cells":5000},"HER2 - primed Dendritic cells",{"EARLY_PHASE1":5001,"PHASE1":5003,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5002,"activeCount":101},[],{"trials":5004,"activeCount":97,"soonestReadout":1464},[5005],{"nctId":5006,"briefTitle":5007,"status":111,"phases":5008,"primaryCompletion":1464,"completion":1464,"start":5009,"enrollment":719,"conditions":5010,"interventions":5012},"NCT05504707","DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer",[89],"2022-08-26",[1533,5011],"HER2-negative Breast Cancer",[4999,5013],"HER3 - primed Dendritic cells",{"trials":5015,"activeCount":101},[],{"trials":5017,"activeCount":101},[],{"trials":5019,"activeCount":101},[],{"trials":5021,"activeCount":101},[],{"intervention":5013,"totalTrials":97,"cells":5023},{"EARLY_PHASE1":5024,"PHASE1":5026,"PHASE2":5032,"PHASE3":5034,"PHASE4":5036,"NA":5038},{"trials":5025,"activeCount":101},[],{"trials":5027,"activeCount":97,"soonestReadout":1464},[5028],{"nctId":5006,"briefTitle":5007,"status":111,"phases":5029,"primaryCompletion":1464,"completion":1464,"start":5009,"enrollment":719,"conditions":5030,"interventions":5031},[89],[1533,5011],[4999,5013],{"trials":5033,"activeCount":101},[],{"trials":5035,"activeCount":101},[],{"trials":5037,"activeCount":101},[],{"trials":5039,"activeCount":101},[],{"intervention":1769,"totalTrials":97,"cells":5041},{"EARLY_PHASE1":5042,"PHASE1":5044,"PHASE2":5050,"PHASE3":5052,"PHASE4":5054,"NA":5056},{"trials":5043,"activeCount":101},[],{"trials":5045,"activeCount":97,"soonestReadout":1464},[5046],{"nctId":1763,"briefTitle":1764,"status":111,"phases":5047,"primaryCompletion":1464,"completion":1464,"start":1766,"enrollment":507,"conditions":5048,"interventions":5049},[89],[733],[1769,1770,1756],{"trials":5051,"activeCount":101},[],{"trials":5053,"activeCount":101},[],{"trials":5055,"activeCount":101},[],{"trials":5057,"activeCount":101},[],{"intervention":1770,"totalTrials":97,"cells":5059},{"EARLY_PHASE1":5060,"PHASE1":5062,"PHASE2":5068,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5061,"activeCount":101},[],{"trials":5063,"activeCount":97,"soonestReadout":1464},[5064],{"nctId":1763,"briefTitle":1764,"status":111,"phases":5065,"primaryCompletion":1464,"completion":1464,"start":1766,"enrollment":507,"conditions":5066,"interventions":5067},[89],[733],[1769,1770,1756],{"trials":5069,"activeCount":101},[],{"trials":5071,"activeCount":101},[],{"trials":5073,"activeCount":101},[],{"trials":5075,"activeCount":101},[],{"intervention":287,"totalTrials":97,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5086,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":97,"soonestReadout":278},[5082],{"nctId":275,"briefTitle":276,"status":111,"phases":5083,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":5084,"interventions":5085},[89],[283,284,285],[287,52,157,158,160],{"trials":5087,"activeCount":101},[],{"trials":5089,"activeCount":101},[],{"trials":5091,"activeCount":101},[],{"trials":5093,"activeCount":101},[],{"intervention":5095,"totalTrials":97,"cells":5096},"Elacestrant",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5109,"PHASE3":5111,"PHASE4":5113,"NA":5115},{"trials":5098,"activeCount":101},[],{"trials":5100,"activeCount":97,"soonestReadout":3456},[5101],{"nctId":5102,"briefTitle":5103,"status":111,"phases":5104,"primaryCompletion":3456,"completion":2032,"start":1912,"enrollment":1095,"conditions":5105,"interventions":5107},"NCT06691035","Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer",[89],[5106,5011],"Breast Cancer Metastatic Breast Cancer",[5095,5108],"DC1 native\u002Fmutated ESR1",{"trials":5110,"activeCount":101},[],{"trials":5112,"activeCount":101},[],{"trials":5114,"activeCount":101},[],{"trials":5116,"activeCount":101},[],{"intervention":5108,"totalTrials":97,"cells":5118},{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5127,"PHASE3":5129,"PHASE4":5131,"NA":5133},{"trials":5120,"activeCount":101},[],{"trials":5122,"activeCount":97,"soonestReadout":3456},[5123],{"nctId":5102,"briefTitle":5103,"status":111,"phases":5124,"primaryCompletion":3456,"completion":2032,"start":1912,"enrollment":1095,"conditions":5125,"interventions":5126},[89],[5106,5011],[5095,5108],{"trials":5128,"activeCount":101},[],{"trials":5130,"activeCount":101},[],{"trials":5132,"activeCount":101},[],{"trials":5134,"activeCount":101},[],{"intervention":4472,"totalTrials":97,"cells":5136},{"EARLY_PHASE1":5137,"PHASE1":5139,"PHASE2":5145,"PHASE3":5147,"PHASE4":5149,"NA":5151},{"trials":5138,"activeCount":101},[],{"trials":5140,"activeCount":97,"soonestReadout":46},[5141],{"nctId":44,"briefTitle":45,"status":177,"phases":5142,"primaryCompletion":46,"completion":4468,"start":4469,"enrollment":19,"conditions":5143,"interventions":5144},[89],[32,154],[47,4451,4472],{"trials":5146,"activeCount":101},[],{"trials":5148,"activeCount":101},[],{"trials":5150,"activeCount":101},[],{"trials":5152,"activeCount":101},[],{"intervention":5154,"totalTrials":97,"cells":5155},"Gamma Delta T-Cell",{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5168,"PHASE3":5170,"PHASE4":5172,"NA":5174},{"trials":5157,"activeCount":101},[],{"trials":5159,"activeCount":97,"soonestReadout":5164},[5160],{"nctId":5161,"briefTitle":5162,"status":177,"phases":5163,"primaryCompletion":5164,"completion":677,"start":5165,"enrollment":281,"conditions":5166,"interventions":5167},"NCT05015426","Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT",[89],"2025-08-30","2022-03-21",[1132],[5154],{"trials":5169,"activeCount":101},[],{"trials":5171,"activeCount":101},[],{"trials":5173,"activeCount":101},[],{"trials":5175,"activeCount":101},[],{"intervention":806,"totalTrials":97,"cells":5177},{"EARLY_PHASE1":5178,"PHASE1":5180,"PHASE2":5186,"PHASE3":5188,"PHASE4":5190,"NA":5192},{"trials":5179,"activeCount":101},[],{"trials":5181,"activeCount":97,"soonestReadout":798},[5182],{"nctId":795,"briefTitle":796,"status":111,"phases":5183,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":5184,"interventions":5185},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":5187,"activeCount":101},[],{"trials":5189,"activeCount":101},[],{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[],{"intervention":5195,"totalTrials":97,"cells":5196},"Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2",{"EARLY_PHASE1":5197,"PHASE1":5199,"PHASE2":5211,"PHASE3":5213,"PHASE4":5215,"NA":5217},{"trials":5198,"activeCount":101},[],{"trials":5200,"activeCount":97,"soonestReadout":5205},[5201],{"nctId":5202,"briefTitle":5203,"status":111,"phases":5204,"primaryCompletion":5205,"completion":5206,"start":5207,"enrollment":719,"conditions":5208,"interventions":5210},"NCT06047977","Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors",[89],"2026-12-01","2027-12-01","2025-06-02",[5209],"Lymphocytes",[5195],{"trials":5212,"activeCount":101},[],{"trials":5214,"activeCount":101},[],{"trials":5216,"activeCount":101},[],{"trials":5218,"activeCount":101},[],{"intervention":1192,"totalTrials":97,"cells":5220},{"EARLY_PHASE1":5221,"PHASE1":5223,"PHASE2":5229,"PHASE3":5231,"PHASE4":5233,"NA":5235},{"trials":5222,"activeCount":101},[],{"trials":5224,"activeCount":97,"soonestReadout":293},[5225],{"nctId":1185,"briefTitle":1186,"status":111,"phases":5226,"primaryCompletion":293,"completion":180,"start":1188,"enrollment":125,"conditions":5227,"interventions":5228},[89],[1190],[1192,572,1193,1194],{"trials":5230,"activeCount":101},[],{"trials":5232,"activeCount":101},[],{"trials":5234,"activeCount":101},[],{"trials":5236,"activeCount":101},[],{"intervention":1193,"totalTrials":97,"cells":5238},{"EARLY_PHASE1":5239,"PHASE1":5241,"PHASE2":5247,"PHASE3":5249,"PHASE4":5251,"NA":5253},{"trials":5240,"activeCount":101},[],{"trials":5242,"activeCount":97,"soonestReadout":293},[5243],{"nctId":1185,"briefTitle":1186,"status":111,"phases":5244,"primaryCompletion":293,"completion":180,"start":1188,"enrollment":125,"conditions":5245,"interventions":5246},[89],[1190],[1192,572,1193,1194],{"trials":5248,"activeCount":101},[],{"trials":5250,"activeCount":101},[],{"trials":5252,"activeCount":101},[],{"trials":5254,"activeCount":101},[],{"intervention":1194,"totalTrials":97,"cells":5256},{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5265,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5258,"activeCount":101},[],{"trials":5260,"activeCount":97,"soonestReadout":293},[5261],{"nctId":1185,"briefTitle":1186,"status":111,"phases":5262,"primaryCompletion":293,"completion":180,"start":1188,"enrollment":125,"conditions":5263,"interventions":5264},[89],[1190],[1192,572,1193,1194],{"trials":5266,"activeCount":101},[],{"trials":5268,"activeCount":101},[],{"trials":5270,"activeCount":101},[],{"trials":5272,"activeCount":101},[],{"intervention":809,"totalTrials":2139,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5285,"PHASE2":5320,"PHASE3":5336,"PHASE4":5338,"NA":5340},{"trials":5276,"activeCount":101},[5277],{"nctId":5278,"briefTitle":5279,"status":249,"phases":5280,"primaryCompletion":359,"completion":359,"start":5281,"enrollment":730,"conditions":5282,"interventions":5284},"NCT03927274","Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III\u002F IV Glioma",[88],"2019-06-20",[5283],"Glioma of Brain",[809],{"trials":5286,"activeCount":97,"soonestReadout":798},[5287,5294,5308,5316],{"nctId":5288,"briefTitle":5289,"status":147,"phases":5290,"primaryCompletion":4266,"completion":4266,"start":5291,"enrollment":1059,"conditions":5292,"interventions":5293},"NCT01683149","Sorafenib and Topotecan in Refractory\u002FRecurrent Pediatric Malignancies",[89],"2013-01",[237],[809,4596],{"nctId":5295,"briefTitle":5296,"status":147,"phases":5297,"primaryCompletion":5298,"completion":5299,"start":5300,"enrollment":5301,"conditions":5302,"interventions":5304},"NCT00005792","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[89],"2006-07-01","2018-11-01","1998-06-02",131,[21,5303],"Plasma Cell Neoplasm",[5305,5306,5307],"etoposide phosphate","melphalan","topotecan",{"nctId":5309,"briefTitle":5310,"status":147,"phases":5311,"primaryCompletion":2266,"completion":2266,"start":5312,"enrollment":1531,"conditions":5313,"interventions":5315},"NCT00215956","A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma",[89],"2001-11",[5314],"Rectal Neoplasms",[5307],{"nctId":795,"briefTitle":796,"status":111,"phases":5317,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":5318,"interventions":5319},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":5321,"activeCount":101},[5322,5326],{"nctId":4210,"briefTitle":4211,"status":147,"phases":5323,"primaryCompletion":2612,"completion":4213,"start":4214,"enrollment":4215,"conditions":5324,"interventions":5325},[89,90],[35],[2525,4218,810,809],{"nctId":5327,"briefTitle":5328,"status":147,"phases":5329,"primaryCompletion":5330,"completion":5331,"start":5332,"enrollment":5333,"conditions":5334,"interventions":5335},"NCT00325416","Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.",[89,90],"2013-07-15","2018-01-30","2001-11-19",177,[21],[5306,5307],{"trials":5337,"activeCount":101},[],{"trials":5339,"activeCount":101},[],{"trials":5341,"activeCount":101},[5342],{"nctId":5343,"briefTitle":5344,"status":249,"phases":5345,"primaryCompletion":1355,"completion":1355,"start":1645,"enrollment":812,"conditions":5346,"interventions":5347},"NCT00720096","Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan",[93],[632],[5348,809],"Liposomal Doxorubicin",{"intervention":811,"totalTrials":730,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5359,"PHASE3":5365,"PHASE4":5367,"NA":5369},{"trials":5352,"activeCount":101},[],{"trials":5354,"activeCount":97,"soonestReadout":798},[5355],{"nctId":795,"briefTitle":796,"status":111,"phases":5356,"primaryCompletion":798,"completion":798,"start":799,"enrollment":36,"conditions":5357,"interventions":5358},[89],[801],[803,804,157,805,806,807,808,809,527,810,811],{"trials":5360,"activeCount":101},[5361],{"nctId":2239,"briefTitle":2240,"status":147,"phases":5362,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":125,"conditions":5363,"interventions":5364},[89,90],[21],[2247,811,888],{"trials":5366,"activeCount":101},[],{"trials":5368,"activeCount":101},[],{"trials":5370,"activeCount":101},[5371],{"nctId":5343,"briefTitle":5344,"status":249,"phases":5372,"primaryCompletion":1355,"completion":1355,"start":1645,"enrollment":812,"conditions":5373,"interventions":5374},[93],[632],[5348,809],{"intervention":72,"totalTrials":507,"cells":5376},{"EARLY_PHASE1":5377,"PHASE1":5386,"PHASE2":5406,"PHASE3":5429,"PHASE4":5431,"NA":5433},{"trials":5378,"activeCount":97,"soonestReadout":71},[5379],{"nctId":69,"briefTitle":70,"status":177,"phases":5380,"primaryCompletion":71,"completion":1464,"start":5381,"enrollment":281,"conditions":5382,"interventions":5384},[88],"2021-12-23",[5383],"Rectal Adenocarcinoma",[72,5385],"FOLFOX regimen",{"trials":5387,"activeCount":101},[5388,5392,5402],{"nctId":2079,"briefTitle":2080,"status":147,"phases":5389,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":281,"conditions":5390,"interventions":5391},[89],[2085],[2087,2088,2089],{"nctId":5393,"briefTitle":5394,"status":147,"phases":5395,"primaryCompletion":5396,"completion":5397,"start":5398,"enrollment":281,"conditions":5399,"interventions":5401},"NCT02935309","Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma",[89],"2019-10-11","2020-05-14","2016-10-14",[5400,5383],"Rectal Cancer",[672,72],{"nctId":1896,"briefTitle":1897,"status":147,"phases":5403,"primaryCompletion":1899,"completion":1900,"start":1901,"enrollment":1059,"conditions":5404,"interventions":5405},[89],[1903],[1889,72],{"trials":5407,"activeCount":101},[5408,5421,5425],{"nctId":5409,"briefTitle":5410,"status":147,"phases":5411,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":2139,"conditions":5415,"interventions":5418},"NCT02218164","Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable\u002FMetastatic Cutaneous Squamous Cell Carcinoma",[90],"2017-07-19","2018-06-25","2014-08-12",[5416,5417],"Squamous Cell Carcinoma of Skin","Carcinoma, Squamous Cell",[5419,72,5420],"Pegylated Interferon alpha-2b","5-FU",{"nctId":2661,"briefTitle":2662,"status":147,"phases":5422,"primaryCompletion":830,"completion":830,"start":2664,"enrollment":821,"conditions":5423,"interventions":5424},[90],[269],[2088,573,807],{"nctId":1342,"briefTitle":1343,"status":249,"phases":5426,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":253,"conditions":5427,"interventions":5428},[90],[24],[72,1246,1264,1350],{"trials":5430,"activeCount":101},[],{"trials":5432,"activeCount":101},[],{"trials":5434,"activeCount":101},[],{"intervention":42,"totalTrials":97,"cells":5436},{"EARLY_PHASE1":5437,"PHASE1":5444,"PHASE2":5446,"PHASE3":5448,"PHASE4":5450,"NA":5452},{"trials":5438,"activeCount":97,"soonestReadout":41},[5439],{"nctId":39,"briefTitle":40,"status":177,"phases":5440,"primaryCompletion":41,"completion":382,"start":5441,"enrollment":336,"conditions":5442,"interventions":5443},[88],"2015-04-13",[18],[42],{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":101},[],{"trials":5449,"activeCount":101},[],{"trials":5451,"activeCount":101},[],{"trials":5453,"activeCount":101},[],{"intervention":142,"totalTrials":97,"cells":5455},{"EARLY_PHASE1":5456,"PHASE1":5462,"PHASE2":5464,"PHASE3":5466,"PHASE4":5468,"NA":5470},{"trials":5457,"activeCount":97,"soonestReadout":133},[5458],{"nctId":130,"briefTitle":131,"status":111,"phases":5459,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":5460,"interventions":5461},[88],[138,139,140],[142,143,52],{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[],{"trials":5469,"activeCount":101},[],{"trials":5471,"activeCount":101},[],{"intervention":143,"totalTrials":97,"cells":5473},{"EARLY_PHASE1":5474,"PHASE1":5480,"PHASE2":5482,"PHASE3":5484,"PHASE4":5486,"NA":5488},{"trials":5475,"activeCount":97,"soonestReadout":133},[5476],{"nctId":130,"briefTitle":131,"status":111,"phases":5477,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":5478,"interventions":5479},[88],[138,139,140],[142,143,52],{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[],{"trials":5489,"activeCount":101},[],{"intervention":5491,"totalTrials":97,"cells":5492},"Checkpoint Blockade, Immune",{"EARLY_PHASE1":5493,"PHASE1":5503,"PHASE2":5505,"PHASE3":5507,"PHASE4":5509,"NA":5511},{"trials":5494,"activeCount":97,"soonestReadout":5499},[5495],{"nctId":5496,"briefTitle":5497,"status":177,"phases":5498,"primaryCompletion":5499,"completion":391,"start":5500,"enrollment":27,"conditions":5501,"interventions":5502},"NCT05358938","Exercise to Boost Response to Checkpoint Blockade Immunotherapy",[88],"2024-10-06","2022-06-21",[785,4551,475],[5491],{"trials":5504,"activeCount":101},[],{"trials":5506,"activeCount":101},[],{"trials":5508,"activeCount":101},[],{"trials":5510,"activeCount":101},[],{"trials":5512,"activeCount":101},[],{"intervention":5514,"totalTrials":97,"cells":5515},"Aspirin 325mg",{"EARLY_PHASE1":5516,"PHASE1":5527,"PHASE2":5529,"PHASE3":5531,"PHASE4":5533,"NA":5535},{"trials":5517,"activeCount":97,"soonestReadout":382},[5518],{"nctId":5519,"briefTitle":5520,"status":111,"phases":5521,"primaryCompletion":382,"completion":180,"start":5522,"enrollment":5523,"conditions":5524,"interventions":5526},"NCT05080946","Using Aspirin to Improve Immunological Features of Ovarian Tumors",[88],"2021-11-02",100,[632,1292,5525],"Peritoneal Cancer",[5514],{"trials":5528,"activeCount":101},[],{"trials":5530,"activeCount":101},[],{"trials":5532,"activeCount":101},[],{"trials":5534,"activeCount":101},[],{"trials":5536,"activeCount":101},[],{"intervention":5538,"totalTrials":97,"cells":5539},"Vismodegib 150 MG Oral",{"EARLY_PHASE1":5540,"PHASE1":5551,"PHASE2":5553,"PHASE3":5555,"PHASE4":5557,"NA":5559},{"trials":5541,"activeCount":97,"soonestReadout":1484},[5542],{"nctId":5543,"briefTitle":5544,"status":111,"phases":5545,"primaryCompletion":1484,"completion":5546,"start":5547,"enrollment":1130,"conditions":5548,"interventions":5550},"NCT05651828","Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma",[88],"2029-12","2023-03-23",[5549],"Advanced Basal Cell Carcinoma",[5538],{"trials":5552,"activeCount":101},[],{"trials":5554,"activeCount":101},[],{"trials":5556,"activeCount":101},[],{"trials":5558,"activeCount":101},[],{"trials":5560,"activeCount":101},[],{"intervention":5562,"totalTrials":97,"cells":5563},"Dendritic Cell (DC) Vaccine",{"EARLY_PHASE1":5564,"PHASE1":5573,"PHASE2":5575,"PHASE3":5577,"PHASE4":5579,"NA":5581},{"trials":5565,"activeCount":97,"soonestReadout":114},[5566],{"nctId":5567,"briefTitle":5568,"status":111,"phases":5569,"primaryCompletion":114,"completion":114,"start":5570,"enrollment":33,"conditions":5571,"interventions":5572},"NCT06435351","Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy",[88],"2024-06-12",[15,1533],[5562],{"trials":5574,"activeCount":101},[],{"trials":5576,"activeCount":101},[],{"trials":5578,"activeCount":101},[],{"trials":5580,"activeCount":101},[],{"trials":5582,"activeCount":101},[],{"intervention":57,"totalTrials":97,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5591,"PHASE2":5593,"PHASE3":5595,"PHASE4":5597,"NA":5599},{"trials":5586,"activeCount":97,"soonestReadout":56},[5587],{"nctId":54,"briefTitle":55,"status":177,"phases":5588,"primaryCompletion":56,"completion":677,"start":1711,"enrollment":30,"conditions":5589,"interventions":5590},[88],[18,1336,1713,1714],[57,1716,920],{"trials":5592,"activeCount":101},[],{"trials":5594,"activeCount":101},[],{"trials":5596,"activeCount":101},[],{"trials":5598,"activeCount":101},[],{"trials":5600,"activeCount":101},[],{"intervention":5385,"totalTrials":97,"cells":5602},{"EARLY_PHASE1":5603,"PHASE1":5609,"PHASE2":5611,"PHASE3":5613,"PHASE4":5615,"NA":5617},{"trials":5604,"activeCount":97,"soonestReadout":71},[5605],{"nctId":69,"briefTitle":70,"status":177,"phases":5606,"primaryCompletion":71,"completion":1464,"start":5381,"enrollment":281,"conditions":5607,"interventions":5608},[88],[5383],[72,5385],{"trials":5610,"activeCount":101},[],{"trials":5612,"activeCount":101},[],{"trials":5614,"activeCount":101},[],{"trials":5616,"activeCount":101},[],{"trials":5618,"activeCount":101},[],{"intervention":187,"totalTrials":97,"cells":5620},{"EARLY_PHASE1":5621,"PHASE1":5627,"PHASE2":5629,"PHASE3":5631,"PHASE4":5633,"NA":5635},{"trials":5622,"activeCount":97,"soonestReadout":179},[5623],{"nctId":175,"briefTitle":176,"status":177,"phases":5624,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":5625,"interventions":5626},[88],[153,154,184,185],[187,188,52],{"trials":5628,"activeCount":101},[],{"trials":5630,"activeCount":101},[],{"trials":5632,"activeCount":101},[],{"trials":5634,"activeCount":101},[],{"trials":5636,"activeCount":101},[],{"intervention":5638,"totalTrials":487,"cells":5639},"Nicotine patch",{"EARLY_PHASE1":5640,"PHASE1":5651,"PHASE2":5653,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5641,"activeCount":101},[5642],{"nctId":5643,"briefTitle":5644,"status":147,"phases":5645,"primaryCompletion":5646,"completion":5646,"start":5647,"enrollment":136,"conditions":5648,"interventions":5649},"NCT03404596","Applying mHealth to Tobacco-related Health Disparities",[88],"2020-12-14","2018-07-16",[29],[5650],"Nicotine Patch",{"trials":5652,"activeCount":101},[],{"trials":5654,"activeCount":101},[],{"trials":5656,"activeCount":101},[],{"trials":5658,"activeCount":101},[],{"trials":5660,"activeCount":730,"soonestReadout":5695},[5661,5672,5682,5691,5700],{"nctId":5662,"briefTitle":5663,"status":147,"phases":5664,"primaryCompletion":5665,"completion":5665,"start":5666,"enrollment":5667,"conditions":5668,"interventions":5670},"NCT02157610","Smoking Cessation for Cervical Cancer Survivors",[93],"2021-08","2015-01",202,[2967,5669,29],"Tobacco Use",[5650,5671],"Nicotine lozenge",{"nctId":5673,"briefTitle":5674,"status":111,"phases":5675,"primaryCompletion":5676,"completion":5676,"start":5677,"enrollment":5678,"conditions":5679,"interventions":5681},"NCT05746442","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS",[93],"2027-02-28","2023-01-11",800,[29,5680],"HIV",[5638],{"nctId":5683,"briefTitle":5684,"status":147,"phases":5685,"primaryCompletion":5686,"completion":4479,"start":5687,"enrollment":5688,"conditions":5689,"interventions":5690},"NCT05004662","Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers",[93],"2025-06-05","2021-12-01",520,[29],[5638,5671],{"nctId":5692,"briefTitle":5693,"status":177,"phases":5694,"primaryCompletion":5695,"completion":5696,"start":2062,"enrollment":5697,"conditions":5698,"interventions":5699},"NCT05014282","Automated Video-Assisted Smoking Treatment for People Living With HIV",[93],"2025-09-23","2026-09-23",638,[29],[5638,5671],{"nctId":5701,"briefTitle":5702,"status":177,"phases":5703,"primaryCompletion":2491,"completion":2061,"start":5704,"enrollment":5705,"conditions":5706,"interventions":5708},"NCT05645146","Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)",[93],"2022-11-29",360,[29,2967,5707],"High Grade Cervical Dysplasia",[5638,5709],"Nicotine Lozenge",{"intervention":5671,"totalTrials":812,"cells":5711},{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5716,"PHASE3":5718,"PHASE4":5720,"NA":5722},{"trials":5713,"activeCount":101},[],{"trials":5715,"activeCount":101},[],{"trials":5717,"activeCount":101},[],{"trials":5719,"activeCount":101},[],{"trials":5721,"activeCount":101},[],{"trials":5723,"activeCount":189,"soonestReadout":5695},[5724,5728,5732,5736],{"nctId":5662,"briefTitle":5663,"status":147,"phases":5725,"primaryCompletion":5665,"completion":5665,"start":5666,"enrollment":5667,"conditions":5726,"interventions":5727},[93],[2967,5669,29],[5650,5671],{"nctId":5683,"briefTitle":5684,"status":147,"phases":5729,"primaryCompletion":5686,"completion":4479,"start":5687,"enrollment":5688,"conditions":5730,"interventions":5731},[93],[29],[5638,5671],{"nctId":5692,"briefTitle":5693,"status":177,"phases":5733,"primaryCompletion":5695,"completion":5696,"start":2062,"enrollment":5697,"conditions":5734,"interventions":5735},[93],[29],[5638,5671],{"nctId":5701,"briefTitle":5702,"status":177,"phases":5737,"primaryCompletion":2491,"completion":2061,"start":5704,"enrollment":5705,"conditions":5738,"interventions":5739},[93],[29,2967,5707],[5638,5709],{"intervention":5741,"totalTrials":97,"cells":5742},"Immunomodulatory Agent",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5747,"PHASE3":5749,"PHASE4":5751,"NA":5753},{"trials":5744,"activeCount":101},[],{"trials":5746,"activeCount":101},[],{"trials":5748,"activeCount":101},[],{"trials":5750,"activeCount":101},[],{"trials":5752,"activeCount":101},[],{"trials":5754,"activeCount":97,"soonestReadout":5759},[5755],{"nctId":5756,"briefTitle":5757,"status":177,"phases":5758,"primaryCompletion":5759,"completion":180,"start":5760,"enrollment":1668,"conditions":5761,"interventions":5762},"NCT05271630","Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant",[],"2025-12-04","2022-04-20",[21],[5741,5763],"Proteasome Inhibitor",{"intervention":5763,"totalTrials":97,"cells":5765},{"EARLY_PHASE1":5766,"PHASE1":5768,"PHASE2":5770,"PHASE3":5772,"PHASE4":5774,"NA":5776},{"trials":5767,"activeCount":101},[],{"trials":5769,"activeCount":101},[],{"trials":5771,"activeCount":101},[],{"trials":5773,"activeCount":101},[],{"trials":5775,"activeCount":101},[],{"trials":5777,"activeCount":97,"soonestReadout":5759},[5778],{"nctId":5756,"briefTitle":5757,"status":177,"phases":5779,"primaryCompletion":5759,"completion":180,"start":5760,"enrollment":1668,"conditions":5780,"interventions":5781},[],[21],[5741,5763],{"intervention":5783,"totalTrials":97,"cells":5784},"Bruton's tyrosine kinase inhibitor",{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5789,"PHASE3":5791,"PHASE4":5793,"NA":5795},{"trials":5786,"activeCount":101},[],{"trials":5788,"activeCount":101},[],{"trials":5790,"activeCount":101},[],{"trials":5792,"activeCount":101},[],{"trials":5794,"activeCount":101},[],{"trials":5796,"activeCount":97,"soonestReadout":4748},[5797],{"nctId":5798,"briefTitle":5799,"status":111,"phases":5800,"primaryCompletion":4748,"completion":4748,"start":5801,"enrollment":5523,"conditions":5802,"interventions":5805},"NCT07030400","Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma",[],"2025-07-17",[5803,5804],"Small Lymphocytic Lymphoma (SLL)","Chronic Lymphocytic Leukemia (CLL)",[5783,5806],"B-Cell Lymphoma 2 Protein Inhibitor",{"intervention":5806,"totalTrials":97,"cells":5808},{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5817,"NA":5819},{"trials":5810,"activeCount":101},[],{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[],{"trials":5818,"activeCount":101},[],{"trials":5820,"activeCount":97,"soonestReadout":4748},[5821],{"nctId":5798,"briefTitle":5799,"status":111,"phases":5822,"primaryCompletion":4748,"completion":4748,"start":5801,"enrollment":5523,"conditions":5823,"interventions":5824},[],[5803,5804],[5783,5806],{"intervention":5826,"totalTrials":97,"cells":5827},"Standard of Care: Docetaxel",{"EARLY_PHASE1":5828,"PHASE1":5830,"PHASE2":5832,"PHASE3":5834,"PHASE4":5836,"NA":5847},{"trials":5829,"activeCount":101},[],{"trials":5831,"activeCount":101},[],{"trials":5833,"activeCount":101},[],{"trials":5835,"activeCount":101},[],{"trials":5837,"activeCount":101},[5838],{"nctId":5839,"briefTitle":5840,"status":147,"phases":5841,"primaryCompletion":5842,"completion":1666,"start":5843,"enrollment":253,"conditions":5844,"interventions":5845},"NCT02502864","Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide",[92],"2017-09-29","2016-02-09",[15,1207],[5826,5846],"Standard of Care: Cyclophosphamide",{"trials":5848,"activeCount":101},[],{"intervention":5846,"totalTrials":97,"cells":5850},{"EARLY_PHASE1":5851,"PHASE1":5853,"PHASE2":5855,"PHASE3":5857,"PHASE4":5859,"NA":5865},{"trials":5852,"activeCount":101},[],{"trials":5854,"activeCount":101},[],{"trials":5856,"activeCount":101},[],{"trials":5858,"activeCount":101},[],{"trials":5860,"activeCount":101},[5861],{"nctId":5839,"briefTitle":5840,"status":147,"phases":5862,"primaryCompletion":5842,"completion":1666,"start":5843,"enrollment":253,"conditions":5863,"interventions":5864},[92],[15,1207],[5826,5846],{"trials":5866,"activeCount":101},[],{"intervention":1594,"totalTrials":97,"cells":5868},{"EARLY_PHASE1":5869,"PHASE1":5871,"PHASE2":5873,"PHASE3":5875,"PHASE4":5881,"NA":5883},{"trials":5870,"activeCount":101},[],{"trials":5872,"activeCount":101},[],{"trials":5874,"activeCount":101},[],{"trials":5876,"activeCount":101},[5877],{"nctId":1588,"briefTitle":1589,"status":249,"phases":5878,"primaryCompletion":1300,"completion":1300,"start":1591,"enrollment":424,"conditions":5879,"interventions":5880},[91],[21],[1594,1595,1596,1597,1598],{"trials":5882,"activeCount":101},[],{"trials":5884,"activeCount":101},[],{"intervention":1596,"totalTrials":97,"cells":5886},{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5893,"PHASE4":5899,"NA":5901},{"trials":5888,"activeCount":101},[],{"trials":5890,"activeCount":101},[],{"trials":5892,"activeCount":101},[],{"trials":5894,"activeCount":101},[5895],{"nctId":1588,"briefTitle":1589,"status":249,"phases":5896,"primaryCompletion":1300,"completion":1300,"start":1591,"enrollment":424,"conditions":5897,"interventions":5898},[91],[21],[1594,1595,1596,1597,1598],{"trials":5900,"activeCount":101},[],{"trials":5902,"activeCount":101},[],{"intervention":1598,"totalTrials":97,"cells":5904},{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5909,"PHASE3":5911,"PHASE4":5917,"NA":5919},{"trials":5906,"activeCount":101},[],{"trials":5908,"activeCount":101},[],{"trials":5910,"activeCount":101},[],{"trials":5912,"activeCount":101},[5913],{"nctId":1588,"briefTitle":1589,"status":249,"phases":5914,"primaryCompletion":1300,"completion":1300,"start":1591,"enrollment":424,"conditions":5915,"interventions":5916},[91],[21],[1594,1595,1596,1597,1598],{"trials":5918,"activeCount":101},[],{"trials":5920,"activeCount":101},[],{"intervention":5922,"totalTrials":507,"cells":5923},"Tacrolimus",{"EARLY_PHASE1":5924,"PHASE1":5926,"PHASE2":5940,"PHASE3":5999,"PHASE4":6001,"NA":6003},{"trials":5925,"activeCount":101},[],{"trials":5927,"activeCount":101},[5928],{"nctId":5929,"briefTitle":5930,"status":147,"phases":5931,"primaryCompletion":5932,"completion":5932,"start":5933,"enrollment":556,"conditions":5934,"interventions":5938},"NCT03605927","CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease",[89],"2023-07-25","2019-02-15",[5935,5936,5937],"Graft-versus-host-disease","GVHD","GVHD, Acute",[5939,759,5922],"BMS-986004",{"trials":5941,"activeCount":101},[5942,5953,5962,5970,5980,5990],{"nctId":5943,"briefTitle":5944,"status":147,"phases":5945,"primaryCompletion":5946,"completion":5947,"start":5948,"enrollment":582,"conditions":5949,"interventions":5951},"NCT02891603","A Phase I\u002FII GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression",[89,90],"2022-01-28","2022-04-18","2017-06-08",[5950,5936],"Graft Vs Host Disease",[5952,759,5922],"Pacritinib",{"nctId":5954,"briefTitle":5955,"status":147,"phases":5956,"primaryCompletion":946,"completion":946,"start":948,"enrollment":5957,"conditions":5958,"interventions":5960},"NCT00803010","Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation",[90],74,[5959],"Acute Graft Versus Host Disease",[5922,2196,5961],"Rapamycin",{"nctId":5963,"briefTitle":5964,"status":147,"phases":5965,"primaryCompletion":5966,"completion":5967,"start":2191,"enrollment":630,"conditions":5968,"interventions":5969},"NCT02588339","Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention",[90],"2018-12-07","2021-07-13",[869,5936],[998,759,5922],{"nctId":5971,"briefTitle":5972,"status":147,"phases":5973,"primaryCompletion":5974,"completion":5975,"start":5976,"enrollment":281,"conditions":5977,"interventions":5979},"NCT01927120","In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis",[90],"2016-08-25","2017-03-09","2014-03-25",[5978],"Graft-Versus-Host-Disease",[922,5922,759],{"nctId":5981,"briefTitle":5982,"status":147,"phases":5983,"primaryCompletion":5984,"completion":181,"start":5985,"enrollment":361,"conditions":5986,"interventions":5988},"NCT01713400","Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease",[90],"2014-10-27","2013-02-25",[5987],"Graft vs. Host Disease",[5989,5922,759],"Ustekinumab",{"nctId":5991,"briefTitle":5992,"status":249,"phases":5993,"primaryCompletion":2754,"completion":2754,"start":5994,"enrollment":2139,"conditions":5995,"interventions":5996},"NCT00720629","Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation",[90],"2007-12",[869],[5997,5922,2196,5998,5922,2196],"Visilizumab","Antithymocyte globulin",{"trials":6000,"activeCount":101},[],{"trials":6002,"activeCount":101},[],{"trials":6004,"activeCount":101},[],{"intervention":759,"totalTrials":487,"cells":6006},{"EARLY_PHASE1":6007,"PHASE1":6009,"PHASE2":6019,"PHASE3":6037,"PHASE4":6039,"NA":6041},{"trials":6008,"activeCount":101},[],{"trials":6010,"activeCount":101},[6011,6015],{"nctId":743,"briefTitle":744,"status":147,"phases":6012,"primaryCompletion":746,"completion":747,"start":748,"enrollment":544,"conditions":6013,"interventions":6014},[89],[750,751,752,753,754,755,756,21],[158,758,157,759,760,761],{"nctId":5929,"briefTitle":5930,"status":147,"phases":6016,"primaryCompletion":5932,"completion":5932,"start":5933,"enrollment":556,"conditions":6017,"interventions":6018},[89],[5935,5936,5937],[5939,759,5922],{"trials":6020,"activeCount":101},[6021,6025,6029,6033],{"nctId":5943,"briefTitle":5944,"status":147,"phases":6022,"primaryCompletion":5946,"completion":5947,"start":5948,"enrollment":582,"conditions":6023,"interventions":6024},[89,90],[5950,5936],[5952,759,5922],{"nctId":5963,"briefTitle":5964,"status":147,"phases":6026,"primaryCompletion":5966,"completion":5967,"start":2191,"enrollment":630,"conditions":6027,"interventions":6028},[90],[869,5936],[998,759,5922],{"nctId":5971,"briefTitle":5972,"status":147,"phases":6030,"primaryCompletion":5974,"completion":5975,"start":5976,"enrollment":281,"conditions":6031,"interventions":6032},[90],[5978],[922,5922,759],{"nctId":5981,"briefTitle":5982,"status":147,"phases":6034,"primaryCompletion":5984,"completion":181,"start":5985,"enrollment":361,"conditions":6035,"interventions":6036},[90],[5987],[5989,5922,759],{"trials":6038,"activeCount":101},[],{"trials":6040,"activeCount":101},[],{"trials":6042,"activeCount":101},[],{"intervention":215,"totalTrials":487,"cells":6044},{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6065,"PHASE3":6083,"PHASE4":6085,"NA":6087},{"trials":6046,"activeCount":101},[],{"trials":6048,"activeCount":101},[6049,6053,6057,6061],{"nctId":205,"briefTitle":206,"status":147,"phases":6050,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":6051,"interventions":6052},[89],[213],[52,215,172],{"nctId":2949,"briefTitle":2950,"status":249,"phases":6054,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":189,"conditions":6055,"interventions":6056},[89],[2955],[2957,215,2942],{"nctId":2716,"briefTitle":2717,"status":147,"phases":6058,"primaryCompletion":2719,"completion":2719,"start":948,"enrollment":336,"conditions":6059,"interventions":6060},[89],[523],[86,215,807],{"nctId":538,"briefTitle":539,"status":147,"phases":6062,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":6063,"interventions":6064},[89],[213],[495,215],{"trials":6066,"activeCount":101},[6067,6079],{"nctId":6068,"briefTitle":6069,"status":249,"phases":6070,"primaryCompletion":6071,"completion":6071,"start":6072,"enrollment":6073,"conditions":6074,"interventions":6076},"NCT00127036","Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)",[90],"2010-12","2003-10",65,[6075,271],"Adenocarcinoma",[6077,6078,215],"XELOX","XELIRI",{"nctId":2609,"briefTitle":2610,"status":249,"phases":6080,"primaryCompletion":948,"completion":948,"start":2612,"enrollment":2139,"conditions":6081,"interventions":6082},[89,90],[242],[215,2615,620],{"trials":6084,"activeCount":101},[],{"trials":6086,"activeCount":101},[],{"trials":6088,"activeCount":101},[],{"intervention":998,"totalTrials":487,"cells":6090},{"EARLY_PHASE1":6091,"PHASE1":6093,"PHASE2":6108,"PHASE3":6137,"PHASE4":6139,"NA":6141},{"trials":6092,"activeCount":101},[],{"trials":6094,"activeCount":101},[6095,6099],{"nctId":990,"briefTitle":991,"status":147,"phases":6096,"primaryCompletion":993,"completion":994,"start":995,"enrollment":30,"conditions":6097,"interventions":6098},[89],[32,154],[998,172],{"nctId":6100,"briefTitle":6101,"status":147,"phases":6102,"primaryCompletion":1787,"completion":6103,"start":6104,"enrollment":445,"conditions":6105,"interventions":6107},"NCT00738751","Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers",[89],"2015-02","2008-11",[26,6106],"Head and Neck Cancer",[998,2089],{"trials":6109,"activeCount":101},[6110,6114,6118,6127],{"nctId":2249,"briefTitle":2250,"status":345,"phases":6111,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":101,"conditions":6112,"interventions":6113},[89,90],[21],[998,2257,1732,888],{"nctId":5963,"briefTitle":5964,"status":147,"phases":6115,"primaryCompletion":5966,"completion":5967,"start":2191,"enrollment":630,"conditions":6116,"interventions":6117},[90],[869,5936],[998,759,5922],{"nctId":6119,"briefTitle":6120,"status":147,"phases":6121,"primaryCompletion":6122,"completion":6123,"start":6124,"enrollment":719,"conditions":6125,"interventions":6126},"NCT02722941","Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)",[90],"2020-06-07","2021-01-18","2016-06-10",[21],[998],{"nctId":6128,"briefTitle":6129,"status":147,"phases":6130,"primaryCompletion":6131,"completion":6132,"start":6133,"enrollment":27,"conditions":6134,"interventions":6136},"NCT01111526","Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)",[89,90],"2015-10","2016-06","2010-04",[6135],"Graft-Versus-Host Disease",[998],{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[],{"trials":6142,"activeCount":101},[],{"intervention":1147,"totalTrials":487,"cells":6144},{"EARLY_PHASE1":6145,"PHASE1":6147,"PHASE2":6153,"PHASE3":6175,"PHASE4":6177,"NA":6179},{"trials":6146,"activeCount":101},[],{"trials":6148,"activeCount":101},[6149],{"nctId":5295,"briefTitle":5296,"status":147,"phases":6150,"primaryCompletion":5298,"completion":5299,"start":5300,"enrollment":5301,"conditions":6151,"interventions":6152},[89],[21,5303],[5305,5306,5307],{"trials":6154,"activeCount":101},[6155,6159,6163,6167,6171],{"nctId":5327,"briefTitle":5328,"status":147,"phases":6156,"primaryCompletion":5330,"completion":5331,"start":5332,"enrollment":5333,"conditions":6157,"interventions":6158},[89,90],[21],[5306,5307],{"nctId":1124,"briefTitle":1125,"status":147,"phases":6160,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":6161,"interventions":6162},[90],[1132,733,1133,1134,1135,755,1136,1137,1138,732,756,1139,1140,1141,1142,1143,1144,1145],[158,1147],{"nctId":2293,"briefTitle":2294,"status":147,"phases":6164,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":27,"conditions":6165,"interventions":6166},[89,90],[21],[2247,1147,888,2301],{"nctId":1149,"briefTitle":1150,"status":147,"phases":6168,"primaryCompletion":1152,"completion":483,"start":1153,"enrollment":1154,"conditions":6169,"interventions":6170},[90],[21],[1157,1147,158],{"nctId":2785,"briefTitle":2786,"status":147,"phases":6172,"primaryCompletion":1093,"completion":1093,"start":1416,"enrollment":719,"conditions":6173,"interventions":6174},[90],[21,2789],[1157,1147],{"trials":6176,"activeCount":101},[],{"trials":6178,"activeCount":101},[],{"trials":6180,"activeCount":101},[],{"intervention":2615,"totalTrials":9,"cells":6182},{"EARLY_PHASE1":6183,"PHASE1":6185,"PHASE2":6204,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6184,"activeCount":101},[],{"trials":6186,"activeCount":101},[6187,6191,6200],{"nctId":2079,"briefTitle":2080,"status":147,"phases":6188,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":281,"conditions":6189,"interventions":6190},[89],[2085],[2087,2088,2089],{"nctId":6192,"briefTitle":6193,"status":147,"phases":6194,"primaryCompletion":6195,"completion":6195,"start":6196,"enrollment":917,"conditions":6197,"interventions":6198},"NCT01859026","A Phase I\u002FIB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation",[89],"2019-08-22","2013-12-30",[26,242],[6199,2615],"MEK162",{"nctId":6100,"briefTitle":6101,"status":147,"phases":6201,"primaryCompletion":1787,"completion":6103,"start":6104,"enrollment":445,"conditions":6202,"interventions":6203},[89],[26,6106],[998,2089],{"trials":6205,"activeCount":101},[6206,6213],{"nctId":6207,"briefTitle":6208,"status":147,"phases":6209,"primaryCompletion":819,"completion":819,"start":6210,"enrollment":16,"conditions":6211,"interventions":6212},"NCT00977548","Erlotinib Study for Myelodysplastic Syndrome (MDS)",[90],"2009-09",[1729],[2615],{"nctId":2609,"briefTitle":2610,"status":249,"phases":6214,"primaryCompletion":948,"completion":948,"start":2612,"enrollment":2139,"conditions":6215,"interventions":6216},[89,90],[242],[215,2615,620],{"trials":6218,"activeCount":101},[],{"trials":6220,"activeCount":101},[],{"trials":6222,"activeCount":101},[],{"intervention":2247,"totalTrials":9,"cells":6224},{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6243,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6226,"activeCount":101},[],{"trials":6228,"activeCount":101},[6229,6233],{"nctId":4262,"briefTitle":4263,"status":249,"phases":6230,"primaryCompletion":4265,"completion":4266,"start":4267,"enrollment":730,"conditions":6231,"interventions":6232},[89],[2557,569],[2247,807],{"nctId":6234,"briefTitle":6235,"status":147,"phases":6236,"primaryCompletion":6237,"completion":6238,"start":6239,"enrollment":198,"conditions":6240,"interventions":6242},"NCT02403310","A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML",[89],"2016-09-13","2021-02-01","2015-06-18",[35,1132,6241],"AML",[2247,4218,2525],{"trials":6244,"activeCount":101},[6245,6249,6253],{"nctId":2239,"briefTitle":2240,"status":147,"phases":6246,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":125,"conditions":6247,"interventions":6248},[89,90],[21],[2247,811,888],{"nctId":2293,"briefTitle":2294,"status":147,"phases":6250,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":27,"conditions":6251,"interventions":6252},[89,90],[21],[2247,1147,888,2301],{"nctId":6254,"briefTitle":6255,"status":147,"phases":6256,"primaryCompletion":6257,"completion":4322,"start":6258,"enrollment":1265,"conditions":6259,"interventions":6260},"NCT02402764","Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)",[90],"2016-03-10","2015-07-08",[15],[2247],{"trials":6262,"activeCount":101},[],{"trials":6264,"activeCount":101},[],{"trials":6266,"activeCount":101},[],{"intervention":2196,"totalTrials":9,"cells":6268},{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6300,"PHASE4":6302,"NA":6304},{"trials":6270,"activeCount":101},[],{"trials":6272,"activeCount":101},[],{"trials":6274,"activeCount":101},[6275,6284,6288,6292,6296],{"nctId":6276,"briefTitle":6277,"status":147,"phases":6278,"completion":6279,"start":2342,"conditions":6280,"interventions":6281},"NCT00006033","Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer",[90],"2004-06",[6106],[6282,6283,898],"gene therapy","interleukin-2 gene",{"nctId":5954,"briefTitle":5955,"status":147,"phases":6285,"primaryCompletion":946,"completion":946,"start":948,"enrollment":5957,"conditions":6286,"interventions":6287},[90],[5959],[5922,2196,5961],{"nctId":2186,"briefTitle":2187,"status":147,"phases":6289,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1130,"conditions":6290,"interventions":6291},[90],[2193,2194],[618,2196,1246],{"nctId":890,"briefTitle":891,"status":249,"phases":6293,"primaryCompletion":893,"completion":893,"start":894,"conditions":6294,"interventions":6295},[90],[834,869,35,870,755],[872,838,860,875,897,898,876],{"nctId":5991,"briefTitle":5992,"status":249,"phases":6297,"primaryCompletion":2754,"completion":2754,"start":5994,"enrollment":2139,"conditions":6298,"interventions":6299},[90],[869],[5997,5922,2196,5998,5922,2196],{"trials":6301,"activeCount":101},[],{"trials":6303,"activeCount":101},[],{"trials":6305,"activeCount":101},[],{"intervention":6307,"totalTrials":812,"cells":6308},"Sunitinib Malate",{"EARLY_PHASE1":6309,"PHASE1":6311,"PHASE2":6313,"PHASE3":6348,"PHASE4":6350,"NA":6352},{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[],{"trials":6314,"activeCount":101},[6315,6324,6334,6341],{"nctId":6316,"briefTitle":6317,"status":147,"phases":6318,"primaryCompletion":1170,"completion":1170,"start":4213,"enrollment":16,"conditions":6319,"interventions":6322},"NCT00434109","Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization",[90],[6320,6321],"Neuroendocrine Tumor","Islet Cell Tumor",[6323],"Sunitinib malate",{"nctId":6325,"briefTitle":6326,"status":147,"phases":6327,"primaryCompletion":4244,"completion":4244,"start":4213,"enrollment":1627,"conditions":6328,"interventions":6333},"NCT00400569","Phase II Study of Sunitinib Malate for Metastatic and\u002For Surgically Unresectable Soft Tissue Sarcoma",[90],[6329,6330,6331,6332],"Liposarcoma","Leiomyosarcoma","Fibrosarcoma","Malignant Fibrous Histiocytoma",[6307],{"nctId":6335,"briefTitle":6336,"status":249,"phases":6337,"primaryCompletion":6071,"completion":6071,"start":820,"enrollment":211,"conditions":6338,"interventions":6340},"NCT00495625","Sunitinib Malate (SUO11248) In Subjects W\u002F Metastatic And\u002FOr Surgically Unresectable Hepatocellular Cancers (HCC)",[90],[6339],"Liver Cancer",[6307],{"nctId":6342,"briefTitle":6343,"status":147,"phases":6344,"primaryCompletion":1300,"completion":1300,"start":1290,"enrollment":719,"conditions":6345,"interventions":6347},"NCT00606008","A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma",[90],[6346,523],"Anaplastic Astrocytoma",[6307],{"trials":6349,"activeCount":101},[],{"trials":6351,"activeCount":101},[],{"trials":6353,"activeCount":101},[],{"intervention":922,"totalTrials":730,"cells":6355},{"EARLY_PHASE1":6356,"PHASE1":6358,"PHASE2":6360,"PHASE3":6379,"PHASE4":6381,"NA":6383},{"trials":6357,"activeCount":101},[],{"trials":6359,"activeCount":101},[],{"trials":6361,"activeCount":101},[6362,6371,6375],{"nctId":6363,"briefTitle":6364,"status":147,"phases":6365,"primaryCompletion":6366,"completion":2719,"start":6367,"enrollment":1095,"conditions":6368,"interventions":6369},"NCT00100906","Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer",[90],"2006-06","2004-08",[597],[922,6370],"ATRA",{"nctId":5971,"briefTitle":5972,"status":147,"phases":6372,"primaryCompletion":5974,"completion":5975,"start":5976,"enrollment":281,"conditions":6373,"interventions":6374},[90],[5978],[922,5922,759],{"nctId":911,"briefTitle":912,"status":147,"phases":6376,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":6377,"interventions":6378},[90],[858],[157,804,803,920,888,921,922],{"trials":6380,"activeCount":101},[],{"trials":6382,"activeCount":101},[],{"trials":6384,"activeCount":101},[],{"intervention":2466,"totalTrials":730,"cells":6386},{"EARLY_PHASE1":6387,"PHASE1":6389,"PHASE2":6391,"PHASE3":6409,"PHASE4":6411,"NA":6413},{"trials":6388,"activeCount":101},[],{"trials":6390,"activeCount":101},[],{"trials":6392,"activeCount":101},[6393,6397,6405],{"nctId":2456,"briefTitle":2457,"status":147,"phases":6394,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":556,"conditions":6395,"interventions":6396},[90],[606,2463],[2465,2466,1732],{"nctId":6398,"briefTitle":6399,"status":147,"phases":6400,"primaryCompletion":319,"completion":149,"start":6401,"enrollment":445,"conditions":6402,"interventions":6404},"NCT01680965","Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease",[89,90],"2012-11-14",[6403],"Chronic Graft Versus Host Disease",[2466],{"nctId":2498,"briefTitle":2499,"status":147,"phases":6406,"primaryCompletion":994,"completion":2501,"start":2502,"enrollment":385,"conditions":6407,"interventions":6408},[90],[606,2463],[2465,2466,1732],{"trials":6410,"activeCount":101},[],{"trials":6412,"activeCount":101},[],{"trials":6414,"activeCount":101},[],{"intervention":2525,"totalTrials":730,"cells":6416},{"EARLY_PHASE1":6417,"PHASE1":6419,"PHASE2":6425,"PHASE3":6435,"PHASE4":6437,"NA":6439},{"trials":6418,"activeCount":101},[],{"trials":6420,"activeCount":101},[6421],{"nctId":6234,"briefTitle":6235,"status":147,"phases":6422,"primaryCompletion":6237,"completion":6238,"start":6239,"enrollment":198,"conditions":6423,"interventions":6424},[89],[35,1132,6241],[2247,4218,2525],{"trials":6426,"activeCount":101},[6427,6431],{"nctId":4210,"briefTitle":4211,"status":147,"phases":6428,"primaryCompletion":2612,"completion":4213,"start":4214,"enrollment":4215,"conditions":6429,"interventions":6430},[89,90],[35],[2525,4218,810,809],{"nctId":2516,"briefTitle":2517,"status":147,"phases":6432,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":1204,"conditions":6433,"interventions":6434},[89,90],[1729,1132],[2524,2525,1732],{"trials":6436,"activeCount":101},[],{"trials":6438,"activeCount":101},[],{"trials":6440,"activeCount":101},[],{"intervention":672,"totalTrials":730,"cells":6442},{"EARLY_PHASE1":6443,"PHASE1":6445,"PHASE2":6451,"PHASE3":6461,"PHASE4":6463,"NA":6465},{"trials":6444,"activeCount":101},[],{"trials":6446,"activeCount":101},[6447],{"nctId":5393,"briefTitle":5394,"status":147,"phases":6448,"primaryCompletion":5396,"completion":5397,"start":5398,"enrollment":281,"conditions":6449,"interventions":6450},[89],[5400,5383],[672,72],{"trials":6452,"activeCount":101},[6453,6457],{"nctId":4583,"briefTitle":4584,"status":249,"phases":6454,"primaryCompletion":4586,"completion":579,"start":4587,"enrollment":487,"conditions":6455,"interventions":6456},[90],[4589,4590,4591,4592,4593,4594],[672,4596,808,4597],{"nctId":661,"briefTitle":662,"status":147,"phases":6458,"primaryCompletion":664,"completion":665,"start":666,"enrollment":281,"conditions":6459,"interventions":6460},[90],[668,669,670],[495,672],{"trials":6462,"activeCount":101},[],{"trials":6464,"activeCount":101},[],{"trials":6466,"activeCount":101},[],{"intervention":587,"totalTrials":730,"cells":6468},{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6473,"PHASE3":6493,"PHASE4":6495,"NA":6497},{"trials":6470,"activeCount":101},[],{"trials":6472,"activeCount":101},[],{"trials":6474,"activeCount":101},[6475,6479,6483],{"nctId":576,"briefTitle":577,"status":147,"phases":6476,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":6477,"interventions":6478},[89,90],[271,269,584,585],[495,587],{"nctId":600,"briefTitle":601,"status":249,"phases":6480,"primaryCompletion":603,"completion":603,"start":604,"enrollment":9,"conditions":6481,"interventions":6482},[90],[606],[495,587],{"nctId":6484,"briefTitle":6485,"status":147,"phases":6486,"primaryCompletion":592,"completion":6487,"start":6488,"enrollment":281,"conditions":6489,"interventions":6492},"NCT02575300","Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",[90],"2019-11-04","2015-10-09",[6490,6491],"Carcinoid Tumors","Pancreatic NET",[587],{"trials":6494,"activeCount":101},[],{"trials":6496,"activeCount":101},[],{"trials":6498,"activeCount":101},[],{"intervention":4396,"totalTrials":730,"cells":6500},{"EARLY_PHASE1":6501,"PHASE1":6503,"PHASE2":6522,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6502,"activeCount":101},[],{"trials":6504,"activeCount":101},[6505,6518],{"nctId":6506,"briefTitle":6507,"status":147,"phases":6508,"primaryCompletion":2755,"completion":2755,"start":6509,"enrollment":6510,"conditions":6511,"interventions":6513},"NCT00246103","Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies",[89],"2004-03",82,[6512],"Neoplasms, Advanced",[6514,6515,6516,6517],"Valproic acid","Epirubicin","5-fluorouracil","Cyclophosphamide.",{"nctId":4389,"briefTitle":4390,"status":249,"phases":6519,"primaryCompletion":4392,"completion":4392,"start":4393,"enrollment":1265,"conditions":6520,"interventions":6521},[89],[225],[527,4396],{"trials":6523,"activeCount":101},[6524],{"nctId":6525,"briefTitle":6526,"status":249,"phases":6527,"primaryCompletion":2083,"completion":2083,"start":6528,"enrollment":630,"conditions":6529,"interventions":6531},"NCT00358319","Phase I\u002FII Trial of Valproic Acid and Karenitecin for Melanoma",[89,90],"2005-03",[6530],"Malignant Melanoma",[6532,4396],"Karenitecin",{"trials":6534,"activeCount":101},[],{"trials":6536,"activeCount":101},[],{"trials":6538,"activeCount":101},[],{"intervention":873,"totalTrials":730,"cells":6540},{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6545,"PHASE3":6559,"PHASE4":6561,"NA":6563},{"trials":6542,"activeCount":101},[],{"trials":6544,"activeCount":101},[],{"trials":6546,"activeCount":101},[6547,6551,6555],{"nctId":864,"briefTitle":865,"status":249,"phases":6548,"primaryCompletion":830,"completion":830,"start":867,"conditions":6549,"interventions":6550},[90],[834,869,35,858,870,755],[872,873,874,860,875,876],{"nctId":900,"briefTitle":901,"status":249,"phases":6552,"primaryCompletion":903,"completion":903,"start":904,"enrollment":730,"conditions":6553,"interventions":6554},[89,90],[632],[873,907,860,861,908,909],{"nctId":1359,"briefTitle":1360,"status":147,"phases":6556,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":556,"conditions":6557,"interventions":6558},[90],[15],[1367,1264,804],{"trials":6560,"activeCount":101},[],{"trials":6562,"activeCount":101},[],{"trials":6564,"activeCount":101},[],{"intervention":1350,"totalTrials":730,"cells":6566},{"EARLY_PHASE1":6567,"PHASE1":6569,"PHASE2":6582,"PHASE3":6588,"PHASE4":6590,"NA":6592},{"trials":6568,"activeCount":101},[],{"trials":6570,"activeCount":101},[6571,6578],{"nctId":6572,"briefTitle":6573,"status":147,"phases":6574,"primaryCompletion":2095,"completion":6575,"start":2096,"enrollment":1095,"conditions":6576,"interventions":6577},"NCT01376453","Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer",[89],"2016-03",[5400],[4596,1350],{"nctId":6506,"briefTitle":6507,"status":147,"phases":6579,"primaryCompletion":2755,"completion":2755,"start":6509,"enrollment":6510,"conditions":6580,"interventions":6581},[89],[6512],[6514,6515,6516,6517],{"trials":6583,"activeCount":101},[6584],{"nctId":1342,"briefTitle":1343,"status":249,"phases":6585,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":253,"conditions":6586,"interventions":6587},[90],[24],[72,1246,1264,1350],{"trials":6589,"activeCount":101},[],{"trials":6591,"activeCount":101},[],{"trials":6593,"activeCount":101},[],{"intervention":909,"totalTrials":730,"cells":6595},{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6614,"PHASE4":6616,"NA":6618},{"trials":6597,"activeCount":101},[],{"trials":6599,"activeCount":101},[],{"trials":6601,"activeCount":101},[6602,6606,6610],{"nctId":900,"briefTitle":901,"status":249,"phases":6603,"primaryCompletion":903,"completion":903,"start":904,"enrollment":730,"conditions":6604,"interventions":6605},[89,90],[632],[873,907,860,861,908,909],{"nctId":4232,"briefTitle":4233,"status":249,"phases":6607,"primaryCompletion":4235,"completion":4235,"start":4236,"conditions":6608,"interventions":6609},[90],[15],[861,4239,909],{"nctId":4241,"briefTitle":4242,"status":147,"phases":6611,"primaryCompletion":820,"completion":4244,"start":4245,"enrollment":595,"conditions":6612,"interventions":6613},[90],[858],[861,4239,909,4248],{"trials":6615,"activeCount":101},[],{"trials":6617,"activeCount":101},[],{"trials":6619,"activeCount":101},[],{"intervention":1295,"totalTrials":189,"cells":6621},{"EARLY_PHASE1":6622,"PHASE1":6624,"PHASE2":6626,"PHASE3":6636,"PHASE4":6638,"NA":6640},{"trials":6623,"activeCount":101},[],{"trials":6625,"activeCount":101},[],{"trials":6627,"activeCount":101},[6628,6632],{"nctId":1287,"briefTitle":1288,"status":147,"phases":6629,"primaryCompletion":914,"completion":914,"start":1290,"enrollment":556,"conditions":6630,"interventions":6631},[90],[1292,632,1293],[1295,1264],{"nctId":2303,"briefTitle":2304,"status":249,"phases":6633,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":97,"conditions":6634,"interventions":6635},[90],[24],[1295,2310,804,2311,888,2312],{"trials":6637,"activeCount":101},[],{"trials":6639,"activeCount":101},[],{"trials":6641,"activeCount":101},[],{"intervention":2157,"totalTrials":189,"cells":6643},{"EARLY_PHASE1":6644,"PHASE1":6646,"PHASE2":6652,"PHASE3":6658,"PHASE4":6660,"NA":6662},{"trials":6645,"activeCount":101},[],{"trials":6647,"activeCount":101},[6648],{"nctId":2125,"briefTitle":2126,"status":147,"phases":6649,"primaryCompletion":2128,"completion":2129,"start":2130,"enrollment":1035,"conditions":6650,"interventions":6651},[89],[24],[1951,1246,2133],{"trials":6653,"activeCount":101},[6654],{"nctId":2146,"briefTitle":2147,"status":147,"phases":6655,"primaryCompletion":2149,"completion":2150,"start":2151,"enrollment":2152,"conditions":6656,"interventions":6657},[90],[296,2154,960,2155],[2157,1246],{"trials":6659,"activeCount":101},[],{"trials":6661,"activeCount":101},[],{"trials":6663,"activeCount":101},[],{"intervention":2465,"totalTrials":189,"cells":6665},{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6670,"PHASE3":6680,"PHASE4":6682,"NA":6684},{"trials":6667,"activeCount":101},[],{"trials":6669,"activeCount":101},[],{"trials":6671,"activeCount":101},[6672,6676],{"nctId":2456,"briefTitle":2457,"status":147,"phases":6673,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":556,"conditions":6674,"interventions":6675},[90],[606,2463],[2465,2466,1732],{"nctId":2498,"briefTitle":2499,"status":147,"phases":6677,"primaryCompletion":994,"completion":2501,"start":2502,"enrollment":385,"conditions":6678,"interventions":6679},[90],[606,2463],[2465,2466,1732],{"trials":6681,"activeCount":101},[],{"trials":6683,"activeCount":101},[],{"trials":6685,"activeCount":101},[],{"intervention":4218,"totalTrials":189,"cells":6687},{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6696,"PHASE3":6702,"PHASE4":6704,"NA":6706},{"trials":6689,"activeCount":101},[],{"trials":6691,"activeCount":101},[6692],{"nctId":6234,"briefTitle":6235,"status":147,"phases":6693,"primaryCompletion":6237,"completion":6238,"start":6239,"enrollment":198,"conditions":6694,"interventions":6695},[89],[35,1132,6241],[2247,4218,2525],{"trials":6697,"activeCount":101},[6698],{"nctId":4210,"briefTitle":4211,"status":147,"phases":6699,"primaryCompletion":2612,"completion":4213,"start":4214,"enrollment":4215,"conditions":6700,"interventions":6701},[89,90],[35],[2525,4218,810,809],{"trials":6703,"activeCount":101},[],{"trials":6705,"activeCount":101},[],{"trials":6707,"activeCount":101},[],{"intervention":1099,"totalTrials":189,"cells":6709},{"EARLY_PHASE1":6710,"PHASE1":6712,"PHASE2":6718,"PHASE3":6728,"PHASE4":6730,"NA":6732},{"trials":6711,"activeCount":101},[],{"trials":6713,"activeCount":101},[6714],{"nctId":1090,"briefTitle":1091,"status":147,"phases":6715,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":6716,"interventions":6717},[89],[1097,153],[1099,158,1100],{"trials":6719,"activeCount":101},[6720],{"nctId":6721,"briefTitle":6722,"status":147,"phases":6723,"primaryCompletion":1787,"completion":6724,"start":6725,"enrollment":281,"conditions":6726,"interventions":6727},"NCT01347034","Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)",[90],"2016-04","2011-01",[2155],[1099],{"trials":6729,"activeCount":101},[],{"trials":6731,"activeCount":101},[],{"trials":6733,"activeCount":101},[],{"intervention":872,"totalTrials":189,"cells":6735},{"EARLY_PHASE1":6736,"PHASE1":6738,"PHASE2":6740,"PHASE3":6750,"PHASE4":6752,"NA":6754},{"trials":6737,"activeCount":101},[],{"trials":6739,"activeCount":101},[],{"trials":6741,"activeCount":101},[6742,6746],{"nctId":864,"briefTitle":865,"status":249,"phases":6743,"primaryCompletion":830,"completion":830,"start":867,"conditions":6744,"interventions":6745},[90],[834,869,35,858,870,755],[872,873,874,860,875,876],{"nctId":890,"briefTitle":891,"status":249,"phases":6747,"primaryCompletion":893,"completion":893,"start":894,"conditions":6748,"interventions":6749},[90],[834,869,35,870,755],[872,838,860,875,897,898,876],{"trials":6751,"activeCount":101},[],{"trials":6753,"activeCount":101},[],{"trials":6755,"activeCount":101},[],{"intervention":875,"totalTrials":189,"cells":6757},{"EARLY_PHASE1":6758,"PHASE1":6760,"PHASE2":6762,"PHASE3":6772,"PHASE4":6774,"NA":6776},{"trials":6759,"activeCount":101},[],{"trials":6761,"activeCount":101},[],{"trials":6763,"activeCount":101},[6764,6768],{"nctId":864,"briefTitle":865,"status":249,"phases":6765,"primaryCompletion":830,"completion":830,"start":867,"conditions":6766,"interventions":6767},[90],[834,869,35,858,870,755],[872,873,874,860,875,876],{"nctId":890,"briefTitle":891,"status":249,"phases":6769,"primaryCompletion":893,"completion":893,"start":894,"conditions":6770,"interventions":6771},[90],[834,869,35,870,755],[872,838,860,875,897,898,876],{"trials":6773,"activeCount":101},[],{"trials":6775,"activeCount":101},[],{"trials":6777,"activeCount":101},[],{"intervention":876,"totalTrials":189,"cells":6779},{"EARLY_PHASE1":6780,"PHASE1":6782,"PHASE2":6784,"PHASE3":6794,"PHASE4":6796,"NA":6798},{"trials":6781,"activeCount":101},[],{"trials":6783,"activeCount":101},[],{"trials":6785,"activeCount":101},[6786,6790],{"nctId":864,"briefTitle":865,"status":249,"phases":6787,"primaryCompletion":830,"completion":830,"start":867,"conditions":6788,"interventions":6789},[90],[834,869,35,858,870,755],[872,873,874,860,875,876],{"nctId":890,"briefTitle":891,"status":249,"phases":6791,"primaryCompletion":893,"completion":893,"start":894,"conditions":6792,"interventions":6793},[90],[834,869,35,870,755],[872,838,860,875,897,898,876],{"trials":6795,"activeCount":101},[],{"trials":6797,"activeCount":101},[],{"trials":6799,"activeCount":101},[],{"intervention":273,"totalTrials":189,"cells":6801},{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6810,"PHASE3":6821,"PHASE4":6823,"NA":6825},{"trials":6803,"activeCount":101},[],{"trials":6805,"activeCount":101},[6806],{"nctId":261,"briefTitle":262,"status":147,"phases":6807,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":6808,"interventions":6809},[89],[269,270,271],[273,52],{"trials":6811,"activeCount":101},[6812],{"nctId":6813,"briefTitle":6814,"status":147,"phases":6815,"primaryCompletion":2510,"completion":6816,"start":6817,"enrollment":16,"conditions":6818,"interventions":6820},"NCT02115542","Single Agent Regorafenib in Refractory Advanced Biliary Cancers",[90],"2021-09-20","2014-06-05",[6819],"Cancer of the Bile Duct",[273],{"trials":6822,"activeCount":101},[],{"trials":6824,"activeCount":101},[],{"trials":6826,"activeCount":101},[],{"intervention":6828,"totalTrials":189,"cells":6829},"chemotherapy",{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6857,"PHASE4":6859,"NA":6861},{"trials":6831,"activeCount":101},[],{"trials":6833,"activeCount":101},[],{"trials":6835,"activeCount":101},[6836,6845],{"nctId":6837,"briefTitle":6838,"status":147,"phases":6839,"completion":6840,"start":4236,"conditions":6841,"interventions":6843},"NCT00006376","R115777 in Treating Patients With Advanced Bladder Cancer",[90],"2005-05",[201,6842],"Transitional Cell Cancer of the Renal Pelvis and Ureter",[6828,6844],"tipifarnib",{"nctId":6846,"briefTitle":6847,"status":345,"phases":6848,"primaryCompletion":6849,"completion":6850,"start":348,"enrollment":101,"conditions":6851,"interventions":6855},"NCT03628144","Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer",[90],"2022-09","2023-09",[283,240,616,1280,6852,6853,6854],"Non-small Cell Lung Cancer Stage ⅢA","NSCLC Stage IIIB","NSCLC, Stage IIIA",[6856],"Chemotherapy",{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[],{"intervention":6864,"totalTrials":97,"cells":6865},"Pasireotide Long Acting Release",{"EARLY_PHASE1":6866,"PHASE1":6868,"PHASE2":6870,"PHASE3":6880,"PHASE4":6882,"NA":6884},{"trials":6867,"activeCount":101},[],{"trials":6869,"activeCount":101},[],{"trials":6871,"activeCount":101},[6872],{"nctId":6873,"briefTitle":6874,"status":147,"phases":6875,"primaryCompletion":2459,"completion":6876,"start":6877,"enrollment":385,"conditions":6878,"interventions":6879},"NCT01253161","Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)",[90],"2023-03-02","2011-02-01",[668,6490],[6864],{"trials":6881,"activeCount":101},[],{"trials":6883,"activeCount":101},[],{"trials":6885,"activeCount":101},[],{"intervention":6887,"totalTrials":97,"cells":6888},"Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes",{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6901,"PHASE4":6903,"NA":6905},{"trials":6890,"activeCount":101},[],{"trials":6892,"activeCount":101},[],{"trials":6894,"activeCount":101},[6895],{"nctId":6896,"briefTitle":6897,"status":249,"phases":6898,"primaryCompletion":854,"completion":2138,"start":1376,"enrollment":189,"conditions":6899,"interventions":6900},"NCT00776295","Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer",[90],[436],[6887],{"trials":6902,"activeCount":101},[],{"trials":6904,"activeCount":101},[],{"trials":6906,"activeCount":101},[],{"intervention":6908,"totalTrials":97,"cells":6909},"Very Low Nicotine Content (VLNC) Cigarettes",{"EARLY_PHASE1":6910,"PHASE1":6912,"PHASE2":6914,"PHASE3":6924,"PHASE4":6926,"NA":6928},{"trials":6911,"activeCount":101},[],{"trials":6913,"activeCount":101},[],{"trials":6915,"activeCount":101},[6916],{"nctId":6917,"briefTitle":6918,"status":147,"phases":6919,"primaryCompletion":2542,"completion":2542,"start":6920,"enrollment":6921,"conditions":6922,"interventions":6923},"NCT02796391","Facilitating Smoking Cessation With Reduced Nicotine Cigarettes",[90],"2017-09-07",163,[29],[6908],{"trials":6925,"activeCount":101},[],{"trials":6927,"activeCount":101},[],{"trials":6929,"activeCount":101},[],{"intervention":6931,"totalTrials":97,"cells":6932},"suberoylanilide hydroxamic acid",{"EARLY_PHASE1":6933,"PHASE1":6935,"PHASE2":6937,"PHASE3":6947,"PHASE4":6949,"NA":6951},{"trials":6934,"activeCount":101},[],{"trials":6936,"activeCount":101},[],{"trials":6938,"activeCount":101},[6939],{"nctId":6940,"briefTitle":6941,"status":147,"phases":6942,"primaryCompletion":6943,"completion":1300,"start":1094,"enrollment":917,"conditions":6944,"interventions":6945},"NCT00365599","Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer",[90],"2011-04",[15],[6931,6946],"tamoxifen citrate",{"trials":6948,"activeCount":101},[],{"trials":6950,"activeCount":101},[],{"trials":6952,"activeCount":101},[],{"intervention":6946,"totalTrials":97,"cells":6954},{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6965,"PHASE4":6967,"NA":6969},{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":101},[],{"trials":6960,"activeCount":101},[6961],{"nctId":6940,"briefTitle":6941,"status":147,"phases":6962,"primaryCompletion":6943,"completion":1300,"start":1094,"enrollment":917,"conditions":6963,"interventions":6964},[90],[15],[6931,6946],{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[],{"trials":6970,"activeCount":101},[],{"intervention":824,"totalTrials":97,"cells":6972},{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6974,"activeCount":101},[],{"trials":6976,"activeCount":101},[],{"trials":6978,"activeCount":101},[6979],{"nctId":816,"briefTitle":817,"status":147,"phases":6980,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":6981,"interventions":6982},[90],[26],[824,157,825],{"trials":6984,"activeCount":101},[],{"trials":6986,"activeCount":101},[],{"trials":6988,"activeCount":101},[],{"intervention":825,"totalTrials":97,"cells":6990},{"EARLY_PHASE1":6991,"PHASE1":6993,"PHASE2":6995,"PHASE3":7001,"PHASE4":7003,"NA":7005},{"trials":6992,"activeCount":101},[],{"trials":6994,"activeCount":101},[],{"trials":6996,"activeCount":101},[6997],{"nctId":816,"briefTitle":817,"status":147,"phases":6998,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":6999,"interventions":7000},[90],[26],[824,157,825],{"trials":7002,"activeCount":101},[],{"trials":7004,"activeCount":101},[],{"trials":7006,"activeCount":101},[],{"intervention":1209,"totalTrials":97,"cells":7008},{"EARLY_PHASE1":7009,"PHASE1":7011,"PHASE2":7013,"PHASE3":7019,"PHASE4":7021,"NA":7023},{"trials":7010,"activeCount":101},[],{"trials":7012,"activeCount":101},[],{"trials":7014,"activeCount":101},[7015],{"nctId":1198,"briefTitle":1199,"status":147,"phases":7016,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":7017,"interventions":7018},[89,90],[15,1206,1207,1190],[1209,622,572],{"trials":7020,"activeCount":101},[],{"trials":7022,"activeCount":101},[],{"trials":7024,"activeCount":101},[],{"intervention":7026,"totalTrials":97,"cells":7027},"FTI",{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7032,"PHASE3":7043,"PHASE4":7045,"NA":7047},{"trials":7029,"activeCount":101},[],{"trials":7031,"activeCount":101},[],{"trials":7033,"activeCount":101},[7034],{"nctId":7035,"briefTitle":7036,"status":147,"phases":7037,"primaryCompletion":7038,"completion":7039,"start":7040,"enrollment":445,"conditions":7041,"interventions":7042},"NCT00012350","Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma",[90],"2003-09","2010-01","2001-01",[21],[7026],{"trials":7044,"activeCount":101},[],{"trials":7046,"activeCount":101},[],{"trials":7048,"activeCount":101},[],{"intervention":7050,"totalTrials":97,"cells":7051},"FOLFIRINOX",{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7071,"PHASE4":7073,"NA":7075},{"trials":7053,"activeCount":101},[],{"trials":7055,"activeCount":101},[],{"trials":7057,"activeCount":101},[7058],{"nctId":7059,"briefTitle":7060,"status":249,"phases":7061,"primaryCompletion":7062,"completion":7063,"start":7064,"enrollment":189,"conditions":7065,"interventions":7069},"NCT03042780","FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas",[90],"2018-01-03","2018-09-07","2017-02-01",[7066,24,7067,7068],"Gastro-enteropancreatic Neuroendocrine Tumor","Neuroendocrine Carcinomas of Pancreas","Islet Cell Carcinoma",[7050,7070],"Granulocyte colony-stimulating factor",{"trials":7072,"activeCount":101},[],{"trials":7074,"activeCount":101},[],{"trials":7076,"activeCount":101},[],{"intervention":7070,"totalTrials":97,"cells":7078},{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7083,"PHASE3":7089,"PHASE4":7091,"NA":7093},{"trials":7080,"activeCount":101},[],{"trials":7082,"activeCount":101},[],{"trials":7084,"activeCount":101},[7085],{"nctId":7059,"briefTitle":7060,"status":249,"phases":7086,"primaryCompletion":7062,"completion":7063,"start":7064,"enrollment":189,"conditions":7087,"interventions":7088},[90],[7066,24,7067,7068],[7050,7070],{"trials":7090,"activeCount":101},[],{"trials":7092,"activeCount":101},[],{"trials":7094,"activeCount":101},[],{"intervention":7096,"totalTrials":97,"cells":7097},"Interferon alfa",{"EARLY_PHASE1":7098,"PHASE1":7100,"PHASE2":7102,"PHASE3":7112,"PHASE4":7114,"NA":7116},{"trials":7099,"activeCount":101},[],{"trials":7101,"activeCount":101},[],{"trials":7103,"activeCount":101},[7104],{"nctId":7105,"briefTitle":7106,"status":147,"phases":7107,"primaryCompletion":7108,"completion":7108,"start":7109,"enrollment":821,"conditions":7110,"interventions":7111},"NCT00005615","Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa",[89,90],"2005-12","1997-07",[153],[7096],{"trials":7113,"activeCount":101},[],{"trials":7115,"activeCount":101},[],{"trials":7117,"activeCount":101},[],{"intervention":5952,"totalTrials":97,"cells":7119},{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7124,"PHASE3":7130,"PHASE4":7132,"NA":7134},{"trials":7121,"activeCount":101},[],{"trials":7123,"activeCount":101},[],{"trials":7125,"activeCount":101},[7126],{"nctId":5943,"briefTitle":5944,"status":147,"phases":7127,"primaryCompletion":5946,"completion":5947,"start":5948,"enrollment":582,"conditions":7128,"interventions":7129},[89,90],[5950,5936],[5952,759,5922],{"trials":7131,"activeCount":101},[],{"trials":7133,"activeCount":101},[],{"trials":7135,"activeCount":101},[],{"intervention":6370,"totalTrials":97,"cells":7137},{"EARLY_PHASE1":7138,"PHASE1":7140,"PHASE2":7142,"PHASE3":7148,"PHASE4":7150,"NA":7152},{"trials":7139,"activeCount":101},[],{"trials":7141,"activeCount":101},[],{"trials":7143,"activeCount":101},[7144],{"nctId":6363,"briefTitle":6364,"status":147,"phases":7145,"primaryCompletion":6366,"completion":2719,"start":6367,"enrollment":1095,"conditions":7146,"interventions":7147},[90],[597],[922,6370],{"trials":7149,"activeCount":101},[],{"trials":7151,"activeCount":101},[],{"trials":7153,"activeCount":101},[],{"intervention":7155,"totalTrials":97,"cells":7156},"Nuvigil®",{"EARLY_PHASE1":7157,"PHASE1":7159,"PHASE2":7161,"PHASE3":7170,"PHASE4":7172,"NA":7174},{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[],{"trials":7162,"activeCount":101},[7163],{"nctId":7164,"briefTitle":7165,"status":249,"phases":7166,"primaryCompletion":946,"completion":7167,"start":6071,"enrollment":487,"conditions":7168,"interventions":7169},"NCT01400958","Nuvigil or Placebo in Newly Diagnosed Malignant Glioma",[90],"2013-09",[213],[7155],{"trials":7171,"activeCount":101},[],{"trials":7173,"activeCount":101},[],{"trials":7175,"activeCount":101},[],{"intervention":559,"totalTrials":97,"cells":7177},{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7179,"activeCount":101},[],{"trials":7181,"activeCount":101},[],{"trials":7183,"activeCount":101},[7184],{"nctId":550,"briefTitle":551,"status":552,"phases":7185,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":7186,"interventions":7187},[89,90],[283,26],[495,559],{"trials":7189,"activeCount":101},[],{"trials":7191,"activeCount":101},[],{"trials":7193,"activeCount":101},[],{"intervention":1421,"totalTrials":97,"cells":7195},{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7200,"PHASE3":7206,"PHASE4":7208,"NA":7210},{"trials":7197,"activeCount":101},[],{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":101},[7202],{"nctId":1413,"briefTitle":1414,"status":147,"phases":7203,"primaryCompletion":1416,"completion":819,"start":1417,"enrollment":1418,"conditions":7204,"interventions":7205},[90],[597],[160,1421],{"trials":7207,"activeCount":101},[],{"trials":7209,"activeCount":101},[],{"trials":7211,"activeCount":101},[],{"intervention":7213,"totalTrials":97,"cells":7214},"PF-04449913",{"EARLY_PHASE1":7215,"PHASE1":7217,"PHASE2":7219,"PHASE3":7233,"PHASE4":7235,"NA":7237},{"trials":7216,"activeCount":101},[],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[7221],{"nctId":7222,"briefTitle":7223,"status":147,"phases":7224,"primaryCompletion":7225,"completion":7226,"start":7227,"enrollment":7228,"conditions":7229,"interventions":7232},"NCT01842646","Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)",[90],"2016-01-31","2021-06-10","2013-08-29",35,[7230,7231],"Myelodysplastic Syndrome (MDS)","Chronic Myelomonocytic Leukemia (CMML)",[7213],{"trials":7234,"activeCount":101},[],{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[],{"intervention":6077,"totalTrials":97,"cells":7240},{"EARLY_PHASE1":7241,"PHASE1":7243,"PHASE2":7245,"PHASE3":7251,"PHASE4":7253,"NA":7255},{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[],{"trials":7246,"activeCount":101},[7247],{"nctId":6068,"briefTitle":6069,"status":249,"phases":7248,"primaryCompletion":6071,"completion":6071,"start":6072,"enrollment":6073,"conditions":7249,"interventions":7250},[90],[6075,271],[6077,6078,215],{"trials":7252,"activeCount":101},[],{"trials":7254,"activeCount":101},[],{"trials":7256,"activeCount":101},[],{"intervention":6078,"totalTrials":97,"cells":7258},{"EARLY_PHASE1":7259,"PHASE1":7261,"PHASE2":7263,"PHASE3":7269,"PHASE4":7271,"NA":7273},{"trials":7260,"activeCount":101},[],{"trials":7262,"activeCount":101},[],{"trials":7264,"activeCount":101},[7265],{"nctId":6068,"briefTitle":6069,"status":249,"phases":7266,"primaryCompletion":6071,"completion":6071,"start":6072,"enrollment":6073,"conditions":7267,"interventions":7268},[90],[6075,271],[6077,6078,215],{"trials":7270,"activeCount":101},[],{"trials":7272,"activeCount":101},[],{"trials":7274,"activeCount":101},[],{"intervention":7276,"totalTrials":97,"cells":7277},"Sulforaphane Administration",{"EARLY_PHASE1":7278,"PHASE1":7280,"PHASE2":7282,"PHASE3":7293,"PHASE4":7295,"NA":7297},{"trials":7279,"activeCount":101},[],{"trials":7281,"activeCount":101},[],{"trials":7283,"activeCount":101},[7284],{"nctId":7285,"briefTitle":7286,"status":345,"phases":7287,"primaryCompletion":7288,"completion":7289,"start":627,"enrollment":101,"conditions":7290,"interventions":7292},"NCT03517995","Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention",[90],"2021-12","2022-12",[201,7291,239],"Bladder Tumor",[7276],{"trials":7294,"activeCount":101},[],{"trials":7296,"activeCount":101},[],{"trials":7298,"activeCount":101},[],{"intervention":353,"totalTrials":97,"cells":7300},{"EARLY_PHASE1":7301,"PHASE1":7303,"PHASE2":7305,"PHASE3":7311,"PHASE4":7313,"NA":7315},{"trials":7302,"activeCount":101},[],{"trials":7304,"activeCount":101},[],{"trials":7306,"activeCount":101},[7307],{"nctId":343,"briefTitle":344,"status":345,"phases":7308,"primaryCompletion":347,"completion":348,"start":349,"enrollment":101,"conditions":7309,"interventions":7310},[89,90],[26,351],[52,353],{"trials":7312,"activeCount":101},[],{"trials":7314,"activeCount":101},[],{"trials":7316,"activeCount":101},[],{"intervention":2375,"totalTrials":97,"cells":7318},{"EARLY_PHASE1":7319,"PHASE1":7321,"PHASE2":7323,"PHASE3":7329,"PHASE4":7331,"NA":7333},{"trials":7320,"activeCount":101},[],{"trials":7322,"activeCount":101},[],{"trials":7324,"activeCount":101},[7325],{"nctId":2368,"briefTitle":2369,"status":147,"phases":7326,"primaryCompletion":2371,"completion":2094,"start":1646,"enrollment":2372,"conditions":7327,"interventions":7328},[89,90],[26],[2375,619,810],{"trials":7330,"activeCount":101},[],{"trials":7332,"activeCount":101},[],{"trials":7334,"activeCount":101},[],{"intervention":7336,"totalTrials":97,"cells":7337},"Pimonidazole hydrochloride",{"EARLY_PHASE1":7338,"PHASE1":7340,"PHASE2":7342,"PHASE3":7352,"PHASE4":7354,"NA":7356},{"trials":7339,"activeCount":101},[],{"trials":7341,"activeCount":101},[],{"trials":7343,"activeCount":101},[7344],{"nctId":7345,"briefTitle":7346,"status":345,"phases":7347,"primaryCompletion":7348,"completion":7348,"start":1346,"enrollment":101,"conditions":7349,"interventions":7350},"NCT02061007","Biomarker Correlates of Hypoxia in Metastatic Melanoma",[90],"2016-02",[32,154],[7336,7351],"Optional 18F-FMISO PET scan",{"trials":7353,"activeCount":101},[],{"trials":7355,"activeCount":101},[],{"trials":7357,"activeCount":101},[],{"intervention":7351,"totalTrials":97,"cells":7359},{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7364,"PHASE3":7370,"PHASE4":7372,"NA":7374},{"trials":7361,"activeCount":101},[],{"trials":7363,"activeCount":101},[],{"trials":7365,"activeCount":101},[7366],{"nctId":7345,"briefTitle":7346,"status":345,"phases":7367,"primaryCompletion":7348,"completion":7348,"start":1346,"enrollment":101,"conditions":7368,"interventions":7369},[90],[32,154],[7336,7351],{"trials":7371,"activeCount":101},[],{"trials":7373,"activeCount":101},[],{"trials":7375,"activeCount":101},[],{"intervention":2257,"totalTrials":97,"cells":7377},{"EARLY_PHASE1":7378,"PHASE1":7380,"PHASE2":7382,"PHASE3":7388,"PHASE4":7390,"NA":7392},{"trials":7379,"activeCount":101},[],{"trials":7381,"activeCount":101},[],{"trials":7383,"activeCount":101},[7384],{"nctId":2249,"briefTitle":2250,"status":345,"phases":7385,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":101,"conditions":7386,"interventions":7387},[89,90],[21],[998,2257,1732,888],{"trials":7389,"activeCount":101},[],{"trials":7391,"activeCount":101},[],{"trials":7393,"activeCount":101},[],{"intervention":7395,"totalTrials":97,"cells":7396},"aminoglutethimide",{"EARLY_PHASE1":7397,"PHASE1":7399,"PHASE2":7401,"PHASE3":7412,"PHASE4":7414,"NA":7416},{"trials":7398,"activeCount":101},[],{"trials":7400,"activeCount":101},[],{"trials":7402,"activeCount":101},[7403],{"nctId":7404,"briefTitle":7405,"status":249,"phases":7406,"primaryCompletion":7407,"completion":7407,"start":1417,"enrollment":189,"conditions":7408,"interventions":7409},"NCT00006371","A Phase II Trial of Early Medical Adrenalectomy for \"D0.5\" Prostate Cancer",[90],"2001-12",[18],[7395,7410,7411],"ketoconazole","therapeutic hydrocortisone",{"trials":7413,"activeCount":101},[],{"trials":7415,"activeCount":101},[],{"trials":7417,"activeCount":101},[],{"intervention":7410,"totalTrials":97,"cells":7419},{"EARLY_PHASE1":7420,"PHASE1":7422,"PHASE2":7424,"PHASE3":7430,"PHASE4":7432,"NA":7434},{"trials":7421,"activeCount":101},[],{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[7426],{"nctId":7404,"briefTitle":7405,"status":249,"phases":7427,"primaryCompletion":7407,"completion":7407,"start":1417,"enrollment":189,"conditions":7428,"interventions":7429},[90],[18],[7395,7410,7411],{"trials":7431,"activeCount":101},[],{"trials":7433,"activeCount":101},[],{"trials":7435,"activeCount":101},[],{"intervention":7411,"totalTrials":97,"cells":7437},{"EARLY_PHASE1":7438,"PHASE1":7440,"PHASE2":7442,"PHASE3":7448,"PHASE4":7450,"NA":7452},{"trials":7439,"activeCount":101},[],{"trials":7441,"activeCount":101},[],{"trials":7443,"activeCount":101},[7444],{"nctId":7404,"briefTitle":7405,"status":249,"phases":7445,"primaryCompletion":7407,"completion":7407,"start":1417,"enrollment":189,"conditions":7446,"interventions":7447},[90],[18],[7395,7410,7411],{"trials":7449,"activeCount":101},[],{"trials":7451,"activeCount":101},[],{"trials":7453,"activeCount":101},[],{"intervention":7455,"totalTrials":97,"cells":7456},"MK-0646",{"EARLY_PHASE1":7457,"PHASE1":7459,"PHASE2":7461,"PHASE3":7471,"PHASE4":7473,"NA":7475},{"trials":7458,"activeCount":101},[],{"trials":7460,"activeCount":101},[],{"trials":7462,"activeCount":101},[7463],{"nctId":7464,"briefTitle":7465,"status":345,"phases":7466,"primaryCompletion":7467,"completion":7467,"start":7468,"enrollment":101,"conditions":7469,"interventions":7470},"NCT01175291","FOLFOX\u002FBevacizumab +\u002F- MK-0646 in Metastatic Colorectal Cancer",[90],"2012-07","2010-09",[270],[7455],{"trials":7472,"activeCount":101},[],{"trials":7474,"activeCount":101},[],{"trials":7476,"activeCount":101},[],{"intervention":839,"totalTrials":97,"cells":7478},{"EARLY_PHASE1":7479,"PHASE1":7481,"PHASE2":7483,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7480,"activeCount":101},[],{"trials":7482,"activeCount":101},[],{"trials":7484,"activeCount":101},[7485],{"nctId":827,"briefTitle":828,"status":147,"phases":7486,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":7487,"interventions":7488},[90],[834,35,835,755,836],[838,157,839],{"trials":7490,"activeCount":101},[],{"trials":7492,"activeCount":101},[],{"trials":7494,"activeCount":101},[],{"intervention":7496,"totalTrials":97,"cells":7497},"CPX-351",{"EARLY_PHASE1":7498,"PHASE1":7500,"PHASE2":7502,"PHASE3":7516,"PHASE4":7518,"NA":7520},{"trials":7499,"activeCount":101},[],{"trials":7501,"activeCount":101},[],{"trials":7503,"activeCount":101},[7504],{"nctId":7505,"briefTitle":7506,"status":147,"phases":7507,"primaryCompletion":7508,"completion":7509,"start":7510,"enrollment":151,"conditions":7511,"interventions":7515},"NCT03575325","Vyxeos(CPX-351) in Adults w R\u002FR Acute Lymphoblastic Leukemia",[90],"2021-06-07","2023-09-14","2018-10-11",[7512,733,7513,7514],"Lymphoid Leukemia","Refractory Acute Lymphoblastic Leukemia","Relapsed Acute Lymphoblastic Leukemia",[7496],{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[],{"trials":7521,"activeCount":101},[],{"intervention":4355,"totalTrials":97,"cells":7523},{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7528,"PHASE3":7534,"PHASE4":7536,"NA":7538},{"trials":7525,"activeCount":101},[],{"trials":7527,"activeCount":101},[],{"trials":7529,"activeCount":101},[7530],{"nctId":4346,"briefTitle":4347,"status":249,"phases":7531,"primaryCompletion":4349,"completion":4350,"start":4351,"enrollment":30,"conditions":7532,"interventions":7533},[90],[15,4353],[67,4355,4356,4357],{"trials":7535,"activeCount":101},[],{"trials":7537,"activeCount":101},[],{"trials":7539,"activeCount":101},[],{"intervention":4356,"totalTrials":97,"cells":7541},{"EARLY_PHASE1":7542,"PHASE1":7544,"PHASE2":7546,"PHASE3":7552,"PHASE4":7554,"NA":7556},{"trials":7543,"activeCount":101},[],{"trials":7545,"activeCount":101},[],{"trials":7547,"activeCount":101},[7548],{"nctId":4346,"briefTitle":4347,"status":249,"phases":7549,"primaryCompletion":4349,"completion":4350,"start":4351,"enrollment":30,"conditions":7550,"interventions":7551},[90],[15,4353],[67,4355,4356,4357],{"trials":7553,"activeCount":101},[],{"trials":7555,"activeCount":101},[],{"trials":7557,"activeCount":101},[],{"intervention":4357,"totalTrials":97,"cells":7559},{"EARLY_PHASE1":7560,"PHASE1":7562,"PHASE2":7564,"PHASE3":7570,"PHASE4":7572,"NA":7574},{"trials":7561,"activeCount":101},[],{"trials":7563,"activeCount":101},[],{"trials":7565,"activeCount":101},[7566],{"nctId":4346,"briefTitle":4347,"status":249,"phases":7567,"primaryCompletion":4349,"completion":4350,"start":4351,"enrollment":30,"conditions":7568,"interventions":7569},[90],[15,4353],[67,4355,4356,4357],{"trials":7571,"activeCount":101},[],{"trials":7573,"activeCount":101},[],{"trials":7575,"activeCount":101},[],{"intervention":1791,"totalTrials":97,"cells":7577},{"EARLY_PHASE1":7578,"PHASE1":7580,"PHASE2":7582,"PHASE3":7588,"PHASE4":7590,"NA":7592},{"trials":7579,"activeCount":101},[],{"trials":7581,"activeCount":101},[],{"trials":7583,"activeCount":101},[7584],{"nctId":1784,"briefTitle":1785,"status":147,"phases":7585,"primaryCompletion":1374,"completion":1787,"start":830,"enrollment":630,"conditions":7586,"interventions":7587},[90],[1789],[1791,758,1756],{"trials":7589,"activeCount":101},[],{"trials":7591,"activeCount":101},[],{"trials":7593,"activeCount":101},[],{"intervention":7595,"totalTrials":97,"cells":7596},"Carboplatin, Bevacizumab and Pemetrexed",{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7601,"PHASE3":7609,"PHASE4":7611,"NA":7613},{"trials":7598,"activeCount":101},[],{"trials":7600,"activeCount":101},[],{"trials":7602,"activeCount":101},[7603],{"nctId":7604,"briefTitle":7605,"status":249,"phases":7606,"primaryCompletion":6725,"completion":6725,"start":1779,"enrollment":1059,"conditions":7607,"interventions":7608},"NCT00604461","Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",[89,90],[2194],[7595],{"trials":7610,"activeCount":101},[],{"trials":7612,"activeCount":101},[],{"trials":7614,"activeCount":101},[],{"intervention":6282,"totalTrials":97,"cells":7616},{"EARLY_PHASE1":7617,"PHASE1":7619,"PHASE2":7621,"PHASE3":7627,"PHASE4":7629,"NA":7631},{"trials":7618,"activeCount":101},[],{"trials":7620,"activeCount":101},[],{"trials":7622,"activeCount":101},[7623],{"nctId":6276,"briefTitle":6277,"status":147,"phases":7624,"completion":6279,"start":2342,"conditions":7625,"interventions":7626},[90],[6106],[6282,6283,898],{"trials":7628,"activeCount":101},[],{"trials":7630,"activeCount":101},[],{"trials":7632,"activeCount":101},[],{"intervention":6283,"totalTrials":97,"cells":7634},{"EARLY_PHASE1":7635,"PHASE1":7637,"PHASE2":7639,"PHASE3":7645,"PHASE4":7647,"NA":7649},{"trials":7636,"activeCount":101},[],{"trials":7638,"activeCount":101},[],{"trials":7640,"activeCount":101},[7641],{"nctId":6276,"briefTitle":6277,"status":147,"phases":7642,"completion":6279,"start":2342,"conditions":7643,"interventions":7644},[90],[6106],[6282,6283,898],{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[],{"intervention":7652,"totalTrials":97,"cells":7653},"HER2 DC1 Vaccine",{"EARLY_PHASE1":7654,"PHASE1":7656,"PHASE2":7658,"PHASE3":7670,"PHASE4":7672,"NA":7674},{"trials":7655,"activeCount":101},[],{"trials":7657,"activeCount":101},[],{"trials":7659,"activeCount":101},[7660],{"nctId":7661,"briefTitle":7662,"status":249,"phases":7663,"primaryCompletion":7664,"completion":7664,"start":7665,"enrollment":33,"conditions":7666,"interventions":7669},"NCT03630809","Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1",[90],"2022-04-11","2019-01-10",[15,1190,7667,3871,7668,1206,1207],"HER-2 Gene Amplification","HER-2 Protein Overexpression",[7652],{"trials":7671,"activeCount":101},[],{"trials":7673,"activeCount":101},[],{"trials":7675,"activeCount":101},[],{"intervention":6532,"totalTrials":97,"cells":7677},{"EARLY_PHASE1":7678,"PHASE1":7680,"PHASE2":7682,"PHASE3":7688,"PHASE4":7690,"NA":7692},{"trials":7679,"activeCount":101},[],{"trials":7681,"activeCount":101},[],{"trials":7683,"activeCount":101},[7684],{"nctId":6525,"briefTitle":6526,"status":249,"phases":7685,"primaryCompletion":2083,"completion":2083,"start":6528,"enrollment":630,"conditions":7686,"interventions":7687},[89,90],[6530],[6532,4396],{"trials":7689,"activeCount":101},[],{"trials":7691,"activeCount":101},[],{"trials":7693,"activeCount":101},[],{"intervention":5419,"totalTrials":97,"cells":7695},{"EARLY_PHASE1":7696,"PHASE1":7698,"PHASE2":7700,"PHASE3":7706,"PHASE4":7708,"NA":7710},{"trials":7697,"activeCount":101},[],{"trials":7699,"activeCount":101},[],{"trials":7701,"activeCount":101},[7702],{"nctId":5409,"briefTitle":5410,"status":147,"phases":7703,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":2139,"conditions":7704,"interventions":7705},[90],[5416,5417],[5419,72,5420],{"trials":7707,"activeCount":101},[],{"trials":7709,"activeCount":101},[],{"trials":7711,"activeCount":101},[],{"intervention":5420,"totalTrials":97,"cells":7713},{"EARLY_PHASE1":7714,"PHASE1":7716,"PHASE2":7718,"PHASE3":7724,"PHASE4":7726,"NA":7728},{"trials":7715,"activeCount":101},[],{"trials":7717,"activeCount":101},[],{"trials":7719,"activeCount":101},[7720],{"nctId":5409,"briefTitle":5410,"status":147,"phases":7721,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":2139,"conditions":7722,"interventions":7723},[90],[5416,5417],[5419,72,5420],{"trials":7725,"activeCount":101},[],{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[],{"intervention":7731,"totalTrials":97,"cells":7732},"PS-341",{"EARLY_PHASE1":7733,"PHASE1":7735,"PHASE2":7737,"PHASE3":7746,"PHASE4":7748,"NA":7750},{"trials":7734,"activeCount":101},[],{"trials":7736,"activeCount":101},[],{"trials":7738,"activeCount":101},[7739],{"nctId":7740,"briefTitle":7741,"status":249,"phases":7742,"primaryCompletion":2371,"completion":2371,"start":1171,"enrollment":630,"conditions":7743,"interventions":7744},"NCT00361088","A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma",[89,90],[21],[7731,7745],"R11577",{"trials":7747,"activeCount":101},[],{"trials":7749,"activeCount":101},[],{"trials":7751,"activeCount":101},[],{"intervention":7745,"totalTrials":97,"cells":7753},{"EARLY_PHASE1":7754,"PHASE1":7756,"PHASE2":7758,"PHASE3":7764,"PHASE4":7766,"NA":7768},{"trials":7755,"activeCount":101},[],{"trials":7757,"activeCount":101},[],{"trials":7759,"activeCount":101},[7760],{"nctId":7740,"briefTitle":7741,"status":249,"phases":7761,"primaryCompletion":2371,"completion":2371,"start":1171,"enrollment":630,"conditions":7762,"interventions":7763},[89,90],[21],[7731,7745],{"trials":7765,"activeCount":101},[],{"trials":7767,"activeCount":101},[],{"trials":7769,"activeCount":101},[],{"intervention":2559,"totalTrials":97,"cells":7771},{"EARLY_PHASE1":7772,"PHASE1":7774,"PHASE2":7776,"PHASE3":7782,"PHASE4":7784,"NA":7786},{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[],{"trials":7777,"activeCount":101},[7778],{"nctId":2553,"briefTitle":2554,"status":147,"phases":7779,"primaryCompletion":1376,"completion":1376,"start":1301,"enrollment":198,"conditions":7780,"interventions":7781},[90],[2557,569],[618,807,2559],{"trials":7783,"activeCount":101},[],{"trials":7785,"activeCount":101},[],{"trials":7787,"activeCount":101},[],{"intervention":7789,"totalTrials":97,"cells":7790},"ERA-923",{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7804,"PHASE4":7806,"NA":7808},{"trials":7792,"activeCount":101},[],{"trials":7794,"activeCount":101},[],{"trials":7796,"activeCount":101},[7797],{"nctId":7798,"briefTitle":7799,"status":7800,"phases":7801,"start":2342,"conditions":7802,"interventions":7803},"NCT00006369","ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer","UNKNOWN",[90],[15],[7789],{"trials":7805,"activeCount":101},[],{"trials":7807,"activeCount":101},[],{"trials":7809,"activeCount":101},[],{"intervention":2270,"totalTrials":97,"cells":7811},{"EARLY_PHASE1":7812,"PHASE1":7814,"PHASE2":7816,"PHASE3":7822,"PHASE4":7824,"NA":7826},{"trials":7813,"activeCount":101},[],{"trials":7815,"activeCount":101},[],{"trials":7817,"activeCount":101},[7818],{"nctId":2263,"briefTitle":2264,"status":147,"phases":7819,"primaryCompletion":1374,"completion":1374,"start":2266,"enrollment":2267,"conditions":7820,"interventions":7821},[90],[21],[1732,2270,888],{"trials":7823,"activeCount":101},[],{"trials":7825,"activeCount":101},[],{"trials":7827,"activeCount":101},[],{"intervention":7829,"totalTrials":97,"cells":7830},"Sunitinib",{"EARLY_PHASE1":7831,"PHASE1":7833,"PHASE2":7835,"PHASE3":7845,"PHASE4":7847,"NA":7849},{"trials":7832,"activeCount":101},[],{"trials":7834,"activeCount":101},[],{"trials":7836,"activeCount":101},[7837],{"nctId":7838,"briefTitle":7839,"status":249,"phases":7840,"primaryCompletion":2371,"completion":2371,"start":7841,"enrollment":151,"conditions":7842,"interventions":7843},"NCT00496223","A Phase I\u002FII Study of Sunitinib and Dacarbazine",[89,90],"2006-09",[32],[7829,7844],"Dacarbazine",{"trials":7846,"activeCount":101},[],{"trials":7848,"activeCount":101},[],{"trials":7850,"activeCount":101},[],{"intervention":7844,"totalTrials":97,"cells":7852},{"EARLY_PHASE1":7853,"PHASE1":7855,"PHASE2":7857,"PHASE3":7863,"PHASE4":7865,"NA":7867},{"trials":7854,"activeCount":101},[],{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[7859],{"nctId":7838,"briefTitle":7839,"status":249,"phases":7860,"primaryCompletion":2371,"completion":2371,"start":7841,"enrollment":151,"conditions":7861,"interventions":7862},[89,90],[32],[7829,7844],{"trials":7864,"activeCount":101},[],{"trials":7866,"activeCount":101},[],{"trials":7868,"activeCount":101},[],{"intervention":7870,"totalTrials":97,"cells":7871},"Arsenic Trioxide",{"EARLY_PHASE1":7872,"PHASE1":7874,"PHASE2":7876,"PHASE3":7886,"PHASE4":7888,"NA":7890},{"trials":7873,"activeCount":101},[],{"trials":7875,"activeCount":101},[],{"trials":7877,"activeCount":101},[7878],{"nctId":7879,"briefTitle":7880,"status":249,"phases":7881,"primaryCompletion":7882,"completion":7882,"start":7883,"enrollment":189,"conditions":7884,"interventions":7885},"NCT00006092","Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia",[90],"2003-03","2000-08",[35],[7870],{"trials":7887,"activeCount":101},[],{"trials":7889,"activeCount":101},[],{"trials":7891,"activeCount":101},[],{"intervention":7893,"totalTrials":97,"cells":7894},"CI-994",{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7899,"PHASE3":7908,"PHASE4":7910,"NA":7912},{"trials":7896,"activeCount":101},[],{"trials":7898,"activeCount":101},[],{"trials":7900,"activeCount":101},[7901],{"nctId":7902,"briefTitle":7903,"status":147,"phases":7904,"primaryCompletion":2341,"completion":2341,"start":7905,"enrollment":487,"conditions":7906,"interventions":7907},"NCT00005624","CI-994 in Treating Patients With Advanced Myeloma",[90],"1997-08",[21],[7893],{"trials":7909,"activeCount":101},[],{"trials":7911,"activeCount":101},[],{"trials":7913,"activeCount":101},[],{"intervention":5961,"totalTrials":97,"cells":7915},{"EARLY_PHASE1":7916,"PHASE1":7918,"PHASE2":7920,"PHASE3":7926,"PHASE4":7928,"NA":7930},{"trials":7917,"activeCount":101},[],{"trials":7919,"activeCount":101},[],{"trials":7921,"activeCount":101},[7922],{"nctId":5954,"briefTitle":5955,"status":147,"phases":7923,"primaryCompletion":946,"completion":946,"start":948,"enrollment":5957,"conditions":7924,"interventions":7925},[90],[5959],[5922,2196,5961],{"trials":7927,"activeCount":101},[],{"trials":7929,"activeCount":101},[],{"trials":7931,"activeCount":101},[],{"intervention":7933,"totalTrials":97,"cells":7934},"adenovirus-p53 transduced dendritic cell (DC) vaccine",{"EARLY_PHASE1":7935,"PHASE1":7937,"PHASE2":7939,"PHASE3":7954,"PHASE4":7956,"NA":7958},{"trials":7936,"activeCount":101},[],{"trials":7938,"activeCount":101},[],{"trials":7940,"activeCount":101},[7941],{"nctId":7942,"briefTitle":7943,"status":147,"phases":7944,"primaryCompletion":7945,"completion":7946,"start":7947,"enrollment":445,"conditions":7948,"interventions":7952},"NCT01042535","Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer",[89,90],"2014-12-01","2018-02-27","2009-12-28",[7949,7950,7951,2344],"Male Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer",[7933,7953],"1-methyl-d-tryptophan",{"trials":7955,"activeCount":101},[],{"trials":7957,"activeCount":101},[],{"trials":7959,"activeCount":101},[],{"intervention":4597,"totalTrials":97,"cells":7961},{"EARLY_PHASE1":7962,"PHASE1":7964,"PHASE2":7966,"PHASE3":7972,"PHASE4":7974,"NA":7976},{"trials":7963,"activeCount":101},[],{"trials":7965,"activeCount":101},[],{"trials":7967,"activeCount":101},[7968],{"nctId":4583,"briefTitle":4584,"status":249,"phases":7969,"primaryCompletion":4586,"completion":579,"start":4587,"enrollment":487,"conditions":7970,"interventions":7971},[90],[4589,4590,4591,4592,4593,4594],[672,4596,808,4597],{"trials":7973,"activeCount":101},[],{"trials":7975,"activeCount":101},[],{"trials":7977,"activeCount":101},[],{"intervention":7979,"totalTrials":97,"cells":7980},"Androgen Ablation",{"EARLY_PHASE1":7981,"PHASE1":7983,"PHASE2":7985,"PHASE3":7997,"PHASE4":7999,"NA":8001},{"trials":7982,"activeCount":101},[],{"trials":7984,"activeCount":101},[],{"trials":7986,"activeCount":101},[7987],{"nctId":7988,"briefTitle":7989,"status":249,"phases":7990,"primaryCompletion":7167,"completion":1866,"start":1363,"enrollment":189,"conditions":7991,"interventions":7992},"NCT01531205","Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA",[90],[18],[7979,7993,7994,7995,7996],"Cabazitaxel","Salvage Therapy","Neoadjuvant Treatment - Hormonal Therapy","Neoadjuvant Treatment - Cabazitaxel",{"trials":7998,"activeCount":101},[],{"trials":8000,"activeCount":101},[],{"trials":8002,"activeCount":101},[],{"intervention":7993,"totalTrials":97,"cells":8004},{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8009,"PHASE3":8015,"PHASE4":8017,"NA":8019},{"trials":8006,"activeCount":101},[],{"trials":8008,"activeCount":101},[],{"trials":8010,"activeCount":101},[8011],{"nctId":7988,"briefTitle":7989,"status":249,"phases":8012,"primaryCompletion":7167,"completion":1866,"start":1363,"enrollment":189,"conditions":8013,"interventions":8014},[90],[18],[7979,7993,7994,7995,7996],{"trials":8016,"activeCount":101},[],{"trials":8018,"activeCount":101},[],{"trials":8020,"activeCount":101},[],{"intervention":7994,"totalTrials":97,"cells":8022},{"EARLY_PHASE1":8023,"PHASE1":8025,"PHASE2":8027,"PHASE3":8033,"PHASE4":8035,"NA":8037},{"trials":8024,"activeCount":101},[],{"trials":8026,"activeCount":101},[],{"trials":8028,"activeCount":101},[8029],{"nctId":7988,"briefTitle":7989,"status":249,"phases":8030,"primaryCompletion":7167,"completion":1866,"start":1363,"enrollment":189,"conditions":8031,"interventions":8032},[90],[18],[7979,7993,7994,7995,7996],{"trials":8034,"activeCount":101},[],{"trials":8036,"activeCount":101},[],{"trials":8038,"activeCount":101},[],{"intervention":7995,"totalTrials":97,"cells":8040},{"EARLY_PHASE1":8041,"PHASE1":8043,"PHASE2":8045,"PHASE3":8051,"PHASE4":8053,"NA":8055},{"trials":8042,"activeCount":101},[],{"trials":8044,"activeCount":101},[],{"trials":8046,"activeCount":101},[8047],{"nctId":7988,"briefTitle":7989,"status":249,"phases":8048,"primaryCompletion":7167,"completion":1866,"start":1363,"enrollment":189,"conditions":8049,"interventions":8050},[90],[18],[7979,7993,7994,7995,7996],{"trials":8052,"activeCount":101},[],{"trials":8054,"activeCount":101},[],{"trials":8056,"activeCount":101},[],{"intervention":7996,"totalTrials":97,"cells":8058},{"EARLY_PHASE1":8059,"PHASE1":8061,"PHASE2":8063,"PHASE3":8069,"PHASE4":8071,"NA":8073},{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[],{"trials":8064,"activeCount":101},[8065],{"nctId":7988,"briefTitle":7989,"status":249,"phases":8066,"primaryCompletion":7167,"completion":1866,"start":1363,"enrollment":189,"conditions":8067,"interventions":8068},[90],[18],[7979,7993,7994,7995,7996],{"trials":8070,"activeCount":101},[],{"trials":8072,"activeCount":101},[],{"trials":8074,"activeCount":101},[],{"intervention":8076,"totalTrials":97,"cells":8077},"GTX",{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8082,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8079,"activeCount":101},[],{"trials":8081,"activeCount":101},[],{"trials":8083,"activeCount":101},[8084],{"nctId":8085,"briefTitle":8086,"status":249,"phases":8087,"primaryCompletion":8088,"completion":8088,"start":8089,"enrollment":189,"conditions":8090,"interventions":8092},"NCT00833859","Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery",[90],"2010-03","2009-03",[8091],"Pancreatic Neoplasms",[8076],{"trials":8094,"activeCount":101},[],{"trials":8096,"activeCount":101},[],{"trials":8098,"activeCount":101},[],{"intervention":2280,"totalTrials":97,"cells":8100},{"EARLY_PHASE1":8101,"PHASE1":8103,"PHASE2":8105,"PHASE3":8111,"PHASE4":8113,"NA":8115},{"trials":8102,"activeCount":101},[],{"trials":8104,"activeCount":101},[],{"trials":8106,"activeCount":101},[8107],{"nctId":2272,"briefTitle":2273,"status":249,"phases":8108,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":1095,"conditions":8109,"interventions":8110},[90],[21],[2280,1732,888],{"trials":8112,"activeCount":101},[],{"trials":8114,"activeCount":101},[],{"trials":8116,"activeCount":101},[],{"intervention":2184,"totalTrials":97,"cells":8118},{"EARLY_PHASE1":8119,"PHASE1":8121,"PHASE2":8123,"PHASE3":8129,"PHASE4":8131,"NA":8133},{"trials":8120,"activeCount":101},[],{"trials":8122,"activeCount":101},[],{"trials":8124,"activeCount":101},[8125],{"nctId":2172,"briefTitle":2173,"status":147,"phases":8126,"primaryCompletion":2175,"completion":2176,"start":2177,"enrollment":821,"conditions":8127,"interventions":8128},[90],[2179,2180,2181,2182],[618,1246,2184],{"trials":8130,"activeCount":101},[],{"trials":8132,"activeCount":101},[],{"trials":8134,"activeCount":101},[],{"intervention":8136,"totalTrials":97,"cells":8137},"Umbralisib",{"EARLY_PHASE1":8138,"PHASE1":8140,"PHASE2":8142,"PHASE3":8152,"PHASE4":8154,"NA":8156},{"trials":8139,"activeCount":101},[],{"trials":8141,"activeCount":101},[],{"trials":8143,"activeCount":101},[8144],{"nctId":8145,"briefTitle":8146,"status":249,"phases":8147,"primaryCompletion":8148,"completion":8148,"start":8149,"enrollment":233,"conditions":8150,"interventions":8151},"NCT04163718","TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)",[90],"2022-10-19","2019-11-12",[606],[8136],{"trials":8153,"activeCount":101},[],{"trials":8155,"activeCount":101},[],{"trials":8157,"activeCount":101},[],{"intervention":8159,"totalTrials":97,"cells":8160},"RAD001",{"EARLY_PHASE1":8161,"PHASE1":8163,"PHASE2":8165,"PHASE3":8174,"PHASE4":8176,"NA":8178},{"trials":8162,"activeCount":101},[],{"trials":8164,"activeCount":101},[],{"trials":8166,"activeCount":101},[8167],{"nctId":8168,"briefTitle":8169,"status":249,"phases":8170,"primaryCompletion":8171,"completion":8171,"start":7039,"enrollment":189,"conditions":8172,"interventions":8173},"NCT01048723","Study of RAD001 in Soft Tissue Extremity and\u002For Retroperitoneal Sarcomas",[90],"2011-10",[299],[8159],{"trials":8175,"activeCount":101},[],{"trials":8177,"activeCount":101},[],{"trials":8179,"activeCount":101},[],{"intervention":849,"totalTrials":97,"cells":8181},{"EARLY_PHASE1":8182,"PHASE1":8184,"PHASE2":8186,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8183,"activeCount":101},[],{"trials":8185,"activeCount":101},[],{"trials":8187,"activeCount":101},[8188],{"nctId":841,"briefTitle":842,"status":147,"phases":8189,"primaryCompletion":844,"completion":830,"start":845,"enrollment":846,"conditions":8190,"interventions":8191},[90],[15],[619,157,849],{"trials":8193,"activeCount":101},[],{"trials":8195,"activeCount":101},[],{"trials":8197,"activeCount":101},[],{"intervention":8199,"totalTrials":97,"cells":8200},"MAGE-A3 ASCI injections without Poly IC:LC",{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8205,"PHASE3":8216,"PHASE4":8218,"NA":8220},{"trials":8202,"activeCount":101},[],{"trials":8204,"activeCount":101},[],{"trials":8206,"activeCount":101},[8207],{"nctId":8208,"briefTitle":8209,"status":249,"phases":8210,"primaryCompletion":8211,"completion":8211,"start":8212,"enrollment":182,"conditions":8213,"interventions":8214},"NCT01437605","Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC",[90],"2018-07-18","2011-10-11",[32],[8199,8215],"MAGE-A3 ASCI injections with Poly IC:LC",{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[],{"trials":8221,"activeCount":101},[],{"intervention":8215,"totalTrials":97,"cells":8223},{"EARLY_PHASE1":8224,"PHASE1":8226,"PHASE2":8228,"PHASE3":8234,"PHASE4":8236,"NA":8238},{"trials":8225,"activeCount":101},[],{"trials":8227,"activeCount":101},[],{"trials":8229,"activeCount":101},[8230],{"nctId":8208,"briefTitle":8209,"status":249,"phases":8231,"primaryCompletion":8211,"completion":8211,"start":8212,"enrollment":182,"conditions":8232,"interventions":8233},[90],[32],[8199,8215],{"trials":8235,"activeCount":101},[],{"trials":8237,"activeCount":101},[],{"trials":8239,"activeCount":101},[],{"intervention":862,"totalTrials":97,"cells":8241},{"EARLY_PHASE1":8242,"PHASE1":8244,"PHASE2":8246,"PHASE3":8252,"PHASE4":8254,"NA":8256},{"trials":8243,"activeCount":101},[],{"trials":8245,"activeCount":101},[],{"trials":8247,"activeCount":101},[8248],{"nctId":851,"briefTitle":852,"status":147,"phases":8249,"primaryCompletion":820,"completion":854,"start":855,"enrollment":856,"conditions":8250,"interventions":8251},[90],[858],[860,861,862],{"trials":8253,"activeCount":101},[],{"trials":8255,"activeCount":101},[],{"trials":8257,"activeCount":101},[],{"intervention":8259,"totalTrials":97,"cells":8260},"Gardasil",{"EARLY_PHASE1":8261,"PHASE1":8263,"PHASE2":8265,"PHASE3":8278,"PHASE4":8280,"NA":8282},{"trials":8262,"activeCount":101},[],{"trials":8264,"activeCount":101},[],{"trials":8266,"activeCount":101},[8267],{"nctId":8268,"briefTitle":8269,"status":147,"phases":8270,"primaryCompletion":8271,"completion":8272,"start":8273,"enrollment":8274,"conditions":8275,"interventions":8277},"NCT01432574","Study of Gardasil in Mid-Adult Males (MAM)",[90],"2014-05-23","2020-11-03","2013-02-19",150,[8276],"Human Papillomavirus",[8259],{"trials":8279,"activeCount":101},[],{"trials":8281,"activeCount":101},[],{"trials":8283,"activeCount":101},[],{"intervention":8285,"totalTrials":97,"cells":8286},"Dasatinib and Dacarbazine",{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8291,"PHASE3":8301,"PHASE4":8303,"NA":8305},{"trials":8288,"activeCount":101},[],{"trials":8290,"activeCount":101},[],{"trials":8292,"activeCount":101},[8293],{"nctId":8294,"briefTitle":8295,"status":147,"phases":8296,"primaryCompletion":8297,"completion":8297,"start":8298,"enrollment":136,"conditions":8299,"interventions":8300},"NCT00597038","A Phase I\u002FII Study of Dasatinib and Dacarbazine",[89,90],"2011-09","2007-11",[169],[8285],{"trials":8302,"activeCount":101},[],{"trials":8304,"activeCount":101},[],{"trials":8306,"activeCount":101},[],{"intervention":874,"totalTrials":97,"cells":8308},{"EARLY_PHASE1":8309,"PHASE1":8311,"PHASE2":8313,"PHASE3":8319,"PHASE4":8321,"NA":8323},{"trials":8310,"activeCount":101},[],{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[8315],{"nctId":864,"briefTitle":865,"status":249,"phases":8316,"primaryCompletion":830,"completion":830,"start":867,"conditions":8317,"interventions":8318},[90],[834,869,35,858,870,755],[872,873,874,860,875,876],{"trials":8320,"activeCount":101},[],{"trials":8322,"activeCount":101},[],{"trials":8324,"activeCount":101},[],{"intervention":887,"totalTrials":97,"cells":8326},{"EARLY_PHASE1":8327,"PHASE1":8329,"PHASE2":8331,"PHASE3":8337,"PHASE4":8339,"NA":8341},{"trials":8328,"activeCount":101},[],{"trials":8330,"activeCount":101},[],{"trials":8332,"activeCount":101},[8333],{"nctId":878,"briefTitle":879,"status":147,"phases":8334,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":8335,"interventions":8336},[89,90],[885],[887,888,157],{"trials":8338,"activeCount":101},[],{"trials":8340,"activeCount":101},[],{"trials":8342,"activeCount":101},[],{"intervention":4483,"totalTrials":97,"cells":8344},{"EARLY_PHASE1":8345,"PHASE1":8347,"PHASE2":8349,"PHASE3":8355,"PHASE4":8357,"NA":8359},{"trials":8346,"activeCount":101},[],{"trials":8348,"activeCount":101},[],{"trials":8350,"activeCount":101},[8351],{"nctId":4476,"briefTitle":4477,"status":147,"phases":8352,"primaryCompletion":2459,"completion":4479,"start":4480,"enrollment":30,"conditions":8353,"interventions":8354},[90],[169],[4483,4451,4484],{"trials":8356,"activeCount":101},[],{"trials":8358,"activeCount":101},[],{"trials":8360,"activeCount":101},[],{"intervention":4484,"totalTrials":97,"cells":8362},{"EARLY_PHASE1":8363,"PHASE1":8365,"PHASE2":8367,"PHASE3":8373,"PHASE4":8375,"NA":8377},{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[],{"trials":8368,"activeCount":101},[8369],{"nctId":4476,"briefTitle":4477,"status":147,"phases":8370,"primaryCompletion":2459,"completion":4479,"start":4480,"enrollment":30,"conditions":8371,"interventions":8372},[90],[169],[4483,4451,4484],{"trials":8374,"activeCount":101},[],{"trials":8376,"activeCount":101},[],{"trials":8378,"activeCount":101},[],{"intervention":8380,"totalTrials":97,"cells":8381},"TAS 102",{"EARLY_PHASE1":8382,"PHASE1":8384,"PHASE2":8386,"PHASE3":8400,"PHASE4":8402,"NA":8404},{"trials":8383,"activeCount":101},[],{"trials":8385,"activeCount":101},[],{"trials":8387,"activeCount":101},[8388],{"nctId":8389,"briefTitle":8390,"status":147,"phases":8391,"primaryCompletion":8392,"completion":8393,"start":8394,"enrollment":22,"conditions":8395,"interventions":8398},"NCT03686488","TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[90],"2022-01-19","2024-05-31","2018-12-20",[8396,8397,569],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[8380,8399],"Ramucirumab 10 MG\u002FML Intravenous Solution [CYRAMZA]",{"trials":8401,"activeCount":101},[],{"trials":8403,"activeCount":101},[],{"trials":8405,"activeCount":101},[],{"intervention":8399,"totalTrials":97,"cells":8407},{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8412,"PHASE3":8418,"PHASE4":8420,"NA":8422},{"trials":8409,"activeCount":101},[],{"trials":8411,"activeCount":101},[],{"trials":8413,"activeCount":101},[8414],{"nctId":8389,"briefTitle":8390,"status":147,"phases":8415,"primaryCompletion":8392,"completion":8393,"start":8394,"enrollment":22,"conditions":8416,"interventions":8417},[90],[8396,8397,569],[8380,8399],{"trials":8419,"activeCount":101},[],{"trials":8421,"activeCount":101},[],{"trials":8423,"activeCount":101},[],{"intervention":8425,"totalTrials":97,"cells":8426},"T-VEC",{"EARLY_PHASE1":8427,"PHASE1":8429,"PHASE2":8431,"PHASE3":8442,"PHASE4":8444,"NA":8446},{"trials":8428,"activeCount":101},[],{"trials":8430,"activeCount":101},[],{"trials":8432,"activeCount":101},[8433],{"nctId":8434,"briefTitle":8435,"status":249,"phases":8436,"primaryCompletion":8437,"completion":8437,"start":8438,"enrollment":9,"conditions":8439,"interventions":8441},"NCT03921073","Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma",[90],"2021-09-28","2019-08-20",[8440],"Angiosarcoma of Skin",[8425],{"trials":8443,"activeCount":101},[],{"trials":8445,"activeCount":101},[],{"trials":8447,"activeCount":101},[],{"intervention":8449,"totalTrials":97,"cells":8450},"Polyphenon E",{"EARLY_PHASE1":8451,"PHASE1":8453,"PHASE2":8455,"PHASE3":8467,"PHASE4":8469,"NA":8471},{"trials":8452,"activeCount":101},[],{"trials":8454,"activeCount":101},[],{"trials":8456,"activeCount":101},[8457],{"nctId":8458,"briefTitle":8459,"status":147,"phases":8460,"primaryCompletion":5976,"completion":8461,"start":8462,"enrollment":8463,"conditions":8464,"interventions":8466},"NCT00596011","Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia",[90],"2018-07-27","2007-11-14",97,[8465],"Prostatic Hyperplasia",[8449],{"trials":8468,"activeCount":101},[],{"trials":8470,"activeCount":101},[],{"trials":8472,"activeCount":101},[],{"intervention":6844,"totalTrials":97,"cells":8474},{"EARLY_PHASE1":8475,"PHASE1":8477,"PHASE2":8479,"PHASE3":8485,"PHASE4":8487,"NA":8489},{"trials":8476,"activeCount":101},[],{"trials":8478,"activeCount":101},[],{"trials":8480,"activeCount":101},[8481],{"nctId":6837,"briefTitle":6838,"status":147,"phases":8482,"completion":6840,"start":4236,"conditions":8483,"interventions":8484},[90],[201,6842],[6828,6844],{"trials":8486,"activeCount":101},[],{"trials":8488,"activeCount":101},[],{"trials":8490,"activeCount":101},[],{"intervention":897,"totalTrials":97,"cells":8492},{"EARLY_PHASE1":8493,"PHASE1":8495,"PHASE2":8497,"PHASE3":8503,"PHASE4":8505,"NA":8507},{"trials":8494,"activeCount":101},[],{"trials":8496,"activeCount":101},[],{"trials":8498,"activeCount":101},[8499],{"nctId":890,"briefTitle":891,"status":249,"phases":8500,"primaryCompletion":893,"completion":893,"start":894,"conditions":8501,"interventions":8502},[90],[834,869,35,870,755],[872,838,860,875,897,898,876],{"trials":8504,"activeCount":101},[],{"trials":8506,"activeCount":101},[],{"trials":8508,"activeCount":101},[],{"intervention":8510,"totalTrials":97,"cells":8511},"Dendritic Cell (DC) Injections",{"EARLY_PHASE1":8512,"PHASE1":8514,"PHASE2":8516,"PHASE3":8525,"PHASE4":8527,"NA":8529},{"trials":8513,"activeCount":101},[],{"trials":8515,"activeCount":101},[],{"trials":8517,"activeCount":101},[8518],{"nctId":8519,"briefTitle":8520,"status":147,"phases":8521,"primaryCompletion":819,"completion":819,"start":8522,"enrollment":30,"conditions":8523,"interventions":8524},"NCT00365872","External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma",[90],"2006-05",[2155],[8510],{"trials":8526,"activeCount":101},[],{"trials":8528,"activeCount":101},[],{"trials":8530,"activeCount":101},[],{"intervention":1671,"totalTrials":97,"cells":8532},{"EARLY_PHASE1":8533,"PHASE1":8535,"PHASE2":8537,"PHASE3":8543,"PHASE4":8545,"NA":8547},{"trials":8534,"activeCount":101},[],{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[8539],{"nctId":1662,"briefTitle":1663,"status":147,"phases":8540,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":8541,"interventions":8542},[90],[436],[622,1671,1672],{"trials":8544,"activeCount":101},[],{"trials":8546,"activeCount":101},[],{"trials":8548,"activeCount":101},[],{"intervention":1672,"totalTrials":97,"cells":8550},{"EARLY_PHASE1":8551,"PHASE1":8553,"PHASE2":8555,"PHASE3":8561,"PHASE4":8563,"NA":8565},{"trials":8552,"activeCount":101},[],{"trials":8554,"activeCount":101},[],{"trials":8556,"activeCount":101},[8557],{"nctId":1662,"briefTitle":1663,"status":147,"phases":8558,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":8559,"interventions":8560},[90],[436],[622,1671,1672],{"trials":8562,"activeCount":101},[],{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[],{"intervention":8568,"totalTrials":97,"cells":8569},"Phase I - GM.CD40L.CCL21 Vaccinations",{"EARLY_PHASE1":8570,"PHASE1":8572,"PHASE2":8574,"PHASE3":8585,"PHASE4":8587,"NA":8589},{"trials":8571,"activeCount":101},[],{"trials":8573,"activeCount":101},[],{"trials":8575,"activeCount":101},[8576],{"nctId":8577,"briefTitle":8578,"status":147,"phases":8579,"primaryCompletion":7225,"completion":1277,"start":8580,"enrollment":322,"conditions":8581,"interventions":8582},"NCT01433172","Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer",[89,90],"2012-03-26",[26,6075],[8568,8583,8584],"Phase II - GM.CD40L cells Vaccinations","Phase II - GM.CD40L.CCL21 Vaccinations",{"trials":8586,"activeCount":101},[],{"trials":8588,"activeCount":101},[],{"trials":8590,"activeCount":101},[],{"intervention":8583,"totalTrials":97,"cells":8592},{"EARLY_PHASE1":8593,"PHASE1":8595,"PHASE2":8597,"PHASE3":8603,"PHASE4":8605,"NA":8607},{"trials":8594,"activeCount":101},[],{"trials":8596,"activeCount":101},[],{"trials":8598,"activeCount":101},[8599],{"nctId":8577,"briefTitle":8578,"status":147,"phases":8600,"primaryCompletion":7225,"completion":1277,"start":8580,"enrollment":322,"conditions":8601,"interventions":8602},[89,90],[26,6075],[8568,8583,8584],{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":101},[],{"trials":8608,"activeCount":101},[],{"intervention":8584,"totalTrials":97,"cells":8610},{"EARLY_PHASE1":8611,"PHASE1":8613,"PHASE2":8615,"PHASE3":8621,"PHASE4":8623,"NA":8625},{"trials":8612,"activeCount":101},[],{"trials":8614,"activeCount":101},[],{"trials":8616,"activeCount":101},[8617],{"nctId":8577,"briefTitle":8578,"status":147,"phases":8618,"primaryCompletion":7225,"completion":1277,"start":8580,"enrollment":322,"conditions":8619,"interventions":8620},[89,90],[26,6075],[8568,8583,8584],{"trials":8622,"activeCount":101},[],{"trials":8624,"activeCount":101},[],{"trials":8626,"activeCount":101},[],{"intervention":8628,"totalTrials":97,"cells":8629},"INCB024360",{"EARLY_PHASE1":8630,"PHASE1":8632,"PHASE2":8634,"PHASE3":8642,"PHASE4":8644,"NA":8646},{"trials":8631,"activeCount":101},[],{"trials":8633,"activeCount":101},[],{"trials":8635,"activeCount":101},[8636],{"nctId":8637,"briefTitle":8638,"status":147,"phases":8639,"primaryCompletion":5666,"completion":6103,"start":2719,"enrollment":36,"conditions":8640,"interventions":8641},"NCT01822691","Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)",[90],[755],[8628],{"trials":8643,"activeCount":101},[],{"trials":8645,"activeCount":101},[],{"trials":8647,"activeCount":101},[],{"intervention":8649,"totalTrials":97,"cells":8650},"Gemcitabine hydrochloride",{"EARLY_PHASE1":8651,"PHASE1":8653,"PHASE2":8655,"PHASE3":8663,"PHASE4":8665,"NA":8667},{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[],{"trials":8656,"activeCount":101},[8657],{"nctId":8658,"briefTitle":8659,"status":345,"phases":8660,"primaryCompletion":2342,"completion":2342,"start":904,"enrollment":101,"conditions":8661,"interventions":8662},"NCT00005614","Management of Metastatic Breast Cancer in Frail Patients",[90],[15],[8649],{"trials":8664,"activeCount":101},[],{"trials":8666,"activeCount":101},[],{"trials":8668,"activeCount":101},[],{"intervention":8670,"totalTrials":97,"cells":8671},"ZK-EPO",{"EARLY_PHASE1":8672,"PHASE1":8674,"PHASE2":8676,"PHASE3":8684,"PHASE4":8686,"NA":8688},{"trials":8673,"activeCount":101},[],{"trials":8675,"activeCount":101},[],{"trials":8677,"activeCount":101},[8678],{"nctId":8679,"briefTitle":8680,"status":147,"phases":8681,"primaryCompletion":5291,"completion":5291,"start":1376,"enrollment":7228,"conditions":8682,"interventions":8683},"NCT00598507","Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma",[90],[32],[8670],{"trials":8685,"activeCount":101},[],{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[],{"intervention":5989,"totalTrials":97,"cells":8691},{"EARLY_PHASE1":8692,"PHASE1":8694,"PHASE2":8696,"PHASE3":8702,"PHASE4":8704,"NA":8706},{"trials":8693,"activeCount":101},[],{"trials":8695,"activeCount":101},[],{"trials":8697,"activeCount":101},[8698],{"nctId":5981,"briefTitle":5982,"status":147,"phases":8699,"primaryCompletion":5984,"completion":181,"start":5985,"enrollment":361,"conditions":8700,"interventions":8701},[90],[5987],[5989,5922,759],{"trials":8703,"activeCount":101},[],{"trials":8705,"activeCount":101},[],{"trials":8707,"activeCount":101},[],{"intervention":8709,"totalTrials":97,"cells":8710},"Purified isoflavones",{"EARLY_PHASE1":8711,"PHASE1":8713,"PHASE2":8715,"PHASE3":8728,"PHASE4":8730,"NA":8732},{"trials":8712,"activeCount":101},[],{"trials":8714,"activeCount":101},[],{"trials":8716,"activeCount":101},[8717],{"nctId":8718,"briefTitle":8719,"status":147,"phases":8720,"primaryCompletion":8721,"completion":8722,"start":8723,"enrollment":8724,"conditions":8725,"interventions":8726},"NCT01036321","Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness",[90],"2014-06-26","2018-04-16","2009-12-11",71,[18],[8709,8727],"Methyl cellulose blend",{"trials":8729,"activeCount":101},[],{"trials":8731,"activeCount":101},[],{"trials":8733,"activeCount":101},[],{"intervention":8727,"totalTrials":97,"cells":8735},{"EARLY_PHASE1":8736,"PHASE1":8738,"PHASE2":8740,"PHASE3":8746,"PHASE4":8748,"NA":8750},{"trials":8737,"activeCount":101},[],{"trials":8739,"activeCount":101},[],{"trials":8741,"activeCount":101},[8742],{"nctId":8718,"briefTitle":8719,"status":147,"phases":8743,"primaryCompletion":8721,"completion":8722,"start":8723,"enrollment":8724,"conditions":8744,"interventions":8745},[90],[18],[8709,8727],{"trials":8747,"activeCount":101},[],{"trials":8749,"activeCount":101},[],{"trials":8751,"activeCount":101},[],{"intervention":8753,"totalTrials":97,"cells":8754},"CLAG Regimen",{"EARLY_PHASE1":8755,"PHASE1":8757,"PHASE2":8759,"PHASE3":8769,"PHASE4":8771,"NA":8773},{"trials":8756,"activeCount":101},[],{"trials":8758,"activeCount":101},[],{"trials":8760,"activeCount":101},[8761],{"nctId":8762,"briefTitle":8763,"status":147,"phases":8764,"primaryCompletion":946,"completion":2094,"start":8765,"enrollment":4750,"conditions":8766,"interventions":8767},"NCT00955916","CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)",[90],"2009-08",[35],[8753,8768],"Gleevec®",{"trials":8770,"activeCount":101},[],{"trials":8772,"activeCount":101},[],{"trials":8774,"activeCount":101},[],{"intervention":8768,"totalTrials":97,"cells":8776},{"EARLY_PHASE1":8777,"PHASE1":8779,"PHASE2":8781,"PHASE3":8787,"PHASE4":8789,"NA":8791},{"trials":8778,"activeCount":101},[],{"trials":8780,"activeCount":101},[],{"trials":8782,"activeCount":101},[8783],{"nctId":8762,"briefTitle":8763,"status":147,"phases":8784,"primaryCompletion":946,"completion":2094,"start":8765,"enrollment":4750,"conditions":8785,"interventions":8786},[90],[35],[8753,8768],{"trials":8788,"activeCount":101},[],{"trials":8790,"activeCount":101},[],{"trials":8792,"activeCount":101},[],{"intervention":2301,"totalTrials":97,"cells":8794},{"EARLY_PHASE1":8795,"PHASE1":8797,"PHASE2":8799,"PHASE3":8805,"PHASE4":8807,"NA":8809},{"trials":8796,"activeCount":101},[],{"trials":8798,"activeCount":101},[],{"trials":8800,"activeCount":101},[8801],{"nctId":2293,"briefTitle":2294,"status":147,"phases":8802,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":27,"conditions":8803,"interventions":8804},[89,90],[21],[2247,1147,888,2301],{"trials":8806,"activeCount":101},[],{"trials":8808,"activeCount":101},[],{"trials":8810,"activeCount":101},[],{"intervention":1881,"totalTrials":97,"cells":8812},{"EARLY_PHASE1":8813,"PHASE1":8815,"PHASE2":8817,"PHASE3":8823,"PHASE4":8825,"NA":8827},{"trials":8814,"activeCount":101},[],{"trials":8816,"activeCount":101},[],{"trials":8818,"activeCount":101},[8819],{"nctId":1872,"briefTitle":1873,"status":147,"phases":8820,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":8821,"interventions":8822},[89,90],[1729,1132,1137,754],[1881,301],{"trials":8824,"activeCount":101},[],{"trials":8826,"activeCount":101},[],{"trials":8828,"activeCount":101},[],{"intervention":1685,"totalTrials":97,"cells":8830},{"EARLY_PHASE1":8831,"PHASE1":8833,"PHASE2":8835,"PHASE3":8841,"PHASE4":8843,"NA":8845},{"trials":8832,"activeCount":101},[],{"trials":8834,"activeCount":101},[],{"trials":8836,"activeCount":101},[8837],{"nctId":1678,"briefTitle":1679,"status":147,"phases":8838,"primaryCompletion":1681,"completion":81,"start":1682,"enrollment":630,"conditions":8839,"interventions":8840},[90],[26],[619,622,1685],{"trials":8842,"activeCount":101},[],{"trials":8844,"activeCount":101},[],{"trials":8846,"activeCount":101},[],{"intervention":2310,"totalTrials":97,"cells":8848},{"EARLY_PHASE1":8849,"PHASE1":8851,"PHASE2":8853,"PHASE3":8859,"PHASE4":8861,"NA":8863},{"trials":8850,"activeCount":101},[],{"trials":8852,"activeCount":101},[],{"trials":8854,"activeCount":101},[8855],{"nctId":2303,"briefTitle":2304,"status":249,"phases":8856,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":97,"conditions":8857,"interventions":8858},[90],[24],[1295,2310,804,2311,888,2312],{"trials":8860,"activeCount":101},[],{"trials":8862,"activeCount":101},[],{"trials":8864,"activeCount":101},[],{"intervention":2311,"totalTrials":97,"cells":8866},{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8871,"PHASE3":8877,"PHASE4":8879,"NA":8881},{"trials":8868,"activeCount":101},[],{"trials":8870,"activeCount":101},[],{"trials":8872,"activeCount":101},[8873],{"nctId":2303,"briefTitle":2304,"status":249,"phases":8874,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":97,"conditions":8875,"interventions":8876},[90],[24],[1295,2310,804,2311,888,2312],{"trials":8878,"activeCount":101},[],{"trials":8880,"activeCount":101},[],{"trials":8882,"activeCount":101},[],{"intervention":2312,"totalTrials":97,"cells":8884},{"EARLY_PHASE1":8885,"PHASE1":8887,"PHASE2":8889,"PHASE3":8895,"PHASE4":8897,"NA":8899},{"trials":8886,"activeCount":101},[],{"trials":8888,"activeCount":101},[],{"trials":8890,"activeCount":101},[8891],{"nctId":2303,"briefTitle":2304,"status":249,"phases":8892,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":97,"conditions":8893,"interventions":8894},[90],[24],[1295,2310,804,2311,888,2312],{"trials":8896,"activeCount":101},[],{"trials":8898,"activeCount":101},[],{"trials":8900,"activeCount":101},[],{"intervention":4248,"totalTrials":97,"cells":8902},{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8907,"PHASE3":8913,"PHASE4":8915,"NA":8917},{"trials":8904,"activeCount":101},[],{"trials":8906,"activeCount":101},[],{"trials":8908,"activeCount":101},[8909],{"nctId":4241,"briefTitle":4242,"status":147,"phases":8910,"primaryCompletion":820,"completion":4244,"start":4245,"enrollment":595,"conditions":8911,"interventions":8912},[90],[858],[861,4239,909,4248],{"trials":8914,"activeCount":101},[],{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":101},[],{"intervention":8920,"totalTrials":97,"cells":8921},"LBH589",{"EARLY_PHASE1":8922,"PHASE1":8924,"PHASE2":8926,"PHASE3":8935,"PHASE4":8937,"NA":8939},{"trials":8923,"activeCount":101},[],{"trials":8925,"activeCount":101},[],{"trials":8927,"activeCount":101},[8928],{"nctId":8929,"briefTitle":8930,"status":249,"phases":8931,"primaryCompletion":8932,"completion":8932,"start":8088,"enrollment":97,"conditions":8933,"interventions":8934},"NCT01090973","Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)",[90],"2011-03",[750],[8920],{"trials":8936,"activeCount":101},[],{"trials":8938,"activeCount":101},[],{"trials":8940,"activeCount":101},[],{"intervention":5997,"totalTrials":97,"cells":8942},{"EARLY_PHASE1":8943,"PHASE1":8945,"PHASE2":8947,"PHASE3":8953,"PHASE4":8955,"NA":8957},{"trials":8944,"activeCount":101},[],{"trials":8946,"activeCount":101},[],{"trials":8948,"activeCount":101},[8949],{"nctId":5991,"briefTitle":5992,"status":249,"phases":8950,"primaryCompletion":2754,"completion":2754,"start":5994,"enrollment":2139,"conditions":8951,"interventions":8952},[90],[869],[5997,5922,2196,5998,5922,2196],{"trials":8954,"activeCount":101},[],{"trials":8956,"activeCount":101},[],{"trials":8958,"activeCount":101},[],{"intervention":5998,"totalTrials":97,"cells":8960},{"EARLY_PHASE1":8961,"PHASE1":8963,"PHASE2":8965,"PHASE3":8971,"PHASE4":8973,"NA":8975},{"trials":8962,"activeCount":101},[],{"trials":8964,"activeCount":101},[],{"trials":8966,"activeCount":101},[8967],{"nctId":5991,"briefTitle":5992,"status":249,"phases":8968,"primaryCompletion":2754,"completion":2754,"start":5994,"enrollment":2139,"conditions":8969,"interventions":8970},[90],[869],[5997,5922,2196,5998,5922,2196],{"trials":8972,"activeCount":101},[],{"trials":8974,"activeCount":101},[],{"trials":8976,"activeCount":101},[],{"intervention":921,"totalTrials":97,"cells":8978},{"EARLY_PHASE1":8979,"PHASE1":8981,"PHASE2":8983,"PHASE3":8989,"PHASE4":8991,"NA":8993},{"trials":8980,"activeCount":101},[],{"trials":8982,"activeCount":101},[],{"trials":8984,"activeCount":101},[8985],{"nctId":911,"briefTitle":912,"status":147,"phases":8986,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":8987,"interventions":8988},[90],[858],[157,804,803,920,888,921,922],{"trials":8990,"activeCount":101},[],{"trials":8992,"activeCount":101},[],{"trials":8994,"activeCount":101},[],{"intervention":8996,"totalTrials":97,"cells":8997},"Bystander-Based Autologous Tumor Cell Vaccine",{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9002,"PHASE3":9011,"PHASE4":9013,"NA":9015},{"trials":8999,"activeCount":101},[],{"trials":9001,"activeCount":101},[],{"trials":9003,"activeCount":101},[9004],{"nctId":9005,"briefTitle":9006,"status":147,"phases":9007,"primaryCompletion":8088,"completion":8088,"start":9008,"enrollment":917,"conditions":9009,"interventions":9010},"NCT00101166","Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma",[90],"2004-10",[153],[8996],{"trials":9012,"activeCount":101},[],{"trials":9014,"activeCount":101},[],{"trials":9016,"activeCount":101},[],{"intervention":9018,"totalTrials":97,"cells":9019},"CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes",{"EARLY_PHASE1":9020,"PHASE1":9022,"PHASE2":9024,"PHASE3":9036,"PHASE4":9038,"NA":9040},{"trials":9021,"activeCount":101},[],{"trials":9023,"activeCount":101},[],{"trials":9025,"activeCount":101},[9026],{"nctId":9027,"briefTitle":9028,"status":147,"phases":9029,"primaryCompletion":9030,"completion":9030,"start":9031,"enrollment":336,"conditions":9032,"interventions":9034},"NCT04620681","CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML",[89,90],"2024-07-20","2021-01-14",[755,9033],"Secondary Acute Myeloid Leukemia",[9018,9035],"Standard of Care Chemotherapy",{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[],{"trials":9041,"activeCount":101},[],{"intervention":9035,"totalTrials":97,"cells":9043},{"EARLY_PHASE1":9044,"PHASE1":9046,"PHASE2":9048,"PHASE3":9054,"PHASE4":9056,"NA":9058},{"trials":9045,"activeCount":101},[],{"trials":9047,"activeCount":101},[],{"trials":9049,"activeCount":101},[9050],{"nctId":9027,"briefTitle":9028,"status":147,"phases":9051,"primaryCompletion":9030,"completion":9030,"start":9031,"enrollment":336,"conditions":9052,"interventions":9053},[89,90],[755,9033],[9018,9035],{"trials":9055,"activeCount":101},[],{"trials":9057,"activeCount":101},[],{"trials":9059,"activeCount":101},[],{"intervention":459,"totalTrials":97,"cells":9061},{"EARLY_PHASE1":9062,"PHASE1":9064,"PHASE2":9066,"PHASE3":9072,"PHASE4":9074,"NA":9076},{"trials":9063,"activeCount":101},[],{"trials":9065,"activeCount":101},[],{"trials":9067,"activeCount":101},[9068],{"nctId":451,"briefTitle":452,"status":147,"phases":9069,"primaryCompletion":454,"completion":455,"start":456,"enrollment":30,"conditions":9070,"interventions":9071},[90],[32],[459,52],{"trials":9073,"activeCount":101},[],{"trials":9075,"activeCount":101},[],{"trials":9077,"activeCount":101},[],{"intervention":469,"totalTrials":97,"cells":9079},{"EARLY_PHASE1":9080,"PHASE1":9082,"PHASE2":9084,"PHASE3":9090,"PHASE4":9092,"NA":9094},{"trials":9081,"activeCount":101},[],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[9086],{"nctId":461,"briefTitle":462,"status":249,"phases":9087,"primaryCompletion":464,"completion":465,"start":466,"enrollment":182,"conditions":9088,"interventions":9089},[90],[436,26,256],[52,172,469],{"trials":9091,"activeCount":101},[],{"trials":9093,"activeCount":101},[],{"trials":9095,"activeCount":101},[],{"intervention":486,"totalTrials":97,"cells":9097},{"EARLY_PHASE1":9098,"PHASE1":9100,"PHASE2":9102,"PHASE3":9108,"PHASE4":9110,"NA":9112},{"trials":9099,"activeCount":101},[],{"trials":9101,"activeCount":101},[],{"trials":9103,"activeCount":101},[9104],{"nctId":478,"briefTitle":479,"status":147,"phases":9105,"primaryCompletion":481,"completion":482,"start":483,"enrollment":22,"conditions":9106,"interventions":9107},[90],[32],[486,52],{"trials":9109,"activeCount":101},[],{"trials":9111,"activeCount":101},[],{"trials":9113,"activeCount":101},[],{"intervention":1698,"totalTrials":97,"cells":9115},{"EARLY_PHASE1":9116,"PHASE1":9118,"PHASE2":9120,"PHASE3":9126,"PHASE4":9128,"NA":9130},{"trials":9117,"activeCount":101},[],{"trials":9119,"activeCount":101},[],{"trials":9121,"activeCount":101},[9122],{"nctId":1687,"briefTitle":1688,"status":147,"phases":9123,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":136,"conditions":9124,"interventions":9125},[89,90],[15,1694,1695,1696],[1698,622],{"trials":9127,"activeCount":101},[],{"trials":9129,"activeCount":101},[],{"trials":9131,"activeCount":101},[],{"intervention":9133,"totalTrials":97,"cells":9134},"FOLFOX7",{"EARLY_PHASE1":9135,"PHASE1":9137,"PHASE2":9139,"PHASE3":9148,"PHASE4":9150,"NA":9152},{"trials":9136,"activeCount":101},[],{"trials":9138,"activeCount":101},[],{"trials":9140,"activeCount":101},[9141],{"nctId":9142,"briefTitle":9143,"status":147,"phases":9144,"primaryCompletion":7348,"completion":6575,"start":9145,"enrollment":253,"conditions":9146,"interventions":9147},"NCT01581307","Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets",[90],"2012-04",[6339,24],[9133],{"trials":9149,"activeCount":101},[],{"trials":9151,"activeCount":101},[],{"trials":9153,"activeCount":101},[],{"intervention":9155,"totalTrials":97,"cells":9156},"Irinotecan Hydrochloride (HCI) Treatment",{"EARLY_PHASE1":9157,"PHASE1":9159,"PHASE2":9161,"PHASE3":9174,"PHASE4":9176,"NA":9178},{"trials":9158,"activeCount":101},[],{"trials":9160,"activeCount":101},[],{"trials":9162,"activeCount":101},[9163],{"nctId":9164,"briefTitle":9165,"status":249,"phases":9166,"primaryCompletion":9167,"completion":9167,"start":1094,"enrollment":1265,"conditions":9168,"interventions":9172},"NCT00360828","Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas",[90],"2010-10",[9169,9170,9171],"Astrocytoma","Glioma","Oligodendroglioma",[9155,9173],"Continued Irinotecan Hydrochloride (HCI) Treatment",{"trials":9175,"activeCount":101},[],{"trials":9177,"activeCount":101},[],{"trials":9179,"activeCount":101},[],{"intervention":9173,"totalTrials":97,"cells":9181},{"EARLY_PHASE1":9182,"PHASE1":9184,"PHASE2":9186,"PHASE3":9192,"PHASE4":9194,"NA":9196},{"trials":9183,"activeCount":101},[],{"trials":9185,"activeCount":101},[],{"trials":9187,"activeCount":101},[9188],{"nctId":9164,"briefTitle":9165,"status":249,"phases":9189,"primaryCompletion":9167,"completion":9167,"start":1094,"enrollment":1265,"conditions":9190,"interventions":9191},[90],[9169,9170,9171],[9155,9173],{"trials":9193,"activeCount":101},[],{"trials":9195,"activeCount":101},[],{"trials":9197,"activeCount":101},[],{"intervention":9199,"totalTrials":97,"cells":9200},"Octreotide LAR",{"EARLY_PHASE1":9201,"PHASE1":9203,"PHASE2":9205,"PHASE3":9213,"PHASE4":9215,"NA":9217},{"trials":9202,"activeCount":101},[],{"trials":9204,"activeCount":101},[],{"trials":9206,"activeCount":101},[9207],{"nctId":9208,"briefTitle":9209,"status":249,"phases":9210,"primaryCompletion":1867,"completion":1346,"start":2754,"enrollment":189,"conditions":9211,"interventions":9212},"NCT01886287","P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome",[90],[669],[9199],{"trials":9214,"activeCount":101},[],{"trials":9216,"activeCount":101},[],{"trials":9218,"activeCount":101},[],{"intervention":952,"totalTrials":97,"cells":9220},{"EARLY_PHASE1":9221,"PHASE1":9223,"PHASE2":9225,"PHASE3":9231,"PHASE4":9233,"NA":9235},{"trials":9222,"activeCount":101},[],{"trials":9224,"activeCount":101},[],{"trials":9226,"activeCount":101},[9227],{"nctId":943,"briefTitle":944,"status":147,"phases":9228,"primaryCompletion":946,"completion":947,"start":948,"enrollment":949,"conditions":9229,"interventions":9230},[89,90],[21],[157,952],{"trials":9232,"activeCount":101},[],{"trials":9234,"activeCount":101},[],{"trials":9236,"activeCount":101},[],{"intervention":2514,"totalTrials":97,"cells":9238},{"EARLY_PHASE1":9239,"PHASE1":9241,"PHASE2":9243,"PHASE3":9249,"PHASE4":9251,"NA":9253},{"trials":9240,"activeCount":101},[],{"trials":9242,"activeCount":101},[],{"trials":9244,"activeCount":101},[9245],{"nctId":2506,"briefTitle":2507,"status":147,"phases":9246,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":30,"conditions":9247,"interventions":9248},[90],[201],[2514,1732],{"trials":9250,"activeCount":101},[],{"trials":9252,"activeCount":101},[],{"trials":9254,"activeCount":101},[],{"intervention":2524,"totalTrials":97,"cells":9256},{"EARLY_PHASE1":9257,"PHASE1":9259,"PHASE2":9261,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9258,"activeCount":101},[],{"trials":9260,"activeCount":101},[],{"trials":9262,"activeCount":101},[9263],{"nctId":2516,"briefTitle":2517,"status":147,"phases":9264,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":1204,"conditions":9265,"interventions":9266},[89,90],[1729,1132],[2524,2525,1732],{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"trials":9272,"activeCount":101},[],{"intervention":9274,"totalTrials":730,"cells":9275},"Vitamin E δ-Tocotrienol",{"EARLY_PHASE1":9276,"PHASE1":9278,"PHASE2":9301,"PHASE3":9303,"PHASE4":9305,"NA":9307},{"trials":9277,"activeCount":101},[],{"trials":9279,"activeCount":101},[9280,9287,9294],{"nctId":9281,"briefTitle":9282,"status":147,"phases":9283,"primaryCompletion":9284,"completion":6724,"start":8171,"enrollment":1095,"conditions":9285,"interventions":9286},"NCT01450046","Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects",[89],"2013-03",[24],[9274],{"nctId":9288,"briefTitle":9289,"status":147,"phases":9290,"primaryCompletion":9291,"completion":6724,"start":8297,"enrollment":1095,"conditions":9292,"interventions":9293},"NCT01446952","Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects",[89],"2012-09",[24],[9274],{"nctId":9295,"briefTitle":9296,"status":147,"phases":9297,"primaryCompletion":9298,"completion":7348,"start":6210,"enrollment":19,"conditions":9299,"interventions":9300},"NCT00985777","Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia",[89],"2015-06",[8091],[9274],{"trials":9302,"activeCount":101},[],{"trials":9304,"activeCount":101},[],{"trials":9306,"activeCount":101},[],{"trials":9308,"activeCount":101},[],{"intervention":159,"totalTrials":189,"cells":9310},{"EARLY_PHASE1":9311,"PHASE1":9317,"PHASE2":9323,"PHASE3":9325,"PHASE4":9327,"NA":9329},{"trials":9312,"activeCount":101},[9313],{"nctId":145,"briefTitle":146,"status":147,"phases":9314,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":9315,"interventions":9316},[88],[153,154],[52,156,157,158,159,160],{"trials":9318,"activeCount":101},[9319],{"nctId":767,"briefTitle":768,"status":147,"phases":9320,"primaryCompletion":770,"completion":771,"start":772,"enrollment":253,"conditions":9321,"interventions":9322},[89],[299],[159,160,158,157],{"trials":9324,"activeCount":101},[],{"trials":9326,"activeCount":101},[],{"trials":9328,"activeCount":101},[],{"trials":9330,"activeCount":101},[],{"intervention":4702,"totalTrials":189,"cells":9332},{"EARLY_PHASE1":9333,"PHASE1":9335,"PHASE2":9351,"PHASE3":9353,"PHASE4":9355,"NA":9357},{"trials":9334,"activeCount":101},[],{"trials":9336,"activeCount":101},[9337,9347],{"nctId":9338,"briefTitle":9339,"status":147,"phases":9340,"primaryCompletion":9341,"completion":9342,"start":9343,"enrollment":30,"conditions":9344,"interventions":9346},"NCT02292173","Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer",[89],"2018-12-18","2021-01","2015-02-18",[9345,6339],"Hepatocellular Cancer",[4702,4596],{"nctId":4694,"briefTitle":4695,"status":147,"phases":9348,"primaryCompletion":4697,"completion":4698,"start":4699,"enrollment":595,"conditions":9349,"interventions":9350},[89],[32,782,426],[1283,4702],{"trials":9352,"activeCount":101},[],{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[],{"intervention":9360,"totalTrials":189,"cells":9361},"HER-2 pulsed Dendritic Cell Vaccine",{"EARLY_PHASE1":9362,"PHASE1":9364,"PHASE2":9383,"PHASE3":9385,"PHASE4":9387,"NA":9389},{"trials":9363,"activeCount":101},[],{"trials":9365,"activeCount":101},[9366,9375],{"nctId":9367,"briefTitle":9368,"status":147,"phases":9369,"primaryCompletion":9370,"completion":9371,"start":9372,"enrollment":507,"conditions":9373,"interventions":9374},"NCT02061423","HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy",[89],"2019-02","2024-02-21","2014-04-08",[15],[9360],{"nctId":9376,"briefTitle":9377,"status":147,"phases":9378,"primaryCompletion":9379,"completion":6849,"start":9380,"enrollment":36,"conditions":9381,"interventions":9382},"NCT02063724","HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer",[89],"2017-09","2014-10-01",[15],[9360],{"trials":9384,"activeCount":101},[],{"trials":9386,"activeCount":101},[],{"trials":9388,"activeCount":101},[],{"trials":9390,"activeCount":101},[],{"intervention":9392,"totalTrials":189,"cells":9393},"Granulocyte-colony Stimulating Factor",{"EARLY_PHASE1":9394,"PHASE1":9406,"PHASE2":9412,"PHASE3":9414,"PHASE4":9416,"NA":9418},{"trials":9395,"activeCount":101},[9396],{"nctId":9397,"briefTitle":9398,"status":147,"phases":9399,"primaryCompletion":5647,"completion":9400,"start":9401,"enrollment":182,"conditions":9402,"interventions":9403},"NCT02851056","Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)",[88],"2018-08-09","2016-09-27",[21],[9404,9405,9392],"Survivin Vaccine","Prevnar 13",{"trials":9407,"activeCount":101},[9408],{"nctId":743,"briefTitle":744,"status":147,"phases":9409,"primaryCompletion":746,"completion":747,"start":748,"enrollment":544,"conditions":9410,"interventions":9411},[89],[750,751,752,753,754,755,756,21],[158,758,157,759,760,761],{"trials":9413,"activeCount":101},[],{"trials":9415,"activeCount":101},[],{"trials":9417,"activeCount":101},[],{"trials":9419,"activeCount":101},[],{"intervention":2346,"totalTrials":189,"cells":9421},{"EARLY_PHASE1":9422,"PHASE1":9424,"PHASE2":9436,"PHASE3":9438,"PHASE4":9440,"NA":9442},{"trials":9423,"activeCount":101},[],{"trials":9425,"activeCount":101},[9426,9430],{"nctId":2338,"briefTitle":2339,"status":147,"phases":9427,"primaryCompletion":2341,"start":2342,"conditions":9428,"interventions":9429},[89],[2344],[2346,907],{"nctId":9431,"briefTitle":9432,"status":7800,"phases":9433,"conditions":9434,"interventions":9435},"NCT00005611","BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment",[89],[2344],[2346],{"trials":9437,"activeCount":101},[],{"trials":9439,"activeCount":101},[],{"trials":9441,"activeCount":101},[],{"trials":9443,"activeCount":101},[],{"intervention":1559,"totalTrials":189,"cells":9445},{"EARLY_PHASE1":9446,"PHASE1":9448,"PHASE2":9458,"PHASE3":9460,"PHASE4":9462,"NA":9464},{"trials":9447,"activeCount":101},[],{"trials":9449,"activeCount":101},[9450,9454],{"nctId":1549,"briefTitle":1550,"status":147,"phases":9451,"primaryCompletion":1552,"completion":1553,"start":1554,"enrollment":19,"conditions":9452,"interventions":9453},[89],[1556,1557],[803,807,527,1559],{"nctId":1561,"briefTitle":1562,"status":147,"phases":9455,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":182,"conditions":9456,"interventions":9457},[89],[733],[1559,803,888,1569,804,1570],{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[],{"trials":9463,"activeCount":101},[],{"trials":9465,"activeCount":101},[],{"intervention":326,"totalTrials":189,"cells":9467},{"EARLY_PHASE1":9468,"PHASE1":9470,"PHASE2":9490,"PHASE3":9492,"PHASE4":9494,"NA":9496},{"trials":9469,"activeCount":101},[],{"trials":9471,"activeCount":101},[9472,9486],{"nctId":9473,"briefTitle":9474,"status":147,"phases":9475,"primaryCompletion":9476,"completion":9476,"start":9477,"enrollment":9478,"conditions":9479,"interventions":9480},"NCT01176461","Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558",[89],"2016-12-12","2010-08-04",127,[153],[9481,9482,9483,326,9484,9485],"MART-1","NY-ESO-1","gp100:209-217","Montanide ISA 51 VG","BMS-936558",{"nctId":316,"briefTitle":317,"status":147,"phases":9487,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":9488,"interventions":9489},[89],[153],[325,52,326,327,172],{"trials":9491,"activeCount":101},[],{"trials":9493,"activeCount":101},[],{"trials":9495,"activeCount":101},[],{"trials":9497,"activeCount":101},[],{"intervention":9499,"totalTrials":97,"cells":9500},"Xevinapant",{"EARLY_PHASE1":9501,"PHASE1":9503,"PHASE2":9513,"PHASE3":9515,"PHASE4":9517,"NA":9519},{"trials":9502,"activeCount":101},[],{"trials":9504,"activeCount":101},[9505],{"nctId":9506,"briefTitle":9507,"status":345,"phases":9508,"primaryCompletion":3249,"completion":3249,"start":9509,"enrollment":101,"conditions":9510,"interventions":9512},"NCT06463184","Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)",[89],"2024-07-22",[9511],"Recurrent High-grade Glioma",[9499],{"trials":9514,"activeCount":101},[],{"trials":9516,"activeCount":101},[],{"trials":9518,"activeCount":101},[],{"trials":9520,"activeCount":101},[],{"intervention":2099,"totalTrials":97,"cells":9522},{"EARLY_PHASE1":9523,"PHASE1":9525,"PHASE2":9531,"PHASE3":9533,"PHASE4":9535,"NA":9537},{"trials":9524,"activeCount":101},[],{"trials":9526,"activeCount":101},[9527],{"nctId":2091,"briefTitle":2092,"status":147,"phases":9528,"primaryCompletion":2094,"completion":2095,"start":2096,"enrollment":281,"conditions":9529,"interventions":9530},[89],[24],[2099,1246],{"trials":9532,"activeCount":101},[],{"trials":9534,"activeCount":101},[],{"trials":9536,"activeCount":101},[],{"trials":9538,"activeCount":101},[],{"intervention":9540,"totalTrials":97,"cells":9541},"Erlotinib in combination with Dasatinib",{"EARLY_PHASE1":9542,"PHASE1":9544,"PHASE2":9553,"PHASE3":9555,"PHASE4":9557,"NA":9559},{"trials":9543,"activeCount":101},[],{"trials":9545,"activeCount":101},[9546],{"nctId":9547,"briefTitle":9548,"status":147,"phases":9549,"primaryCompletion":2138,"completion":2138,"start":1290,"enrollment":1130,"conditions":9550,"interventions":9552},"NCT00444015","Phase I Dasatinib\u002FErlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)",[89],[9551],"Non-Small-Cell Lung Carcinoma",[9540],{"trials":9554,"activeCount":101},[],{"trials":9556,"activeCount":101},[],{"trials":9558,"activeCount":101},[],{"trials":9560,"activeCount":101},[],{"intervention":1619,"totalTrials":97,"cells":9562},{"EARLY_PHASE1":9563,"PHASE1":9565,"PHASE2":9571,"PHASE3":9573,"PHASE4":9575,"NA":9577},{"trials":9564,"activeCount":101},[],{"trials":9566,"activeCount":101},[9567],{"nctId":1610,"briefTitle":1611,"status":147,"phases":9568,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":821,"conditions":9569,"interventions":9570},[89],[1617,632],[1619,622,907],{"trials":9572,"activeCount":101},[],{"trials":9574,"activeCount":101},[],{"trials":9576,"activeCount":101},[],{"trials":9578,"activeCount":101},[],{"intervention":2448,"totalTrials":97,"cells":9580},{"EARLY_PHASE1":9581,"PHASE1":9583,"PHASE2":9589,"PHASE3":9591,"PHASE4":9593,"NA":9595},{"trials":9582,"activeCount":101},[],{"trials":9584,"activeCount":101},[9585],{"nctId":2439,"briefTitle":2440,"status":147,"phases":9586,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":27,"conditions":9587,"interventions":9588},[89],[35],[2447,2448],{"trials":9590,"activeCount":101},[],{"trials":9592,"activeCount":101},[],{"trials":9594,"activeCount":101},[],{"trials":9596,"activeCount":101},[],{"intervention":737,"totalTrials":97,"cells":9598},{"EARLY_PHASE1":9599,"PHASE1":9601,"PHASE2":9607,"PHASE3":9609,"PHASE4":9611,"NA":9613},{"trials":9600,"activeCount":101},[],{"trials":9602,"activeCount":101},[9603],{"nctId":725,"briefTitle":726,"status":147,"phases":9604,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":9605,"interventions":9606},[89],[606,732,733,734,735],[158,157,737],{"trials":9608,"activeCount":101},[],{"trials":9610,"activeCount":101},[],{"trials":9612,"activeCount":101},[],{"trials":9614,"activeCount":101},[],{"intervention":9616,"totalTrials":97,"cells":9617},"Valrubicin",{"EARLY_PHASE1":9618,"PHASE1":9620,"PHASE2":9628,"PHASE3":9630,"PHASE4":9632,"NA":9634},{"trials":9619,"activeCount":101},[],{"trials":9621,"activeCount":101},[9622],{"nctId":9623,"briefTitle":9624,"status":147,"phases":9625,"primaryCompletion":6724,"completion":6724,"start":7467,"enrollment":812,"conditions":9626,"interventions":9627},"NCT01606345","Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma",[89],[239],[9616],{"trials":9629,"activeCount":101},[],{"trials":9631,"activeCount":101},[],{"trials":9633,"activeCount":101},[],{"trials":9635,"activeCount":101},[],{"intervention":9637,"totalTrials":97,"cells":9638},"Bendamustine",{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9649,"PHASE3":9651,"PHASE4":9653,"NA":9655},{"trials":9640,"activeCount":101},[],{"trials":9642,"activeCount":101},[9643],{"nctId":9644,"briefTitle":9645,"status":249,"phases":9646,"primaryCompletion":2082,"completion":946,"start":4392,"enrollment":233,"conditions":9647,"interventions":9648},"NCT00879073","Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors",[89],[225],[9637],{"trials":9650,"activeCount":101},[],{"trials":9652,"activeCount":101},[],{"trials":9654,"activeCount":101},[],{"trials":9656,"activeCount":101},[],{"intervention":4319,"totalTrials":97,"cells":9658},{"EARLY_PHASE1":9659,"PHASE1":9661,"PHASE2":9667,"PHASE3":9669,"PHASE4":9671,"NA":9673},{"trials":9660,"activeCount":101},[],{"trials":9662,"activeCount":101},[9663],{"nctId":4313,"briefTitle":4314,"status":552,"phases":9664,"primaryCompletion":564,"completion":564,"start":4316,"enrollment":233,"conditions":9665,"interventions":9666},[89],[201],[4319,67],{"trials":9668,"activeCount":101},[],{"trials":9670,"activeCount":101},[],{"trials":9672,"activeCount":101},[],{"trials":9674,"activeCount":101},[],{"intervention":6199,"totalTrials":97,"cells":9676},{"EARLY_PHASE1":9677,"PHASE1":9679,"PHASE2":9685,"PHASE3":9687,"PHASE4":9689,"NA":9691},{"trials":9678,"activeCount":101},[],{"trials":9680,"activeCount":101},[9681],{"nctId":6192,"briefTitle":6193,"status":147,"phases":9682,"primaryCompletion":6195,"completion":6195,"start":6196,"enrollment":917,"conditions":9683,"interventions":9684},[89],[26,242],[6199,2615],{"trials":9686,"activeCount":101},[],{"trials":9688,"activeCount":101},[],{"trials":9690,"activeCount":101},[],{"trials":9692,"activeCount":101},[],{"intervention":2905,"totalTrials":97,"cells":9694},{"EARLY_PHASE1":9695,"PHASE1":9697,"PHASE2":9703,"PHASE3":9705,"PHASE4":9707,"NA":9709},{"trials":9696,"activeCount":101},[],{"trials":9698,"activeCount":101},[9699],{"nctId":2895,"briefTitle":2896,"status":147,"phases":9700,"primaryCompletion":2898,"completion":2899,"start":2900,"enrollment":507,"conditions":9701,"interventions":9702},[89],[15,2902,2903],[2905,1520,2906],{"trials":9704,"activeCount":101},[],{"trials":9706,"activeCount":101},[],{"trials":9708,"activeCount":101},[],{"trials":9710,"activeCount":101},[],{"intervention":2906,"totalTrials":97,"cells":9712},{"EARLY_PHASE1":9713,"PHASE1":9715,"PHASE2":9721,"PHASE3":9723,"PHASE4":9725,"NA":9727},{"trials":9714,"activeCount":101},[],{"trials":9716,"activeCount":101},[9717],{"nctId":2895,"briefTitle":2896,"status":147,"phases":9718,"primaryCompletion":2898,"completion":2899,"start":2900,"enrollment":507,"conditions":9719,"interventions":9720},[89],[15,2902,2903],[2905,1520,2906],{"trials":9722,"activeCount":101},[],{"trials":9724,"activeCount":101},[],{"trials":9726,"activeCount":101},[],{"trials":9728,"activeCount":101},[],{"intervention":9730,"totalTrials":97,"cells":9731},"Bavituximab",{"EARLY_PHASE1":9732,"PHASE1":9734,"PHASE2":9746,"PHASE3":9748,"PHASE4":9750,"NA":9752},{"trials":9733,"activeCount":101},[],{"trials":9735,"activeCount":101},[9736],{"nctId":9737,"briefTitle":9738,"status":345,"phases":9739,"primaryCompletion":9740,"completion":9740,"start":9741,"enrollment":101,"conditions":9742,"interventions":9745},"NCT02989870","Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma",[89],"2018-10-15","2017-03-27",[9743,9744,6339],"HepatoCellular Carcinoma","Unresectable HepatoCellular Carcinoma",[4596,9730],{"trials":9747,"activeCount":101},[],{"trials":9749,"activeCount":101},[],{"trials":9751,"activeCount":101},[],{"trials":9753,"activeCount":101},[],{"intervention":2957,"totalTrials":97,"cells":9755},{"EARLY_PHASE1":9756,"PHASE1":9758,"PHASE2":9764,"PHASE3":9766,"PHASE4":9768,"NA":9770},{"trials":9757,"activeCount":101},[],{"trials":9759,"activeCount":101},[9760],{"nctId":2949,"briefTitle":2950,"status":249,"phases":9761,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":189,"conditions":9762,"interventions":9763},[89],[2955],[2957,215,2942],{"trials":9765,"activeCount":101},[],{"trials":9767,"activeCount":101},[],{"trials":9769,"activeCount":101},[],{"trials":9771,"activeCount":101},[],{"intervention":9773,"totalTrials":97,"cells":9774},"CP-609,754",{"EARLY_PHASE1":9775,"PHASE1":9777,"PHASE2":9785,"PHASE3":9787,"PHASE4":9789,"NA":9791},{"trials":9776,"activeCount":101},[],{"trials":9778,"activeCount":101},[9779],{"nctId":9780,"briefTitle":9781,"status":7800,"phases":9782,"start":2342,"conditions":9783,"interventions":9784},"NCT00006085","CP-609,754 in Treating Patients With Advanced Solid Tumors",[89],[2344],[9773],{"trials":9786,"activeCount":101},[],{"trials":9788,"activeCount":101},[],{"trials":9790,"activeCount":101},[],{"trials":9792,"activeCount":101},[],{"intervention":1100,"totalTrials":97,"cells":9794},{"EARLY_PHASE1":9795,"PHASE1":9797,"PHASE2":9803,"PHASE3":9805,"PHASE4":9807,"NA":9809},{"trials":9796,"activeCount":101},[],{"trials":9798,"activeCount":101},[9799],{"nctId":1090,"briefTitle":1091,"status":147,"phases":9800,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":9801,"interventions":9802},[89],[1097,153],[1099,158,1100],{"trials":9804,"activeCount":101},[],{"trials":9806,"activeCount":101},[],{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[],{"intervention":2109,"totalTrials":97,"cells":9812},{"EARLY_PHASE1":9813,"PHASE1":9815,"PHASE2":9821,"PHASE3":9823,"PHASE4":9825,"NA":9827},{"trials":9814,"activeCount":101},[],{"trials":9816,"activeCount":101},[9817],{"nctId":2101,"briefTitle":2102,"status":147,"phases":9818,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":36,"conditions":9819,"interventions":9820},[89],[24],[2109,1246,2110],{"trials":9822,"activeCount":101},[],{"trials":9824,"activeCount":101},[],{"trials":9826,"activeCount":101},[],{"trials":9828,"activeCount":101},[],{"intervention":2110,"totalTrials":97,"cells":9830},{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9839,"PHASE3":9841,"PHASE4":9843,"NA":9845},{"trials":9832,"activeCount":101},[],{"trials":9834,"activeCount":101},[9835],{"nctId":2101,"briefTitle":2102,"status":147,"phases":9836,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":36,"conditions":9837,"interventions":9838},[89],[24],[2109,1246,2110],{"trials":9840,"activeCount":101},[],{"trials":9842,"activeCount":101},[],{"trials":9844,"activeCount":101},[],{"trials":9846,"activeCount":101},[],{"intervention":9848,"totalTrials":97,"cells":9849},"Minnelide",{"EARLY_PHASE1":9850,"PHASE1":9852,"PHASE2":9861,"PHASE3":9863,"PHASE4":9865,"NA":9867},{"trials":9851,"activeCount":101},[],{"trials":9853,"activeCount":101},[9854],{"nctId":9855,"briefTitle":9856,"status":249,"phases":9857,"primaryCompletion":71,"completion":71,"start":9858,"enrollment":595,"conditions":9859,"interventions":9860},"NCT03760523","Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia",[89],"2019-04-18",[1132],[9848],{"trials":9862,"activeCount":101},[],{"trials":9864,"activeCount":101},[],{"trials":9866,"activeCount":101},[],{"trials":9868,"activeCount":101},[],{"intervention":245,"totalTrials":97,"cells":9870},{"EARLY_PHASE1":9871,"PHASE1":9873,"PHASE2":9879,"PHASE3":9881,"PHASE4":9883,"NA":9885},{"trials":9872,"activeCount":101},[],{"trials":9874,"activeCount":101},[9875],{"nctId":228,"briefTitle":229,"status":147,"phases":9876,"primaryCompletion":231,"completion":208,"start":232,"enrollment":233,"conditions":9877,"interventions":9878},[89],[235,236,237,238,239,240,241,242,243],[245,52],{"trials":9880,"activeCount":101},[],{"trials":9882,"activeCount":101},[],{"trials":9884,"activeCount":101},[],{"trials":9886,"activeCount":101},[],{"intervention":259,"totalTrials":97,"cells":9888},{"EARLY_PHASE1":9889,"PHASE1":9891,"PHASE2":9897,"PHASE3":9899,"PHASE4":9901,"NA":9903},{"trials":9890,"activeCount":101},[],{"trials":9892,"activeCount":101},[9893],{"nctId":247,"briefTitle":248,"status":249,"phases":9894,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":9895,"interventions":9896},[89],[255,256,257],[52,172,259],{"trials":9898,"activeCount":101},[],{"trials":9900,"activeCount":101},[],{"trials":9902,"activeCount":101},[],{"trials":9904,"activeCount":101},[],{"intervention":9906,"totalTrials":97,"cells":9907},"Autologous dendritic cell-adenovirus CCL21 vaccine",{"EARLY_PHASE1":9908,"PHASE1":9910,"PHASE2":9918,"PHASE3":9920,"PHASE4":9922,"NA":9924},{"trials":9909,"activeCount":101},[],{"trials":9911,"activeCount":101},[9912],{"nctId":9913,"briefTitle":9914,"status":147,"phases":9915,"primaryCompletion":9145,"completion":9145,"start":6104,"enrollment":1059,"conditions":9916,"interventions":9917},"NCT00798629","Adenovirus CCL-21 Transduced MART-1\u002Fgp100\u002FTyrosinase\u002FNY-ESO-1 Peptide-Pulsed Dendritic Cells Matured",[89],[153],[9906],{"trials":9919,"activeCount":101},[],{"trials":9921,"activeCount":101},[],{"trials":9923,"activeCount":101},[],{"trials":9925,"activeCount":101},[],{"intervention":4342,"totalTrials":97,"cells":9927},{"EARLY_PHASE1":9928,"PHASE1":9930,"PHASE2":9936,"PHASE3":9938,"PHASE4":9940,"NA":9942},{"trials":9929,"activeCount":101},[],{"trials":9931,"activeCount":101},[9932],{"nctId":4329,"briefTitle":4330,"status":147,"phases":9933,"primaryCompletion":4332,"completion":4333,"start":4334,"enrollment":336,"conditions":9934,"interventions":9935},[89],[241,243,510,4336,4337,4338,4339,4340],[67,4342],{"trials":9937,"activeCount":101},[],{"trials":9939,"activeCount":101},[],{"trials":9941,"activeCount":101},[],{"trials":9943,"activeCount":101},[],{"intervention":9945,"totalTrials":97,"cells":9946},"SOM230C LAR",{"EARLY_PHASE1":9947,"PHASE1":9949,"PHASE2":9958,"PHASE3":9960,"PHASE4":9962,"NA":9964},{"trials":9948,"activeCount":101},[],{"trials":9950,"activeCount":101},[9951],{"nctId":9952,"briefTitle":9953,"status":147,"phases":9954,"primaryCompletion":4265,"completion":4265,"start":8297,"enrollment":33,"conditions":9955,"interventions":9956},"NCT01434069","Phase I Trial of Combination of FOLFIRI and SOM 230",[89],[2182],[9945,9957],"FOLFIRI",{"trials":9959,"activeCount":101},[],{"trials":9961,"activeCount":101},[],{"trials":9963,"activeCount":101},[],{"trials":9965,"activeCount":101},[],{"intervention":9957,"totalTrials":97,"cells":9967},{"EARLY_PHASE1":9968,"PHASE1":9970,"PHASE2":9976,"PHASE3":9978,"PHASE4":9980,"NA":9982},{"trials":9969,"activeCount":101},[],{"trials":9971,"activeCount":101},[9972],{"nctId":9952,"briefTitle":9953,"status":147,"phases":9973,"primaryCompletion":4265,"completion":4265,"start":8297,"enrollment":33,"conditions":9974,"interventions":9975},[89],[2182],[9945,9957],{"trials":9977,"activeCount":101},[],{"trials":9979,"activeCount":101},[],{"trials":9981,"activeCount":101},[],{"trials":9983,"activeCount":101},[],{"intervention":9985,"totalTrials":97,"cells":9986},"Dasatinib - 1A",{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":10004,"PHASE3":10006,"PHASE4":10008,"NA":10010},{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[9991],{"nctId":9992,"briefTitle":9993,"status":147,"phases":9994,"primaryCompletion":9995,"completion":9996,"start":9997,"enrollment":1035,"conditions":9998,"interventions":10000},"NCT01999985","Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)",[89],"2017-03-21","2019-05-30","2013-12-31",[26,9999],"Non-small Cell Lung Cancer (NSCLC)",[9985,10001,10002,10003],"Afatinib - 1A","Dasatinib - 1B","Afatinib - 1B",{"trials":10005,"activeCount":101},[],{"trials":10007,"activeCount":101},[],{"trials":10009,"activeCount":101},[],{"trials":10011,"activeCount":101},[],{"intervention":10001,"totalTrials":97,"cells":10013},{"EARLY_PHASE1":10014,"PHASE1":10016,"PHASE2":10022,"PHASE3":10024,"PHASE4":10026,"NA":10028},{"trials":10015,"activeCount":101},[],{"trials":10017,"activeCount":101},[10018],{"nctId":9992,"briefTitle":9993,"status":147,"phases":10019,"primaryCompletion":9995,"completion":9996,"start":9997,"enrollment":1035,"conditions":10020,"interventions":10021},[89],[26,9999],[9985,10001,10002,10003],{"trials":10023,"activeCount":101},[],{"trials":10025,"activeCount":101},[],{"trials":10027,"activeCount":101},[],{"trials":10029,"activeCount":101},[],{"intervention":10002,"totalTrials":97,"cells":10031},{"EARLY_PHASE1":10032,"PHASE1":10034,"PHASE2":10040,"PHASE3":10042,"PHASE4":10044,"NA":10046},{"trials":10033,"activeCount":101},[],{"trials":10035,"activeCount":101},[10036],{"nctId":9992,"briefTitle":9993,"status":147,"phases":10037,"primaryCompletion":9995,"completion":9996,"start":9997,"enrollment":1035,"conditions":10038,"interventions":10039},[89],[26,9999],[9985,10001,10002,10003],{"trials":10041,"activeCount":101},[],{"trials":10043,"activeCount":101},[],{"trials":10045,"activeCount":101},[],{"trials":10047,"activeCount":101},[],{"intervention":10003,"totalTrials":97,"cells":10049},{"EARLY_PHASE1":10050,"PHASE1":10052,"PHASE2":10058,"PHASE3":10060,"PHASE4":10062,"NA":10064},{"trials":10051,"activeCount":101},[],{"trials":10053,"activeCount":101},[10054],{"nctId":9992,"briefTitle":9993,"status":147,"phases":10055,"primaryCompletion":9995,"completion":9996,"start":9997,"enrollment":1035,"conditions":10056,"interventions":10057},[89],[26,9999],[9985,10001,10002,10003],{"trials":10059,"activeCount":101},[],{"trials":10061,"activeCount":101},[],{"trials":10063,"activeCount":101},[],{"trials":10065,"activeCount":101},[],{"intervention":10067,"totalTrials":97,"cells":10068},"KLH and Tumor Lysate Pulsed DC Vaccine",{"EARLY_PHASE1":10069,"PHASE1":10071,"PHASE2":10083,"PHASE3":10085,"PHASE4":10087,"NA":10089},{"trials":10070,"activeCount":101},[],{"trials":10072,"activeCount":101},[10073],{"nctId":10074,"briefTitle":10075,"status":345,"phases":10076,"primaryCompletion":10077,"completion":10077,"start":10078,"enrollment":101,"conditions":10079,"interventions":10082},"NCT02745756","A Combined Cell Therapy Approach to the Treatment of Neuroblastoma",[89],"2017-08-21","2016-04-14",[10080,10081],"Neuroblastoma","Neoplasms, Nerve Tissue",[10067],{"trials":10084,"activeCount":101},[],{"trials":10086,"activeCount":101},[],{"trials":10088,"activeCount":101},[],{"trials":10090,"activeCount":101},[],{"intervention":10092,"totalTrials":97,"cells":10093},"TPI 287",{"EARLY_PHASE1":10094,"PHASE1":10096,"PHASE2":10109,"PHASE3":10111,"PHASE4":10113,"NA":10115},{"trials":10095,"activeCount":101},[],{"trials":10097,"activeCount":101},[10098],{"nctId":10099,"briefTitle":10100,"status":249,"phases":10101,"primaryCompletion":10102,"completion":10103,"start":10104,"enrollment":36,"conditions":10105,"interventions":10108},"NCT02187822","Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases",[89],"2018-02-20","2018-03-31","2014-10-09",[225,10106,10107],"Generalized Malignancy, Primary","Brain Lesions",[10092],{"trials":10110,"activeCount":101},[],{"trials":10112,"activeCount":101},[],{"trials":10114,"activeCount":101},[],{"trials":10116,"activeCount":101},[],{"intervention":10118,"totalTrials":97,"cells":10119},"vinorelbine tartrate",{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10130,"PHASE3":10132,"PHASE4":10134,"NA":10136},{"trials":10121,"activeCount":101},[],{"trials":10123,"activeCount":101},[10124],{"nctId":10125,"briefTitle":10126,"status":7800,"phases":10127,"start":2342,"conditions":10128,"interventions":10129},"NCT00006088","Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors",[89],[2344],[10118],{"trials":10131,"activeCount":101},[],{"trials":10133,"activeCount":101},[],{"trials":10135,"activeCount":101},[],{"trials":10137,"activeCount":101},[],{"intervention":10139,"totalTrials":97,"cells":10140},"BMS-986345",{"EARLY_PHASE1":10141,"PHASE1":10143,"PHASE2":10156,"PHASE3":10158,"PHASE4":10160,"NA":10162},{"trials":10142,"activeCount":101},[],{"trials":10144,"activeCount":101},[10145],{"nctId":10146,"briefTitle":10147,"status":147,"phases":10148,"primaryCompletion":10149,"completion":10150,"start":10151,"enrollment":182,"conditions":10152,"interventions":10154},"NCT05065866","Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy",[89],"2024-01-02","2024-04-24","2021-11-18",[10153,756,885,1781],"Non Hodgkin Lymphoma",[10139,10155],"Duvelisib",{"trials":10157,"activeCount":101},[],{"trials":10159,"activeCount":101},[],{"trials":10161,"activeCount":101},[],{"trials":10163,"activeCount":101},[],{"intervention":10155,"totalTrials":97,"cells":10165},{"EARLY_PHASE1":10166,"PHASE1":10168,"PHASE2":10174,"PHASE3":10176,"PHASE4":10178,"NA":10180},{"trials":10167,"activeCount":101},[],{"trials":10169,"activeCount":101},[10170],{"nctId":10146,"briefTitle":10147,"status":147,"phases":10171,"primaryCompletion":10149,"completion":10150,"start":10151,"enrollment":182,"conditions":10172,"interventions":10173},[89],[10153,756,885,1781],[10139,10155],{"trials":10175,"activeCount":101},[],{"trials":10177,"activeCount":101},[],{"trials":10179,"activeCount":101},[],{"trials":10181,"activeCount":101},[],{"intervention":10183,"totalTrials":97,"cells":10184},"PV-10",{"EARLY_PHASE1":10185,"PHASE1":10187,"PHASE2":10198,"PHASE3":10200,"PHASE4":10202,"NA":10204},{"trials":10186,"activeCount":101},[],{"trials":10188,"activeCount":101},[10189],{"nctId":10190,"briefTitle":10191,"status":147,"phases":10192,"primaryCompletion":10193,"completion":10194,"start":10195,"enrollment":36,"conditions":10196,"interventions":10197},"NCT01760499","Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study",[89],"2015-12-29","2017-04","2013-01-24",[32],[10183],{"trials":10199,"activeCount":101},[],{"trials":10201,"activeCount":101},[],{"trials":10203,"activeCount":101},[],{"trials":10205,"activeCount":101},[],{"intervention":5305,"totalTrials":97,"cells":10207},{"EARLY_PHASE1":10208,"PHASE1":10210,"PHASE2":10216,"PHASE3":10218,"PHASE4":10220,"NA":10222},{"trials":10209,"activeCount":101},[],{"trials":10211,"activeCount":101},[10212],{"nctId":5295,"briefTitle":5296,"status":147,"phases":10213,"primaryCompletion":5298,"completion":5299,"start":5300,"enrollment":5301,"conditions":10214,"interventions":10215},[89],[21,5303],[5305,5306,5307],{"trials":10217,"activeCount":101},[],{"trials":10219,"activeCount":101},[],{"trials":10221,"activeCount":101},[],{"trials":10223,"activeCount":101},[],{"intervention":6515,"totalTrials":97,"cells":10225},{"EARLY_PHASE1":10226,"PHASE1":10228,"PHASE2":10234,"PHASE3":10236,"PHASE4":10238,"NA":10240},{"trials":10227,"activeCount":101},[],{"trials":10229,"activeCount":101},[10230],{"nctId":6506,"briefTitle":6507,"status":147,"phases":10231,"primaryCompletion":2755,"completion":2755,"start":6509,"enrollment":6510,"conditions":10232,"interventions":10233},[89],[6512],[6514,6515,6516,6517],{"trials":10235,"activeCount":101},[],{"trials":10237,"activeCount":101},[],{"trials":10239,"activeCount":101},[],{"trials":10241,"activeCount":101},[],{"intervention":6517,"totalTrials":97,"cells":10243},{"EARLY_PHASE1":10244,"PHASE1":10246,"PHASE2":10252,"PHASE3":10254,"PHASE4":10256,"NA":10258},{"trials":10245,"activeCount":101},[],{"trials":10247,"activeCount":101},[10248],{"nctId":6506,"briefTitle":6507,"status":147,"phases":10249,"primaryCompletion":2755,"completion":2755,"start":6509,"enrollment":6510,"conditions":10250,"interventions":10251},[89],[6512],[6514,6515,6516,6517],{"trials":10253,"activeCount":101},[],{"trials":10255,"activeCount":101},[],{"trials":10257,"activeCount":101},[],{"trials":10259,"activeCount":101},[],{"intervention":10261,"totalTrials":97,"cells":10262},"CP 870,893",{"EARLY_PHASE1":10263,"PHASE1":10265,"PHASE2":10276,"PHASE3":10278,"PHASE4":10280,"NA":10282},{"trials":10264,"activeCount":101},[],{"trials":10266,"activeCount":101},[10267],{"nctId":10268,"briefTitle":10269,"status":147,"phases":10270,"primaryCompletion":7167,"completion":10271,"start":1355,"enrollment":27,"conditions":10272,"interventions":10273},"NCT01008527","Phase I Oncovir Poly IC:LC and NY-ESO-1\u002Fgp100",[89],"2015-09",[32],[10261,10274,10275],"Peptides","Oncovir poly IC:LC",{"trials":10277,"activeCount":101},[],{"trials":10279,"activeCount":101},[],{"trials":10281,"activeCount":101},[],{"trials":10283,"activeCount":101},[],{"intervention":10274,"totalTrials":97,"cells":10285},{"EARLY_PHASE1":10286,"PHASE1":10288,"PHASE2":10294,"PHASE3":10296,"PHASE4":10298,"NA":10300},{"trials":10287,"activeCount":101},[],{"trials":10289,"activeCount":101},[10290],{"nctId":10268,"briefTitle":10269,"status":147,"phases":10291,"primaryCompletion":7167,"completion":10271,"start":1355,"enrollment":27,"conditions":10292,"interventions":10293},[89],[32],[10261,10274,10275],{"trials":10295,"activeCount":101},[],{"trials":10297,"activeCount":101},[],{"trials":10299,"activeCount":101},[],{"trials":10301,"activeCount":101},[],{"intervention":10275,"totalTrials":97,"cells":10303},{"EARLY_PHASE1":10304,"PHASE1":10306,"PHASE2":10312,"PHASE3":10314,"PHASE4":10316,"NA":10318},{"trials":10305,"activeCount":101},[],{"trials":10307,"activeCount":101},[10308],{"nctId":10268,"briefTitle":10269,"status":147,"phases":10309,"primaryCompletion":7167,"completion":10271,"start":1355,"enrollment":27,"conditions":10310,"interventions":10311},[89],[32],[10261,10274,10275],{"trials":10313,"activeCount":101},[],{"trials":10315,"activeCount":101},[],{"trials":10317,"activeCount":101},[],{"trials":10319,"activeCount":101},[],{"intervention":1634,"totalTrials":97,"cells":10321},{"EARLY_PHASE1":10322,"PHASE1":10324,"PHASE2":10330,"PHASE3":10332,"PHASE4":10334,"NA":10336},{"trials":10323,"activeCount":101},[],{"trials":10325,"activeCount":101},[10326],{"nctId":1621,"briefTitle":1622,"status":147,"phases":10327,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1627,"conditions":10328,"interventions":10329},[89],[26,283,1629,1630,1631,1632],[1634,619,622,620],{"trials":10331,"activeCount":101},[],{"trials":10333,"activeCount":101},[],{"trials":10335,"activeCount":101},[],{"trials":10337,"activeCount":101},[],{"intervention":760,"totalTrials":97,"cells":10339},{"EARLY_PHASE1":10340,"PHASE1":10342,"PHASE2":10348,"PHASE3":10350,"PHASE4":10352,"NA":10354},{"trials":10341,"activeCount":101},[],{"trials":10343,"activeCount":101},[10344],{"nctId":743,"briefTitle":744,"status":147,"phases":10345,"primaryCompletion":746,"completion":747,"start":748,"enrollment":544,"conditions":10346,"interventions":10347},[89],[750,751,752,753,754,755,756,21],[158,758,157,759,760,761],{"trials":10349,"activeCount":101},[],{"trials":10351,"activeCount":101},[],{"trials":10353,"activeCount":101},[],{"trials":10355,"activeCount":101},[],{"intervention":5939,"totalTrials":97,"cells":10357},{"EARLY_PHASE1":10358,"PHASE1":10360,"PHASE2":10366,"PHASE3":10368,"PHASE4":10370,"NA":10372},{"trials":10359,"activeCount":101},[],{"trials":10361,"activeCount":101},[10362],{"nctId":5929,"briefTitle":5930,"status":147,"phases":10363,"primaryCompletion":5932,"completion":5932,"start":5933,"enrollment":556,"conditions":10364,"interventions":10365},[89],[5935,5936,5937],[5939,759,5922],{"trials":10367,"activeCount":101},[],{"trials":10369,"activeCount":101},[],{"trials":10371,"activeCount":101},[],{"trials":10373,"activeCount":101},[],{"intervention":1456,"totalTrials":97,"cells":10375},{"EARLY_PHASE1":10376,"PHASE1":10378,"PHASE2":10384,"PHASE3":10386,"PHASE4":10388,"NA":10390},{"trials":10377,"activeCount":101},[],{"trials":10379,"activeCount":101},[10380],{"nctId":1447,"briefTitle":1448,"status":147,"phases":10381,"primaryCompletion":1450,"completion":1451,"start":1452,"enrollment":151,"conditions":10382,"interventions":10383},[89],[1454],[1456,62],{"trials":10385,"activeCount":101},[],{"trials":10387,"activeCount":101},[],{"trials":10389,"activeCount":101},[],{"trials":10391,"activeCount":101},[],{"intervention":10393,"totalTrials":97,"cells":10394},"Cultured Treg cells",{"EARLY_PHASE1":10395,"PHASE1":10397,"PHASE2":10407,"PHASE3":10409,"PHASE4":10411,"NA":10413},{"trials":10396,"activeCount":101},[],{"trials":10398,"activeCount":101},[10399],{"nctId":10400,"briefTitle":10401,"status":147,"phases":10402,"primaryCompletion":10403,"completion":10403,"start":10404,"enrollment":4750,"conditions":10405,"interventions":10406},"NCT01795573","Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease",[89],"2020-08-14","2014-10-29",[869],[10393],{"trials":10408,"activeCount":101},[],{"trials":10410,"activeCount":101},[],{"trials":10412,"activeCount":101},[],{"trials":10414,"activeCount":101},[],{"intervention":2360,"totalTrials":97,"cells":10416},{"EARLY_PHASE1":10417,"PHASE1":10419,"PHASE2":10425,"PHASE3":10427,"PHASE4":10429,"NA":10431},{"trials":10418,"activeCount":101},[],{"trials":10420,"activeCount":101},[10421],{"nctId":2352,"briefTitle":2353,"status":147,"phases":10422,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":336,"conditions":10423,"interventions":10424},[89],[15],[2360,619],{"trials":10426,"activeCount":101},[],{"trials":10428,"activeCount":101},[],{"trials":10430,"activeCount":101},[],{"trials":10432,"activeCount":101},[],{"intervention":10434,"totalTrials":97,"cells":10435},"Sylatron",{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10450,"PHASE3":10452,"PHASE4":10454,"NA":10456},{"trials":10437,"activeCount":101},[],{"trials":10439,"activeCount":101},[10440],{"nctId":10441,"briefTitle":10442,"status":147,"phases":10443,"primaryCompletion":10444,"completion":10445,"start":10446,"enrollment":1531,"conditions":10447,"interventions":10448},"NCT01496807","Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma",[89],"2016-03-16","2016-08-29","2012-02-17",[32],[10434,10449],"Yervoy",{"trials":10451,"activeCount":101},[],{"trials":10453,"activeCount":101},[],{"trials":10455,"activeCount":101},[],{"trials":10457,"activeCount":101},[],{"intervention":10449,"totalTrials":97,"cells":10459},{"EARLY_PHASE1":10460,"PHASE1":10462,"PHASE2":10468,"PHASE3":10470,"PHASE4":10472,"NA":10474},{"trials":10461,"activeCount":101},[],{"trials":10463,"activeCount":101},[10464],{"nctId":10441,"briefTitle":10442,"status":147,"phases":10465,"primaryCompletion":10444,"completion":10445,"start":10446,"enrollment":1531,"conditions":10466,"interventions":10467},[89],[32],[10434,10449],{"trials":10469,"activeCount":101},[],{"trials":10471,"activeCount":101},[],{"trials":10473,"activeCount":101},[],{"trials":10475,"activeCount":101},[],{"intervention":10477,"totalTrials":97,"cells":10478},"Oral Etoposide",{"EARLY_PHASE1":10479,"PHASE1":10481,"PHASE2":10490,"PHASE3":10492,"PHASE4":10494,"NA":10496},{"trials":10480,"activeCount":101},[],{"trials":10482,"activeCount":101},[10483],{"nctId":10484,"briefTitle":10485,"status":147,"phases":10486,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":445,"conditions":10487,"interventions":10488},"NCT00006047","Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide",[89],[2344],[10477,10489],"Oral 9-Nitrocamptothecin",{"trials":10491,"activeCount":101},[],{"trials":10493,"activeCount":101},[],{"trials":10495,"activeCount":101},[],{"trials":10497,"activeCount":101},[],{"intervention":10489,"totalTrials":97,"cells":10499},{"EARLY_PHASE1":10500,"PHASE1":10502,"PHASE2":10508,"PHASE3":10510,"PHASE4":10512,"NA":10514},{"trials":10501,"activeCount":101},[],{"trials":10503,"activeCount":101},[10504],{"nctId":10484,"briefTitle":10485,"status":147,"phases":10505,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":445,"conditions":10506,"interventions":10507},[89],[2344],[10477,10489],{"trials":10509,"activeCount":101},[],{"trials":10511,"activeCount":101},[],{"trials":10513,"activeCount":101},[],{"trials":10515,"activeCount":101},[],{"intervention":10517,"totalTrials":97,"cells":10518},"bleomycin sulfate",{"EARLY_PHASE1":10519,"PHASE1":10521,"PHASE2":10530,"PHASE3":10532,"PHASE4":10534,"NA":10536},{"trials":10520,"activeCount":101},[],{"trials":10522,"activeCount":101},[10523],{"nctId":10524,"briefTitle":10525,"status":7800,"phases":10526,"start":2342,"conditions":10527,"interventions":10528},"NCT00006035","Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma",[89],[153],[10517,10529],"electroporation therapy",{"trials":10531,"activeCount":101},[],{"trials":10533,"activeCount":101},[],{"trials":10535,"activeCount":101},[],{"trials":10537,"activeCount":101},[],{"intervention":10529,"totalTrials":97,"cells":10539},{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10548,"PHASE3":10550,"PHASE4":10552,"NA":10554},{"trials":10541,"activeCount":101},[],{"trials":10543,"activeCount":101},[10544],{"nctId":10524,"briefTitle":10525,"status":7800,"phases":10545,"start":2342,"conditions":10546,"interventions":10547},[89],[153],[10517,10529],{"trials":10549,"activeCount":101},[],{"trials":10551,"activeCount":101},[],{"trials":10553,"activeCount":101},[],{"trials":10555,"activeCount":101},[],{"intervention":10557,"totalTrials":97,"cells":10558},"Avelumab",{"EARLY_PHASE1":10559,"PHASE1":10561,"PHASE2":10573,"PHASE3":10575,"PHASE4":10577,"NA":10579},{"trials":10560,"activeCount":101},[],{"trials":10562,"activeCount":101},[10563],{"nctId":10564,"briefTitle":10565,"status":147,"phases":10566,"primaryCompletion":10567,"completion":10568,"start":10569,"enrollment":33,"conditions":10570,"interventions":10572},"NCT03719768","Avelumab With Radiotherapy in Patients With Leptomeningeal Disease",[89],"2022-07-19","2024-08-21","2019-06-10",[10571,1234],"Leptomeningeal Metastases",[10557],{"trials":10574,"activeCount":101},[],{"trials":10576,"activeCount":101},[],{"trials":10578,"activeCount":101},[],{"trials":10580,"activeCount":101},[],{"intervention":9481,"totalTrials":97,"cells":10582},{"EARLY_PHASE1":10583,"PHASE1":10585,"PHASE2":10591,"PHASE3":10593,"PHASE4":10595,"NA":10597},{"trials":10584,"activeCount":101},[],{"trials":10586,"activeCount":101},[10587],{"nctId":9473,"briefTitle":9474,"status":147,"phases":10588,"primaryCompletion":9476,"completion":9476,"start":9477,"enrollment":9478,"conditions":10589,"interventions":10590},[89],[153],[9481,9482,9483,326,9484,9485],{"trials":10592,"activeCount":101},[],{"trials":10594,"activeCount":101},[],{"trials":10596,"activeCount":101},[],{"trials":10598,"activeCount":101},[],{"intervention":9482,"totalTrials":97,"cells":10600},{"EARLY_PHASE1":10601,"PHASE1":10603,"PHASE2":10609,"PHASE3":10611,"PHASE4":10613,"NA":10615},{"trials":10602,"activeCount":101},[],{"trials":10604,"activeCount":101},[10605],{"nctId":9473,"briefTitle":9474,"status":147,"phases":10606,"primaryCompletion":9476,"completion":9476,"start":9477,"enrollment":9478,"conditions":10607,"interventions":10608},[89],[153],[9481,9482,9483,326,9484,9485],{"trials":10610,"activeCount":101},[],{"trials":10612,"activeCount":101},[],{"trials":10614,"activeCount":101},[],{"trials":10616,"activeCount":101},[],{"intervention":9483,"totalTrials":97,"cells":10618},{"EARLY_PHASE1":10619,"PHASE1":10621,"PHASE2":10627,"PHASE3":10629,"PHASE4":10631,"NA":10633},{"trials":10620,"activeCount":101},[],{"trials":10622,"activeCount":101},[10623],{"nctId":9473,"briefTitle":9474,"status":147,"phases":10624,"primaryCompletion":9476,"completion":9476,"start":9477,"enrollment":9478,"conditions":10625,"interventions":10626},[89],[153],[9481,9482,9483,326,9484,9485],{"trials":10628,"activeCount":101},[],{"trials":10630,"activeCount":101},[],{"trials":10632,"activeCount":101},[],{"trials":10634,"activeCount":101},[],{"intervention":9484,"totalTrials":97,"cells":10636},{"EARLY_PHASE1":10637,"PHASE1":10639,"PHASE2":10645,"PHASE3":10647,"PHASE4":10649,"NA":10651},{"trials":10638,"activeCount":101},[],{"trials":10640,"activeCount":101},[10641],{"nctId":9473,"briefTitle":9474,"status":147,"phases":10642,"primaryCompletion":9476,"completion":9476,"start":9477,"enrollment":9478,"conditions":10643,"interventions":10644},[89],[153],[9481,9482,9483,326,9484,9485],{"trials":10646,"activeCount":101},[],{"trials":10648,"activeCount":101},[],{"trials":10650,"activeCount":101},[],{"trials":10652,"activeCount":101},[],{"intervention":9485,"totalTrials":97,"cells":10654},{"EARLY_PHASE1":10655,"PHASE1":10657,"PHASE2":10663,"PHASE3":10665,"PHASE4":10667,"NA":10669},{"trials":10656,"activeCount":101},[],{"trials":10658,"activeCount":101},[10659],{"nctId":9473,"briefTitle":9474,"status":147,"phases":10660,"primaryCompletion":9476,"completion":9476,"start":9477,"enrollment":9478,"conditions":10661,"interventions":10662},[89],[153],[9481,9482,9483,326,9484,9485],{"trials":10664,"activeCount":101},[],{"trials":10666,"activeCount":101},[],{"trials":10668,"activeCount":101},[],{"trials":10670,"activeCount":101},[],{"intervention":10672,"totalTrials":97,"cells":10673},"Eltrombopag",{"EARLY_PHASE1":10674,"PHASE1":10676,"PHASE2":10688,"PHASE3":10690,"PHASE4":10692,"NA":10694},{"trials":10675,"activeCount":101},[],{"trials":10677,"activeCount":101},[10678],{"nctId":10679,"briefTitle":10680,"status":249,"phases":10681,"primaryCompletion":10682,"completion":10683,"start":10684,"enrollment":645,"conditions":10685,"interventions":10687},"NCT01286038","Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia",[89],"2017-11-03","2018-11-03","2011-04-06",[7230,10686],"Thrombocytopenia",[10672],{"trials":10689,"activeCount":101},[],{"trials":10691,"activeCount":101},[],{"trials":10693,"activeCount":101},[],{"trials":10695,"activeCount":101},[],{"intervention":1569,"totalTrials":97,"cells":10697},{"EARLY_PHASE1":10698,"PHASE1":10700,"PHASE2":10706,"PHASE3":10708,"PHASE4":10710,"NA":10712},{"trials":10699,"activeCount":101},[],{"trials":10701,"activeCount":101},[10702],{"nctId":1561,"briefTitle":1562,"status":147,"phases":10703,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":182,"conditions":10704,"interventions":10705},[89],[733],[1559,803,888,1569,804,1570],{"trials":10707,"activeCount":101},[],{"trials":10709,"activeCount":101},[],{"trials":10711,"activeCount":101},[],{"trials":10713,"activeCount":101},[],{"intervention":1570,"totalTrials":97,"cells":10715},{"EARLY_PHASE1":10716,"PHASE1":10718,"PHASE2":10724,"PHASE3":10726,"PHASE4":10728,"NA":10730},{"trials":10717,"activeCount":101},[],{"trials":10719,"activeCount":101},[10720],{"nctId":1561,"briefTitle":1562,"status":147,"phases":10721,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":182,"conditions":10722,"interventions":10723},[89],[733],[1559,803,888,1569,804,1570],{"trials":10725,"activeCount":101},[],{"trials":10727,"activeCount":101},[],{"trials":10729,"activeCount":101},[],{"trials":10731,"activeCount":101},[],{"intervention":325,"totalTrials":97,"cells":10733},{"EARLY_PHASE1":10734,"PHASE1":10736,"PHASE2":10742,"PHASE3":10744,"PHASE4":10746,"NA":10748},{"trials":10735,"activeCount":101},[],{"trials":10737,"activeCount":101},[10738],{"nctId":316,"briefTitle":317,"status":147,"phases":10739,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":10740,"interventions":10741},[89],[153],[325,52,326,327,172],{"trials":10743,"activeCount":101},[],{"trials":10745,"activeCount":101},[],{"trials":10747,"activeCount":101},[],{"trials":10749,"activeCount":101},[],{"intervention":327,"totalTrials":97,"cells":10751},{"EARLY_PHASE1":10752,"PHASE1":10754,"PHASE2":10760,"PHASE3":10762,"PHASE4":10764,"NA":10766},{"trials":10753,"activeCount":101},[],{"trials":10755,"activeCount":101},[10756],{"nctId":316,"briefTitle":317,"status":147,"phases":10757,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":10758,"interventions":10759},[89],[153],[325,52,326,327,172],{"trials":10761,"activeCount":101},[],{"trials":10763,"activeCount":101},[],{"trials":10765,"activeCount":101},[],{"trials":10767,"activeCount":101},[],{"intervention":10769,"totalTrials":97,"cells":10770},"Pramlintide",{"EARLY_PHASE1":10771,"PHASE1":10781,"PHASE2":10783,"PHASE3":10785,"PHASE4":10787,"NA":10789},{"trials":10772,"activeCount":101},[10773],{"nctId":10774,"briefTitle":10775,"status":345,"phases":10776,"primaryCompletion":10777,"completion":10777,"start":10778,"enrollment":101,"conditions":10779,"interventions":10780},"NCT04252612","Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study",[88],"2023-06-26","2020-01-30",[4551],[10769],{"trials":10782,"activeCount":101},[],{"trials":10784,"activeCount":101},[],{"trials":10786,"activeCount":101},[],{"trials":10788,"activeCount":101},[],{"trials":10790,"activeCount":101},[],{"intervention":156,"totalTrials":97,"cells":10792},{"EARLY_PHASE1":10793,"PHASE1":10799,"PHASE2":10801,"PHASE3":10803,"PHASE4":10805,"NA":10807},{"trials":10794,"activeCount":101},[10795],{"nctId":145,"briefTitle":146,"status":147,"phases":10796,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":10797,"interventions":10798},[88],[153,154],[52,156,157,158,159,160],{"trials":10800,"activeCount":101},[],{"trials":10802,"activeCount":101},[],{"trials":10804,"activeCount":101},[],{"trials":10806,"activeCount":101},[],{"trials":10808,"activeCount":101},[],{"intervention":10810,"totalTrials":97,"cells":10811},"Fermented Wheat Germ Extract",{"EARLY_PHASE1":10812,"PHASE1":10822,"PHASE2":10824,"PHASE3":10826,"PHASE4":10828,"NA":10830},{"trials":10813,"activeCount":101},[10814],{"nctId":10815,"briefTitle":10816,"status":249,"phases":10817,"primaryCompletion":666,"completion":10818,"start":10819,"enrollment":730,"conditions":10820,"interventions":10821},"NCT02411565","Fermented Wheat Germ Extract in Women With Ovarian Cancer",[88],"2018-01-08","2016-03-01",[632],[10810],{"trials":10823,"activeCount":101},[],{"trials":10825,"activeCount":101},[],{"trials":10827,"activeCount":101},[],{"trials":10829,"activeCount":101},[],{"trials":10831,"activeCount":101},[],{"intervention":10833,"totalTrials":97,"cells":10834},"Mogamulizumab-Kpkc",{"EARLY_PHASE1":10835,"PHASE1":10846,"PHASE2":10848,"PHASE3":10850,"PHASE4":10852,"NA":10854},{"trials":10836,"activeCount":101},[10837],{"nctId":10838,"briefTitle":10839,"status":552,"phases":10840,"primaryCompletion":10841,"completion":10842,"start":265,"enrollment":281,"conditions":10843,"interventions":10845},"NCT06235281","Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)",[88],"2026-09-01","2029-09-01",[10844],"Mycosis Fungoides",[10833],{"trials":10847,"activeCount":101},[],{"trials":10849,"activeCount":101},[],{"trials":10851,"activeCount":101},[],{"trials":10853,"activeCount":101},[],{"trials":10855,"activeCount":101},[],{"intervention":4647,"totalTrials":97,"cells":10857},{"EARLY_PHASE1":10858,"PHASE1":10864,"PHASE2":10866,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10859,"activeCount":101},[10860],{"nctId":4636,"briefTitle":4637,"status":147,"phases":10861,"primaryCompletion":4639,"completion":4640,"start":4641,"enrollment":1531,"conditions":10862,"interventions":10863},[88],[15,1207,1206,4643,1190,3871,4644,4645],[4631,4647],{"trials":10865,"activeCount":101},[],{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":101},[],{"trials":10871,"activeCount":101},[],{"trials":10873,"activeCount":101},[],{"intervention":10875,"totalTrials":97,"cells":10876},"2-deoxy-2-[18F]fluoro-D-glucose",{"EARLY_PHASE1":10877,"PHASE1":10887,"PHASE2":10889,"PHASE3":10891,"PHASE4":10893,"NA":10895},{"trials":10878,"activeCount":101},[10879],{"nctId":10880,"briefTitle":10881,"status":345,"phases":10882,"primaryCompletion":7288,"completion":7289,"start":2253,"enrollment":101,"conditions":10883,"interventions":10886},"NCT03295695","PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient",[88],[15,10884,1206,10885],"Breast Cancer, Female","Breast Neoplasms",[10875],{"trials":10888,"activeCount":101},[],{"trials":10890,"activeCount":101},[],{"trials":10892,"activeCount":101},[],{"trials":10894,"activeCount":101},[],{"trials":10896,"activeCount":101},[],{"intervention":2811,"totalTrials":97,"cells":10898},{"EARLY_PHASE1":10899,"PHASE1":10905,"PHASE2":10907,"PHASE3":10909,"PHASE4":10911,"NA":10913},{"trials":10900,"activeCount":101},[10901],{"nctId":2803,"briefTitle":2804,"status":147,"phases":10902,"primaryCompletion":2806,"completion":2807,"start":2808,"enrollment":566,"conditions":10903,"interventions":10904},[88],[15],[2811,2798],{"trials":10906,"activeCount":101},[],{"trials":10908,"activeCount":101},[],{"trials":10910,"activeCount":101},[],{"trials":10912,"activeCount":101},[],{"trials":10914,"activeCount":101},[],{"intervention":9404,"totalTrials":97,"cells":10916},{"EARLY_PHASE1":10917,"PHASE1":10923,"PHASE2":10925,"PHASE3":10927,"PHASE4":10929,"NA":10931},{"trials":10918,"activeCount":101},[10919],{"nctId":9397,"briefTitle":9398,"status":147,"phases":10920,"primaryCompletion":5647,"completion":9400,"start":9401,"enrollment":182,"conditions":10921,"interventions":10922},[88],[21],[9404,9405,9392],{"trials":10924,"activeCount":101},[],{"trials":10926,"activeCount":101},[],{"trials":10928,"activeCount":101},[],{"trials":10930,"activeCount":101},[],{"trials":10932,"activeCount":101},[],{"intervention":9405,"totalTrials":97,"cells":10934},{"EARLY_PHASE1":10935,"PHASE1":10941,"PHASE2":10943,"PHASE3":10945,"PHASE4":10947,"NA":10949},{"trials":10936,"activeCount":101},[10937],{"nctId":9397,"briefTitle":9398,"status":147,"phases":10938,"primaryCompletion":5647,"completion":9400,"start":9401,"enrollment":182,"conditions":10939,"interventions":10940},[88],[21],[9404,9405,9392],{"trials":10942,"activeCount":101},[],{"trials":10944,"activeCount":101},[],{"trials":10946,"activeCount":101},[],{"trials":10948,"activeCount":101},[],{"trials":10950,"activeCount":101},[],{"intervention":10952,"totalTrials":97,"cells":10953},"Pimonidazole",{"EARLY_PHASE1":10954,"PHASE1":10966,"PHASE2":10968,"PHASE3":10970,"PHASE4":10972,"NA":10974},{"trials":10955,"activeCount":101},[10956],{"nctId":10957,"briefTitle":10958,"status":345,"phases":10959,"primaryCompletion":10960,"completion":10961,"start":10962,"enrollment":101,"conditions":10963,"interventions":10965},"NCT03718650","Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer",[88],"2022-04-01","2023-04-01","2021-04-01",[24,10964],"Resectable Pancreatic Cancer",[10952],{"trials":10967,"activeCount":101},[],{"trials":10969,"activeCount":101},[],{"trials":10971,"activeCount":101},[],{"trials":10973,"activeCount":101},[],{"trials":10975,"activeCount":101},[],{"intervention":10977,"totalTrials":97,"cells":10978},"Insulin",{"EARLY_PHASE1":10979,"PHASE1":10990,"PHASE2":10992,"PHASE3":10994,"PHASE4":10996,"NA":10998},{"trials":10980,"activeCount":101},[10981],{"nctId":10982,"briefTitle":10983,"status":147,"phases":10984,"primaryCompletion":10985,"completion":5522,"start":10986,"enrollment":253,"conditions":10987,"interventions":10989},"NCT03904199","Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia",[88],"2020-10-14","2019-04-04",[10988],"Hyperglycemia",[10977],{"trials":10991,"activeCount":101},[],{"trials":10993,"activeCount":101},[],{"trials":10995,"activeCount":101},[],{"trials":10997,"activeCount":101},[],{"trials":10999,"activeCount":101},[],{"intervention":11001,"totalTrials":97,"cells":11002},"Siltuximab",{"EARLY_PHASE1":11003,"PHASE1":11014,"PHASE2":11016,"PHASE3":11018,"PHASE4":11020,"NA":11022},{"trials":11004,"activeCount":101},[11005],{"nctId":11006,"briefTitle":11007,"status":249,"phases":11008,"primaryCompletion":11009,"completion":11009,"start":11010,"enrollment":487,"conditions":11011,"interventions":11013},"NCT05316116","Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)",[88],"2024-10-18","2023-02-15",[11012],"Large Granular Lymphocyte Leukemia",[11001],{"trials":11015,"activeCount":101},[],{"trials":11017,"activeCount":101},[],{"trials":11019,"activeCount":101},[],{"trials":11021,"activeCount":101},[],{"trials":11023,"activeCount":101},[],{"intervention":4596,"totalTrials":487,"cells":11025},{"EARLY_PHASE1":11026,"PHASE1":11028,"PHASE2":11046,"PHASE3":11052,"PHASE4":11054,"NA":11056},{"trials":11027,"activeCount":101},[],{"trials":11029,"activeCount":101},[11030,11034,11038,11042],{"nctId":9338,"briefTitle":9339,"status":147,"phases":11031,"primaryCompletion":9341,"completion":9342,"start":9343,"enrollment":30,"conditions":11032,"interventions":11033},[89],[9345,6339],[4702,4596],{"nctId":5288,"briefTitle":5289,"status":147,"phases":11035,"primaryCompletion":4266,"completion":4266,"start":5291,"enrollment":1059,"conditions":11036,"interventions":11037},[89],[237],[809,4596],{"nctId":9737,"briefTitle":9738,"status":345,"phases":11039,"primaryCompletion":9740,"completion":9740,"start":9741,"enrollment":101,"conditions":11040,"interventions":11041},[89],[9743,9744,6339],[4596,9730],{"nctId":6572,"briefTitle":6573,"status":147,"phases":11043,"primaryCompletion":2095,"completion":6575,"start":2096,"enrollment":1095,"conditions":11044,"interventions":11045},[89],[5400],[4596,1350],{"trials":11047,"activeCount":101},[11048],{"nctId":4583,"briefTitle":4584,"status":249,"phases":11049,"primaryCompletion":4586,"completion":579,"start":4587,"enrollment":487,"conditions":11050,"interventions":11051},[90],[4589,4590,4591,4592,4593,4594],[672,4596,808,4597],{"trials":11053,"activeCount":101},[],{"trials":11055,"activeCount":101},[],{"trials":11057,"activeCount":101},[11058],{"nctId":11059,"briefTitle":11060,"status":249,"phases":11061,"primaryCompletion":11062,"completion":11062,"start":8765,"enrollment":189,"conditions":11063,"interventions":11065},"NCT00964743","Depocyt® With Sorafenib in Neoplastic Meningitis",[93],"2011-02",[11064],"Neoplastic Meningitis",[11066,4596],"DepoCyt",{"intervention":758,"totalTrials":487,"cells":11068},{"EARLY_PHASE1":11069,"PHASE1":11071,"PHASE2":11077,"PHASE3":11091,"PHASE4":11093,"NA":11099},{"trials":11070,"activeCount":101},[],{"trials":11072,"activeCount":101},[11073],{"nctId":743,"briefTitle":744,"status":147,"phases":11074,"primaryCompletion":746,"completion":747,"start":748,"enrollment":544,"conditions":11075,"interventions":11076},[89],[750,751,752,753,754,755,756,21],[158,758,157,759,760,761],{"trials":11078,"activeCount":101},[11079,11083,11087],{"nctId":827,"briefTitle":828,"status":147,"phases":11080,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":11081,"interventions":11082},[90],[834,35,835,755,836],[838,157,839],{"nctId":1784,"briefTitle":1785,"status":147,"phases":11084,"primaryCompletion":1374,"completion":1787,"start":830,"enrollment":630,"conditions":11085,"interventions":11086},[90],[1789],[1791,758,1756],{"nctId":890,"briefTitle":891,"status":249,"phases":11088,"primaryCompletion":893,"completion":893,"start":894,"conditions":11089,"interventions":11090},[90],[834,869,35,870,755],[872,838,860,875,897,898,876],{"trials":11092,"activeCount":101},[],{"trials":11094,"activeCount":101},[11095],{"nctId":1167,"briefTitle":1168,"status":147,"phases":11096,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":930,"conditions":11097,"interventions":11098},[92],[755,1173,1174,885,858],[758,158],{"trials":11100,"activeCount":101},[11101],{"nctId":11102,"briefTitle":11103,"status":249,"phases":11104,"primaryCompletion":11105,"completion":11105,"start":8522,"enrollment":730,"conditions":11106,"interventions":11108},"NCT00363467","Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation",[93],"2009-05",[11107],"Acute Myeloid Leukemia (AML)",[11109,11110,758],"G-CSF","Leukapheresis",{"intervention":11112,"totalTrials":730,"cells":11113},"Sodium Bicarbonate",{"EARLY_PHASE1":11114,"PHASE1":11116,"PHASE2":11136,"PHASE3":11138,"PHASE4":11140,"NA":11142},{"trials":11115,"activeCount":101},[],{"trials":11117,"activeCount":101},[11118,11132],{"nctId":11119,"briefTitle":11120,"status":249,"phases":11121,"primaryCompletion":4267,"completion":11122,"start":7167,"enrollment":253,"conditions":11123,"interventions":11131},"NCT01846429","Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain",[89],"2015-05",[11124,11125,11126,11127,11128,11129,21,858,11130],"Tumor","Cancer","Pain","Malignant Solid Tumor","Unresectable Malignant Neoplasm","Hematologic Malignancy","Neoplasm Metastasis",[11112],{"nctId":2135,"briefTitle":2136,"status":147,"phases":11133,"primaryCompletion":2096,"completion":2096,"start":2138,"enrollment":2139,"conditions":11134,"interventions":11135},[89],[24],[2142,1246],{"trials":11137,"activeCount":101},[],{"trials":11139,"activeCount":101},[],{"trials":11141,"activeCount":101},[],{"trials":11143,"activeCount":101},[11144],{"nctId":11145,"briefTitle":11146,"status":249,"phases":11147,"primaryCompletion":1363,"completion":1363,"start":2138,"enrollment":189,"conditions":11148,"interventions":11150},"NCT01350583","Bicarbonate for Tumor Related Pain",[93],[11149],"Neoplasm Related Pain (Acute) (Chronic)",[11112],{"intervention":11152,"totalTrials":189,"cells":11153},"Varenicline",{"EARLY_PHASE1":11154,"PHASE1":11167,"PHASE2":11169,"PHASE3":11171,"PHASE4":11173,"NA":11175},{"trials":11155,"activeCount":101},[11156],{"nctId":11157,"briefTitle":11158,"status":147,"phases":11159,"primaryCompletion":11160,"completion":11161,"start":11162,"enrollment":11163,"conditions":11164,"interventions":11166},"NCT02202499","Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence",[88],"2015-12-11","2019-06-14","2014-07-17",86,[29,11165],"Tobacco Dependence",[11152],{"trials":11168,"activeCount":101},[],{"trials":11170,"activeCount":101},[],{"trials":11172,"activeCount":101},[],{"trials":11174,"activeCount":101},[],{"trials":11176,"activeCount":101},[11177],{"nctId":11178,"briefTitle":11179,"status":147,"phases":11180,"primaryCompletion":2138,"completion":2138,"start":948,"enrollment":6921,"conditions":11181,"interventions":11182},"NCT00747643","Varenicline Effects on Cue Reactivity and Smoking Reward\u002FReinforcement",[93],[11165],[11183],"varenicline",{"intervention":1305,"totalTrials":189,"cells":11185},{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11196,"PHASE4":11198,"NA":11200},{"trials":11187,"activeCount":101},[],{"trials":11189,"activeCount":101},[],{"trials":11191,"activeCount":101},[11192],{"nctId":1297,"briefTitle":1298,"status":147,"phases":11193,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":445,"conditions":11194,"interventions":11195},[90],[242],[1304,1305],{"trials":11197,"activeCount":101},[],{"trials":11199,"activeCount":101},[],{"trials":11201,"activeCount":101},[11202],{"nctId":11203,"briefTitle":11204,"status":249,"phases":11205,"primaryCompletion":11206,"completion":8089,"start":9008,"enrollment":630,"conditions":11207,"interventions":11208},"NCT00104728","Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates",[93],"2008-05",[26],[1305],{"intervention":11210,"totalTrials":189,"cells":11211},"brentuximab vedotin",{"EARLY_PHASE1":11212,"PHASE1":11214,"PHASE2":11216,"PHASE3":11218,"PHASE4":11220,"NA":11222},{"trials":11213,"activeCount":101},[],{"trials":11215,"activeCount":101},[],{"trials":11217,"activeCount":101},[],{"trials":11219,"activeCount":101},[],{"trials":11221,"activeCount":101},[],{"trials":11223,"activeCount":101},[11224,11230],{"nctId":11225,"briefTitle":11226,"status":345,"phases":11227,"primaryCompletion":2719,"completion":2719,"start":9284,"enrollment":101,"conditions":11228,"interventions":11229},"NCT01671813","Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly",[93],[858],[11210],{"nctId":11231,"briefTitle":11232,"status":249,"phases":11233,"primaryCompletion":11234,"completion":6132,"start":11235,"enrollment":97,"conditions":11236,"interventions":11238},"NCT01841021","Pilot Study of Brentuximab Vedotin in Relapsed\u002FRefractory Peripheral T-Cell Lymphoma Expressing CD30",[93],"2016-05","2014-04",[11237],"Peripheral T-Cell Lymphoma",[11239],"Brentuximab vedotin",{"intervention":11241,"totalTrials":189,"cells":11242},"1-methyl-D-tryptophan",{"EARLY_PHASE1":11243,"PHASE1":11245,"PHASE2":11247,"PHASE3":11253,"PHASE4":11255,"NA":11257},{"trials":11244,"activeCount":101},[],{"trials":11246,"activeCount":101},[],{"trials":11248,"activeCount":101},[11249],{"nctId":7942,"briefTitle":7943,"status":147,"phases":11250,"primaryCompletion":7945,"completion":7946,"start":7947,"enrollment":445,"conditions":11251,"interventions":11252},[89,90],[7949,7950,7951,2344],[7933,7953],{"trials":11254,"activeCount":101},[],{"trials":11256,"activeCount":101},[],{"trials":11258,"activeCount":101},[11259],{"nctId":11260,"briefTitle":11261,"status":345,"phases":11262,"primaryCompletion":4267,"completion":4267,"start":5291,"enrollment":101,"conditions":11263,"interventions":11264},"NCT01302821","C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer",[93],[15],[11265,11241],"Adenovirus-p53 transduced dendritic cell vaccine",{"intervention":11267,"totalTrials":189,"cells":11268},"Dasatinib",{"EARLY_PHASE1":11269,"PHASE1":11271,"PHASE2":11273,"PHASE3":11282,"PHASE4":11284,"NA":11286},{"trials":11270,"activeCount":101},[],{"trials":11272,"activeCount":101},[],{"trials":11274,"activeCount":101},[11275],{"nctId":11276,"briefTitle":11277,"status":249,"phases":11278,"primaryCompletion":11279,"completion":11279,"start":8089,"enrollment":507,"conditions":11280,"interventions":11281},"NCT00858403","Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation",[90],"2010-07",[26],[11267],{"trials":11283,"activeCount":101},[],{"trials":11285,"activeCount":101},[],{"trials":11287,"activeCount":101},[11288],{"nctId":11289,"briefTitle":11290,"status":147,"phases":11291,"primaryCompletion":1363,"completion":1363,"start":11292,"enrollment":1095,"conditions":11293,"interventions":11294},"NCT00624585","Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts",[93],"2008-02",[755],[11267],{"intervention":1062,"totalTrials":189,"cells":11296},{"EARLY_PHASE1":11297,"PHASE1":11299,"PHASE2":11301,"PHASE3":11303,"PHASE4":11305,"NA":11307},{"trials":11298,"activeCount":101},[],{"trials":11300,"activeCount":101},[],{"trials":11302,"activeCount":101},[],{"trials":11304,"activeCount":101},[],{"trials":11306,"activeCount":101},[],{"trials":11308,"activeCount":101},[11309,11313],{"nctId":1053,"briefTitle":1054,"status":147,"phases":11310,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":1059,"conditions":11311,"interventions":11312},[93],[169],[172,1062,1063,1064,1065,1066],{"nctId":11314,"briefTitle":11315,"status":147,"phases":11316,"primaryCompletion":11317,"completion":11318,"start":11319,"enrollment":336,"conditions":11320,"interventions":11321},"NCT01005745","Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma",[93],"2014-01-31","2025-08-18","2009-10-20",[169],[1062,1065],{"intervention":1065,"totalTrials":189,"cells":11323},{"EARLY_PHASE1":11324,"PHASE1":11326,"PHASE2":11328,"PHASE3":11330,"PHASE4":11332,"NA":11334},{"trials":11325,"activeCount":101},[],{"trials":11327,"activeCount":101},[],{"trials":11329,"activeCount":101},[],{"trials":11331,"activeCount":101},[],{"trials":11333,"activeCount":101},[],{"trials":11335,"activeCount":101},[11336,11340],{"nctId":1053,"briefTitle":1054,"status":147,"phases":11337,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":1059,"conditions":11338,"interventions":11339},[93],[169],[172,1062,1063,1064,1065,1066],{"nctId":11314,"briefTitle":11315,"status":147,"phases":11341,"primaryCompletion":11317,"completion":11318,"start":11319,"enrollment":336,"conditions":11342,"interventions":11343},[93],[169],[1062,1065],{"intervention":11345,"totalTrials":97,"cells":11346},"5-azacitidine",{"EARLY_PHASE1":11347,"PHASE1":11349,"PHASE2":11351,"PHASE3":11353,"PHASE4":11355,"NA":11357},{"trials":11348,"activeCount":101},[],{"trials":11350,"activeCount":101},[],{"trials":11352,"activeCount":101},[],{"trials":11354,"activeCount":101},[],{"trials":11356,"activeCount":101},[],{"trials":11358,"activeCount":101},[11359],{"nctId":11360,"briefTitle":11361,"status":147,"phases":11362,"primaryCompletion":2754,"completion":1215,"start":2306,"enrollment":1035,"conditions":11363,"interventions":11364},"NCT00660400","Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant",[93],[35],[11345],{"intervention":11366,"totalTrials":97,"cells":11367},"mRNA-1273",{"EARLY_PHASE1":11368,"PHASE1":11370,"PHASE2":11372,"PHASE3":11374,"PHASE4":11376,"NA":11378},{"trials":11369,"activeCount":101},[],{"trials":11371,"activeCount":101},[],{"trials":11373,"activeCount":101},[],{"trials":11375,"activeCount":101},[],{"trials":11377,"activeCount":101},[],{"trials":11379,"activeCount":101},[11380],{"nctId":11381,"briefTitle":11382,"status":147,"phases":11383,"primaryCompletion":11384,"completion":11385,"start":11386,"enrollment":11387,"conditions":11388,"interventions":11391},"NCT05054218","COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients",[],"2022-07-16","2022-08-29","2021-09-10",336,[11389,11390],"Covid19","SARS-CoV2 Infection",[11366],{"intervention":11109,"totalTrials":97,"cells":11393},{"EARLY_PHASE1":11394,"PHASE1":11396,"PHASE2":11398,"PHASE3":11400,"PHASE4":11402,"NA":11404},{"trials":11395,"activeCount":101},[],{"trials":11397,"activeCount":101},[],{"trials":11399,"activeCount":101},[],{"trials":11401,"activeCount":101},[],{"trials":11403,"activeCount":101},[],{"trials":11405,"activeCount":101},[11406],{"nctId":11102,"briefTitle":11103,"status":249,"phases":11407,"primaryCompletion":11105,"completion":11105,"start":8522,"enrollment":730,"conditions":11408,"interventions":11409},[93],[11107],[11109,11110,758],{"intervention":11110,"totalTrials":97,"cells":11411},{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11418,"PHASE4":11420,"NA":11422},{"trials":11413,"activeCount":101},[],{"trials":11415,"activeCount":101},[],{"trials":11417,"activeCount":101},[],{"trials":11419,"activeCount":101},[],{"trials":11421,"activeCount":101},[],{"trials":11423,"activeCount":101},[11424],{"nctId":11102,"briefTitle":11103,"status":249,"phases":11425,"primaryCompletion":11105,"completion":11105,"start":8522,"enrollment":730,"conditions":11426,"interventions":11427},[93],[11107],[11109,11110,758],{"intervention":11429,"totalTrials":97,"cells":11430},"WT-1",{"EARLY_PHASE1":11431,"PHASE1":11433,"PHASE2":11435,"PHASE3":11437,"PHASE4":11439,"NA":11441},{"trials":11432,"activeCount":101},[],{"trials":11434,"activeCount":101},[],{"trials":11436,"activeCount":101},[],{"trials":11438,"activeCount":101},[],{"trials":11440,"activeCount":101},[],{"trials":11442,"activeCount":101},[11443],{"nctId":11444,"briefTitle":11445,"status":147,"phases":11446,"primaryCompletion":2719,"completion":6103,"start":11447,"enrollment":33,"conditions":11448,"interventions":11449},"NCT00665002","Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms",[93],"2008-06",[35],[11429,11450,11451],"Montanide","Sargramostim",{"intervention":11450,"totalTrials":97,"cells":11453},{"EARLY_PHASE1":11454,"PHASE1":11456,"PHASE2":11458,"PHASE3":11460,"PHASE4":11462,"NA":11464},{"trials":11455,"activeCount":101},[],{"trials":11457,"activeCount":101},[],{"trials":11459,"activeCount":101},[],{"trials":11461,"activeCount":101},[],{"trials":11463,"activeCount":101},[],{"trials":11465,"activeCount":101},[11466],{"nctId":11444,"briefTitle":11445,"status":147,"phases":11467,"primaryCompletion":2719,"completion":6103,"start":11447,"enrollment":33,"conditions":11468,"interventions":11469},[93],[35],[11429,11450,11451],{"intervention":11451,"totalTrials":97,"cells":11471},{"EARLY_PHASE1":11472,"PHASE1":11474,"PHASE2":11476,"PHASE3":11478,"PHASE4":11480,"NA":11482},{"trials":11473,"activeCount":101},[],{"trials":11475,"activeCount":101},[],{"trials":11477,"activeCount":101},[],{"trials":11479,"activeCount":101},[],{"trials":11481,"activeCount":101},[],{"trials":11483,"activeCount":101},[11484],{"nctId":11444,"briefTitle":11445,"status":147,"phases":11485,"primaryCompletion":2719,"completion":6103,"start":11447,"enrollment":33,"conditions":11486,"interventions":11487},[93],[35],[11429,11450,11451],{"intervention":11489,"totalTrials":97,"cells":11490},"Eicosapentaenoic Acid",{"EARLY_PHASE1":11491,"PHASE1":11493,"PHASE2":11495,"PHASE3":11497,"PHASE4":11499,"NA":11501},{"trials":11492,"activeCount":101},[],{"trials":11494,"activeCount":101},[],{"trials":11496,"activeCount":101},[],{"trials":11498,"activeCount":101},[],{"trials":11500,"activeCount":101},[],{"trials":11502,"activeCount":101},[11503],{"nctId":11504,"briefTitle":11505,"status":147,"phases":11506,"primaryCompletion":8088,"completion":2138,"start":830,"enrollment":566,"conditions":11507,"interventions":11509},"NCT00815685","A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia",[93],[11508],"Cancer Cachexia",[11489],{"intervention":11265,"totalTrials":97,"cells":11511},{"EARLY_PHASE1":11512,"PHASE1":11514,"PHASE2":11516,"PHASE3":11518,"PHASE4":11520,"NA":11522},{"trials":11513,"activeCount":101},[],{"trials":11515,"activeCount":101},[],{"trials":11517,"activeCount":101},[],{"trials":11519,"activeCount":101},[],{"trials":11521,"activeCount":101},[],{"trials":11523,"activeCount":101},[11524],{"nctId":11260,"briefTitle":11261,"status":345,"phases":11525,"primaryCompletion":4267,"completion":4267,"start":5291,"enrollment":101,"conditions":11526,"interventions":11527},[93],[15],[11265,11241],{"intervention":1063,"totalTrials":97,"cells":11529},{"EARLY_PHASE1":11530,"PHASE1":11532,"PHASE2":11534,"PHASE3":11536,"PHASE4":11538,"NA":11540},{"trials":11531,"activeCount":101},[],{"trials":11533,"activeCount":101},[],{"trials":11535,"activeCount":101},[],{"trials":11537,"activeCount":101},[],{"trials":11539,"activeCount":101},[],{"trials":11541,"activeCount":101},[11542],{"nctId":1053,"briefTitle":1054,"status":147,"phases":11543,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":1059,"conditions":11544,"interventions":11545},[93],[169],[172,1062,1063,1064,1065,1066],{"intervention":1064,"totalTrials":97,"cells":11547},{"EARLY_PHASE1":11548,"PHASE1":11550,"PHASE2":11552,"PHASE3":11554,"PHASE4":11556,"NA":11558},{"trials":11549,"activeCount":101},[],{"trials":11551,"activeCount":101},[],{"trials":11553,"activeCount":101},[],{"trials":11555,"activeCount":101},[],{"trials":11557,"activeCount":101},[],{"trials":11559,"activeCount":101},[11560],{"nctId":1053,"briefTitle":1054,"status":147,"phases":11561,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":1059,"conditions":11562,"interventions":11563},[93],[169],[172,1062,1063,1064,1065,1066],{"intervention":1066,"totalTrials":97,"cells":11565},{"EARLY_PHASE1":11566,"PHASE1":11568,"PHASE2":11570,"PHASE3":11572,"PHASE4":11574,"NA":11576},{"trials":11567,"activeCount":101},[],{"trials":11569,"activeCount":101},[],{"trials":11571,"activeCount":101},[],{"trials":11573,"activeCount":101},[],{"trials":11575,"activeCount":101},[],{"trials":11577,"activeCount":101},[11578],{"nctId":1053,"briefTitle":1054,"status":147,"phases":11579,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":1059,"conditions":11580,"interventions":11581},[93],[169],[172,1062,1063,1064,1065,1066],{"intervention":11583,"totalTrials":97,"cells":11584},"68Ga-DOTATATE",{"EARLY_PHASE1":11585,"PHASE1":11587,"PHASE2":11589,"PHASE3":11591,"PHASE4":11593,"NA":11595},{"trials":11586,"activeCount":101},[],{"trials":11588,"activeCount":101},[],{"trials":11590,"activeCount":101},[],{"trials":11592,"activeCount":101},[],{"trials":11594,"activeCount":101},[],{"trials":11596,"activeCount":101},[11597],{"nctId":11598,"briefTitle":11599,"status":147,"phases":11600,"primaryCompletion":5207,"completion":5207,"start":994,"enrollment":719,"conditions":11601,"interventions":11602},"NCT04069299","Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract",[],[669],[11583],{"intervention":11604,"totalTrials":97,"cells":11605},"Tac+MTX",{"EARLY_PHASE1":11606,"PHASE1":11608,"PHASE2":11610,"PHASE3":11612,"PHASE4":11614,"NA":11616},{"trials":11607,"activeCount":101},[],{"trials":11609,"activeCount":101},[],{"trials":11611,"activeCount":101},[],{"trials":11613,"activeCount":101},[],{"trials":11615,"activeCount":101},[],{"trials":11617,"activeCount":101},[11618],{"nctId":11619,"briefTitle":11620,"status":147,"phases":11621,"primaryCompletion":6725,"completion":6725,"start":927,"enrollment":11622,"conditions":11623,"interventions":11626},"NCT00360685","Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX",[93],89,[11624,11625],"Mucositis","Graft-versus-host Disease",[11604,11627],"TAC + MMF",{"intervention":11627,"totalTrials":97,"cells":11629},{"EARLY_PHASE1":11630,"PHASE1":11632,"PHASE2":11634,"PHASE3":11636,"PHASE4":11638,"NA":11640},{"trials":11631,"activeCount":101},[],{"trials":11633,"activeCount":101},[],{"trials":11635,"activeCount":101},[],{"trials":11637,"activeCount":101},[],{"trials":11639,"activeCount":101},[],{"trials":11641,"activeCount":101},[11642],{"nctId":11619,"briefTitle":11620,"status":147,"phases":11643,"primaryCompletion":6725,"completion":6725,"start":927,"enrollment":11622,"conditions":11644,"interventions":11645},[93],[11624,11625],[11604,11627],{"intervention":11647,"totalTrials":97,"cells":11648},"5-Aminolevulinic Acid",{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11653,"PHASE3":11655,"PHASE4":11657,"NA":11659},{"trials":11650,"activeCount":101},[],{"trials":11652,"activeCount":101},[],{"trials":11654,"activeCount":101},[],{"trials":11656,"activeCount":101},[],{"trials":11658,"activeCount":101},[],{"trials":11660,"activeCount":101},[11661],{"nctId":11662,"briefTitle":11663,"status":147,"phases":11664,"primaryCompletion":11665,"completion":2297,"start":11666,"enrollment":281,"conditions":11667,"interventions":11668},"NCT04055688","Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas",[],"2019-12-17","2019-08-15",[524,9170],[11647],{"intervention":11670,"totalTrials":97,"cells":11671},"Peptide Vaccine",{"EARLY_PHASE1":11672,"PHASE1":11674,"PHASE2":11676,"PHASE3":11678,"PHASE4":11680,"NA":11682},{"trials":11673,"activeCount":101},[],{"trials":11675,"activeCount":101},[],{"trials":11677,"activeCount":101},[],{"trials":11679,"activeCount":101},[],{"trials":11681,"activeCount":101},[],{"trials":11683,"activeCount":101},[11684],{"nctId":11685,"briefTitle":11686,"status":147,"phases":11687,"primaryCompletion":11688,"completion":11689,"start":11690,"enrollment":385,"conditions":11691,"interventions":11692},"NCT00694551","PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment",[93],"2013-02-28","2018-12-06","2008-12-02",[18],[11670,11693],"Poly IC-LC",{"intervention":11693,"totalTrials":97,"cells":11695},{"EARLY_PHASE1":11696,"PHASE1":11698,"PHASE2":11700,"PHASE3":11702,"PHASE4":11704,"NA":11706},{"trials":11697,"activeCount":101},[],{"trials":11699,"activeCount":101},[],{"trials":11701,"activeCount":101},[],{"trials":11703,"activeCount":101},[],{"trials":11705,"activeCount":101},[],{"trials":11707,"activeCount":101},[11708],{"nctId":11685,"briefTitle":11686,"status":147,"phases":11709,"primaryCompletion":11688,"completion":11689,"start":11690,"enrollment":385,"conditions":11710,"interventions":11711},[93],[18],[11670,11693],{"intervention":11713,"totalTrials":97,"cells":11714},"Genomic and Histological Evaluation",{"EARLY_PHASE1":11715,"PHASE1":11717,"PHASE2":11719,"PHASE3":11721,"PHASE4":11723,"NA":11725},{"trials":11716,"activeCount":101},[],{"trials":11718,"activeCount":101},[],{"trials":11720,"activeCount":101},[],{"trials":11722,"activeCount":101},[],{"trials":11724,"activeCount":101},[],{"trials":11726,"activeCount":101},[11727],{"nctId":11728,"briefTitle":11729,"status":552,"phases":11730,"primaryCompletion":11731,"completion":11731,"start":11732,"enrollment":11733,"conditions":11734,"interventions":11735},"NCT06144619","Non-Invasive Biomarkers in Prostate Cancer Disease Management",[],"2029-01-31","2023-11-21",500,[18],[11713],{"intervention":11737,"totalTrials":97,"cells":11738},"IL-12p DNA",{"EARLY_PHASE1":11739,"PHASE1":11741,"PHASE2":11743,"PHASE3":11745,"PHASE4":11747,"NA":11749},{"trials":11740,"activeCount":101},[],{"trials":11742,"activeCount":101},[],{"trials":11744,"activeCount":101},[],{"trials":11746,"activeCount":101},[],{"trials":11748,"activeCount":101},[],{"trials":11750,"activeCount":101},[11751],{"nctId":11752,"briefTitle":11753,"status":147,"phases":11754,"primaryCompletion":2755,"completion":2755,"start":6279,"enrollment":821,"conditions":11755,"interventions":11756},"NCT00323206","Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma",[93],[6530],[11737],{"intervention":11758,"totalTrials":97,"cells":11759},"Nicotine patch and lozenges",{"EARLY_PHASE1":11760,"PHASE1":11762,"PHASE2":11764,"PHASE3":11766,"PHASE4":11768,"NA":11770},{"trials":11761,"activeCount":101},[],{"trials":11763,"activeCount":101},[],{"trials":11765,"activeCount":101},[],{"trials":11767,"activeCount":101},[],{"trials":11769,"activeCount":101},[],{"trials":11771,"activeCount":101},[11772],{"nctId":11773,"briefTitle":11774,"status":147,"phases":11775,"primaryCompletion":11776,"completion":11776,"start":7508,"enrollment":198,"conditions":11777,"interventions":11779},"NCT05362318","Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free",[93],"2023-01-28",[11778,5669,26],"Smoking",[11758],{"intervention":11781,"totalTrials":97,"cells":11782},"Gardasil Vaccine",{"EARLY_PHASE1":11783,"PHASE1":11785,"PHASE2":11787,"PHASE3":11789,"PHASE4":11791,"NA":11793},{"trials":11784,"activeCount":101},[],{"trials":11786,"activeCount":101},[],{"trials":11788,"activeCount":101},[],{"trials":11790,"activeCount":101},[],{"trials":11792,"activeCount":101},[],{"trials":11794,"activeCount":101},[11795],{"nctId":11796,"briefTitle":11797,"status":147,"phases":11798,"primaryCompletion":11235,"completion":4267,"start":9291,"enrollment":11799,"conditions":11800,"interventions":11802},"NCT01489527","Preparedness Study - HPV Vaccine",[93],406,[11801],"Sexual Transmission of Infection",[11781],{"intervention":11066,"totalTrials":97,"cells":11804},{"EARLY_PHASE1":11805,"PHASE1":11807,"PHASE2":11809,"PHASE3":11811,"PHASE4":11813,"NA":11815},{"trials":11806,"activeCount":101},[],{"trials":11808,"activeCount":101},[],{"trials":11810,"activeCount":101},[],{"trials":11812,"activeCount":101},[],{"trials":11814,"activeCount":101},[],{"trials":11816,"activeCount":101},[11817],{"nctId":11059,"briefTitle":11060,"status":249,"phases":11818,"primaryCompletion":11062,"completion":11062,"start":8765,"enrollment":189,"conditions":11819,"interventions":11820},[93],[11064],[11066,4596],{"intervention":11822,"totalTrials":97,"cells":11823},"PCV 13",{"EARLY_PHASE1":11824,"PHASE1":11826,"PHASE2":11828,"PHASE3":11830,"PHASE4":11832,"NA":11834},{"trials":11825,"activeCount":101},[],{"trials":11827,"activeCount":101},[],{"trials":11829,"activeCount":101},[],{"trials":11831,"activeCount":101},[],{"trials":11833,"activeCount":101},[],{"trials":11835,"activeCount":101},[11836],{"nctId":11837,"briefTitle":11838,"status":147,"phases":11839,"primaryCompletion":6103,"completion":11840,"start":1347,"enrollment":2139,"conditions":11841,"interventions":11842},"NCT01852591","Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant",[93],"2016-10",[21],[11822]]